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Abstract 
Background:  
Pain is frequently reported by people with multiple sclerosis (MS). It has been 
associated with decreased quality of life, psychiatric morbidity, interference with day 
to day activities, and frequent healthcare attendance. It has been reported by people 
with multiple sclerosis to be one of their most important symptoms, and available 
treatments are limited in their effectiveness.  
Despite this, our understanding of the epidemiology and mechanisms of pain in 
people with MS are limited. 
Our understanding of the interactions of central nervous system mechanisms and 
pain states overall is growing. However, the application of this knowledge to MS is 
incomplete. Previous studies have shown that the descending pain modulatory 
system (DPMS) is an endogenous network of cortical and subcortical brain structures 
which act to limit, or accentuate, an individual’s perception of pain, via descending 
brainstem pathways. Associated clinical measures include depression, anxiety, and 
cognitive flexibility. Our understanding of the function or dysfunction of this system 
in MS is limited. We do not know if the MS disease process may adversely affect the 
structure or function of the DPMS. 
Hypothesis:  
In people with neuropathic limb pain in relapsing remitting MS (RRMS), compared 
to people with RRMS who do not have pain, there will be disruption of the 
endogenous descending pain modulatory system. This will manifest as impaired 
descending inhibition of pain. 
Aims and Methods 
Establishing the background using systematic reviews: 
The first aim of this thesis was to establish the prevalence, natural history and 
associations of pain (and pain syndromes) occurring in people with MS.  
  xl 
The second aim was to explore existing knowledge of how the MS disease process 
may contribute to pain states, using a systematic review of neuroimaging studies. 
Prospective clinical study: 
A case-control study of 47 people with RRMS was then carried out.  31 of these had 
neuropathic pain in the limbs, and 16 did not have pain. Using targeted assessments, 
function of the descending pain modulatory system was assessed in the following 
ways: 
First: Detailed clinical, behavioural and neuropsychological assessment, focussing on 
cognitive, behavioural and affective features known to be closely related to the 
DPMS.  
Second: MRI imaging of brain structure, focussing on the volume and location of 
MS lesions, as well as the volume of key grey-matter structures involved in the 
DPMS.  
Third: Resting state functional MRI imaging of the brain, focussing on functional 
connectivity between the rostral anterior cingulate cortex and two other key DPMS 
structures (dorsolateral prefrontal cortex, and periaqueductal gray). 
Results:  
Systematic reviews: 
Meta-analysis of existing prospective studies confirmed that pain is very common in 
MS, affecting about 63% of people with MS on average (95%CI between 55 and 
70%). Many different types of pain contribute to this overall estimate. No significant 
associations with disease course or stage emerged.  
Several neuroimaging studies have assessed people with MS-associated pain using 
MRI. These studies were often small, and with associated methodological issues. It is 
likely that location of MS lesions is implicated in aetiology of pain syndromes in 
some cases, though our overall knowledge is limited. 
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Prospective study: 
In a prospective study, people with and without pain were matched for age and 
gender. Furthermore, groups were balanced for a range of other variables. The pain 
group more frequently received gabapentinoid medications.  
The presence of pain was significantly associated with increased scores for 
depression, fatigue and catastrophising, as well as with specific impairments at 
neuropsychological assessment, including cognitive flexibility. Many of these 
impairments are directly relevant to existing models of the DPMS.  
Overall volume of MS lesions was not different in people with pain, though lesions 
were more likely to occur in the brainstem. Some alterations of grey-matter volumes 
in people with pain which mirrored studies of pain disorders outside MS were found, 
but these did not involve structures key to the DPMS. Affected structures included 
trigeminothalamic nucleus (relative volume increase in pain group), posterior 
cingulate cortex and parahippocampal gyrus (volume decrease in pain group). 
Functional connectivity of the rostral anterior cingulate cortex to the periaqueductal 
grey matter, a key structure in the descending modulation of pain, was stronger in the 
group without pain. Conversely, functional connectivity to the dorsolateral prefrontal 
cortex, repeatedly implicated in the DPMS and thought to be involved in cognitive 
evaluation and flexibility, was stronger in the pain group. MS lesion volume 
appeared to account for some of this difference in a multivariate analysis.  
Limitations: 
Key limitations of this work include cross-sectional design, small sample size, and 
number of statistical comparisons carried out. 
Conclusions: 
Systematic reviews examined the prevalence, natural history and associations of pain 
in MS, as well as examining existing neuroimaging studies which investigated how 
the MS disease process could contribute to pain states.  
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A prospective study found evidence of both emotional/affective and cognitive 
dysfunctions relevant to the hypothesis of dysfunction in the DPMS.  
Higher likelihood of MS lesions in the brainstem could be relevant to DPMS 
function. Separately, there were structural grey-matter volume alterations reflecting 
those found in many pain studies outside MS. Importantly, however, these did not 
affect key DPMS structures.  
Resting state functional MRI however demonstrated altered connectivity of core 
DPMS structures, which may be partly mediated by MS lesion volume. Functional 
connectivity findings could be consistent with the hypothesis of impaired descending 
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Lay Summary 
Background:  
Multiple Sclerosis (MS) is a common disorder which causes inflammation and cell 
death in the brain and spine. Pain is a common and important symptom for people 
with MS, however our knowledge of how common it is, and why it develops, is 
incomplete. 
Brain and spine scans in people with MS often show abnormalities, including areas 
of damage referred to as lesions. Among other effects, MS lesions are thought to 
damage connections between different parts of the brain. 
Previous studies (though not in people with MS) have identified pain-regulating 
mechanisms existing within the human brain. These have been described as the 
“descending pain modulatory system” – a network of brain structures which can 
interact to increase or decrease a person’s experience of pain. Problems with 
structure or function of this system can be seen on detailed MRI scans, but are also 
associated with a range of problems including anxiety, depression, and inflexible 
thinking styles. 
No previous studies have assessed whether the descending pain modulatory system 
could be damaged by the MS disease process in people with MS-associated pain. 
Hypothesis 
In people with neuropathic limb pain associated with MS, compared to those 
without, there are impairments in the descending pain modulatory system which are 
linked to the MS disease process. 
Aims:  
Firstly, to establish what we currently know about how common pain problems are in 
adults with MS, who is affected by pain problems, and when they are affected.  
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Secondly, to establish what existing studies using scanning of the brain or spine have 
identified about why these pain problems happen.  
Thirdly, to study people with a type of MS (relapsing remitting MS) who had nerve 
pain (neuropathic pain) affecting their limbs, and to compare them to people with the 
same type of MS who did not have neuropathic pain.  
Specifically, I aimed to assess variables that are known to be relevant to individuals’ 
own pain regulating mechanisms, and to study whether these varied between people 
with, and without, neuropathic limb pain. I also aimed to examine the structural 
effects of MS on the brain, and the functional connectivity between key parts of the 
DPMS. 
Methods:  
Firstly, a detailed review (“systematic review”) of existing studies was used to 
identify and assess articles which describe how common pain in MS is, and who it 
affects.  
Secondly, a further systematic review was used to identify and assess articles which 
describe brain and spine scanning of people with MS who have pain problems.  
Thirdly, a study comparing 31 adults with neuropathic limb pain in MS, and 16 
adults with MS who do not have pain was carried out. Medical examination, 
questionnaires, psychology testing, and “MRI” (magnetic resonance imaging) brain 
scanning - looking at both brain structure and function – were used.  
Results:   
How common is pain in MS? Systematic review confirmed that it is very common, 
affecting over half of people with MS (about 63%, though there is a lot of variation 
between studies). There are multiple different types of pain, and they do not affect 
just one particular type of person with MS.  
Do existing scan studies tell us the cause of pain in MS? Several studies have looked 
at scans in people with MS, but they have been relatively limited and have not given 
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us clear answers about why pain happens, in most cases. There is limited evidence 
that MS inflammation areas (“lesions”) in particular parts of the brain or spine may 
be linked to pain, in some cases.  
Are there differences in factors related to pain regulation in a group of people with 
MS who have nerve pain, compared to a group who do not?  
The group with pain showed some characteristics which could be associated with 
impaired ability to regulate pain. These included higher scores for depression, fatigue 
and negative thinking styles as well as limited mental flexibility.  
MRI brain scans showed that the volume of MS lesions is not higher overall in the 
brains of people with pain. Volume of lesions in the brainstem was however higher 
in those with pain.  
The volume of key structures involved in pain regulation was not different in those 
with, and without, pain.  
When functional MRI was used to look at functional connections between these 
areas, however, connectivity between these areas was found to be altered in those 
with pain, compared to those without. In particular, those with pain had reduced 
connectivity between two key structures involved in pain regulation (the anterior 
cingulate cortex, and the periaqueductal gray matter in the brainstem). Volume of 
MS lesions appeared to account for at least some of this connectivity difference. 
Discussion: This work confirms that pain in MS is common, and that existing 
scanning studies do not fully explain why it happens.  
In a new study of people with relapsing remitting MS with and without neuropathic 
limb pain, those with pain were more likely to show depression, fatigue, or inflexible 
thinking styles. While brain structure (for instance volume of key brain structures, or 
volume of MS lesions) did not vary between those with and without pain, functional 
connectivity between key areas involved in pain regulation was altered. In this small 
study, these results could support the possibility of altered function in the descending 
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pain modulatory system in adults with neuropathic limb pain associated with 
relapsing-remitting MS.
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Chapter 1 Introduction 
Some relevant background to the thesis as a whole is discussed, before considering 
specific aims and hypotheses. 
1.1 Background 
1.1.1 Key definitions: pain 
Definition of pain 
Pain is a highly subjective experience. There is a complex relationship between a 
stimulus which may cause pain (nociceptive input) and the perception of pain (1). 
For the purposes of this thesis, pain is defined as 
 “An unpleasant emotional and sensory experience, 
associated with tissue damage, or defined in terms of such 
damage”.  
The definition is based on the International Association for the Study of Pain 
taxonomy taskforce (1994) (2). Pain is considered as a multifactorial experience with 
a range of components including physiological, affective, cognitive, behavioural and 
social (3). 
Definition of neuropathic pain in this thesis 
Throughout this thesis, neuropathic pain is defined as “pain caused by a lesion or 
disease of the somatosensory nervous system” (2). This definition is comparable to 
other proposed definitions, for instance “pain arising as a direct consequence of a 
lesion or disease affecting the somatosensory system”(4).   
Central neuropathic pain is similarly defined in this thesis as “pain caused by a lesion 
or disease of the central somatosensory nervous system” (where central nervous 
system is defined as the brain and spinal cord) (2). 
Definition of neuropathic limb pain in this thesis 
Throughout this thesis, neuropathic limb pain is defined as neuropathic pain affecting 
one or more limbs. Other commonly-used terms including “dysaesthetic pain”, 
“neuropathic extremity pain”, and “central pain”, can allow for ambiguity in 
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interpretation (5). This term is favoured for clarity in terms of stated aetiology and 
location of pain. 
1.1.2 Why is pain in multiple sclerosis an important research 
target? 
A number of strands of evidence suggest that neuropathic pain in multiple sclerosis 
(MS) is an important research target. These include its prevalence, the impact on 
people who experience it, the importance to wider society in terms of healthcare 
utilization, and limited response to medication. 
1.1.2.1.1 Prevalence 
The prevalence of pain in multiple sclerosis, and of particular subtypes of pain, is 
discussed in more detail in Chapter Two. Overall pain prevalence is unclear, with 
estimates ranging widely from 29% to 86% (6, 7).  Studies examining relationships 
of pain prevalence to clinical variables use differing patient samples and study 
design, and report inconsistent conclusions. 
1.1.2.1.2 Patient ratings of the importance of pain in MS 
People with multiple sclerosis have described pain as an important symptom in a 
number of studies. 
In one study of 166 UK outpatients with multiple sclerosis, patients were asked to 
provide an estimate of which “functions” were most important to them (8). Thirteen 
“functions” were presented to patients, who were asked to rate them from 1 to 13 
according to subjective value and relevance. Lack of pain was rated as the fourth 
most important priority to this group (regardless of disease duration). Walking, visual 
function, and speech were the only functions rated as more important. Functions 
rated as less important than pain included power and coordination of hands, thinking 
and memory, continence and mood (8).  
In a further study of 612 UK adults with MS who experienced pain, a survey was 
used to examine experience and correlates of pain (9). On a numerical rating scale of 
1-10, subjects were asked to rate “level of interference” attributed to specific MS 
symptoms. Pain was rated as causing the fourth most interference, after fatigue, 
sexual dysfunction and balance. It was reported to be associated with more 
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interference than several other symptoms including bowel or bladder problems, 
thinking, vision problems, tremor, and speech problems. 
A further cross-sectional study of 117 people with multiple sclerosis admitted to a 
neurology inpatient unit in Denmark (10) identified that 32% listed pain as one of the 
most severe symptoms of MS. 
Together, these data suggest that pain is a major problem for people with MS, that it 
interferes with daily life, and that it can be one of the most severe symptoms of MS. 
1.1.2.1.3 Associations of decreased quality of life with pain in MS 
Several authors have described links between presence or severity of pain in MS, and 
poorer quality of life. 
Kalia and colleagues, writing in 2005, studied 99 Canadian outpatients with multiple 
sclerosis (11) using the SF-36 instrument to measure quality of life. The SF-36 
generates subscores reflecting physical and mental aspects of quality of life (12). 
Chronic pain in this study was defined as a constant or near-constant pain in the 
preceding month, not related to other causes.  The presence of chronic pain was 
significantly associated with decreased vitality and mental health scores, (5% and 1% 
significance levels respectively). Severity of pain was negatively correlated with role 
limitation by emotional processes (p<0.05), vitality, role limitation by physical 
processes and general health (all p<0.01); mental health and social functioning 
(p<0.0001).  
Hirsh and colleagues, in a large 2009 study of 2994 US veterans with multiple 
sclerosis (13) used a postal survey to assess physical and mental health of 
participants, as well as presence and severity of pain. An adapted, shorter, version of 
the SF-36, termed the V-36 (12, 14) was used. In particular, they aimed to assess the 
association of both presence and impact of pain, with several variables. The 
prevalence of pain in the preceding four weeks was high (92% of participants). 
Eighty-five percent of the participants described that pain cause interference in daily 
activities, over the same time period.  
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Physical health measures were significantly associated with pain intensity, and 
perceived interference of pain with ability to complete daily activities (Pearson 
correlation -0.23 and -0.25 respectively, p<0.001). Mental health measures were also 
significantly associated with both pain intensity and interference (Pearson correlation 
-0.38 and -0.42 respectively, both p<0.001), to a greater degree than physical health. 
The strongest predictors of pain interference (i.e. the phenomenon of pain interfering 
in day-to-day activities) were pain intensity (β = 0.73), physical health (β=-0.07) and 
mental health (β=-0.03). There was a statistical interaction between pain intensity 
and physical health, underlining the complexity of these phenomena.   
Presence of pain was also associated with lower scores (indicating worse quality of 
life) in all subscales of the SF-36 in a study of 50 people with MS and pain, 50 
people with MS without pain, and 50 healthy volunteers (15). 
Together, these data suggest that quality of life measures, including measures of both 
physical and mental health, are repeatedly negatively associated with the presence 
and severity of pain in multiple sclerosis. 
1.1.2.1.4 Healthcare utilization for pain in MS 
Several studies demonstrate that people with MS (pwMS) who experience pain, 
frequently access healthcare because of pain.  
In one study of 125 community-dwelling people with MS in the north-western USA 
who reported recent or current pain problems (16), participants were asked about 
health care visits specifically for pain during the past six months. 75% of participants 
reported accessing health care providers for pain in the preceding six months, with a 
mean number of total visits 9.7 in six months (SD 14.4, range 0-81). The three 
specialties most commonly accessed were primary care (62% of participants, mean 
number of visits 2.1), speciality physician (47%, number of visits 1.8) and physical 
or occupational therapy (33%, number of visits 3.5).  
In a study of 61 community-dwelling adults with MS and pain in Australia, around 
half reported accessing their GP because of pain within the preceding 12 months 
(32/61, 52.5%). Other specialists most frequently consulted over the same time 
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period included neurologists (29/61, 47.5%) and physiotherapists (21/61, 34.5%) 
(17).  At follow-up after 7 years, frequency of access to the same practitioners had 
increased in all cases (after seven years, percentages accessing health care for pain 
were: GP 54.1%, physiotherapist 48.6% and neurologist 62.2%).  
These American and Australian studies both describe substantial healthcare 
utilization related to pain, in people with pain related to multiple sclerosis. 
Healthcare utilization was observed across a range of specialties and may increase 
over time. These data could be consistent with MS-associated pain being experienced 
as distressing (leading patients to need to access healthcare), or that it is not easily 
resolved (leading to repeated visits). Economic costs have not been estimated, but 
may be considerable. 
1.1.2.1.5 Treatment of pain in MS 
1.1.2.1.5.1 Perceived efficacy of pharmacological therapy 
Medication has been reported in several studies to be of limited efficacy in treating 
pain, for people with MS. This may, in part, relate to limited mechanistic 
understanding. 
A 2001 study of 83 members of the USA national MS society (18), of whom 90% 
reported experiencing pain, asked participants to rate the eight techniques which 
were most effective, and least effective, in managing their pain. The investigators 
used a survey (by post or in person). Medication overall was rated as effective by 
45% of participants. More specifically, anti-inflammatories were rated as effective 
by 13%, opioids by 5%, antidepressants by 4%, and anticonvulsants by 3%. 
Interestingly, 48% of participants listed medication as among the least effective 
techniques for managing their pain.  
One study of community-dwelling adults with MS in the northwestern USA (n=125 
with current or recent pain (16) specifically examined participants’ perceptions of the 
efficacy of specific pharmacological and non-pharmacological therapies. Participants 
were asked to rate the effectiveness of various pharmacological and non-
pharmacological therapies in relief of their own pain, on a scale 0-10, from “no pain 
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relief” to “complete pain relief”. Data regarding patients’ use of, and perceptions of, 
selected therapies relevant to this study is reproduced below (Table 1).  
Table 1: Use and perceived effectiveness of selected pharmacological therapies for pain:  
reproduced from Ehde et al, 2015 
Medication % of participants 
who had ever 
used 
% of participants 
still using 
Pain relief rating 




Paracetamol 1 78.4% 58.2% 4.8 (2.6) 
NSAID 82.4% 69.9% 5.1 (2.7) 
TCA 27.2% 38.2% 3.9 (2.9) 
Gabapentin 23.2% 62.1% 5.1 (2.8) 
Carbamazepine 17.6% 40.9% 4.2 (4.2) 
Opioids 42.4% 37.7% 6.6 (2.9) 
 
1 Paracetamol described as Acetaminophen in this study in the USA 
NSAID = Non Steroidal Anti Inflammatory Drug 
TCA = Tricyclic Antidepressant 
SD = Standard Deviation 
 
1.1.2.1.5.2 Polypharmacy  
Polypharmacy is also common among patients with multiple sclerosis. This may lead 
to an increased risk of side effects, and of medication interactions. 
In a recent retrospective study of 1090 patients with MS attending a specialist 
inpatient rehabilitation unit in Norway (2009-2012), 342 of 1090 (31%) used at least 
one adjuvant analgesic (19). Of the 1090 subjects studied, mean number of 
medications administered was 5.4, with concomitant use of adjuvant analgesic agents 
along with at least one other drug acting on the central nervous system also being 
common (19).  These data are comparable to other studies, for instance Kalia and 
colleagues’ study of 102 people with MS attending an outpatient MS clinic in 
Toronto between 2000 and 2002 (11). Of these, 26% had received treatment for pain 
in the last month. Fifty percent of those receiving pain therapy were receiving more 
than one type of treatment (though these estimates included non-pharmacological 
therapies). 
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Together, these data suggest that use of medications for pain in MS is common, and 
that perception of utility is variable, though does not suggest marked benefit. 
Polypharmacy is common and could in itself contribute to adverse outcomes. 
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1.1.3 Epidemiology of pain in multiple sclerosis 
There is limited understanding of how often pwMS are affected by pain, which MS 
patient groups suffer most frequently from pain, or of the influence of study 
methodology on pain estimates. For example, some studies have found that the 
presence of pain in MS is associated with increasing disability and disease duration, 
(7, 20-23)  whereas others have found no such relationship. (24-27) The reasons for 
such differences are poorly understood. Lastly, the natural history of pain during the 
disease course is uncertain.  
One previous systematic review carried out  in 2007 (5) usefully explored some of 
these issues. The authors did not however examine the literature published in 
languages other than English, and did not use weighted meta-analysis to calculate 
prevalence estimates. Therefore confidence intervals for estimates are not available, 
and estimate heterogeneity has not been quantified, nor formally explored.  
Better understanding of the prevalence, and natural history, of MS-related pain could 
assist clinicians and healthcare planners in estimating the likely extent of this 
problem, and the size of the population affected. Improved understanding of patient 
groups affected might also assist clinicians in focussing assessment on patient groups 
who are particularly at risk of pain.  
Furthermore, better understanding of the epidemiology of pain in MS could improve 
understanding of symptom mechanisms, and potentially contribute to development of 
targeted treatment strategies. For instance, CNS inflammation and neurodegeneration 
may be most likely to occur in early and late disease, respectively. (28) Variation in 
pain prevalence across the disease course could suggest links to neuroinflammatory 
or neurodegenerative processes. 
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1.1.4 The descending pain modulatory system (DPMS) 
Overview of DPMS 
As discussed, the experience of pain is not straightforward, and is not linearly related 
to nociceptive input (29). The nociceptive input, environment, and behavioural state 
of the person experiencing pain are all particularly important, and interact to 
modulate the experience of pain (30).  
1.1.4.1.1 Descending pain modulation systems: an example in acute injury 
The experience of acute pain related to an injury may differ significantly according 
to a range of variables. The relatively straightforward example of a footballer 
incurring a leg injury during a tackle can be used to highlight some relevant clinical, 
behavioural and psychological themes. 
Firstly, the nature of the injury may vary, leading to varying nociceptive input (for 
instance minor physical impact in comparison to significant trauma). The 
environment in which the injury is incurred (for instance during a crucial moment in 
a major competitive football match) may also critically modulate the severity of 
perceived pain. The experience of the pain associated with the injury may be further 
modulated by cognitive factors – such as the footballer’s appraisal of the significance 
of the injury .Emotional and affective variables (such as the player’s mood) may also 
importantly modulate the experience of pain (31).  
All of the above factors may reduce, or increase, the severity of perceived pain. Pain-
related behaviour may then be modulated.  
Emotional/affective factors and cognitive factors, can exert bidirectional modulatory 
influences on the experience of pain. 
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1.1.4.1.2 Descending Pain Modulatory System: role of cognitive and 
emotional/affective factors 
This complex inter-relationship between emotional/affective factors, cognitive 
factors and the experience of pain is summarised below (Figure 1) (adapted from 
Bushnell et al (31)).  
Figure 1: Inter-relationship of pain with emotional/affective factors, and cognitive factors  




All of these factors are relevant to the descending pain modulation system (DPMS).  
In summary, forebrain and limbic circuits are recognised to exert modulatory input to 
the descending pain modulation system (30). Particularly important areas include 
Prefrontal Cortices, Amygdala, anterior insula, and Anterior Cingulate Cortex (30). 
These exert top-down influences via brainstem circuits which in turn are thought to 
exert influences on the dorsal horn of the spinal cord. Key brainstem circuits are 
centred on the Periaqueductal Gray (PAG) and Rostral ventromedial Medulla (RVM) 
(1, 30, 32). Endogenous opioids as well as serotonergic signalling are thought to be 
key to this system (30).  
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The key neuroanatomical structures involved in the DPMS are highlighted below 
(Figure 2) (after Tracey et al, and Wiech et al (1, 33)). 
Figure 2: Key components of descending pain modulatory system (DPMS) 
 
1.1.4.1.3 Descending pain modulation in chronic pain 
In chronic pain, as found in MS, emotional/affective and cognitive factors are 
crucially important (30).  
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The following section aims to summarise studies relating findings relevant to DPMS 
function or dysfunction in people with MS. There is a particular focus on studies 
describing anxiety, depression, cognitive dysfunction and sensory processing, with 
particular emphasis on studies detailing these variables in relation to the presence or 
severity of pain in MS, where available.  
Is there evidence consistent with DPMS dysfunction in pain related to 
MS? 
1.1.4.1.4 Depression in MS 
The prevalence of major depression in MS has repeatedly been found to be high, 
with several studies reporting a higher prevalence of depression in MS than in 
healthy controls, or in subjects with other chronic disease (34).  
A recent large Canadian study (35) compared the incidence and prevalence of 
psychiatric disorders in the MS population, and in controls who were matched for 
geographic area, age and sex, using population-based administrative health data. 
Case definitions of psychiatric disorders used coding based on ICD-9 or ICD-10 
criteria from 1995 to 2005. Case definitions of multiple sclerosis used coding based 
on the same criteria. 44,452 MS cases, and 220,849 matched controls were identified. 
In 2005, the annual incidence of depression was 979 per 100,000 people with MS 
(0.98%), compared to 0.72% in the matched population without MS. Age-
standardized incidence of depression was 71% higher in the MS population than the 
matched population. Age-standardized prevalence of depression was also higher in 
the MS population than the matched population (20.1% vs 11.9% respectively).  
Three prospective studies using a standardised psychiatric interview have similarly 
estimated the prevalence of major depression to be between 42 and 54% (sample size 
between 50 and 221 people with MS) (34). A fourth larger study of 739 people with 
MS completing a mailed survey (36) used the Centre for Epidemiological Studies’ 
Depression Scale (CES-D), and found that 42% of the sample had “clinically 
significant depressive symptoms” (CES-D score >16.0) and 29% scored in a range 
suggesting moderate or severe depression (CES-D score >21). In this sample, 
younger age, less educational attainment and lack of social support were associated 
with depressive symptoms.  
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1.1.4.1.5 Anxiety in MS 
Incidence and prevalence of anxiety in the Canadian population-based study 
described above (37) was higher in the MS population than the matched population 
(crude annual incidence 0.64% vs 0.42%; crude prevalence 8.7% vs 5.1%).  
A prospective interview study of 140 clinic attenders with MS in Toronto (38) 
administered the structured clinical interview for DSM-IV disorders (SCID-IV) (39) 
as well as the Hospital Anxiety and Depression Scale (HADS) (40). Lifetime 
prevalence of anxiety disorders using the SCID-IV was 35.7%, and point prevalence 
14%. Anxiety disorders were reported to include panic disorder, social phobia, 
specific phobia, obsessive compulsive disorder, and generalized anxiety disorder. 
Using a threshold score of 10 on the HADS, 20.7% of the sample were found to have 
elevated anxiety scores, and 10.7% elevated depression scores.  
1.1.4.1.6 Inter-relationship of anxiety and depression in MS 
In a comparison of subjects with (n=50) and without (n=90) anxiety disorders, a 
diagnosis of major depression was more likely in those with anxiety (62.0% vs 
22.2%, p=0.0001), whereas cognitive impairment was more common in those 
without anxiety (16.3% in those with anxiety, 28.9% in those without, not attaining 
statistical significance p=0.1). Mean HADS anxiety score in those diagnosed with 
anxiety using the SCID-IV interview was 8.8 (SD 4.6), and in those without anxiety 
4.5 (SD 2.8).  
Taken together, these data suggest that significant depressive symptoms affect at 
least 20% of people with MS (35), with some estimates being considerably higher 
(34, 36). Point prevalence of any anxiety disorder in MS has been reported to be 
between 8 (35) and 14% (38), with the two commonly coexisting (38).  
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1.1.4.1.7 Anxiety and depression in MS-related pain disorders 
While not all studies examining the experience of people with MS have evaluated the 
presence or otherwise of affective symptoms (23), symptoms of anxiety and 
depression have repeatedly been found to be associated with presence and severity of 
pain.  
Drulovic and colleagues administered a structured questionnaire to 650 outpatients 
with MS at several MS centres in Serbia, and Bosnia-Herzegovina (41). The severity 
of depressive and anxiety symptoms were rated using the Hamilton Rating Scale for 
Depression (HDRS) (42) and the Hamilton Rating Scale for Anxiety (HARS) (43). 
Mean scores for both depressive and anxiety symptomatology were higher in the 
pain group (patients with pain n=432, patients without pain n=218). For depressive 
symptomatology, mean HDRS score in those without pain was 9.3, and those with 
pain 13.8, (a threshold score >9 was suggested as consistent with mild depression). 
For anxiety symptomatology, mean score in those without pain was 8.5, and those 
with pain 13.0, (a threshold HARS score of >17 was suggested as consistent with 
mild anxiety). 
Kalia and colleagues (11) dichotomized their group of 99 clinic attenders with MS 
around median HADS (40) anxiety score (median 7) and depression score (median 5) 
and found that median pain scores (assessed using the SF36 instrument (12)) were 
significantly higher in groups with higher anxiety scores, and those with higher 
depression scores.  
Archibald and colleagues (44) applied the Mental Health Inventory (MHI) (45) in 85 
patients with MS who underwent structured interviews in an MS referrals unit with a 
focus on pain. Global MHI scores were used, with higher scores reflecting better 
mental health status (highest possible score 226). The MHI scores were significantly 
lower in the group with pain, than the group without (mean 159.2 vs mean 170.4, 
p<0.05). MHI scores were below the mean score of the normative sample for this 
instrument (45), and the mean MHI score of the pain group fell within the lowest 
quartile of distribution of normative scores. 
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Pain and depression are frequently comorbid in MS. Alschuler and colleagues (46) 
used a postal questionnaire study of 161 community-dwelling adults with MS in the 
USA. Pain and depression were found to frequently coexist, with, in particular, pain 
being frequently found in people meeting diagnostic criteria for depression (using the 
PHQ-9 instrument). They describe that, of persons experiencing any pain, 11-34% 
met depression criteria. A slightly higher number (15-37%) met depression criteria 
when only pain of at least moderate severity was considered (46). Participants with 
pain were between two and four times more likely to meet depression criteria than 
those without.  
The above data are consistent with increased depressive and anxiety symptomatology 
in people with pain associated with MS, in comparison to those who do not have 
pain. Most studies examined people with pain of different aetiologies. 
1.1.4.1.7.1 Anxiety and depression in pain disorders other than those associated 
with MS 
Data from pain disorders outside the context of MS are also consistent with the 
above findings. Painful physical symptoms have been reported to occur in between a 
half and two thirds of patients with major depressive disorder, and major depressive 
disorder has been reported in up to half of people receiving specialist treatment for 
chronic pain (47). It is not certain whether the experience of depression may 
predispose to pain, whether the experience of pain may predispose to depression, or 
whether there is a separate independent modulator (47).  
Anxiety is likewise highly prevalent in people with chronic pain. In people with 
chronic pain being treated at tertiary centres, prevalence of any anxiety problem has 
been estimated at between 7 and 28%, while generalised anxiety disorder has been 
found to be present in up to 20% (47).  
Longitudinal population-based studies have suggested that pre-existing mood 
disorders increase risk for developing chronic pain (people with depression but 
without pain are approximately twice as likely to develop chronic musculoskeletal 
pain as people without depression or pain). Similarly some evidence suggests that 
anxiety disorders may precede the onset of pain. In cross-sectional studies or clinical 
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practice, however, it is not always possible to determine direction of causality (if 
any) (29). Depression and pain may influence each other by a range of mechanisms 
(on the biopsychosocial “spectrum”) ranging from potential shared biochemical 
pathways, to effects on cognition, behaviour and the individual’s environment (46). 
 
Introduction  17 
1.1.4.1.8 Cognition in MS: background 
The prevalence of cognitive problems in MS is appreciable, though deficits may not 
always be readily clinically apparent. Estimates depend on the instruments used and 
the population tested. In a population cohort, cognitive impairment on 
neuropsychological assessment may be present in 35% of people with MS, whereas 
in a clinic cohort, up to 60% (48). Extensive research has focussed on the assessment 
(and potential for treatment) of cognitive dysfunction in MS. The ecological validity 
of tests (in other words the impact of tested functions on a person’s capabilities in 
day to day life, or on quality of life) is not always known (48).  
A core deficit in MS is information processing speed, with anterograde episodic 
memory, and executive function the next most frequently affected (49). Cognitive 
impairments can affect people with any stage of MS, including early MS and 
Relapsing Remitting disease (50), though they are thought to be more common in 
people with progressive disease of longer duration (51).  No proven pharmacological 
or non-pharmacological treatment exists for cognitive impairment in MS (48) 
In a recent large study of 1500 Israeli patients with MS using a computerized 
cognitive battery (51), the authors tested multiple cognitive domains including verbal 
and non-verbal memory, executive functions, visual spatial perception, verbal 
fluency, attention, processing speed and motor skills. Patients with significant 
depressive or anxiety symptomatology were excluded (noting the appreciable 
prevalence of affective disorders in MS discussed above). The authors used a range 
of tools generating 65 outcome parameters. Some tools from previous batteries were 
used, while many were novel.  
This cross-sectional study recruited patients with variable disease durations, and 
reported that while cognitive impairment was more pronounced in people with SPMS 
and longer disease durations, the pattern of cognitive impairment was similar in all 
groups of patients. The most frequently impaired functions were information 
processing speed and executive function. Although people with significant anxiety or 
depression on the basis of Hamilton questionnaires were excluded, sub-threshold 
anxiety or depression scores were not accounted for. In addition pain, fatigue and 
sleep were not discussed (51). 
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1.1.4.1.9 Inter-relationship of cognition, pain and other symptoms in MS 
The role of cognitive factors in pain related to MS is incompletely understood. There 
is likely to be a complex inter-relationship between cognitive, affective/emotional 
variables, and pain (Figure 1). This inter-relationship has not however been 
extensively studied. Reliable separation of cognitive and emotional factors is 
extremely difficult. For example a key aspect of depression is cognitive distortion 
(negative appraisal of the self, the world and the future) (52)). As has been discussed 
above, both affective and cognitive problems are prevalent in people with MS. 
In a small study (53) of 48 patients with MS and healthy controls (university 
students), participants underwent a cognitive battery along with other tests aiming to 
establish symptoms of depression and fatigue. Cognitive assessment focussed on 
information processing speed and measures of memory, including the California 
Verbal Learning Test (54) and digit span (including reverse digit span) (55). Patients 
with known unipolar or bipolar depression were excluded. The authors specifically 
focussed on processing speed, felt to be a key deficit in MS. Slower information 
processing was associated with higher depressive symptomatology, impaired verbal 
learning, higher fatigue scores and poorer digit span.  
Evidence of cognitive dysfunction in other chronic pain disorders includes one study 
of 30 people with fibromyalgia compared to 30 healthy controls (56). In particular, 
the authors found deficits in a range of cognitive variables measuring attention, and 
working memory. The fibromyalgia group reported much worse quality of life, 
depression and sleep. After accounting for differences in pain, differences in 
cognition were no longer apparent, leading the researchers to suggest that these 
differences may be accounted for by presence of pain. Effect of medication was 
examined by a contrast between people with fibromyalgia who were taking opioids 
and those who were not (n=9 and 21 respectively). The authors found that those 
taking opioids manifested better cognitive functions, though a small sample size was 
noted. Potential effects of other drugs including tricyclics (46.7% of fibromyalgia 
group vs 6.7% of control group) were not explored. 
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1.1.4.1.9.1 Pain catastrophising and appraisal of pain 
Pain catastrophising is commonly related to the presence and severity of pain 
disorders (33) though has been infrequently assessed in studies of people with MS. 
Pain catastrophising has been defined as an exaggerated negative orientation towards 
painful stimuli during actual or anticipated pain experience (57), or (similarly), an 
exaggerated negative “mental set” brought to bear during painful experiences (58). 
Some studies have assessed the role of pain catastrophising in severity of pain related 
to MS, using a variety of instruments. Significant relationships between 
catastrophising, and pain severity, have been described (57, 59). 
A recent qualitative study carrying out in-depth interviews of 25 people with MS 
who suffered from pain (60) found that two pain management themes were most 
often described by participants – one relating to pain reduction, and the other to 
acceptance. The authors suggested that pain catastrophizing, acceptance and 
endurance could be treatment targets (57). 
 
1.1.4.1.9.2 Executive Functions 
Executive functions have been defined as “those capacities that enable a person to 
engage successfully in independent, purposive, self-serving behaviour” (61). More 
general definitions include supervisory cognitive processes, which involve higher 
level organization, and execution of complex thoughts and behaviour (62) 
Specific executive functions might include initiation, planning, purposive action, 
self-monitoring, self-regulation, volition, inhibition and cognitive flexibility (set-
shifting) (63). Executive functions have most often been localised to the frontal 
lobes. Many tests of executive function are felt to be sensitive, but not specific, 
markers of frontal lobe damage (62). Both frontal and non-frontal regions are likely 
to be necessary for intact executive functions, with involvement of frontal lobes 
likely to be necessary, but not sufficient (62). For these reasons the commonly –used 
term “frontal” functions is not used in this thesis. 
Introduction  20 
There is some evidence for “fractionation” of executive functions (63, 64), with 
specific processes related to specific subdivisions of the frontal cortex. 
Neuropsychological assessments, as described in this thesis, aim to measure specific 
processes, however it should be noted that many tasks will measure more than one at 
one time (63, 64).  
Executive functions, in particular cognitive flexibility or “set-shifting” are thought to 
be important in the descending modulation of pain (33, 65). These have not however 
been assessed in relation to pain in MS.  
1.1.4.1.10 Cortical localisation of tests of cognitive and executive functions 
discussed in this thesis 
The known neuroanatomical structures thought to be relevant to undertaking selected 
cognitive tasks detailed in the neuropsychological battery for this study have been 
briefly detailed (see also Table 2 for summary of cortical localisation, and Table 15 
for a summary of relationships between study instruments, and functions assessed). 
1.1.4.1.10.1 Phonemic verbal Fluency 
In lesion and clinical studies, phonemic verbal fluency has been demonstrated to be 
related to left frontal lobe function (62), in particular dorsolateral prefrontal cortex 
function as well as other frontal areas including ventrolateral prefrontal cortex, 
dorsomedial frontal cortex (63) anterior cingulate and frontal pole (64). Right-sided, 
and non-frontal regions have also been implicated by some studies (62).  
Neuroimaging studies have suggested that phonemic verbal fluency is mainly 
associated with left dorsolateral prefrontal cortex activation, but also other areas 
including ventrolateral prefrontal cortex, thalamus, temporal and parietal cortices, 
and anterior cingulate (62, 64).  
1.1.4.1.10.2 Hayling sentence completion 
In patient and lesion studies, performance in the Hayling Sentence Completion Task 
has been linked to the Anterior Cingulate Cortex, as well as (less often) orbitofrontal 
cortex and frontal pole (64).  In neuroimaging studies, completion of the Hayling test 
has been linked to left lateral prefrontal cortex (including inferior and dorsolateral 
cortex) as well as medial superior frontal cortex including anterior cingulate (64).  
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1.1.4.1.10.3 Reverse digit span 
Patient and lesion studies have suggested that damage to dorsolateral prefrontal 
cortex adversely affects performance on reverse digit span (64). Neuroimaging 
studies have consistently pointed to the significance of DLPFC in performance of the 
reverse digit span, though other areas including Anterior Cingulate, Frontal Pole, 
Orbitofrontal cortex have been implicated (64). 
1.1.4.1.10.4 Number:letter sequencing  
Limited patient and lesion studies have supported the role of dorsolateral prefrontal 
cortex in the Trail-making test, as well as anterior cingulate in one case (64). 
Neuroimaging studies have similarly supported the role of dorsolateral prefrontal 
cortex, and in some studies anterior cingulate (64). 
1.1.4.1.10.5 Summary table 
This data (Table 2) is based on review by MacPherson and colleagues (64) as well as 
articles by Stuss (63), and Alvarez and colleagues (62). For each test/group of tests 
the following are separately listed: “clinical or lesional studies” which typically 
assess the structural imaging correlates of a relevant CNS injury or disease process, 
and “imaging” studies which typically use fMRI to assess functional correlates of 
these tests. 
The symbols “++” and “+” denote my own interpretation of the information provided 
with regards to the strength or repeatability of an observed association. 
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Table 2: Cortical localisation of functions tested in neuropsychological assessments 
  Cortical localisation 
  DLPFC ACC POLE OFC VLPFC OTHER 
Phonemic 
Fluency 
Clin ++ + +  +  
 Img ++ +   + Temporal, 
parietal, 
thalamus 
DKEFS Clin ++ + +    




Hayling Clin  ++ + +   
 Img ++ +     
Reverse 
Digit Span 
Clin ++      
 Img ++ + + +   
Numb:letter 
sequence 
Clin + +     
 Img ++ +     
++ = strong association, frequently reported 
+   = often reported 
 
Clin = clinical or lesional studies  
Img = neuroimaging studies 
 
DKEFS = Delis Kaplan Executive Function System 
DLPFC = Dorsolateral Prefrontal Cortex 
ACC = Anterior Cingulate Cortex 
POLE = Frontal pole 
OFC = Orbitofrontal Cortex 
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1.1.4.1.11 Sensation 
A variety of studies have analysed sensory involvement in MS patients with 
neuropathic pain. Methods used have ranged from standard neurological examination 
(15, 66) to the use of quantitative sensory testing (QST) and other techniques (26, 
67-69). Substantial variation between patients with regard to degree and modality of 
abnormalties has been noted (69) along with discrepancy between bedside and QST 
testing (15).  
Some studies (15, 26) relate no difference between subjects with and without pain, 
while others (67, 69) identify a difference. One frequent theme in several studies has 
been of increased sensitivity to sensory stimuli in those with pain. 
Svendsen and colleagues compared 50 people with MS and pain, 50 people with MS 
without pain, and 50 healthy controls. Relapsing remitting MS patients accounted for 
14/50 (28%) of the MS pain group, and 28/50 (56%) of the MS control group. Cold 
allodynia (using acetone) was present in 9/50 pain subjects, but none of the control 
subjects (p=0.003). Temporal summation of stimuli during repetitive stimulation 
with a nylon filament (increasing pain scores with repeated stimuli) was present in 10 
of the pain group, and 3 of the control group (p=0.03). Allodynia to touch (using 
cotton wool) was present in 4/50 pain subjects, and 0/50 control subjects (15). No 
healthy subjects reported evoked pain or temporal summation. 
Osterberg and Boivie (69) aimed to compare sensory abnormalities in people with 
MS and compared a group with central pain with a group without central pain, using 
a range of tests including bedside sensory testing and formal QST. 32% of the group 
of 62 people with MS and central pain had RRMS. Importantly, the method for 
diagnosing central pain was not stated, though subjects undertook a questionnaire 
before participation. Almost all of the cohort with central pain had abnormal 
sensation in the area of pain, most often described as abnormal sensation to 
temperature or pain. Allodynia (to touch, cold or pinprick) was found in 10 of 62 
people with central pain, and 6 of 16 controls. The results were interpreted as 
suggesting spinothalamic dysfunction in MS central pain. 
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Truini and colleagues (70) studied 10 patients with ongoing neuropathic extremity 
pain selected from a sample of 300 consecutive clinic attenders with MS defined by 
McDonald criteria. Patients with extremity pain predominantly described a burning 
pain predominantly in the lower limbs. They were compared to 18 patients from the 
same group describing Lhermitte’s phenomenon. The authors used laser evoked 
potentials (LEPs) as well somatosensory evoked potentials, and found that LEPs 
were more frequently abnormal in the extremity pain group, than the Lhermitte’s 
group. The opposite was found to be true in the Lhermitte’s group. All had thermal 
pain sensory deficits though the presented results do not mention presence of 
hypersensitivity or allodynia in any case.  
Taken together, these studies suggest that there may be increased sensitivity to 
sensory stimuli in people with MS-associated pain syndromes. Pain syndromes in 
these studies are not always well-defined, and may be heterogeneous. These findings 
could suggest deficits in descending pain modulatory systems in people with pain in 
MS, though spinothalamic dysfunction has also been suggested. 
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1.1.5 Neuroimaging of pain in multiple sclerosis 
Fundamentals of magnetic resonance imaging 
I have given a very brief overview of the physical basis of MRI signal, in order to 
provide context for discussion of specific techniques elsewhere. I have based this 
brief discussion on lecture notes produced by the University of Edinburgh 
“Neuroimaging for Research” distance learning MSc (www.ed.ac.uk/clinical-
sciences/edinburgh-imaging/education-teaching/degree-programmes/neuroimaging-
for-research-msc-dip-cert) as well as published material (71-74). 
Magnetic resonance imaging (originally termed nuclear magnetic resonance) relies 
on the physical properties of an atom’s nucleus, in particular the nuclei of hydrogen 
atoms contained within water, which is found throughout human body tissues in 
vivo. In contrast to X-Ray and CT imaging, it does not require the use of ionizing 
radiation, which may be associated with health concern. 
When a subject lies within an MRI scanner, the single proton which makes up the 
hydrogen nucleus will align parallel to the axis of the scanner’s magnetic field (the 
principal magnetic field of the scanner is referred to as B0, and the axis of this field 
as the z axis). Some protons will align in the same direction as B0, and some in the 
opposite direction. The net magnetization of proton magnetic fields along with B0 is 
referred to as M0 (71). 
Delivery of a brief current to the head coil can be used to create a radiofrequency 
pulse which will “tip” M0 away from the z axis. Subsequent realignment of protons 
along the z axis leads to emission of a radiofrequency pulse, which is detected by the 
head coil.  
The time taken for net proton magnetization to reach around 63% of M0 is referred 
to as “T1”. T1-weighted images can be acquired by early measurement of proton 
magnetization intensity. T1 images are conventionally used for structural MRI brain 
imaging, and show grey matter as darker than white matter, CSF as dark, and fat as 
bright. T2-weighted imaging relies on rotation of protons after administration of the 
radiofrequency pulse. The time taken for the net proton magnetization to reach 37% 
of its original value after administration of the RF pulse is termed T2. On T2 
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weighted imaging, white matter is darker than grey matter, CSF is bright, and fat is 
bright.  
FLAIR (Fluid Attenuated Inversion Recovery) imaging relies on acquiring data when 
CSF magnetization is zero, and has the effect of rendering CSF black in the relevant 
image. This enables clearer identification of parenchymal hyperintensities, 
particularly in areas adjacent to CSF boundaries where hyperintensity might be 
obscured by adjacent high CSF signal on standardT2 imaging. 
Fundamentals of functional MRI imaging 
Imaging techniques used for assessing human brain function in vivo include SPECT 
(single-photon emission computed tomography), PET (positron emission 
tomography) and fMRI (functional MRI). Spatial resolution of fMRI is typically in 
the order of 2-3 mm, whereas PET is typically in the order of 3-4 mm, and SPECT 
around 7-8mm. fMRI is able to resolve events of less than 1s duration, whereas PET 
and SPECT give temporal resolutions of tens of seconds (71). Therefore fMRI has 
relatively favourable spatial resolution, but particularly temporal resolution. FMRI is 
widely employed as a noninvasive and safe experimental technique, which allows 
exploration of human brain function in vivo (75).  
Functional MRI relies on neuronal metabolism and attendant blood flow changes, 
and measures BOLD (“Blood Oxygen Level Dependent”) signal. fMRI was first 
described in 1990 in rats (74). This technique relies on physiology of local 
intracerebral blood supply.  
The brain makes up only around 5% of body weight, but uses around 20% of the 
body’s energy supply. Energy supplied to the brain is almost exclusively in the form 
of glucose delivered through the blood supply. Magnetic resonance imaging is very 
sensitive to the differing magnetic properties of oxyhaemoglobin and 
deoxyhaemoglobin.  
Increased local neuronal activity is thought to lead to increased blood supply to that 
region. The increase in blood flow is greater than that needed to meet the demands of 
neuronal tissue for oxygen. Therefore there a relative surplus of local blood oxygen 
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arises, and the relative amount of oxyhaemoglobin present locally increases. The 
resultant change in MRI signal can be measured as the BOLD signal, and is the basis 
for most fMRI experiments (71, 75) 
In relation to cognitive tasks, BOLD signal is generally felt to reflect the neural 
responses elicited by a stimulus, and BOLD signal changes are linearly related to 
neural responses. BOLD responses have been found to be most correlated with local 
field potentials, which could imply that local BOLD signal is most related to input 
and processing in the relevant area (72, 73).  
Magnetic Resonance Imaging in multiple sclerosis 
Magnetic Resonance Imaging (MRI) plays a key clinical and research role in the 
study of MS. From a diagnostic perspective, MRI measures are critical in the 
diagnosis of multiple sclerosis (76). They are also widely used in the clinical 
assessment of related disorders such as clinically isolated syndromes of 
demyelination, and neuromyelitis optica.  From a research perspective, MRI is 
widely used in studies of multiple sclerosis to quantify both Central Nervous System 
(CNS) demyelination and atrophy in vivo. MRI measures of demyelination and 
atrophy are widely reported in studies of multiple sclerosis treatments, and are 
increasingly reported as surrogate outcome measures in clinical trials (77, 78).  
Separately, MRI is extensively used in the study of CNS structure and function in 
patient suffering from various clinical pain syndromes, as well as in healthy 
volunteers in studies of experimental pain conditions (1, 79, 80). Other functional 
imaging techniques (particularly positron-emission tomography – PET, but also 
single-photon emission-computed tomography -SPECT) are also widely used in the 
study of pain neurobiology in humans (81).  
Despite the central importance of neuroimaging both in the study of MS, and of pain 
mechanisms, however, the use of neuroimaging to study pain syndromes associated 
with MS remains a developing field. Improved understanding of the neuroimaging 
correlates of pain syndromes in MS could guide clinicians in identifying, classifying 
and treating specific MS pain syndromes.  
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Neuroimaging measures could also hold potential to guide development of pain 
treatments in the future. While studies of disease modifying therapies in MS 
commonly employ neuroimaging outcome measures (82, 83), the relationships of 
imaging findings to the development, maintenance or severity of pain syndromes is 
unknown. 
Structural MRI brain imaging of pain and related phenotypes 
This introduction aims to summarise relevant data and themes regarding the 
structural imaging of adults with pain syndromes. A brief discussion of selected 
concepts closely related to pain neuroimaging, for instance neuroimaging in MS, and 
neuroimaging of psychiatric disorders relevant to this thesis – in particular 
depression, is included.  
Structural MRI brain imaging of the MS disease process 
The imaging investigation of focal MS lesions, and regional grey matter volumes in 
people with MS, has been briefly reviewed.  
In imaging studies of people with multiple sclerosis, perhaps the most common 
abnormality investigated are focal lesions. Many studies also assess grey matter 
volumes. Further studies assess other imaging correlates of the MS disease process 
using a variety of more complex techniques (see below). In relapsing remitting MS, 
disease activity is detected between 5 and 10 times more frequently on conventional 
MRI, than clinically (on assessment for relapses). The correlation between T2 lesion 
measures and disability is often, however, limited (84).  
1.1.5.1.1 Imaging of MS lesions 
1.1.5.1.1.1 Typical shape and location of lesions 
MS lesions are typically round or ovoid in shape. Size may range from a few 
millimetres to more than one centimetre. Lesions tend to be preferentially located in 
the periventricular white matter, brainstem and cerebellum (78). 
1.1.5.1.1.2 Imaging and pathological heterogeneity of MS lesions 
Data from pathology studies and advanced in-vivo neuroimaging suggest that MS 
lesions are not identical at the microscopic level.  
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Ex-vivo studies suggest that active MS lesions are typically infiltrated by 
macrophages, and sometimes multinucleated astrocytes termed Creutzfeld-Peters 
cells (78), though there is marked pathological heterogeneity. Lesions may be found 
to include inflammatory, demyelinating, gliotic changes or axonal injury, as well as 
remyelination. However imaging appearances using standard sequences are non-
specific. It has been pointed out that many autopsy or biopsy data may necessarily be 
based on atypical cases, thus introducing potential bias (78). 
T2 hyperintense lesions, which appear radiologically relatively homogeneous, can be 
shown to be radiologically heterogeneous by use of “advanced” imaging techniques 
such as magnetization transfer ratio (MTR) imaging and spectroscopy (84).  
Differentiation between acute and chronic lesions can be difficult and is typically 
assessed by administration of Gadolinium contrast (which is used to assess 
breakdown of the blood-brain barrier). Contrast enhancement may persist for 
approximately 2-6 weeks (78). 
1.1.5.1.1.3 Normal-appearing white matter (NAWM) 
This term is used to refer to white matter tracts which appear normal on conventional 
structural MRI imaging, but pathologically (and/or using advanced imaging 
methods) may be found to manifest abnormalities which at a cellular level include 
gliosis, demyelination and infiltration by macrophages and round cells. Axonal 
density is also typically reduced (78). 
Tract abnormalities in NAWM have been found to overlap only to some extent with 
T2 lesion location, suggesting that mechanisms of NAWM damage operate at least 
partly independently of T2 lesion location (85). Although the structural assessment 
of NAWM is not included in this study, it is relevant to note that apparently normal 
white matter may harbour pathologically and clinically significant abnormalities. 
1.1.5.1.1.4 Grey matter lesions 
Specific imaging sequences such as double inversion recovery, and phase sensitive 
inversion recovery, have been developed to increase sensitivity of MRI imaging to 
cortical lesions (86). These methods are not however widely used for reasons which 
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include availability of imaging sequences, inter-observer agreement, and 
vulnerability to imaging artefacts (85). Magnetization Transfer Ratio (MTR) imaging 
is often used to explore grey matter integrity along with other techniques such as 
diffusion tensor imaging, and spectroscopy (85). 
1.1.5.1.2 Imaging of grey matter atrophy in MS 
Marked atrophy of the brain is frequently reported in imaging studies of MS. 
Specifically, local and overall brain volume is often significantly reduced compared 
to healthy controls without MS. This is particularly the case in progressive phases of 
MS (78). Estimates have suggested that in healthy subjects, brain atrophy will occur 
at a rate of between 0.1 and 0.3% per year, whereas in people with MS, this rate will 
be considerably higher at 0.5% to 1% per year (84). Frontal, temporal and parietal 
regions may be the most often affected by atrophy. Grey matter atrophy can occur 
even in early disease (78). 
1.1.5.1.2.1 Possible substrates of imaging findings of atrophy 
Neuronal and glial loss have been associated with grey matter atrophy, and have 
been suggested as a likely substrate (78). Cortical atrophy has been associated with 
severe reduction in synaptic density. This in turn may suggest atrophy of nerve cell 
processes, and an impairment of inter-neuronal connectivity (78). Outside the context 
of MS, grey matter volume loss has been related to be associated with neuronal loss 
and reduced cell density, or alternatively changes in glia or cell volume. Other 
evidence points towards reduction in synaptic density (87).  
1.1.5.1.3 Structural MRI in people with comorbid MS and depression 
One older study (2004) described the comparison of relatively small groups of 
people with MS, with (n=21) and without (n=19) major depression by DSM-IV (88) 
definitions (89). 1.5Tesla MRI brain imaging was used, and lesions were segmented 
using a semi-automated intensity-based technique in Analyze. Regional lesion 
distribution relied on compartmentalisation using landmarks in the Tailarach atlas. 
There were no between-group differences for any of the cognitive assessments from 
the Rao Brief Repeatable Battery (90). There was no between-group difference for 
overall lesion load, total white matter or grey matter volumes. Depressed patients 
were said to have more extensive hyper- and hypo-intense lesions in the left medial 
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inferior frontal region, and measures of atrophy in the left anterior temporal region 
(89). 
A recent large study from the MAGNIMS collaboration used lesion distribution 
mapping and VBM to examine grey matter morphology and lesion distribution 
contributions to the presence and severity of fatigue and depression (91). 123 MS 
patients (69 of whom were depressed and 54 not depressed) and 90 healthy controls 
were included (total n=213). 3.0 Tesla brain MRI imaging was used. VBM analysis 
was carried out in SPM 8.  Lesions were segmented using Jim.  Regional GM 
volumes did not differ between depressed and non-depressed, or between fatigued 
and non-fatigued patients with MS. T2 and T1 focal lesion volume or distribution did 
not vary according to presence of depression or fatigue. 
Atrophy of the left middle frontal gyrus and right inferior frontal gyrus were related 
to the severity of depression (rather than presence of depression), after controlling for 
fatigue. These regions include the dorsolateral prefrontal cortices, and have been 
reported to be involved in depression in previous studies of people with depression, 
not comorbid with MS. The authors concluded that the structural correlates of 
depression in MS were not striking, but might be comparable to those in people 
without MS (91). 
1.1.5.1.4 Structural MRI in cognitive dysfunction associated with MS 
MRI has also been widely used in the assessment of cognitive dysfunction associated 
with MS. Several authors describe that particular cognitive domains are differentially 
affected in MS. These include information processing speed, episodic memory, and 
less frequently executive functions (including verbal fluency and word list 
generation)(85). 
Many studies have reported an association between the volume and/or location of T2 
hyperintense and T2 hypointense lesions with cognitive performance, both overall 
and in specific tests. A disconnection syndrome has been suggested, such that focal 
MS lesions disrupt key tracts which are core to information processing (85). 
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Many authors comment, however, that cognitive impairment correlates more closely 
with measures of grey matter volume loss than with T2 hyperintense lesions. Cortical 
volumes have been reported to be significantly lower in cognitively impaired people 
with RRMS, than cognitively “preserved” groups (84). In cognitive and other 
presentations, however, the relationship between MRI findings and clinical correlates 
is often modest  (84). This has been termed the clinico-radiological paradox. 
One recent study of cognitively impaired and cognitively intact people with MS used 
voxel based morphometry, lesion probability mapping, and diffusion tensor imaging 
(DTI) to explore structural and microstructural differences between the groups (92). 
The authors included 35 people with MS without cognitive impairment, 20 with 
cognitive impairment, and 30 healthy controls (total n=85). Symptoms of anxiety, 
depression and fatigue were considered as nuisance variables. Cognitive assessments 
included verbal memory and learning (using a Dutch language version of the CVLT), 
information processing speed (measured by an adaptation of the SDMT), spatial 
memory (assessed with the location learning test) and working memory (assessed 
with the digit span of the WAIS). Semantic memory (word fluency) was also tested. 
Patients were defined as cognitively impaired when their score on at least two of five 
neuropsychological tests fell more than 2 standard deviations below the scores of 
healthy controls.   
No difference between cognitively impaired and cognitively intact participants was 
found for measures of regional grey matter volume or lesion distribution. The groups 
did however differ on microstructural WM tract integrity as measured by DTI (with 
more severe white matter integrity changes seen in the cognitively impaired group, 
particularly in the corpus callosum, corticospinal tracts, forceps major, cingulum and 
fornices (92). 
A further multi-centre study from the MAGNIMS group measured cortical thinning 
using FreeSurfer in 60 people with RRMS, and 65 healthy controls (total n=125) 
(93). Tests included the Brief Repeatable Battery (90) and Wisconsin Card Sorting 
Test (94).Of the RRMS subjects, twenty were classified as cognitively impaired, as 
they scored more than 2 standard deviations below a normative value, for at least two 
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tests. The most common cognitive deficits were in attention, visual memory and 
verbal memory.  
Global cortical thickness did not differ between cognitively impaired and intact 
subjects. Using a lobar analysis, there was a marginally statistically significant 
decrease in temporal lobe thickness in the cognitively intact group (p=0.050) with a 
trend to significance in the cingulate cortex (p=0.055). Using vertex-wise analysis, 
no difference was seen between cognitively intact and impaired subjects, and no 
correlations between cortical thickness and global cognitive scores, disability or 
disease duration. In analysis of cognitive subscores, verbal memory scores correlated 
to insular cortical thinning, whereas visual memory scores correlated to decreased 
thickness in parietal cortex. These recent studies may suggest that neuroimaging 
differences between cognitively impaired and intact subjects with RRMS are not 
marked. 
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1.1.5.1.5 Structural brain MRI in pain syndromes outside MS 
The current literature contains many reports of differences in brain structure, 
assessed by MRI, between people with and without chronic pain disorders. These 
studies aim to further understanding of the mechanisms of central nervous system 
representation and processing of chronic pain.  
The large majority of these studies (in contradistinction to the study described 
elsewhere in this thesis) include subjects with brains which appear normal to 
conventional MRI imaging. These subjects include people with fibromyalgia, 
irritable bowel syndrome, low back pain, migraine, temporomandibular joint 
dysfunction, vulvar pain, phantom limb pain, arthritis, menstrual pain and complex 
regional pain syndrome (79, 87, 95). Often these subjects are compared with healthy 
volunteers in a cross-sectional study design, aiming to assess central nervous system 
structural correlates of chronic pain syndromes.  
Study designs vary in relation to the pain phenotype studied, specifics of the imaging 
techniques and analysis techniques used, and findings. There are however certain 
common themes. There is a particular focus on studies which assess grey matter 
volume and distribution.  
Volumetric differences in a range of cortical and subcortical structures have been 
reported in groups with chronic pain, compared to healthy volunteers. Structures 
such as prefrontal cortex, insula, anterior cingulate and mid cingulate cortex are 
commonly reported to show volume differences in this comparison. Other regions 
which have been reported to be similarly affected are thalamus, basal ganglia, 
sensory cortex (often referred to as “S1”), sensory association cortex (“S2”) and 
brainstem. In addition, some studies have reported abnormalities in the temporal lobe 
and posterior cingulum (79, 87). Volumes have often been reported to be decreased 
in pain modulation regions (possibly suggesting dysfunctional pain modulatory 
systems) and increased in sensory/nociceptive areas (including sensory cortex) 
(moayedi79, 87, 96).  
The temporal association of grey matter abnormalities and pain syndromes is often 
unclear, although evidence of decreasing grey matter volume in association with pain 
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duration (in cross-sectional studies) has been interpreted as suggesting a possible 
causal relationship. Some authors hypothesise that the presence of chronic pain (and 
related variables) could be causally related to grey matter volume loss (96, 97). 
Longitudinal studies (80, 87) have lent support to this hypothesis and have reported 
reversibility of grey matter volume loss in some instances after resolution of pain 
syndromes (for instance an operation for hip pain due to osteoarthritis (80).  
However, potential confounding influences, even in longitudinal studies, include use 
of analgesics, physical activity, and concomitant affective disturbances. Such studies 
may however indicate that grey matter volume loss is at least partly secondary to the 
experience of chronic pain (79).  
1.1.5.1.6 Two comparable studies of similar pain syndromes 
Two studies of similar pain syndromes have been briefly reviewed, in order to 
illustrate differences and common themes in methodology and findings. 
Younger and colleagues’ study of 15 women with myofascial temporomandibular 
pain in comparison with 15 age- and gender-matched healthy controls used 3 Tesla 
1mm isotropic T1 MRI brain data in a Voxel Based Morphometry (VBM) study. 
Analysis was implemented in SPM version 8 (97). Relative to healthy controls, 
patients were found to have higher grey matter volumes in a variety of regions 
including inferior frontal gyrus, anterior insula, thalamus, brainstem trigeminal 
nuclei and cerebellar peduncles. Lower volume was only seen in the right primary 
somatosensory cortex. Severity of pain was negatively correlated with grey matter 
volume in the anterior cingulate cortex and posterior cingulate/precuneus (97). No 
positive associations of grey matter volumes with pain severity were found. On an 
examination of pain sensitivity (defined using pressure algometry) greater grey 
matter volumes in the trigeminal nucleus regions were positively associated with 
pain tolerance (ie inversely related to pain sensitivity) (97). 
Moayedi and colleagues’ study of 17 females with temporomandibular pain and 17 
healthy females used 3 tesla MRI brain imaging (0.94 x 0.94 x 1.5mm voxels), 
included analysis for cortical thickness using FreeSurfer, and subcortical volume 
using VBM in SPM version 5 (96). The authors state that their definition of 
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temporomandibular pain was not as narrow as that used by Younger and colleagues. 
The authors used masks of a sensorimotor/pain network (comprising S1, S2, motor 
association cortex and mid cingulate cortex - MCC) and a cognitive/modulatory 
mask (comprising orbitofrontal cortex, prefrontal cortex, insula, anterior cingulate 
and mid cingulate). Patients were found to have lower cortical thickness in S1, 
frontal pole, and ventrolateral prefrontal cortex. Similar to comparable work 
discussed above (97), pain severity was negatively correlated with grey matter 
thickness in the anterior-mid cingulate (whereas Younger and colleagues described 
an association of pain severity with slightly more anterior cortex). A decrease in grey 
matter thickness in the ventrolateral aspect of the motor cortex was also found. No 
association of subcortical volumes with either the presence or severity of pain was 
found (96).  
 These two studies of comparable disorders illustrate the overlapping yet different 
techniques used, with comparable yet separable results. In common with the majority 
of the published literature, study subjects were compared with healthy volunteers, 
and brain structure was normal on conventional structural MRI imaging. In 
comparison to the structural imaging studies of cognition and fatigue in MS briefly 
described above (92, 93), sample sizes are much smaller. 
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1.1.5.1.7 Structural MRI in depressed subjects without MS  
Because of the association of depression with chronic pain, literature assessing 
structural imaging correlates of depression has been reviewed. 
A large recent meta-analysis assessed existing VBM studies of major depressive 
disorder and bipolar disorder (98). 50 studies including 4101 individuals were 
identified for major depression (of which statistical maps were available for 9, with a 
total of 1736 patients and 2365 healthy controls). On analysis of these 9 studies, 
depressive disorders were associated with smaller grey-matter volumes relative to 
controls in the insular cortices, inferior frontal gyrus and anterior superior temporal 
gyrus. There was also lower volume in ventromedial prefrontal cortex, anterior 
cingulate, posterior cingulate, and some lateral prefrontal regions as well as in 
subcortical structures including left caudate, hippocampus and parahippocampal 
gyrus. Some of these structures can be seen to overlap with those identified in studies 
of pain, as discussed above. 
These findings echo previous meta-analyses of structural MRI studies including that 
by Arnone and colleagues (99) (101 studies, using a meta-analytical approach) which 
have similarly identified no global difference in global brain volume measures 
between depressed and non-depressed individuals, but reduced volume in depressed 
individuals in frontal cortex, orbitofrontal cortex, cingulate, hippocampus and 
striatum. 
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1.1.6 Functional neuroimaging relevant to pain in multiple 
sclerosis 
In this thesis, the use of resting state functional MRI (fMRI) to investigate the 
functional connectivity of structures key to the descending modulation of pain is 
described. 
Resting state fMRI 
Resting state functional MRI techniques aim to identify patterns in Blood Oxygen 
Level Dependent (BOLD) signal using imaging acquired while the subject is lying at 
“rest” in the MRI scanner. Specifically the acquisition does not involve 
administration or execution of a “task” to the experimental subject. In the context of 
this study, it is particularly useful in assessing the functional integration of separate 
structures within the brain, specifically the key nodes of the descending pain 
modulatory system.  
Later in this thesis, a seed-based approach to assessing functional connectivity in the 
resting state is described (75). Briefly, this approach involves firstly identifying a 
“seed” region based on pre-existing hypothesis and/or existing literature. The BOLD 
timecourse of the voxels within this seed is then computed for the duration of the 
imaging acquisition. The correlation of the seed BOLD timecourse with all other 
voxels within the brain is then computed, and, after thresholding, provides evidence 
of covariance in BOLD signal (and, by inference, neuronal activity (73)) across 
structures.  
From an analysis perspective, the timecourse of the seed region can be viewed as the 
independent variable in a linear model, with timecourses of other voxels viewed as 
dependent variables. The analysis of relationship between independent and 
dependent variables can then be viewed as a linear model. Other variables can be 
introduced into this “general linear model” (GLM), for instance to adjust for their 
effect (in this context the additional variable is referred to as a covariaate of no 
interest, or nuisance covariate).  
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Resting state fMRI, in providing information on functional connectivity across the 
brain, may provide information which is complementary to structural and clinical 
analyses (also described in this thesis) 
1.1.6.1.1 Issues in application and interpretation of resting state fMRI 
1.1.6.1.1.1 Inferring causality 
The current study assesses correlations between BOLD timecourses across the brain. 
It cannot infer causality and the presence of a true correlation could be present for a 
variety of reasons including a direct causal relationship, indirect causal relationship 
mediated by another structure/network, or shared influence of a common inputting 
region (75, 100).  
1.1.6.1.1.2 Sources of extraneous signal, or noise 
One prominent problem in the analysis of resting state fMRI data is the approach (or 
approaches) used to deal with extraneous sources of noise. These may be particularly 
problematic in clinical populations (as well as paediatric or elderly populations) (75, 
101). For the purposes of this brief introduction, there is a particular focus on 
analysis techniques aiming to address these issues. 
Typically, prominent sources of noise may include head movement (which can be 
slow or sudden, and may involve various combinations of translation and rotation), 
CSF signal, white matter signal and cardiorespiratory noise, which can be 
particularly problematic in brainstem imaging (because of nearby CSF voids and 
arterial pulsation). Any of these sources of noise may decrease the sensitivity of the 
above model to detecting correlations of neuronal BOLD activity.  
Sudden head motion is particularly problematic, however, and is known to induce 
spurious correlations in BOLD timecourses between closely anatomically related 
structures (while tending to diminish correlations between more anatomically distant 
structures). This remains the case even after including head motion regressors in a 
general linear model (101, 102). Approaches to this problem may include ICA 
decomposition of data followed by removal of components thought to represent 
extraneous noise (103) (as used in the current study) (this method may be applied 
“manually”, or automatically after training on a dataset (104)), or “censoring” of 
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volumes manifesting high subject motion (often referred to as scrubbing, this 
technique is available in FSL as fsl_motion_outliers) (105).  
1.1.6.1.2 Strengths of the use of resting state fMRI in clinical populations 
Traditionally, task based paradigms have been the mainstay of functional MRI 
research. These designs rely intrinsically on administration of a stimulus, and 
therefore a subject successfully processing this stimulus, and/or executing a specific 
task (75, 85). In patients with MS, however, cognitive, motor, and other 
manifestations may interfere with ability to execute tasks during fMRI acquisition. 
For instance, at the most basic level, if a subject with MS asked to tap a button, there 
may be motor weakness. At a less obvious level, ability to comprehend or follow 
instructions may be differentially affected in those with MS. Resting state fMRI 
techniques, in avoiding the need for appreciation and/or compliance of a stimulus, 
may limit such problematic issues. 
Functional MRI in multiple sclerosis 
fMRI studies in people with MS have often shown that, in comparison with healthy 
controls, there is more widely distributed cortical recruitment during task fMRI. It 
has been proposed that this altered recruitment pattern represents cortical plasticity or 
functional reorganization (in other words increased cortical recruitment is required to 
maintain the same level of performance). These conclusions have been supported by 
demonstrated correlations between measures of fMRI activation pattern, and 
measures of brain structural damage (including lesion volume, damage to normal-
appearing white matter, and grey matter damage) (79;102). As discussed, however, 
this conceptualisation may represent an over-simplification. 
Loitfelder and colleagues (2011) studied a group of people with MS and clinically 
isolated syndrome (CIS) using cognitive assessments and functional MRI, in order to 
assess the idea of functional reorganization or plasticity in relation to cognition 
(106). Their cross-sectional study included 30 people with MS/CIS (10 CIS, 10 
RRMS, 10 SPMS) and 28 healthy controls. Exclusion criteria included known 
psychiatric disorder, clinically significant depression or fatigue, and recent relapse or 
steroid. Functional MRI included a go/no-go discrimination test. Cognitive 
assessment included the Wisconsin Card Sorting Test (94) and Brief Repeatable 
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Battery. In fMRI analyses, higher T2 lesion volume was negatively correlated with 
activation in the right parahippocampal gyrus, middle frontal gyri and left putamen. 
Although people with MS performed worse than people without MS on the cognitive 
tests, performance among those with MS was similar. There was, however, evidence 
of more widespread BOLD signal in those with RRMS and SPMS when executing 
the same task (in comparison with healthy controls and CIS patients) which was 
interpreted as evidence of functional reorganization/plasticity. 
Sbardella and colleagues (107) used resting state seed-based functional MRI as a 
component of multiparametric imaging and cognitive assessment of 54 people with 
RRMS, and 24 healthy controls. A seed based in the bilateral dentate nuclei of the 
cerebellum was used, in order to investigate clinical correlates of dentate nucleus 
functional connectivity. Patients with MS were found to manifest higher functional 
connectivity than healthy controls to a range of structures including frontal gyri 
(superior, middle and inferior), supplementary motor area and pre-central gyrus. 
Functional connectivity with the cerebellum, right thalamus, frontal and parieto-
occiptal cortices was inversely correlated with lesion volume. Functional 
connectivity was also inversely correlated with fractal anisotropy values from 
Diffusion Tensor Imaging. The authors did not comment on any positive correlation 
of functional connectivity with lesion volume. Within the areas where functional 
connectivity was higher in people with MS than in controls, functional connectivity 
was found to be inversely correlated with clinical impairments (higher connectivity 
to mid-cingulate and dorsolateral prefrontal cortex was correlated with better PASAT 
scores, and better EDSS scores).   
Higher functional connectivity in patients in comparison with controls was 
interpreted as possibly representing compensatory functional reorganization, as was 
the inverse correlation of functional connectivity with structural damage. Structural 
imaging variables including T2 lesion volume and fractal anisotropy were however 
also found to be correlated to EDSS and cognitive performance, thus suggesting that 
apparent changes in functional connectivity may be among many factors associated 
with clinical outcomes. 
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More recently, Dobryakova and colleagues (108) used a novel data-driven Bayesian 
analysis of task fMRI data in 84 people with MS and 37 age- and gender-matched 
healthy controls, in order to make a detailed assessment of connectivity changes in 
relation to executive functions. Effective connectivity analysis was used to infer 
connectivity between specific structural nodes identified as key to the Stroop 
interference task.  
While detailed discussion of this methodology is beyond the scope of this thesis, the 
authors did demonstrate a complex mixed picture of hyperconnectivity, loss of 
connections and reversal of connections in people with RRMS. Extra connections 
were found to be associated with performance deficits on the Stroop task in people 
with benign and secondary progressive MS (both of which were of long duration) but 
not in people with relapsing remitting MS (of shorter duration). The authors 
suggested that extra connections might therefore become maladaptive as time (and 
also disease duration and disability) increased. The authors suggested that a 
diverging connectivity patterns might suggest diverging compensatory mechanisms.  
While this analysis technique is beyond that discussed in this thesis, this work may 
highlight that hypotheses of the relationship between functional connectivity and 
clinical outcomes are increasingly nuanced, and may not be adequately reflected by a 
simple model of compensatory functional reorganization. In particular, there were no 
correlations (in the RRMS group) between behavioural outcomes during the Stroop 
test (including reaction times and accuracy) and the strength of extra or reversed 
connections (108). A complex mixture of increased and decreased connectivity was 
found, with the possibility of adaptive and maladaptive changes considered. 
Functional anatomy of descending pain modulatory system 
Key structures of the DPMS have been discussed. Please also see above (Table 2: 
Cortical localisation of functions tested in neuropsychological assessments) for an 
overview of the involvement of these, and other, structures in cognitive and 
executive functions.  
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1.1.6.1.3 Anterior Cingulate Cortex (ACC) 
The anterior cingulate cortex is reliably activated in fMRI studies assessing the pain 
condition. It has been found to be key to the descending modulation of pain, in 
particular the modulation of pain by attention and expectation (33, 109). It is thought 
to exert top-down influences to the periaqueductal gray matter in association with 
prefrontal cortices, in particular the dorsolateral prefrontal cortex and ventromedial 
prefrontal cortex. The rostral ACC in particular plays a key role in mediation of 
placebo responses, and in this context functional connectivity between rostral ACC 
(rACC) and PAG has been found to be particularly important (110) (see below).  
In healthy controls, direct structural connectivity between rACC and PAG has been 
demonstrated using diffusion tensor imaging (111). 
The ACC has also been found to be strongly involved in emotional processing, and 
this role may be particularly important in the interaction of emotional/affective state 
and the descending modulation of pain (29). It has been suggested to be important in 
a range of functions including cognitive modulation of pain affect and placebo 
analgesia, emotional-affective processing of pain (29), and attentional modulation of 
pain (33). 
1.1.6.1.4 Periaqueductal Grey matter (PAG) 
The periaqueductal gray matter (PAG) is a key node in the descending modulation of 
pain and is involved in both inhibitory and excitatory top-down regulation of pain (1, 
30, 32, 110). Its anatomical and functional subdivisions are however not yet fully 
understood. In addition to its role in the modulation of pain, it has been found to be 
involved in respiration, fear, anxiety and other physiological responses.  
It has also been found to play a critical role in encoding error judgements related to 
prediction errors, following top-down influence from the ventromedial prefrontal 
cortex. The “avoidance value” of pain might then be updated by PAG input to the 
orbitofrontal cortex and anterior midcingulate (112).There is thought to be 
functionally relevant subdivision of the PAG, with the ventrolateral PAG in 
particular being involved in opioid-mediated descending modulation of pain (113). 
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1.1.6.1.5 Prefrontal cortex, especially dorsolateral prefrontal cortex 
The prefrontal cortex (and in particular the dorsolateral prefrontal cortex) has also 
shown to be closely related to the ACC, and may have a role in “keeping pain out of 
mind”, perhaps mediated through the ACC (and/or the ventrolateral prefrontal 
cortex) (33). The prefrontal cortices (particularly dorsolateral prefrontal cortex, but 
also ventromedial prefrontal cortex) are thought to impose a top-down bidirectional 
influence on key structures such as PAG, amygdala and anterior insula (1, 29). Key 
relevant cognitive roles include attention, expectations and appraisal in the 
experience of pain. Distraction may be part of the mechanism whereby prefrontal 
cortices contribute to the DPMS (33) 
The prefrontal cortex has particularly been implicated in distancing the self from the 
experience of pain, which could be linked to alterations in learning about anxiety-
related cues, selective attention, and interpretative biases (29). The ventrolateral 
prefrontal cortext (VLPFC) may also have an important role in the modulation of 
aversive stimuli based on reappraisal (33).  
1.1.6.1.6 Inter-relationships of rACC, PAG and DLPFC in investigation of 
descending pain modulation 
1.1.6.1.6.1 Characterisation of PAG functional connectivity without intervention  
A recent resting state fMRI functional connectivity study assessed 79 healthy 
volunteers, specifically examining the differential functional connectivity of different 
locations within the PAG (113) with the aim of delineating functional neuroanatomy. 
The authors used 3Tesla acquisitions with TR of 2 seconds, and a total of 150 
volumes acquired. Following statistical clustering of PAG anatomy (into a 
bicolumnar model) the authors described functional subspecialisation within the 
PAG, particularly including the ventrolateral PAG (MNI coordinates ±3, -32, -12) 
and dorsolateral PAG (MNI coordinates ±2, -32, -5).  
The ventrolateral PAG was found to be functionally connected to rostral Anterior 
Cingulate Cortex, Thalamus, Pons, Cerebellum, Caudate and Putamen. Functional 
connectivity of the ventrolateral PAG (in contrast to other PAG subdivisions) was 
found to be stronger to the dorsolateral prefrontal cortex, frontal pole, various 
subcortical structures (thalamus, putamen and caudate) and parietal cortex, as well as 
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parahippocamapal gyrus/hippocampus. Dorsolateral PAG was found to be 
functionally connected to premotor cortex, dorsolateral prefrontal cortex, caudate, 
putamen, thalamus and frontal pole. Stronger functional connectivity (in comparison 
to the ventrolateral PAG) was found to the premotor cortex, motor cortex, and 
supraparietal lobule.  
1.1.6.1.6.2 Characterisation of PAG structural connectivity without intervention 
These findings are concordant with a separate study in healthy volunteers, which 
used DTI imaging to assess structural (rather than functional) connectivity of the 
PAG. The authors used 3Tesla MRI brain imaging (including diffusion data) and 
imaged 19 healthy subjects. Brainstem optimisation of the imaging protocol included 
cardiac gating of the structural imaging, to limit the effects of CSF pulsatility. 
Structures involved in modulation of pain, stress and anxiety (including prefrontal 
cortex, hypothalamus and amygdala) were found to be dominantly connected to the 
ventrolateral PAG (114). 
1.1.6.1.6.3 Interventional fMRI study investigating placebo response (healthy 
volunteers) 
In an fMRI study of 48 healthy volunteers, Eippert and colleagues used the 
administration of a placebo analgesic, as well as naloxone, to investigate the 
behavioural and physiological responses to pain and their modulation by the placebo 
response, as well as the role of opioidergic signalling in the placebo response (which 
was inferred by interactions with administration of naloxone)  (110). The analysis 
was particularly focussed on structures known to be relevant to endogenous 
modulation of pain (DPMS), in this case focussing on the placebo response. The 
authors particularly focussed on DLPFC, rostral ACC and PAG, as well as 
examining other structures including amygdala, hypothalamus and rostral 
ventromedial medulla (RVM).The findings in general supported a hypothesis that 
functional connectivity of these regions was important in the endogenous modulation 
of pain. Specifically, the individual functional coupling between rACC and PAG (ie 
the strength of association of BOLD timecourses of the two regions) was found to be 
strongly related to the strength of clinical placebo response. The strength of this 
coupling was also associated with RVM BOLD responses, further suggesting that 
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this coupling is linked to recognised DPMS pathways. The DLPFC showed 
significant activations under placebo compared to control conditions. Furthermore, 
the administration of naloxone substantially interfered with behavioural and 
physiological findings related to placebo response, suggesting that endogenous 
opioidergic signalling is key to this system. 
1.1.6.1.6.4 Resting state fMRI examinations of descending pain modulation, in 
subjects with pain conditions 
1.1.6.1.6.4.1 Chronic back pain 
Yu and colleagues studied functional connectivity of a small PAG seed (set in the 
ventrolateral PAG) with other brain regions including seeds in rACC/ventromedial 
prefrontal cortex (ie rACC or slightly more anterior), insula and amygdala (115). 
They studied 18 people with chronic non-specific low back pain, and 18 healthy 
controls matched for age and gender. The data were acquired on a 3T Siemens 
scanner with 32 channel head coil, and 6 minute acquisition at TR 3000ms (between 
103 and 113 volumes remained after censoring of high-motion timepoints). Subjects 
lay with their eyes open during the acquisition. Connectivity between PAG and 
rACC/vmPFC was found to be increased in subjects with pain, compared with 
healthy controls. This was interpreted as either an enhanced inhibition, or facilitation 
of pain by endogenous mechanisms. The authors also described a negative 
correlation between PAG:rACC/vmPFC coupling with pain severity. 
1.1.6.1.6.4.2 Migraine (interictal study) 
Mainero and colleagues (103) studied 17 people with migraine interictally, and 17 
healthy controls (gender and age matched) with resting state fMRI (3T Siemens 
system, 32-channel coil , TR 3000ms). Bilateral PAG spherical ROIs (3mm radius) 
were used for the seed analysis, and the data preprocessed in a similar way to that 
described in the current study (including ICA denoising, but without the CSF or WM 
nuisance regressors used here). Functional connectivity of PAG with brain regions 
implicated in pain modulation (prefrontal cortex, anterior cingulate and amygdala) 
was found to be weaker in those with more migraine attacks. Specifically, when 
tested against frequency of migraine attacks, there was a negative correlation with 
PAG connectivity with regions including dorsomedial PFC as well as right rostral 
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anterior cingulate (peak coordinates x=6, y=52, z=16).Furthermore, decreased 
connectivity of PAG with structures including R dorsolateral prefrontal cortex (x=36, 
y=50, z=6) was found in those with, compared to those without, allodynia. It is worth 
noting that these coordinates are described as frontal pole using probabilistic atlases 
packaged with FSL (116), thus perhaps suggesting overlap with other frontal cortical 
structures known to be implicated in cognitive modulation of pain (96). 
Structural imaging of cervical cord 
As discussed elsewhere, the structural imaging data described in the current study is 
designed to acquire MRI imaging of the brain.  
As a complex neuroinflammatory and neurodegenerative condition, however, 
multiple sclerosis affects both the brain and spinal cord (28, 117). Cervical and 
thoracic spinal cord imaging indices have repeatedly been strongly associated with 
disability in multiple sclerosis (117-119).  
MRI detectable lesions of the spinal cord can be found in up to 90% of patients with 
definite MS. Cord atrophy is also found, and is most severe in progressive forms of 
the disease (84).  Most white matter pathology in the spinal cord is seen in the 
cervical cord, whereas grey matter damage is seen more extensively throughout the 
cord (78) 
Typically, however, spinal cord imaging studies in multiple sclerosis use tailored 
spinal imaging sequences including appropriate centring of the field of view, use of a 
specific spinal cord coil, and in the context of research studies, often a specific 
acquisition optimised for research studies (such as Phase Sensitive Inversion 
Recovery - PSIR (119)).  
The research utility, if any, of upper cord data available from brain imaging studies, 
as in the current study, is unknown. Signal drop-out and artefact towards the edge of 
the scanned volume might adversely affect the utility of this data.  
Acquisition of brain and spinal imaging was judged to be prohibitive for the current 
study in terms of patient imaging burden, particularly taking into account possible 
effects of increasing imaging duration on subject movement, movement artefact and 
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image quality. Please see Appendix: Participants’ Experience (p400) for participants’ 
own assessments of imaging duration, and comfort in the MRI scanner within this 
study. 
One recent published study by Liu and colleagues (118) has attempted to assess the 
feasibility of using volumetric brain imaging data (as acquired in the current study) 
in a post-hoc analysis of cervical cord cross-sectional area including people with MS. 
One other conference abstract (120) assessing a similar technique has not yet been 
subject to peer review at time of writing.  
Liu and colleagues (118) used a 3T Philips Achieva system, with a 32-channel head 
coil, and acquired volumetric 1mm3 T1-weighted brain imaging without use of 
additional spinal sequences or a spinal coil. Data from 13 healthy controls, and 37 
people with MS (mixed phenotype, 17 RRMS and 20 progressive MS subtypes) were 
studied. The software package Jim was used for image analysis, implementing a 
seed-growing technique for cord/CSF boundary segmentation  (121). Papinutto and 
colleagues (120) describe in their abstract, that volumetric  MPRAGE sequences 
were acquired using a 20-channel head and neck coil. Other spinal imaging (PSIR or 
T2 weighted images) was also acquired in a total of 80 patients at two centres 
(Boston, and San Francisco). Again the proprietary software package Jim was used 
for analysis (121). 
In the one peer-reviewed study examining this technique specifically, CC-CSA 
measures at different levels were found to be highly correlated with each other, and 
moderately-highly with ICV. Correlation with disability measured by EDSS was 
weak, though correlation with other clinical measures such as timed 25foot walk (not 
measured in the current study) was higher. Effects of gender are not reported by Liu 
and colleagues, however previous studies have reported higher CC-CSA in males 
than females (122). 
The clinical and research implications of this data are as yet not fully understood. 
Furthermore, the utility in studies of pain have not been investigated. For this reason 
an exploration of the use of this data is included in the current thesis. 
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1.2 Overview of thesis structure 
Five experimental chapters are included in this thesis.  
1.2.1 Systematic Reviews 
The first and second experimental chapters (Chapters Two and Three, with Chapter 
One the Thesis Introduction) deal with separate systematic reviews respectively 
addressing aspects of the epidemiology, and neuroimaging correlates, of pain 
syndromes in MS.  
1.2.2 Prospective clinical study 
The Fourth, Fifth and Sixth chapters deal with the three separate sets of data drawn 
from the same prospective controlled study of people with relapsing remitting MS, 
with and without neuropathic limb pain. 
These chapters discuss  
 Clinical assessments (including neuropsychological and other assessments) 
 Structural MRI imaging assessment 
 Functional MRI imaging assessment (in the resting state). 
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1.3 Aims of thesis 
These aims are divided into five chapters, reflecting the experimental chapters 
included in this thesis. 
1.3.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
Pain prevalence 
Aims were to establish: 
 The estimated overall prevalence of pain in people with MS 
 The heterogeneity associated with this estimate 
 Possible roles of study design and study sample factors associated with 
reported prevalence of pain in MS. 
 The prevalence of common pain syndromes in MS 
 The prevalence of simultaneously co-occurring pain syndromes in MS. 
Pain incidence 
Aims were to establish: 
 Any estimates of pain incidence (defined as rates of first occurrence of any 
pain syndrome) in pwMS. 
Natural history of pain in MS 
Aims were to ascertain: 
 Estimates of longitudinal variation of pain prevalence in MS throughout the 
disease course, using, where available: 
o Estimates at specific pre-defined time points in the disease course, and 
o Longitudinal follow up of a population in which prevalence of pain 
had been quantified at baseline. 
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Relevance to design of clinical study 
The design of this systematic review, and results arising from it, are directly relevant 
to design of the clinical study described elsewhere in this thesis. Areas of particular 
relevance are outline below (Table 3). 
Table 3: Planned use of systematic review data in design of clinical study 
Data sought from systematic 
review 
Relevance to design of clinical study 
Overall prevalence of pain in 
populations with MS. 
Will inform estimations of possible pool from which 
subjects with pain might be recruited. 
Prevalence of specific pain 
syndromes 
Will inform estimates of possible pool from which 
subjects with specific pain syndromes might be 
recruited. 
Clinical associations of pain in MS May identify potential demographic differences (if 
any) which might be anticipated between subjects 
with and without pain, in a case-control study 
Variations of pain prevalence 
during disease course 
Will inform estimations of possible pool from which 
subjects might be recruited, in early vs late disease, 
and in RRMS vs progressive disease subtypes. 
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1.3.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis 
In order to identify gaps in knowledge, and highlight future research priorities, this 
review summarises and appraises existing studies of neuroimaging correlates of MS 
pain (using MRI, PET or SPECT), and assesses neuroimaging evidence for aetiology 
of individual pain syndromes in MS. 
Specifically, aims included to establish: 
 Existing knowledge of the relationship between any pain syndromes, and 
neuroimaging findings in adults with MS  
 Methodological characteristics of existing studies  
o Including type of imaging used, and study quality 
 The strength of any identified associations between neuroimaging findings 
and pain syndromes.  
Relevance to clinical study 
Detailed knowledge of the existing literature will provide a basis for design of 
clinical and neuroimaging studies described elsewhere in this thesis.  
 In particular, detailed knowledge of MS disease features seen using 
neuroimaging in specific pain syndromes (including focal demyelinating 
plaques, lesion burden and atrophy) will inform the imaging acquisitions and 
analysis planned for the neuroimaging study described later in this thesis. 
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1.3.3 Prospective experimental study: Clinical, behavioural 
and neuropsychological associations of neuropathic 
limb pain in adults with relapsing remitting multiple 
sclerosis 
Study aims included to: 
Recruit a group of people with relapsing remitting MS and well-characterised 
neuropathic limb pain, along with a control group of people with MS, but without a 
pain disorder. 
Carry out targetted assessment of a range of variables known to be relevant to the 
descending modulation of pain in these groups, including 
 Pain severity 
 Medications 
 Emotional/affective variables:  
o anxiety, depression, pain catastrophising, fatigue 
 Cognitive variables:  
o Memory, executive functions and in particular cognitive flexibility 
 Sensory:  
o hypersensitivity and allodynia 
 
Assess other variables relevant to existing consensus and patient-led 
recommendations (123, 124) for studies of clinical pain disorders. 
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1.3.4 Prospective experimental study: Structural imaging 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis 
Quantification of structural brain imaging characteristics 
Study aims were to: 
 Measure overall tissue class volumes and compare these in relation to 
presence and severity of pain 
 
 Measure and compare volumes of T2 hyperintense lesions, both overall and 
specifically in the brainstem 
 
 Measure and compare topography (three-dimensional distribution) of T2 
hyperintense lesions, using distribution probability mapping 
 
 Measure and compare local grey matter volumes, in relation to presence and 
severity of pain 
 
 Measure any association of regional grey matter volumes with the duration of 
neuropathic pain. 
 
Exploration of methods: 
Study aims were to: 
 Compare manual and automated methods of intracranial volume estimation in 
a subset of the study population,  
o In order to assess suitability of automated methods for use in the 
whole population, in further analyses 
 
 Measure intra-rater reliability in measurement of T2 hyperintense lesion 
volume. 
 
 Explore manual and automated approaches to estimating cervical cord cross-
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1.3.5 Prospective experimental study: Functional 
connectivity of the descending pain modulatory system 
in adults with neuropathic limb pain associated with 
multiple sclerosis 
Aims were to: 
 Examine functional connectivity between key structures identified as relevant 
to the descending pain modulatory system, and to clinical findings in the 
current study cohort.  
o Specifically, functional connectivity between rostral anterior cingulate 
cortex (rACC), dorsolateral prefrontal cortex (DLPFC) and 
periaqueductal grey matter (PAG) was examined.  
 Compare functional connectivity between pain and control groups, and also 
to examine functional connectivity as a correlate of pain severity at time of 
imaging.  
 Investigate the impact of T2 hyperintense lesion volume on any differential 
functional connectivity 
 Investigate functional connectivity with a “region of no interest” structure not 
thought to be involved in the DPMS (in order to assess specificity of any 
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1.4 Hypotheses 
Hypotheses are discussed separately in relation to each experimental chapter, as well 
as stating overall hypotheses for the prospective clinical study. 
 
1.4.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
Based on existing literature, the following hypotheses were made: 
 Pain is highly prevalent in people with MS 
 Various separate pain syndromes would be found in people with MS,  
o Often co-existing in the same individual. 
 Prevalence of pain in people with MS will be higher in older populations with 
higher levels of disability.  
o Therefore pain would be increasingly prevalent during longitudinal 
follow-up studies. 
1.4.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis 
 
Based on knowledge of the literature, the following hypotheses were made: 
 The number of existing studies examining associations between 
neuroimaging features of MS, and occurrence of pain syndromes will  be 
limited. 
 Identified studies will focus on the role of focal demyelinating lesions in pain 
syndromes associated with MS 
 Existing literature would most often employ structural MRI imaging 
 Some studies would link location of focal CNS demyelinating lesions to 
specific pain syndromes. 
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1.4.3 Prospective experimental study: Overall 
 
The following hypothesis was made: 
In adults with relapsing remitting MS, dysfunction of the descending pain 
modulatory system will be associated with the presence, and severity, of neuropathic 
limb pain.  
 
1.4.4 Prospective experimental study: Clinical, behavioural 
and neuropsychological associations of neuropathic 
limb pain in adults with relapsing remitting multiple 
sclerosis 
Based on evidence reviewed above, in people with MS and neuropathic limb pain, 
the following hypotheses were made: 
 Adverse affective and emotional symptoms will be related to the 
presence, and increasing severity, of neuropathic pain.  
 
 Cognitive dysfunction, in particular reductions in cognitive flexibility 
relevant to prefrontal cortex function, will be associated with presence, 
and increasing severity, of neuropathic pain 
 
 Sensory signs of hypersensitivity including allodynia will be associated 
with the presence, and increasing severity, of neuropathic pain. 
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1.4.5 Prospective experimental study: Structural imaging 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis 
 
The following hypotheses were made: 
 Detailed analysis of structural brain imaging will show differences (in T2 
hyperintense lesion distribution, and/or localised grey matter volume) which 
are consistent with the overall hypothesis of impaired descending inhibition 
of pain, on comparison of the group who experience pain, with the group who 
do not. 
 
 Similar differences will be found in association with pain severity, within the 
group who have neuropathic pain. 
 
 There will be negative associations of regional grey matter volumes with 
increasing pain duration. 
 
 Exploratory measurements of cervical cord cross-sectional area, from the 
brain imaging acquired in this study, will be possible. 
 
Tissue class volumes 
 There will be no difference in overall volume of grey matter, brain 
parenchymal fraction or intracranial volume in relation to presence or 
severity of neuropathic pain.  
 
T2 Hyperintense lesion volume and distribution 
 
 There will be no difference in overall volume of T2 hyperintense lesions in 
relation to presence or severity of neuropathic pain 
 
 The distribution of T2 hyperintense lesions will differentially involve 
structures known to be relevant to the descending modulation of pain, or 
tracts connecting these structures, in subjects with neuropathic pain.  
 
o Specifically these structures include the brainstem, which is critical to 
key nodes of the DPMS (PAG and RVM) and their connection to the 
spinal cord. 
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Grey matter volumes 
 There will be differences in local grey matter volumes detected between the 
groups with and without pain.  
 
 These will specifically involve structures known to be relevant to the 
descending modulation of pain. 
 
 
 Both increased and decreased regional grey matter volumes relative to 
subjects without pain will be observed. 
 
Exploration of cross-sectional cervical cord area from MPRAGE brain 
data 
 
 It will be possible to extract limited data on cross-sectional area of upper 
cervical cord from the available brain imaging data. 
 
 There will be no difference in cross-sectional area of the upper cervical cord 
between subjects with and without pain. 
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1.4.6 Prospective experimental study: Functional 
connectivity of the descending pain modulatory system 
in adults with neuropathic limb pain associated with 
multiple sclerosis 
The following hypotheses were made: 
 Functional connectivity between the rostral ACC, DLPFC and PAG will vary 
between groups with and without neuropathic pain.  
 It is most likely that functional connectivity of the DPMS will be strongest in 
the control group, reflecting functional integration of these structures in the 
descending modulation of pain.  
o As described, however (108), increased functional connectivity in the 
presence of a lesioned central nervous system has been repeatedly 
described in MS, and often attributed to compensatory functional 
reorganization.  
 Inclusion of T2 hyperintense lesion volume as a covariate of no interest in the 
above analyses will reduce any effect observed.  
 Functional connectivity with a “region of no interest” structure will not 
recapitulate any patterns of differential functional connectivity observed in 
DPMS structures.  
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Chapter 2 Prevalence, Incidence and Clinical 
Associations of Pain in Adults with 
Multiple Sclerosis: Systematic 




As described in the Introduction to this thesis (page 1), understanding of the 
prevalence, associations and natural history of pain in multiple sclerosis is limited.  
More detailed knowledge of these factors could allow better mechanistic 
understanding, as well as influencing the design of future clinical studies.  
Experimental aims and hypotheses are discussed in detail in the Introduction (see 
page 50). 
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2.1.1 Peer-reviewed publication related to this work 
 
Sections of this work were published as 
P Foley, H Vesterinen, B Laird, E Sena, L Colvin, S Chandran, M MacLeod, M 
Fallon 
 “Prevalence and natural history of pain in adults with multiple sclerosis: 
systematic review and meta-analysis” 
 Pain, Volume 154 (5), 2013, p632-642  
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2.2 Methods 
 
2.2.1 Literature search and selection criteria 
 
Search Strategies 
A database search strategy based upon detailed searches employed in recent 
Cochrane Database systematic reviews (125-129) was used to search Medline (from 
1977), EMBASE (from 1974), and the Cochrane Library. Searches were carried out 
on 11th November 2011. Comprehensive sensitive searches for multiple sclerosis, 
and for pain, were combined using the Boolean operator “AND”.  
A “forward search” was also carried out by using Cited Reference Search (Web of 
Science) to identify articles referencing identified publications (3rd January, 2012). 
Searches were limited only to studies of humans. Specifically, publications in 
languages other than English were included. In addition, reference lists were hand-
searched, and authors were contacted to identify unpublished data.  
2.2.1.1.1 Update of literature search for thesis chapter 
During the preparation of this thesis chapter, the cited reference search was rerun 
using Cited Reference Search (Web of Science) in August 2016. The full search 
described in this chapter was not rerun, because the data generated by the principal 
literature search had already been subject to peer review, and had been published in a 
peer reviewed journal. The process of the initial literature search was deliberately 
exhaustive, and therefore time-consuming. For the purposes of updating the searches 
for this thesis chapter, I felt that the priority was to identify most papers published 
since the original searches, and to identify their contribution to the literature when 
viewed in the context of those already identified. 
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Database search strategies are shown below (Table 4): 
Table 4: Database Search Strategies 
PubMed  Embase Cochrane Database 





























(pain* or analgesi* 
or neuralgi* or 
headache* or 
toothache*or 
earache* or sciatica 
or causalgi* or 
arthralgi* or colic* 




MeSH descriptor Multiple Sclerosis 
explode all trees 
#2 
MeSH descriptor Demyelinating 
Diseases, this term only 
#3 
MeSH descriptor Myelitis, 
Transverse, this term only 
#4 
MeSH descriptor Optic Neuritis 




Disseminated, this term only 




#8 (transverse NEXT myelitis):ti,ab,kw 
#9 (neuromyelitis optica):ti,ab,kw 






(#1 OR #2 OR #3 OR #4 OR #5 OR 
#6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12) 
#14 
MeSH descriptor Pain explode all 
trees 
#15 
MeSH descriptor Analgesia explode 
all trees 
#16 
MeSH descriptor Analgesics explode 
all trees 
#17 
(pain* OR analgesi* OR neuralgi* 
OR sciatica OR headache* or colic* 
or toothache* OR earache* OR 
dysmenorrhea OR dysmenorrhoea 
OR arthralgi* OR arthriti* OR 
neuropath*):ti,ab,kw 
#18 (#14 OR #15 OR #16 OR #17) 





(pain* or analgesi* or neuralgi* 
or headache* or toothache* or 
earache* or sciatica or causalgi* 
or arthralgi* or colic* or 




or exp demyelinating 
disease/ or exp 








,ti. or devic.ab,ti.  
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Inclusion and exclusion criteria 
 
2.2.1.1.2 Inclusion criteria 
 
Studies characterising clearly defined pain in adults with definite MS were included.  
The diagnosis of MS was considered as definite where use of recognised 
contemporaneous criteria including McDonald (130), revised McDonald (131) or 
Poser  (132) was described, or, if diagnostic criteria were not specified, where the 
diagnosis was explicitly confirmed by a neurologist (21, 44, 133, 134). The latter 
provision (diagnosis by a neurologist) was included in order to avoid inappropriate 
exclusion of rare studies where the diagnosis was confirmed by a neurologist, 
although specific diagnostic criteria were not stated.  
Because it was hypothesised that retrospective and prospective studies of pain 
prevalence might differ in pain prevalence estimates, and that prospective estimates 
would be less prone to recall bias, only prospective studies were included.  
2.2.1.1.3 Exclusion criteria 
 
Studies investigating pain attributed solely to a treatment or intervention were 
excluded (because our experimental aims concerned pain related to the disease 
itself). Other study types excluded were those where subjects included in the study 
sample were selected for symptoms including pain (because sample selection for 
symptoms in this way  would render calculation of pain prevalence in a sample 
problematic), those reporting insufficient data to calculate pain incidence or 
prevalence, studies of childhood onset MS (because of possible epidemiological 
differences from MS with adult onset  (135)), and re-published data. Where 
interventional trials described the presence of pain, only baseline data was assessed 
(in order to eliminate possible effects of trial interventions).  
Process of review by researchers 
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Titles and abstracts of all identified studies were reviewed. Potentially relevant 
articles published in English were then independently reviewed in full by two 
researchers (PF, BL) using a standardised data extraction form compiled by PF. 
Disagreements were resolved by consensus.  
Studies published in languages other than English were reviewed by fluent medically 
qualified volunteers. Volunteers were identified by word of mouth, and by email 
requests to the University of Edinburgh Clinical Neurosciences department. No 
payments were made for volunteers’ time. Of ten volunteers who assisted with study 
translation, all were medically qualified, and fluent in the language of interest. Nine 
of ten were specifically qualified in, or training in, clinical neurosciences or closely 
related disciplines. 




Methodological data was extracted including; pain types studied and excluded and 
assessment instruments used. The timeframe over which pain was assessed in 
relation to the study time point (termed “pain timeframe”) was recorded. For 
example some studies recorded pain within the week prior to subject interview, 
whereas some recorded pain in the month (or longer) prior to interview.  
Furthermore, the following data were recorded: demographic properties of the 
sample, the prevalence of pain overall, and, where available, prevalence of pain 
syndromes, including prevalence of “neuropathic” or “somatic” pain syndromes 
(after O’Connor and colleagues) (5) as reported by investigators. Investigators’ 
estimates of prevalence of co-occurring pain syndromes (ie clinically separate pain 
syndromes coexisting in a single individual) were also noted.  
Investigators’ estimates of likely pain aetiology were used because data leading to 
investigators’ estimates (such as questionnaire results, clinical examination or 
clinical investigation results, or clinical interview) were not normally available to the 
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review’s authors, and were not homogeneous between studies. Pain syndromes were 
selected according to availability of data, and clinical relevance. Headache subtypes 
could not be analysed because of overlapping groups. (136)   
Quality Assessment of included studies 
 
Quality assessment was carried out according to four criteria. These criteria were 
identified as being relevant to our experimental aims as described above. The 
following were noted: investigator blinding of any type (for instance clinical 
assessment blinded to pain status, which we hypothesised might reduce assessment 
bias on the part of the assessing  team), use of, or reference to, externally available 
validated instruments (relevant to prevalence estimation, and in particular 
comparison of results with those of other studies), presence of control groups 
(relevant to comparison of patients with multiple sclerosis to the general population), 
and description of longitudinal follow-up (relevant to longitudinal characterisation 
respectively). 
Meta-analytical and statistical analysis 
 
95% confidence intervals of proportions were calculated by the Clopper-Pearson 
method, an “exact” method deriving the confidence interval from the binomial 
distribution. (1;2) Estimating the 95% confidence interval of a proportion by 
approximation to the normal distribution was judged to be inappropriate given the 
low number of outcomes reported in some study estimates. (137) Pooled proportions 
were calculated by DerSimonian and Laird random effects meta-analysis. (138) 
Where study numbers allowed, pooled proportions were stratified by pain timeframe 
into studies examining pain within one month prior to assessment, and studies 
examining pain over longer periods. The threshold of one month was chosen to 
balance study numbers in each stratum. The I2 statistic (139) was used to estimate 
heterogeneity. Funnel plots were created and visually inspected, Egger and Begg-
Mazumdar tests were used to estimate risk of publication bias. 
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Meta-regression was used to explore study and demographic variables which might 
influence estimate heterogeneity. Meta-regression was used because individual 
patient data, although preferred for this application (140) were not available. Study 
numbers were judged to be sufficient to allow meta-regression for estimates of 
overall pain prevalence, and estimates of headache prevalence. Study numbers were 
insufficient to allow meta-regression for other pain syndromes.  
Specific methodological characteristics of studies were selected (investigator 
blinding, outpatient population studied and pain timeframe used); as well as 
demographic characteristics of the sample (mean EDSS, proportion female, 
proportion progressive MS, and mean disease duration) as independent variables 
based on availability of data, and on previously reported associations. (5)  
A distinction was not made between primary progressive and secondary progressive 
MS (141) in the primary analysis given low numbers of studies using this 
classification. Given limited study numbers, univariate analyses rather than 
multivariate analyses were used.  The significance threshold was set at the 5% level. 
We used a Bonferroni correction of significance level for multiple comparisons.  
Relationships between pain prevalence or incidence and the MS disease course were 
also studied using estimates at disease milestones (prior to disease onset, at disease 
onset, and at relapse), and longitudinal cohort studies of overall pain. STATA v10 
(meta-regression) and StatsDirect v2.7.8b (proportion meta-analysis) were used.  
2.2.2.1.1 Contributions to analysis 
Meta-regression was carried out by Hanna M Vesterinen. Other meta-analysis was 
carried out by Peter Foley. 
2.3 Results 
Seventeen estimates of overall pain, (7, 11, 20-27, 44, 66, 142-146) and seventeen 
estimates of overall headache (11, 22, 24, 27, 44, 133, 136, 143, 145, 147-153) were 
analysed. 
From 3674 abstracts 28 studies, including 7101 subjects, which met inclusion criteria 
were identified (Figure 3). 
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Figure 3: Flowchart describing selection of studies 
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2.3.1 Characteristics and quality assessment of included 
studies 
 
17 studies (5319 subjects) described overall pain and 11 (1782 subjects) described 
specific pain subtypes. The majority of the studies which investigated a specific pain 
syndrome assessed headache (ten studies, 1581 subjects, one of which (147)  
included two patient samples). Study methodology and quality assessment are 
summarised in Table 5. 
 In each sample between 55%(7) and 96% (148) of subjects were female, between 
30% (144) and 100% (147) had relapsing remitting MS, mean age was between 30.8 
(147) and 54 (144) years, mean EDSS score was between 1.1 (147) and 5.3, (26) and 
mean disease duration was between 2.5 (25)  and 23 (144) years .  On quality 
assessment using our four pre-specified criteria, only eight studies described any 
control population (six contemporaneous, (26, 145, 148-151) two historical (11, 
154)), four described blinding procedure of any sort, (150, 151, 153, 154) and five 
described follow-up. (7, 25, 133, 148, 150) Seventeen used at least one externally 
available validated instrument, of which nine (133, 147-149, 151-153) were 
headache studies referring to International Headache Society Criteria. (155, 156) Of 
overall pain studies, two studies (7, 146) met one criterion, four (11, 25, 26, 145) met 
two and none met more than two. Of pain subtype studies, four studies (134, 136, 
147, 152) met one criterion, three (133, 149, 153) met two, three (148, 151, 154) met 
three and one (150) all four. 
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Table 5: Characteristics of Included Studies 
 
 
QUALITY ASSESSMENT PAIN ASSESSMENT DETAILS 

















GENERAL PAIN PREVALENCE STUDIES 
  
archibald et al 
[1]  
85 0.53 NO NO NO NO general  structured interview none recorded Up to one month 
beiske et al [2] 142 0.65 NO NO NO NO general structured interview primary headache Up to one month 
boneschi et al 
[3] 
428 0.40 NO NO NO NO general semistructured 
questionnaire 
chronic pain lasting 
less than 6 months 
Longer than one 
month 
brochet et al 
[5] 
68 0.74 YES NO YES NO bodily pain SEP-59  none recorded Up to one month 
douglas et al 
[9] 
219 0.67 NO NO NO NO general  piloted questionnaire 
booklet, interview 
everyday pain - minor 
headaches, sprains 
and toothache 
Up to one month 
fryze et al [11] 104 0.70 NO NO NO NO general authors’ 
questionnaire 
none recorded Longer than one 
month 
grasso et al 
[13] 
128 0.48 NO YESb YES NO general  sfMPQ, VAS, 
component of SF36 
VAS score less than 3 Up to one month 
grau-lopez et al 
[14] 
134 0.55 NO NO NO NO general  semi-structured 
interview 
none recorded Up to one month 
indaco et al 
[18] 
122 0.57 NO NO NO NO general interview chronic headache, 
pain syndromes 
relieved by analgesics 
Longer than one 
month 
kalia et al [20] 99 0.69 NO YESc YES NO any chronic VAS, sfMPQ, 
component of SF36 
chronic pain due to 
other diagnosis or 
trauma 
Up to one month 
kassirer, 
osterberg [21] 
28 0.82 NO NO NO NO general  questionnaire none recorded Longer than one 
month 
osterberg et al 
[32] 
364 0.57 NO NO NO NO general, 
particularly central 
postal questionnaire  
interview in person 
back pain, tension 
headache, migraine, 
optic neuritis 
Longer than one 
month 
solaro et al [39] 1672 0.43 NO NO NO NO general  structured 
questionnaire 
headache, acute pain 
due to ON, somatic 
pain other than back 
Up to one month 
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pain, tendonitis, 
capsulitis 
stenager et al 
[41] 
49 0.86 YES NO NO NO general interview, 
examination 
headache, minor pain 
relieved by analgesics 
Longer than one 
month 
svendsen et al 
[43] 
627 0.79 NO YESb YES NO general  MPQ none recorded Up to one month 
vermote et al 
[47] 
83 0.54 NO NO NO NO general questionnaire with 
elements of MPQ 
headache, visceral 
pain 
Up to one month 
zajicek et al 
[51] 
967 0.70 NO NO YES NO general authors’ 
questionnaire, SF36 
none recorded Up to one month 
SPECIFIC PAIN SUBTYPE PREVALENCE STUDIES 
d'amico et al 
[7] 
116 0.58 NO NO YES NO headache authors’ 
questionnaire,e 
non-headache pain Longer than one 
month 
ergun et al 
(remission 
phase) [10] 
34 0.74 NO NO YES NO headache interview e trigeminal neuralgia 
optic neuritis, other 
cranial neuralgia 
Longer than one 
month 
ergun et al 
(relapse phase) 
[10] 
18 0.39 NO NO YES NO headache interview e non-headache pain Up to one month 
katsiari et 
al[22] 
48 0.50 YES YESb YES NO headache interview e non-headache pain Longer than one 
month 
kister et al [23] 204 0.64 NO YESc YES YES migraine multiple 
questionnaires  
related to trauma, 
infection or 
medication 








Longer than one 
month 




104 0.52 YES YESb YES YES headache authors’ interviews, 
psychiatric interview f 
optic neuritis, 
trigeminal neuralgia 
Longer than one 
month 
vacca et al[45] 238 0.51 NO YESb YES YES headache semistructured 
interview e 
non-headache pain Longer than one 
month 





non-headache pain Longer than one 
month 









201 N/Ad NO NO YES 
 





none recorded  Up to one month 
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a - period of interest over which pain occurrence was investigated, stratified into; up to and including 
one month prior to assessment, and longer periods prior to assessment (as described in text) 
b – contemporaneous controls  
c – historical controls 
d - overall pain prevalence not available (pain subtype prevalence data presented) 
e –  based on International Headache Society Criteria (1988 or 2004 versions)  
 f -  based on definitions of Ad Hoc Committee on Classification of Headache (1962) 
VAS – Visual Analogue Scale for pain  
MPQ – McGill Pain Questionnaire 
sfMPQ– short form McGill Pain Questionnaire 
NEADL – Nottingham Extended Activities of Daily Living scale  
SF36 – short form 36 scale 
MSQOL-54 – Multiple Sclerosis Quality of Life-54 scale 
SEP-59 – “Sclerose en Plaques-59” French Language scale derived from SF36 and MSQOL54 
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2.3.2 Prevalence of pain overall 
 
Pooled overall pain prevalence from 17 estimates (7, 11, 20-27, 44, 66, 142-146)  
was 62.8% (95%CI 55.1% to 70.3%). Pain prevalence stratified by study pain 
timeframe (for studies examining pain within the last month prior to assessment, and 
studies examining pain over longer periods) was 61.8% (95%CI 51.6% to 71.5%) 
and 64.7% (95%CI 51.7% to 76.7%) respectively (Figure 4). 
Figure 4: Overall prevalence of pain in multiple sclerosis (seventeen studies) 
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2.3.3 Prevalence of specific pain syndromes 
 
From 17 estimates of headache prevalence (11, 22, 24, 27, 44, 133, 136, 143, 145, 
147-153) pooled prevalence was 42.5% (95%CI 33.2% to 52.1%). Headache 
prevalence stratified by study pain timeframe was 28.8% (95%CI 15.8% to 44.0%) 
for studies examining pain within the month prior to study, and 50.5% (95%CI 
40.4% to 60.6%) for studies examining pain over longer periods (Figure 5). 
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Pooled prevalences (95%CI) of specific pain syndromes were; neuropathic extremity 
pain 26.6% (7.1% to 52.8%), back pain 20.0% (13.3% to 27.7%), painful spasms 
15.0% (8.5% to 23.0%),  Lhermitte’s sign 16.6% (9.7% to 25.0%) and trigeminal 
neuralgia 3.8% (2.0% to 6.0%) (Figure 6). There was insufficient data to allow 
pooled estimates for other pain syndromes (such as painful optic neuritis). Low risk 
of small study bias was found for all described estimates. 
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Figure 6: Prevalence of specific pain syndromes 
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Nociceptive and Neuropathic pain 
 
Pooled overall prevalence of investigator-defined neuropathic pain was 28.5% 
(23.5% to 33.8%), and of somatic/nociceptive pain 18.2% (14.0% to 23.0%) (Figure 
7).  
Figure 7: Reported aetiology of pain syndromes 
 
Pain at more than one site 
Three studies which explicitly described prevalence of pain at multiple bodily sites 
were found (22, 44, 145).  Random effects meta-analysis suggested that, in these 
three studies, 81% of those reporting pain (95% confidence interval 75 to 87%) 
reported pain at multiple sites  (Figure 8). 
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Figure 8: Prevalence of pain occurring at multiple body sites 
 
 
Comparison of pain prevalence in MS subtypes 
 
 In an additional post-hoc analysis pain prevalence was further analysed in the few 
studies detailing the number of subjects with relapsing remitting MS (RRMS), 
primary progressive MS (PPMS) and secondary progressive MS (SPMS) (141). This 
data was available in nine studies of overall pain (7, 11, 20-24, 144, 146) and four 
headache studies (149, 151-153). Of these studies five studies of overall pain (20-23, 
146) presented pain prevalence separately for each disease subgroup. For these five 
studies pooled pain prevalence in relapsing-remitting disease was 50.0% (95%CI 
35.4% to 64.5%) (five studies (20-23, 146) , 2089 subjects with RRMS, I2 97.1%). In 
secondary progressive MS pooled pain prevalence was 69.8% (95%CI 54.7% to 
83.0%) (five studies (20-23, 146) , 673 patients with SPMS, I2 92.6%) and for 
primary progressive MS pooled pain prevalence was 70.3% (95%CI 59.9% to 
79.8%) (five studies (20-23, 146) , 393 patients with PPMS, I2 72.4%).  
Of the four headache studies detailing the number of subjects with relapsing 
remitting, primary progressive and secondary progressive MS (149, 151-153) only 
two presented headache prevalence separately for each subgroup (152, 153). Given 
the low number of studies weighted meta-analysis was not carried out, however in 
each study separately headache prevalence in RRMS was 74.7% (83 subjects with 
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RRMS, 95%CI 64.0% to 83.6%) (152) and 76.3% (118 subjects with RRMS, 95%CI 
67.6% to 83.6%) (153); and in SPMS 63.2% (19 subjects with SPMS, 95%CI 38.4% 
to 83.7%) (152) and 65.4% (26 subjects with SPMS, 95%CI 44.3% to 82.8%) (153). 
No subjects in these two studies were classified as having PPMS. Although the 
limited number of studies and subjects included in this post-hoc analysis did not 
suggest a statistically significant difference in overall pain prevalence or headache 
prevalence according to disease subgroup, given the small number of studies 
reporting pain prevalence by MS subgroup, a clinically important difference between 
groups cannot be excluded.  
2.3.4 Associations of study-level pain prevalence: meta-
regression analysis 
 
No studies of overall pain which used investigator blinding of any type were 
identified, and only one study of headache prevalence describing an inpatient 
population. The amount of estimate heterogeneity accounted for by these variables 
could not therefore by meta-regression.  
For overall pain estimates none of the pre-specified methodological or sample 
demographic variables significantly explained estimate heterogeneity. For headache 
estimates only the study pain timeframe (up to a month prior to assessment, 
compared to greater than a month) accounted for a significant proportion of between-
study heterogeneity. Timeframe of assessment of longer than one month prior to 
assessment was associated with higher headache prevalence then estimates assessing 
only headache in the preceding month (Table 6). 
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Table 6: Meta-regression analysis of study- and population- level associations with pain prevalence estimates 
Studies analysing overall pain prevalence 
(total 17 estimates) 
 
 Studies analysing headache prevalence 
(total 17 estimates) 













Study variables       
Blinding No blinded study identified, therefore meta-
regression not carried out 
17 
 
3 blinding used, 








4 inpatient sample 
-3.12% 0.497a Only one inpatient study identified, therefore 
meta-regression not carried out 
Pain timeframe (pain within 
one month/longer than one 




10 pain within last 
month only, 
7 longer timeframe 
-4.81% 0.506a 17 





Demographic variables       
EDSS (mean) 7 -16.22% 0.675b 10 43.86% 0.026b 




-7.05% 0.868b 17 -5.02% 0.667b 




-6.08% 0.617b 11 15.05% 0.145b 
Disease duration (mean) 12 -10.30% 0.768b 12 28.12% 0.051b 
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a threshold significance value p<0.017 for individual analyses, based on Bonferroni correction (3 comparisons) with p<0.05 
significance threshold 
b threshold significance value p<0.012 for individual analyses, based on Bonferroni correction (4 comparisons) with p<0.05 
significance threshold. 
c  negative adjusted R2 values may arise in the case of small sample sizes where R-squared value is less than expected by chance 
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In an additional post-hoc meta-regression analysis, separately examining the 
proportion of patients with SPMS and PPMS as independent variables did not 
significantly explain the observed heterogeneity in overall pain estimates (nine 
studies; SPMS: adjusted R2 -10.19%, p value 0.586; PPMS adjusted R2 17.91%, p 
value 0.172; threshold p value for both comparisons 0.0083 following Bonferroni 
correction for a total of six demographic variables).  Post-hoc meta-regression 
analysis was not carried out using these independent variables for headache studies, 
as insufficient study numbers were available. 
2.3.5 Pain incidence 
 
No estimates of pain incidence (defined as rates of first occurrence of any pain 
syndrome) were found.  
2.3.6 Pain prevalence at MS disease course milestones 
 
Pain prevalence prior to disease onset 
 
No prospective studies describing prevalence of overall pain prior to MS onset were 
identified (acknowledging the methodological challenges of any such study).  
 
Pain prevalence at disease onset 
One study prospectively estimated pain prevalence soon after diagnosis (73.5% 
prevalence of any pain).(25)   Mean disease duration at assessment was 30.5 months 
(range 3 to 202 months).  
Pain prevalence at relapse 
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Only one study prospectively analysed pain at relapse, reporting headache prevalence 
of 38.9% (number of subjects with headache =7, 5 primary stabbing headache, 2 
migraine). (147)  
 
Pain prevalence during disease evolution 
Only two studies prospectively examined overall pain evolution with disease 
progression. (7, 25) Both describe a population of mixed MS disease types. Brochet 
and colleagues (25) studied 68 subjects with early MS over 2 years.  33% of RRMS 
and 45% of PPMS subjects reported clinically significant pain at all time points. Pain 
prevalence appeared to decrease over time, however this trend was not statistically 
significant. Stenager and colleagues (7) studied 70 subjects at baseline, and 
reassessed 49 of these after 5 years.  They found a significant increase in prevalence 
of overall pain and of several pain syndromes, particularly in subjects with 
deteriorating EDSS.  Brochet and colleagues report no loss to follow-up, whereas 
Stenager and colleagues report loss to follow-up of 30%. 
2.3.7 Further literature since original searches, identified by 
cited reference search 
Estimates of pain prevalence 
2.3.7.1.1 Drulovic and colleagues, 2015 
Drulovic and team’s useful multicentre cross-sectional study carried out in Serbia, 
Bosnia & Herzegovina, and Croatia post-dated the systematic review described 
above (41). This prospective study of 650 people with MS (revised McDonald 
criteria (76)) administered a semistructured questionnaire as well as other 
instruments (including  HADS (157) and  EDSS(158)). Lifetime prevalence of pain 
was found to be 66.5%, and point prevalence 44.3%. Pain prevalence estimates were 
compatible with the findings described above. Neuropathic extremity pain was found 
in 53% of subjects (my estimates 26.6%, with 95% CI 7.1% to 52.8%). The 
prevalence of pain syndromes was similar.  
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Age, progressive disease subtype, disability, depression and anxiety were all 
significantly associated with pain. In a multivariate analysis, anxiety was the main 
independent predictor of the presence of pain. 
2.3.7.1.2 Khan and colleagues, 2007 
Khan and colleagues (159) carried out a single-centre cross-sectional study of pain 
prevalence in 94 people with definite MS based in a neurological clinic in Australia. 
This study was published in 2007 and was excluded from the systematic review 
described above because of the description of inclusion criteria described in the 
study. On review, however, the inclusion criteria for the systematic review were 
probably met.  
Specifically the authors describe that “participants were recruited from the MS 
database… participants included on the database were recruited through the MS 
society and …neurologists”. It was concluded that not all participants therefore had 
MS diagnosed by a neurologist. The authors however separately state “the source of 
these participants (ie participants in their current study) was a pool of persons not 
solely based on membership in the MS society or hospital clinics. These persons… 
(had a) confirmed diagnosis of MS based on Poser’s criteria…”(159). The content of 
this study is therefore discussed as it is likely that Poser’s criteria would have been 
applied by a neurologist. 
This study found that 65% of people with MS had chronic pain, most frequently in 
the lower limbs. Most pain was dysaesethic in nature, mild to moderate in severity, 
and at more than one location. Those with higher pain severity had more disability, 
and more frequent health care visits. There was a significant difference reported 
between people with and without pain, and people with less and more severe pain, in 
a variety of outcomes including quality of life and independent living. Those with 
and without pain did not differ significantly in terms of gender balance, age, disease 
duration, severity or stage of MS.  
Pain in MS relapse 
Pain in MS relapse has been very rarely specifically addressed. My systematic 
review identified no prospective studies in people with definite MS.  
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2.3.7.1.3 Silva and colleagues, 2015 
One recent cross-sectional clinic based study , by Silva and colleagues (160) 
administered a questionnaire to 100 MS patients diagnosed by McDonald criteria. 
The study was sponsored by a pharmaceutical company. The patients attended the 
Antonio Pedro University Hospital (Brazil). Assessment included the DN4 (161, 
162) and LANSS instruments, as well as measures of anxiety and depression (Beck 
Depression Inventory and Anxiety Inventory respectively  (163)). The authors report 
that increased relapses in their sample were associated with a substantial reduction in 
the prevalence of pain in the sample. The presence of pain was independent of 
anxiety, depression and EDSS. A large number of analyses were carried out and the 
effects described apply to patient subgroups restricted by number of relapses. 
Interpretation of these findings remains unclear, and available information relating to 
pain in MS relapse remains very limited.  
Longitudinal characterisation and incidence of pain in MS 
Information on longitudinal characterisation of pain in MS, as described above, is 
limited. Some papers published since the time of the above review offer further 
perspectives. 
2.3.7.1.4 Khan and colleagues, 2013 
Khan and colleagues extended a previous cross-sectional study in 2007 (described 
above (159)) to include a further assessment of the same patient group after a 7-year 
interval. 74 of the 94 people described above were reviewed (21% loss to follow-up). 
At the second time point, 13.8% more participants reported chronic pain that at the 
baseline assessment. No significant differences were reported in average pain 
intensity, though more subjects reported high pain intensity. Greater disability was 
reported at the second time point, and at the second time point the subjects reported 
more healthcare utilization, and use of more non-pharmacological pain therapies.   
2.3.7.1.5 Fiest and colleagues, 2015 
Fiest and colleagues, writing on behalf of the “Canadian Institutes of Health 
Research  team on the Epidemiology and Impact of Comorbidity on Multiple 
Sclerosis” (ECoMS) (37) recruited 949 people with definite MS from four Canadian 
centres, who subsequently underwent review  at 1 year and 2 years after baseline 
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visit. Loss to follow-up was low at 5.4%. This study provides the first annualised 
incidence rate of pain in MS. Over 2 years, the incidence of disruptive pain (defined 
using the Health Utilities Index (164)) was 31.3%.  
The researchers also examined the impact of comorbidity, with particular reference 
to pain which disrupted daily living, and found that fibromyalgia, rheumatoid 
arthritis, irritable bowel syndrome, migraine, chronic lung disease, depression, 
anxiety, hypertension and hypercholesterolaemia were all associated with the 
presence of disruptive pain.  
The mechanism(s) whereby these comorbidities could contribute to, or modulate, 
pain interference, is not always apparent, though some of these disorders are in 
themselves often painful. Specifically, anxiety was associated with worsening pain 
over time. Depression was associated with a 1.58-fold increased prevalence of pain 
at baseline.  This detailed and thorough paper offers useful new information 
regarding pain incidence and comorbidity in particular. The authors did not however 
examine the characteristics of pain in their sample, and, in common with other 
studies described, used a clinic-based population, which may limit generalizability of 
their conclusions.  
2.3.7.1.6 Kister and colleagues, 2013 
Kister and colleagues, writing in 2013 (165) report patient symptom burden in a very 
large population of around 26 thousand North American patients who self-reported a 
diagnosis of MS, and were included in the NARCOMS database. Follow-up was 
available over 30 years.  
The figures presented suggest that at onset, around 59% of subjects reported pain. 
After 15 years, around 77% reported pain, and after 30 years, around 85%. There 
was, however, little change in the distribution of pain severity over time (similar to 
the data presented in the same article for depression, sensation, vision and cognition). 
Assessment of pain used a brief questionnaire asking subjects to grade presence of 
severity and pain on a numerical rating scale from 0 to 5 (normal, minimal, mild, 
moderate, severe, and total disabling pain). Each severity grade was further defined 
in terms of limitation in everyday activities.  
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Although those included in this study may not all have MS, as inclusion in the 
database was by self-report, and the phenotyping of pain is not detailed, the large 
sample size and combination with other data provide convincing estimates of the 









The prevalence of pain in MS has been found to be around 63%. It is composed of a 
variety of pain syndromes and mechanisms. There is significant heterogeneity 
associated with prevalence estimates, though examined aspects of study design and 
sample populations did not significantly explain heterogeneity in overall pain 
estimates. It is most likely that variable study design and execution (even within this 
selected study group) contributes to this heterogeneity. Study findings also included 
that characterisation of pain during the MS disease course is limited, and that 
incidence has not been studied. Therefore, while pain is common in MS, its 
relationships to disease course are poorly quantified.  
Study findings and implications, and study methodology, are discussed in detail in 
the Discussion (Chapter 7). 
Further studies published since this systematic review have found similar pain 
prevalence estimates, and the natural history of pain in MS at time of writing is 
perhaps better characterised than previously (37, 165)  
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Chapter 3 Neuroimaging of Pain Syndromes in 
Adults with Multiple Sclerosis: 
Systematic Review 
3.1 Introduction 
Neuroimaging plays a key role in the diagnosis of multiple sclerosis, and in current 
understanding of pathophysiological mechanisms, and their links to clinical 
manifestations of MS. 
This work aimed to define and to assess the existing literature describing associations 
of pain syndromes in people with MS, with neuroimaging findings.  
Please see the thesis Introduction (page 1) for a detailed discussion of the 
background to this work, aims and hypotheses. 
3.1.1 Peer-reviewed publication related to this work 
Sections of this work were published as  
D Seixas*, P Foley*, J Palace, D Lima, I Ramos, I Tracey 
 “Pain in multiple sclerosis: A systematic review of neuroimaging studies” 
 NeuroImage: Clinical Volume 5, 2014, p322-331 (166) 
 (* = joint first authors) 
3.1.2 Contributions 
Peter Foley (PF) and Daniela Seixas (DS) independently conceived of the study 
concept for this systematic review. DS carried out the first literature searches and 
wrote the first draft of the peer-reviewed journal article (referred to above). PF had 
substantial input at all stages of execution of this study, and has written this thesis 
chapter which includes revised assessment of the identified studies. 
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3.2 Materials and Methods 
The primary outcome of interest was the radiological evidence for the aetiology of 
any pain syndrome in MS.  
3.2.1 Literature search and selection criteria 
Search strategies   
PubMed and Scopus were searched from their inception dates (1977 and 1960, 
respectively), to the 2nd April 2013. Medical Subject Heading (MeSH) keywords 
were used for the PubMed search, and were combined with Boolean operators. Initial 
searches were carried out by DS, and subsequently updated by PF. 
Firstly, a search for studies concerned with pain and multiple sclerosis was 
performed. Keywords were the MeSH terms “pain” AND  “multiple sclerosis” (see 
Table 7).  
A second search for studies using any neuroimaging techniques of interest was 
performed. The keywords “magnetic resonance imaging”, “positron-emission 
tomography” and “tomography, emission-computed, single-photon” were combined 
using the OR operator. 
The first and second searches were then combined using the AND operator to search 
for articles concerned with both pain associated with MS, and relevant neuroimaging 
techniques. All MeSH terms were “exploded” to include all subheadings. Please see 
Table 7 below for a summary: 
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Table 7: PubMED search strategy 
Search topic Search terms 
 ( 








MRI (magnetic resonance imaging[MeSH Terms]) 
 OR 
PET (positron emission tomography[MeSH Terms]) 
 OR 
SPECT (tomography, emission computed, single photon[MeSH Terms]) 
 ) 
 
Search terms for the Scopus search were combined in the same manner as described 
above. Search terms were generated by individually listing MeSH subheadings 
generated by the “index list” function in PubMED for each keyword, as well as the 
MeSH keyword itself. Please see Appendix: Scopus Search Terms for further detail.  
Reference lists in identified manuscripts were also hand-searched, and specialists in 
pain neurobiology (University of Porto, University of Oxford) were consulted in 
order to identify additional relevant material. 
3.2.1.1.1 Update of literature search for thesis chapter 
For preparation of this thesis chapter, the PubMed and SCOPUS searches were rerun 
by PF, in May 2016. New papers not included in the original systematic review were 
identified.  
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Inclusion and Exclusion Criteria 
3.2.1.1.2 Definition of multiple sclerosis  
Papers stating a definite diagnosis of Multiple Sclerosis in adult humans were 
included. The use of specific diagnostic criteria was not mandatory (76, 131, 132). 
Use of diagnostic criteria was however recorded and explored post-hoc (see below).  
Studies of childhood onset MS were excluded (because of possible clinical and 
epidemiological differences from MS of adult onset (135)) and studies of other 
demyelinating disorders (such as neuromyelitis optica, or clinically isolated 
syndrome of CNS demyelination). 
3.2.1.1.3 Definition of pain syndromes  
Any pain syndrome described in the identified study as associated with MS was 
included. Searches were not limited to specific pain syndromes, in order to limit 
possible biases towards any specific pain syndromes.  
3.2.1.1.4 Language 
Only English language studies were included. Studies published in languages other 
than English were not included, because of lack of ready availability of translators 
for studies published in other languages, and because of an anticipated low number 
of studies published in other languages. 
3.2.1.1.5 Imaging modalities 
Studies using MRI, PET or SPECT imaging in human adults, as described above, 
were included. Studies using CT (computed tomography) were excluded because of a 
lack of ability to distinguish relevant CNS neuroimaging findings (77), in particular 
demyelinating MS lesions.  
3.2.1.1.6 Other exclusion criteria 
Re-published data, and review articles were excluded. 
Process of review by researchers 
At first execution of the literature searches, DS reviewed the titles and abstracts of 
identified studies, and excluded duplicate references.  
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Two reviewers (DS, PF) independently reviewed potentially relevant articles 
following the initial literature search. Disagreements were resolved by consensus. 
For purposes of producing this thesis chapter, reasons for excluding potentially 
relevant articles were extracted from the available data. Reasons for excluding titles 
and abstracts at first review were not available for all studies at the screening stage, 
and were estimated from available data. 
3.2.2 Data Extraction and Analysis 
Data Extraction  
For each included study methodological data was extracted including: pain 
syndrome(s) studied, basis for diagnosis of pain syndrome (where stated), basis for 
diagnosis of multiple sclerosis (where stated), description of imaging methods 
(specifically including image acquisition, and image analysis), and methods used to 
investigate temporal associations between any radiological findings and occurrence 
of a pain syndrome. The latter included use of serial imaging and contrast imaging.  
Factors relevant to quality assessment of each study were also recorded: 
Quality assessment of included studies 
Methodological quality of experimental studies was assessed using 12 criteria 
relevant to our review objectives (adapted from Campbell and colleagues (167, 
168)). These criteria were chosen because the design of our studies was not identical, 
necessitating a flexible approach to methodological appraisal (169). Given the low 
number of identified studies, studies were not excluded on the basis of quality 
assessment results.  
These criteria were as follows:  
1. Clearly stated research objective,  
2. Clear description of recruitment procedure,  
3. Clear description of inclusion/exclusion criteria 
4. Description of participation rates 
5. Clear description of sample demographics 
6. Clear description of imaging protocol 
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7. Clear description of pain measurement instruments 
8. Participation rate above 70% at baseline 
9. Image interpretation carried out without knowledge of subjects’ pain status 
(ie blinded to subject pain status) 
10. Use of multivariate analysis (where appropriate)   
11. Reporting of strength of effect 
12. Acknowledgement of study limitations  
While a “score” for each study has been calculated, by simply summing the number 
of quality assessment items identified in each study from a potential total of 12, this 
should not be interpreted as an ordinal scale, but rather as a framework for discussion 
where relevant (see below). 
Categorisation of studies 
Studies were identified as case reports, case series, or experimental studies (defined 
here as any study with hypothesis-driven experimental design). These descriptions 
were used to facilitate discussion and assessment of the included studies. 
In discussion, priority is given to experimental studies. 
Statistical analysis  
Descriptive statistical analysis was carried out where appropriate, using Microsoft 
Excel, or R version 3.1.2 implemented in R Studio, in a Windows 7 environment.  
3.2.2.1.1 Synthesis of results 
Meta-analysis was not carried out as study methodologies were not sufficiently 
similar, and/or appropriate numerical outcomes were not available.  
3.2.2.1.2 Ethics committee approval 
This work was not submitted to an ethics committee because it is a systematic review 
of the literature. We followed PRISMA guidelines for systematic reviews (170). 
 




From 902 abstracts 37 studies which met inclusion criteria were identified (117, 154, 
171-206) Of these, 16 were case reports (172, 173, 175, 177, 180-182, 186, 189, 193, 
194, 196, 199-201, 207), 14 were case series (171, 178, 179, 184, 185, 187, 192, 195, 
198, 202, 204-206, 208) and seven were experimental studies (154, 174, 176, 183, 
188, 191, 197). 
Please see Figure 9 below: 
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Figure 9: Flowchart describing selection of studies 
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3.3.1 Design of experimental studies 
Design of these seven experimental studies is detailed in Table 8 (below).  
Four studies compared people with MS with and without pain (154, 176, 183, 191), 
One used a control group of people with pain but without MS (197), one used a 
control group of healthy volunteers (188) and one used a combination of MS and 
non-MS control groups (174). All examined one specified pain syndrome. 
  Thesis: Pain in Multiple Sclerosis 
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1T, 1.5T, 3T = One, one point five or three tesla MRI acquisitions 
T1-w and T2-w = T1 weighted and T2 weighted MRI acquisitions 
PD = proton density 
MS = multiple sclerosis 
MVD = microvascular decompression 
TN = trigeminal neuralgia 
TOF = time of flight 
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3.3.2 Quality Assessment of included studies 
On quality assessment, the number of quality criteria identified in each study was not 
normally distributed, and was positively skewed. The median number of criteria 
fulfilled by included experimental studies (n=7) was eight (range 3-12). One study 
(154) fulfilled all criteria (Table 9). 
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Balasa   
(197) 
YES YES NO NO NO YES NO NO NO NO NO NO 
Cruccu 
(191) 
NO YES YES YES YES YES NO YES NO NO YES NO 
Deppe  
(188) 
YES YES YES YES NO NO YES NO NO NO YES NO 
Gee  
(183)  
YES YES YES YES YES YES NO YES YES YES YES NO 
Kister  
(154) 




YES YES YES YES YES YES YES YES NO NO NO NO 
T’torella 
(174)  
YES YES YES YES NO YES YES YES NO NO YES NO 
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All identified studies used conventional structural MRI apart from one, which 
investigated a lateralised pain syndrome in a single patient using serial diffusion 
tensor imaging (DTI) (188). No studies used functional imaging (functional MRI, 
SPECT or PET).  
Field Strength  
There were significant limitations in the description of imaging methodology in 
many studies. Overall, field strength was specified in 15 studies (39% of all studies) 
(172, 173, 175, 179, 180, 182, 184, 187-189, 191-194, 196, 198-202, 204, 205, 207) . 
Of these 15 studies, one Tesla (1 T) scanners were used in two studies (190, 197), 1.5 
T scanners were used in nine studies (171, 174, 176-178, 183, 185, 206, 208) and 3 T 
scanners were used in two of the most recent studies (188, 199) (Table 10, see 
below) . Scanners of varying field strengths were employed in two studies (0.6 T, 1.5 
T and 3 T  (154), and 0.5 T and 1.5 T (195)).  
MRI protocols 
Of all the included studies, MRI protocols were described in 15 (39%) (172, 173, 
175, 177-184, 186-189, 191-194, 196, 197, 199, 200, 202, 204, 205, 207).  Of these 
15, five described the scanner, 11 mentioned the field strength, 14 described the type 
of sequences (although only nine of these described all sequences), and nine 
described the sequence parameters used (although only four of these described all 
sequence parameters of all sequences). Imaging methodology was relatively better 
described in the seven experimental studies (please see Table 10). 
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Table 10: Description of MRI imaging techniques in included studies 
MRI image acquisition Papers 
Scanner Deppe 2013; Meaney 1995; Svendsen 2011; Gass 
1997; Eldridge 2003 
Field strength Andrade 2012; Deppe 2013; Meaney 1995; Svendsen 
2011; Gass 1997; Eldridge 2003; Kister 2010; 
Tortorella 2006; Broggi 2004; da Silva 2005; 
Yetimalar 2008 
Sequences  
All the sequences used 
 
 
Some of the sequences used 
Deppe 2013; Haas 1993; Meaney 1995; Kister 2010; 
Tortorella 2006; Svendsen 2001; Broggi 2004; da 
Silva 2005; Gass 1997 
Andrade 2012; Athanasiou 2005; Donat 2011; 
Eldridge 2003; González-Quintanilla 2012 
Sequence parameters  
All sequences and parameters 
described 
 
Tortorella 2006; Svendsen 2011; da Silva 2005; Gass 
1997 
Some sequences used and/or 
some parameters 
Deppe 2013; Haas 1993; Meaney 1995; Broggi 2004; 
Athanasiou 2005 
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3.3.3 Diagnosis of multiple sclerosis in included studies 
Criteria used to confirm the diagnosis of MS were explicitly stated in 17 of the 34 
studies (these included 2010 revisions to the McDonald (76) criteria (181, 188); 
revised McDonald (131) criteria (154, 182, 184, 191, 199); McDonald (130) criteria 
(171, 193, 197, 202); Poser (132) criteria – (195, 202, 206, 207); and Rose (211) 
criteria (205).  
Subtype of MS 
The subtype of MS in subjects was not fully described in 14 studies (154, 171, 179, 
181, 184-186, 191, 194, 197, 198, 204-206). It was relapsing-remitting in 16 (173, 
175, 177, 178, 180, 182, 187, 188, 193, 196, 199-202, 204, 207). Six studies included 
patients with various MS subtypes (174, 176, 183, 190, 195, 208). 
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3.3.4 Pain syndromes assessed in included studies 
All studies examined either neuropathic pain or headache. No studies investigating 
nociceptive/somatic pain, or psychogenic pain (2, 5) were found. Most studies (n=28, 
74% of total) focused on headache or facial pain syndromes, and the remainder on 
bodily pain (eight studies, 21% of total), except for two studies (6%), which included 
both patients with headache/facial pain and body pain (171, 176) .  
Please see Table 11 (below).  
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Table 11: Pain syndromes assessed in included studies 
Type of pain syndrome Study 
Headache Migraine Fragoso 2007; Kister 2010; Tortorella 2006 




Cluster headache – Gentile 2007 
Cluster-like headache – Donat 2011; Leandri 1999 
Cluster-tic syndrome – González-Quintanilla 2012 
SUNCT – Davey 2004; Vilisaar 2006 
Probable trigeminal autonomic cephalalgia with 
allodynia – Liu 2008 
 Cranial neuralgias and 
central causes of facial 
pain 
 
Glossopharyngeal neuralgia – Carrieri 2009; 
Minagar 2000 
Occipital neuralgia – de Santi 2009 (3 cases) 
Painful third nerve palsy – Bentley 2002 
Trigeminal neuralgia – Meaney 1995; Nakashima 
2001; Cordella 2009; Athanasiou 2005; Pichiecchio 
2007; Balasa 2010; Cruccu 2009; Broggi 2004; da 
Silva 2005; Gass 1997; Eldridge 2003 
 Other headache, 
cranial neuralgia, 
central or primary 
facial pain 
Atypical trigeminal neuralgia/facial pain – Tanei 
2010 
Headache – Alstadhaug 2007; Haas 1993 
Body 
pain 
Pseudo-radicular pain Cervical – Tosi 1998 
Sciatica – Marchettini 2006 
Various levels – Ramirez-Lassepas 1992 
 Dysaesthetic pain Burkey 2010; Deppe 2013; Hellwig 2006, Svendsen 
2011 
 Pain and painful 
itching 
Hellwig 2006 
 Painful tonic spams Andrade 2012 
 Visceral pain Marchettini 2006 
Various Yetimalar 2008 
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3.3.5 Imaging correlates of pain syndromes in included 
studies 
Measures of volume (brain or spinal cord) 
No study used volumetric techniques to estimate volume or atrophy of CNS 
structures. 
Lesion location 
All studies described MS lesions thought to be responsible for pain syndromes, or 
searched for MS lesions in neuroanatomical areas felt to be linked to specific pain 
syndromes.  
Table 12 describes lesion locations in the 25 included case reports and series. Of 
these, 21 describe demyelinating lesions in areas thought likely to be responsible for 
a pain syndrome. Four (189, 193, 198, 204) did not find demyelinating lesions 
thought likely to be responsible.  
Lesions were identified in the CNS (compatible with central neuropathic pain) in 21 
studies. Of these, lesions were located in the spinal cord in six studies (173, 179, 187, 
194, 200, 202) (three cases in de Santi and colleagues’ study (187), two cases 
documented with MRI in Hellwig and colleagues’ study (202) and five in 
Marchettini and colleagues’ study (179)). Lesions were identified in the brainstem in 
13 studies (172, 175, 178, 180-182, 184, 186, 192, 196, 201, 206, 207), in the 
thalamus in one study (188) and in multiple locations throughout the pyramidal tract 
in another study (199).  
All identified brainstem lesions corresponded to headache disorders, except for a 
lesion in the cerebral peduncle (among other lesions identified in the pyramidal tract) 
in a case of painful tonic spams of the upper limb (199). The reported spinal cord 
lesions corresponded either to headache disorders (two studies reporting high 
cervical lesions at C1 or C2 levels (187, 200)) or to body pain (four studies) (Table 
12). Lesions including both the peripheral and central nervous system were described 
in one study (which described lesions involving the brainstem and trigeminal nerve 
(177)).  
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Four studies found incidental structural lesions, which were unrelated to MS but felt 
to explain neuropathic pain syndromes (179, 185, 198, 206). These included 
neurovascular contacts in the case of trigeminal neuralgia (185, 198, 206), and 
lumbar spine degenerative disease (179). 
3.3.5.1.1 Evidence linking demyelinating lesions to pain syndromes 
3.3.5.1.1.1 Lesion location 
Most authors assigned lesions as the likely cause of pain syndromes by anatomical 
location.  
3.3.5.1.1.2 Temporal correlation between lesion and pain syndrome 
Relatively few investigators further studied the age or evolution of the lesion in 
relation to the pain syndrome by use of either serial imaging, or intravenous contrast 
(used to highlight acute demyelinating lesions).  
Please see Table 12 (below) for further details.  
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Table 12: Location of demyelinating lesions linked to pain syndromes in identified studies 
Study  Pain syndrome 
or location 










Radicular Cervical (C5-C6) dorsal root 







Posterior part of the upper 















Posterior upper thoracic 
spinal cord; cord lesions at 
the level of C1, C4/5, T3 
(two cases) 
A, C 




Right antero-lateral spinal 
cord at C2; C1, C2, C3 and 
T1-T2; C2-C3 lesion (three 
cases) 







Spinal cord location of the 
lesions assumed; MRI was 
used to exclude other causes 










the left upper 
limb 
Pyramidal tract lesions 
(cerebral peduncle, internal 
capsule and corona radiata) 







Midbrain adjacent to right 











Cluster-tic Left and right trigeminal root 
inlet and main sensory 























Right lateral tegmentum of 
the lower pons 
 
A, S 
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TAC Root entry zone of the 















Root entry zone of both 
trigeminal nerves (one case 




TN Left trigeminal root entry 


















TN Trigeminal root entry zone 
bilaterally and enhancement 




SUNCT Anterior pons, right cerebral 




A – anatomically plausible lesion; 
S – serial imaging demonstrating emergence or disappearance of plaque in line with 
clinical pain syndrome;  
C – contrast enhancing plaque; n/a = not applicable;  
TN – trigeminal neuralgia;  
TAC – trigeminal autonomic cephalalgia;  
SUNCT – short-lasting unilateral neuralgiform headache with conjunctival injection and 
tearing;  
MRI – magnetic resonance imaging 
 
3.3.6 Treatment of pain 
In seven of the studies (20.6% of total), although neuroimaging was used to study 
pain syndromes in MS, the main focus of the study was an invasive pain treatment. 
These studies addressed microvascular decompression for trigeminal neuralgia (TN) 
(185, 195, 198), CNS stimulation (175, 192, 194), and intrathecal administration of 
steroid (202). These interventions or their efficacy are not further discussed here, as 
this was not the stated objective of the systematic review.  
3.3.7 Further literature identified by search update 
Two studies were identified by re-running search strategies, as described. 
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Lincoln and colleagues, 2016 (212) 
Lincoln and colleagues published an educational case report, describing a young man 
presenting with multiple discrete episodes of multifocal demyelination. The 
differential was felt to lie between multiphasic ADEM (acute disseminated 
encephalomyelitis) and MS. A diagnosis of MS was made. Headache was reported as 
part of his presentations, however this was accompanied by several other symptoms, 
and was not attributed to any specific demyelinating plaque (212). Headache is a 
well-established clinical feature of ADEM, and diagnostic difficulty may occur in 
distinguishing multiphasic ADEM from MS (213). Regardless of the application of a 
diagnosis of MS, this report does not therefore add significantly to the above 
conclusions. 
Seixas and colleagues, 2016 (214) 
Seixas and colleagues carried out a case:control study of 23 people with MS, with 
and without chronic central neuropathic pain (12 with pain, 11 without, mixed 
phenotype of relapsing remitting, secondary progressive and primary progressive 
MS). Subjects with and without pain were matched at the group level for gender, age, 
disability (EDSS (158)) and disease duration. All had definite MS by McDonald 
criteria (131). Neuropathic pain questionnaire scores were reported to be consistent 
with diagnosis of neuropathic pain.  
Subjects underwent clinical assessment as well as structural MRI and resting state 
functional MRI imaging.  
Relative to subjects without pain, subjects with pain reported higher levels of 
depressive symptoms (but not fatigue or anxiety). Structural MRI (analysed using 
Voxel Based Morphometry, as well as segmentation and volume measurement of 
subcortical structures (215)) did not show a statistically significant difference 
between the groups, after correction for multiple comparisons. Trends towards 
differences in cortical volume (reported as density, though a modulated VBM 
protocol was used) between groups were seen at the 5% significance level without 
correction for multiple comparisons. These were interpreted as reflecting trends 
towards higher cortical density in orbitofrontal and frontal polar cortices, among 
other locations, in the group without pain.  
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Default Mode Network connectivity to the caudate and nucleus accumbens was 
found to be decreased in the pain group. This was interpreted as suggesting alteration 
in reward networks in the group with chronic pain. White matter lesion volume and 
location was not reported.  
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This systematic review is the first to collate and synthesise existing imaging studies 
of pain syndromes in adults with multiple sclerosis. Please see the thesis Discussion 
(page 271) for a full discussion of the study findings and methodology, and relevance 
to the wider field.  
In summary, findings included that neuroimaging studies of pain in MS are relatively 
low in number, and of variable design and quality. Some relatively rare pain 
syndromes (including Trigeminal Neuralgia) were the focus of a majority of studies. 
Other, more common, pain syndromes were less frequently studied. Significant 
methodological issues relating to study design, execution and reporting were 
identified.  
Investigators using different study methodologies have reached differing conclusions 
regarding the neuroradiological correlates of specific pain syndromes in MS. 
Methodologically higher-quality studies were however less likely to report positive 
associations of lesion location to the presence of headache, or of chronic central 
neuropathic pain (154, 176). 
Despite, therefore, the prevalence and impact of pain in MS, the insight into pain 
mechanisms currently afforded by neuroimaging studies remains limited.  
The current evidence does support the hypothesis that focal demyelinating lesions are 
sometimes associated with the occurrence of specific pain syndromes in MS, in some 
cases. Study methodology has not, however, always been sufficient to further explore 
any association. Several studies have not found a clear association of lesion location 
with the occurrence of specific pain syndromes, and it is possible that MRI-visible 
lesion location does not explain a significant proportion of the burden of pain 
syndromes in MS. 
There is considerable opportunity to advance our mechanistic understanding of MS-
associated pain, and thus its therapy, through future research.  
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Chapter 4 Clinical, behavioural and cognitive 
associations of neuropathic limb 




In this chapter, the clinical and neuropsychological assessment undertaken as part of 
a prospective case:control study of adults with and without neuropathic limb pain are 
discussed.  
Please see the Introduction (page 1) for a detailed discussion of background, aims 
and hypotheses.  
4.2 Methods 
 
4.2.1 Ethics Committee Review 
All procedures described were reviewed and approved by the West of Scotland 
Research Ethics Committee (study reference 13/WOS/0094). 
4.2.2 Participant Recruitment 
Study groups: principal groups 
There were two principal study groups.  
4.2.2.1.1 MS pain group 
This group comprised people with confirmed relapsing remitting multiple sclerosis, 
who experienced chronic neuropathic pain in one or more limbs (termed here “MS 
pain group”) 
4.2.2.1.2 MS controls 
The second was of people with confirmed relapsing remitting multiple sclerosis, who 
did not experience chronic pain (termed here “MS controls”). 
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4.2.2.1.3 Subgroup: MS participants without adjuvant analgesics 
Where appropriate, and where discussed below, exploratory post-hoc comparisons of 
the above groups included only subjects who were not administered adjuvant 
analgesics. 
 
A third study group was established to allow testing of sensory examination 
techniques in healthy volunteers: 
4.2.2.1.4 Healthy controls for sensory testing only 
These participants underwent only quantitative sensory testing, and recording of their 
current medication.  
 
Matching of groups 
The MS neuropathic pain group, and the MS control group were matched for age and 
gender, at the group level.  
During recruitment of the MS control group, subjects with non-painful sensory 
disturbance were preferred if possible. Priority was given to matching for the above 
variables. 
The healthy control group was matched with the MS participant groups for age and 
gender. 
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Participants with MS: 
 
Inclusion and exclusion criteria were designed with the intention of identifying a 
cohort of patients with relapsing remitting multiple sclerosis, who experienced 
clinically definite neuropathic pain in at least one limb, and of at least one month’s 
duration.  
4.2.2.1.5 Inclusion criteria 
The following inclusion criteria were applied for people with multiple sclerosis: 
 Definite diagnosis of multiple sclerosis, by McDonald criteria (76, 131) 
 Relapsing Remitting disease course 
o Confirmed by referring clinician/team,  
o And on review of the patient’s clinical notes,  
 Or on focussed patient history (if necessary). 
 Physically able to undertake the study (including MRI, see Chapters Five and 
Six) 
o Physical assistance was available for entering/leaving MRI scanner, 
where needed. 
 For people with pain: 
o clinical diagnosis of definite neuropathic pain in at least one limb 
o of at least one month’s duration 
 Able to provide consent 
 Able to communicate freely in English language, including by use of a 
translator if needed.  
4.2.2.1.6 Exclusion criteria 
The following exclusion criteria were applied for people with multiple sclerosis: 
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 Lacking capacity to provide informed consent for study participation, in the 
opinion of the researcher taking consent.  
 Receiving “strong” opiates  
o Defined according to step three of World Health Organization (WHO) 
analgesic ladder (216) 
 Confirmed dementia or severe cognitive deficit, previously recorded and 
likely to negatively influence the patient’s ability to undertake the study 
protocol, and/or provide informed consent. 
 Known contraindication to MRI.  
o For the purpose of this study, pregnancy was considered a 
contraindication to research MRI imaging.  
o Clinical notes were reviewed, and patients questioned about known 
contraindications to MRI. 
 Course of steroids within the last month  
 Clinically confirmed relapse within the last month 
o Participants were excluded if a prior diagnosis of MS relapse within 
the last month had been made at time of first study visit.  
 Unstable or severe psychiatric disease which in the opinion of the lead 
researcher (PF) would likely impair the patient’s ability to tolerate the study 
protocol.  
o Patients with psychotic or delusional disorders were excluded from 
study participation. 
o Patients with a known diagnosis of depression or anxiety were not 
excluded from the study, as long as the diagnosis was felt to be 
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secure, and appropriate management and/or review was in place, on 
review of the clinical notes.  
 
4.2.2.1.7 Medication 
It was not felt to be in keeping with ethical practice to ask patients to stop their 
adjuvant analgesics prior to study participation. In addition, previous investigators 
suggested that study participants might well opt not to stop their analgesic 
medications (214). 
Patients receiving strong opiates were excluded (see below) because these might 
impact adversely on ability to complete cognitive assessments. 
Healthy controls (for sensory testing only) 
Healthy controls were recruited from advertisements in the University, and 
University staff. 
Healthy controls were excluded from participation if 
 They had a known history of any neurological disorder 
 They had a known history of a chronic pain disorder 
 They had used analgesia within the preceding 24 hours 
 
4.2.3 Data acquisition 
All data described in this chapter were acquired in a single visit to the Anne Rowling 
Regenerative Neurology Clinic.  
Patients were seen in a clinic room. Patients were routinely given a break during 
these assessments, and encouraged to ask for and take more breaks, as necessary.  
RM acquired neuropsychological data for a subset of the subjects. All other data was 
acquired by PF. Standardised data entry forms were used where applicable. 
Neuropsychology assessment were carried out after other assessments, and after a 
patient break, in all cases. 
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4.2.4 Study Measures 
Demographics  
Core demographic data gathered included subject age, gender, duration of MS, 
duration of neuropathic pain (for subjects with pain) and current medication.  
Age (years) and gender were recorded according to participant self-report, and 
recorded as a continuous variable and binary variable respectively.  
Duration of MS (in years) was recorded according to time elapsed since diagnosis. 
This measure was used, rather than time since first symptom, as aetiology of reported 
first symptoms could not be confirmed in retrospect. Disease duration was recorded 
to the nearest 0.5 years (6 months), and was checked against clinical records, where 
participants were uncertain.  
Duration of neuropathic pain (years) was determined by participant self-report, and 
recorded to the nearest 0.5 years (ie 6 months).  
Medication 
Current medication was related by participants, and checked against clinical records 
where participants were uncertain.  
Full listing of all medication (and dosing where known) is presented.  
For the purposes of statistical analysis, current use of the following groups of 
medication was recorded as a binary variable (Table 13). 
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Table 13: Classification of medication consumption 
medication type example comments 
Weak opiates dihydrocodeine participants taking strong opiates (WHO 




















Any antidepressant Any antidepressant 
of any class 
Whether or not typically used for analgesic 
effects 
Baclofen   
 
  
Study Instruments: Pain 
4.2.4.1.1 Clinical diagnosis of neuropathic pain, in study pain group 
The following steps were carried out to ensure recruitment of subjects experiencing 
clinically definite neuropathic pain, affecting one or more limb, of at least a month’s 
duration. 
 Existing secure clinical diagnosis of neuropathic pain made at multiple 
sclerosis clinic, and/or pain clinic. 
 Confirmation of pain of at least one month’s duration, affecting at least one 
limb. Based on clinical interview by trained neurologist (PF). 
 Confirmation of neuropathic nature of pain, based on clinical interview by a 
trained neurologist (PF). The interview took into account 
o Pain descriptors 
o Distribution of pain 
o Timecourse of pain 
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o Other sensory symptoms in affected area and elsewhere. 
 Exclusion of other causes of pain (such as peripheral neuropathy or nerve 
root impingement) based on clinical interview and examination.  
 No imaging or other investigation (eg neurophysiological assessment) was 
mandatory in order to rule out other aetiologies of a pain syndrome within the 
study, although some study participants had undergone such assessment for 
clinical reasons prior to study referral.  
4.2.4.1.1.1 Self-report Leeds Assessment of Neurological Symptoms and Signs 
questionnaire: role in clinical diagnosis of neuropathic pain. 
The sLANSS questionnaire score was recorded, but was not required to make a 
diagnosis of neuropathic pain. No instrument is validated specifically to differentiate 
neuropathic and non-neuropathic pain in people with MS. The only scale validated 
for MS neuropathic pain is the Neuropathic Pain Scale, which is felt to be most 
valuable in evaluating treatment effects (217) (not directly relevant in the current 
study). The sLANSS instrument has however been used in several studies (9, 218).  
There is clinical evidence that some neuropathic pain may be “missed” by screening 
questionnaires, which are not designed for the purposed discussed. Thus the sLANSS 
is used to define the extent of neuropathic nature of their pain in a similar fashion to 
previous studies  (Gwilym et al (219)). Please see below (Self Report Leeds 
Assessment of Neuropathic Symptoms and Signs (sLANSS).for more details. 
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4.2.4.1.2 Compatibility of clinical definitions of neuropathic pain, with 
previous research definitions of neuropathic pain 
 
Relevant research definitions for the diagnosis of neuropathic pain to the recruited 
cohort post-hoc were applied (see “results”) in order to compare the definitions used 
above, to international guidelines on definition of neuropathic pain. In particular, 
application of relevant IASP and EFNS guidelines (4, 217) was examined. 
4.2.4.1.2.1 European Federation of Neurological Sciences (EFNS) criteria, 2010  
Cruccu and colleagues (217) suggest 3 criteria for definition of neuropathic pain  
1. history –  
a. character and distribution in accordance with neuropathic pain 
b. Relevant lesion or disease in nervous system probably responsible for 
pain 
2. Clinical  examination reveals negative or positive sensory signs relevant to 
underlying disease and lesion 
3. Further diagnostic tests document specific underlying neurological disease, or 
confirm sensory lesion within pain distribution 
4.2.4.1.2.2 International Association for Study of Pain; Neuropathic Pain Special 
Interest Group 2008 (IASP NeuPSIG)  
Treede and colleagues (4), suggested that the probable or definite presence of 
neuropathic pain could be assessed by the combination of three main criteria (two of 
these with sub-criteria): 
1. Presence of pain 
2. History 
a. Pain distribution neuroanatomically plausible; and 
b. History suggests relevant lesion or disease 
3. Confirmatory tests 
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a. Negative or positive sensory signs, confined to innervation territory of 
the lesioned nervous structure 
b. Diagnostic test confirming lesion or disease explaining neuropathic 
pain 
For a diagnosis of “definite neuropathic pain” the authors suggest that all of the 
above criteria are met. For a diagnosis of “probable neuropathic pain” the authors 
suggest that criteria 1, 2a) and 2b); and either 3a) or 3b) are met. 
 
4.2.4.1.3 Pain severity within pain group 
The Brief Pain Inventory(220) (short form) was used to measure pain severity, as 
well as pain interference. The BPI has been validated in non-malignant pain. A 
sample of 440 outpatients with chronic pain of non-malignant aetiology was used for 
validation. These included patients referred from neurology and physical 
rehabilitation specialties (221). 
Within the BPI, four estimates of pain severity are available (“worst pain in last 24 
hours”, “least pain in last 24 hours”, “average” pain, and “pain right now”). In this 
study the pain severity index (PSI) was used. The PSI is simply calculated by a sum 
of these four pain severity ratings (222, 223). This technique was chosen to reflect as 
wide an assessment of participants’ pain experience as possible. 
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4.2.4.1.4 Assessment of lack of pain, in study control group 
Because pain is a universal human experience, study aims included to exclude  
participants with “significant” pain from the control arm of the study. It was not 
possible to exclude participants with no experience of pain at all. For the purposes of 
this study, and on discussion among the study team, a question based on phrasing in 
the Brief Pain Inventory (221, 222) and incorporating definitions of acute and 
chronic pain to exclude marked acute or chronic pain was used. While some studies 
of chronic pain define chronicity at pain duration over 6 months (224), a more 
stringent threshold was employed in this study.  
All control group participants were presented the following question, with pre-amble. 
A forced-choice “yes/no” answer was required.  
All control group participants answered “no” to the following question: 
"Throughout our lives, most of us have had pain from time to 
time (such as minor headaches, sprains, and toothaches).  
Have you had pain other than these every-day kinds of pain 
within the last 24 hours, or do you have a problem with pain 
which has lasted for more than 3 months?" 
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Study Instruments: Clinical assessment and symptoms 
Instruments used in this study were selected according to the following criteria. An 
iterative process was followed, so that, if possible, an instrument meeting criterion 
one was used. If this was not possible, an instrument meeting criterion two was used, 
and so on:  
1. Validated in studies of multiple sclerosis 
2. Validation in studies of neurological or other disease 
3. Widely used in studies of MS. 
The following criteria were also met where possible: 
Relevance to guidelines for instrument choice in studies of pain interventions 
reported in the peer-reviewed literature (124). 
Relevance to patient reported preferences for measures relevant to pain, reported in 
the peer-reviewed literature (123). 
In the view of the investigating team, could be carried out by study participants 
within a reasonable timeframe, and without undue burden on study participants. For 
a more detailed discussion of burden on study participants, see Chapter 7: Participant 
Experience. 
 
4.2.4.1.5 Expanded Disability Status Scale 
The Expanded Disability Status Scale (EDSS) is a clinician-administered scale, 
generating a score ranging from 0 (normal neurological status) to 10 (death) in half-
point increments. The score is generated from a neurological examination, which 
may require 10 minutes or longer. The lower values of the EDSS measure specific 
impairments on “functional systems” elicited by clinical examination. Higher scores 
are heavily dependent on walking ability (158).  
It is validated in multiple sclerosis (158). Internationally, it is the most widely used 
tool to measure multiple-sclerosis related disability (225). The EDSS, however, has 
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been criticised as being heavily examiner-dependent. All EDSS examinations 
described in this study were carried out by a single researcher (PF), having received 
prior recognised and standardised training in the administration of this instrument, 
and with several years’ experience of administering this instrument in a clinical and 
research environment.  
4.2.4.1.6 Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) (40) is a brief instrument 
designed to elicit symptoms suggestive of anxiety and depression. Administration 
requires 2-3 minutes in most cases. It was initially developed in a general medical 
population. It has been validated in MS (157) and has been used in a number of 
studies of people with MS.  
For the purposes of this study, separate anxiety and depression scales were 
generated. A threshold score of eight on the depression subscale has been reported as 
providing a sensitivity of 90% and specificity of 87.3% for major depression in 
people with multiple sclerosis (using the Structured Clinical Interview for DSM-IV 
as a gold standard) (157).  
The same threshold score of eight on the anxiety subscale has been reported as 
providing a sensitivity of 88.5% and specificity of 80.7% for generalized anxiety 
disorder, in the same study, and using the same gold standard comparator (157).  
Use of the HADS meets recommendations for inclusion of measures of emotional 
function from the IMMPACT collaboration and the IMMPACT collaboration’s 
patient survey on useful measures (123, 124) . 
4.2.4.1.7 Short Form 36 Quality of Life Scale 
The Short Form 36 scale (SF36) (12) is an instrument designed to elicit specific 
aspects of quality of life. It is very widely used internationally and is used in 
interventional trials in MS (226).  
Completion of the SF-36 takes around ten minutes. It generates eight subscales 
namely physical functioning, role limitations due to physical health, energy/fatigue, 
pain, general health, emotional well-being, role limitations due to emotional 
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problems, and social functioning. Although the SF 36 is widely used, it has been 
criticised for possible underestimation of mental health problems (227). Floor and 
ceiling effects have been reported for certain subscales, and in the UK population the 
use of summary scales has been questioned (228). Shorter versions including the SF-
12 are available. 
SF-36 was chosen for use in this study because of its wide use, relative ease of use 
by patients, validation in MS, and inclusion of a pain measure.  
4.2.4.1.8 Fatigue Severity Scale 
The fatigue severity scale (FSS) is a simple self-administered instrument which takes 
1-2 minutes to complete for most subjects. It yields an overall estimate of fatigue 
severity. It has been validated in people with multiple sclerosis (229) and is widely 
used in studies of multiple sclerosis (230).   
The mean fatigue severity score in Krupp et al’s original study was 4.8 from a 
maximum of seven (in a sample of 25 people with progressive subtypes of MS, and 
EDSS scores ranging from 3.0 to 6.5). Cronbach’s alpha was 0.81 (229).  
Measurement of fatigue meets recommendations by the IMMPACT collaborators to 
measure emotional functioning and physical function (FSS questions cover both), 
and recommendations by patients with chronic pain to measure fatigue (123, 124). 
4.2.4.1.9 Pain Catastrophizing Scale 
The Pain Catastrophizing Scale (PCS) has been validated in adults with pain 
conditions including low back pain, fibromyalgia (231) and other medical conditions 
(232). It has been extensively used in multiple sclerosis (59). 
Throughout this thesis, the UK spelling of “catastrophising” is used to refer to the 
concept of pain catastrophising. The USA spelling of “catastrophizing” is used to 
refer to the original spelling of the PCS. 
Pain catastrophising has been described as an exaggerated negative “mental set” 
brought to bear during painful experiences (58). Participants are asked to what extent 
they agree with a range of statements, which include “I worry all the time whether 
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the pain will end”, “I feel I can’t go on” and “It’s awful and it overwhelms me” 
(233). The pain catastrophizing scale is further discussed in the Introduction to this 
thesis (1.1.4.1.9). 
4.2.4.1.10 Pittsburgh Sleep Quality Inventory 
The Pittsburgh Sleep Quality Inventory (PSQI) is a self-rated questionnaire which 
assesses sleep quality and disturbances over the preceding month. Therefore, the data 
relies largely on self-report.  
Additional collateral history from a bed-partner can be added to this questionnaire. 
This was not used in this study because of practical difficulties in obtaining this 
information, and limited relevance to the study objectives. 
Seven component scores (subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of medication for insomnia, and 
daytime dysfunction) are generated, as well as a sum global score. It was developed 
in healthy subjects and “poor sleepers” (the latter with depression or sleep disorder). 
Global score>5 was reported as yielding a diagnostic sensitivity of 89.6% and 
specificity of 86.5% in distinguishing “good” and “poor” sleepers (234).  
It has been widely used in studies of MS (235) though is not specifically validated in 
MS. Assessment of sleep addresses recommendations by the IMMPACT 
collaboration and pain patients (123, 124). 
4.2.4.1.11 Self Report Leeds Assessment of Neuropathic Symptoms and 
Signs (sLANSS). 
The self-administered sLANSS instrument estimates the extent of the neuropathic 
nature of pain, and is completed within about 2 minutes. It comprises self-report of 
specific symptoms, as well as basic examination carried out by the participant on 
themselves (for instance sensation to pressure within a pain area).  
It has been validated in patients attending outpatient pain services for the purpose of 
binary distinction between neuropathic and non-neuropathic pain (162). It is not 
validated in MS, though has been used in studies of pwMS (13, 218).  
  Thesis: Pain in Multiple Sclerosis 




It is used in this study as an estimate of the extent of neuropathic symptoms (219), 
rather than to make a binary distinction between neuropathic and non-neuropathic 
pain. The latter distinction is made by clinical assessment (see above: Self-report 
Leeds Assessment of Neurological Symptoms and Signs questionnaire: role in 
clinical diagnosis of neuropathic pain.).  
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Study instruments: Neuropsychology 
4.2.4.1.12 Overview 
Please see below (Table 14) for an overview of these instruments, and duration of 
assessment. 
The instruments themselves are then discussed individually, and the specific 
neuropsychological functions tested by each instrument are described (see Table 15 
for summary) 
Table 14: Overview of neuropsychology instruments, and duration of administration 
 
 
4.2.4.1.13 Brief International Cognitive Assessment for MS (BICAMS) 
The BICAMS neuropsychological assessment battery (50) comprises three separate 
tests which together aim to generate an assessment of verbal memory (immediate and 
delayed), visual memory and processing speed.  
The BICAMS battery lasts around 15 minutes, though there is a requirement for a 25 
minute gap to allow assessment of delayed verbal recall. The scales included in the 
BICAMS battery were chosen (50) for reliability, validity and sensitivity (to MS-
Test Approximate Duration  
(mins) 
BICAMS cognition battery for multiple sclerosis (50), 
includes  
Symbol Digit Modalities Test (oral form)(236),  
California Verbal Learning Test-II (54),  
Brief Visuospatial Memory Test –Revised T1-3(237) 
15 
Letter fluency (letter S), and restrained fluency (letter T, 
four letters)(238, 239) 
2 
Reverse digit span, letter:number alternation (238) 4 
Hayling sentence completion task (238) 5 
Delis-Kaplan card sorting test (240) 
 
10 
Elevator test with distraction (241) 10 
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related cognitive dysfunction), as well as ease of application, with a wider aim of 
standardising international monitoring of cognitive dysfunction in MS. 
4.2.4.1.13.1 BICAMS: verbal memory 
Verbal memory is assessed by the California Verbal Learning Test-II (54) which 
includes two components, the first of which tests immediate and the second of which 
delayed verbal memory. The participant is read a list of 16 nouns. They are asked to 
repeat as many of these as possible, and the number recalled is recorded. This is 
repeated until the list has been read, and recall attempted, 5 times in total. Maximum 
score is 5x16=80.  
Delayed recall is tested by asking the participant to recall the same list after a 25 
minute interval. The CVLT-II has been validated against a range of imaging 
measures of MS disease activity, as well as in differentiating employed from 
unemployed people with MS (50). 
4.2.4.1.13.2 BICAMS: visual memory 
Visual memory is assessed by the Brief Visuospatial Memory Test – revised T1-3 
(237). The participant is shown a 2x3 matrix of 6 simple abstract figures for 10 
seconds. The figures are then removed, and the subject is asked to draw these from 
memory on a sheet of blank paper.  
This process is repeated until the figures have been shown, and recall attempted, a 
total of 3 times. Scoring is by accuracy of recall of the figure shape, and location in 
the 2x3 matrix. Maximum score =2x6x3=36. In common with other instruments in 
the BICAMS battery, scores on the BVMT have been correlated to a variety of 
imaging measures of MS disease activity (50). 
4.2.4.1.13.3 BICAMS: processing speed 
Processing speed is tested by the Symbol Digit Modalities test (SDMT) oral form 
(236). The participant is given a standardised array of abstract shapes, consisting of 9 
separate random shapes repeated at random across several rows.  
A key is presented which links each shape to a number (1-9). The subject is asked to 
translate each symbol to the corresponding number, in order, as quickly and as 
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accurately as possible. A sensitivity of 82%, and specificity of 60% for MS-related 
cognitive impairment are described (242), and the SDMT has been validated against 
a variety of imaging measures, as well as employment status (50) 
4.2.4.1.14 Phonemic verbal fluency (letter fluency) 
Verbal fluency is included as a measure of concept generation. Phonemic verbal 
fluency (letter fluency) (generation of words starting with a particular letter, in 
contradistinction to semantic verbal fluency, which tests generation of words within 
a particular category, such as animals) was used (62, 64). 
 The participant is given instructions to generate as many words as possible starting 
with a single letter, with the exception of names, numbers or places. The number of 
words generated in one minute is recorded.  
This task was first carried out with the letter S. The task was then repeated with the 
letter T, with the subject asked to generate only four-letter words. Letter fluency is 
relatively easy to administer. It is widely used as a measure of concept generation, 
“energization” (defined as a process of initiating and sustaining a response) and 
language (63, 238, 239). It has been described as a sensitive marker of early MS-
related cognitive impairment (239, 243). 
In lesion and clinical studies, phonemic letter fluency has been demonstrated to be 
linked to a variety of cortical localisations which are also linked to descending 
modulation of pain (see chapter 5). 
4.2.4.1.15 Delis-Kaplan card sorting test 
The Delis-Kaplan card sorting test is derived from the Delis-Kaplan Executive 
Function System (D-KEFS) (244), and is also part of the Minimal Assessment of 
Cognitive Function in MS (MACFIMS) battery (245).  The card-sorting test 
comprises administration of two tests, each using their own set of pre-printed cards. 
The test is relatively complex and requires approximately 15 minutes.  
Each of the two sets of cards comprises six cards. Each card is different from the 
others, and is distinguished by shape, size, colour, patterns, and words printed on the 
card. The participant is asked to sort the six cards into two sets of three based on 
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common features, and to explain the rationale for sorting the groups in this way. The 
participant is then asked to continue sorting the cards into new paired groups of 
three, for a total of four minutes.  
The groups described by the participant are matched against a pre-prepared list (for 
example “describes animals” vs “describes means of transport”; “writing in italic 
font” vs “writing in plain font” and so on). The card sorting test is regarded as a 
mixed test of concept formation and suppression, with each new concept requiring to 
be superseded by a new one. It is validated in multiple sclerosis, scores correlate to 
MRI measures of disease activity, and it has been shown to discriminate between 
people with and without MS, and employed and unemployed pwMS.  In particular, 
pwMS made fewer correct “sorts” as well as making more perseverative errors, in 
comparison to healthy controls.(240).  
The scoring described here assesses the number of correct group allocations 
(“sorts”), and the recognition of correct sorts when shown to the participant by the 
examiner. Perseveration was not examined. 
4.2.4.1.16 Hayling sentence completion task 
The participant is firstly asked, during a dummy run, to generate words which 
correctly complete a sentence. During the test itself, the instruction is modified so 
that the participant is asked to generate words which are not related to the word 
which should complete the sentence. The score allocated to the participant is highest 
where the word is unrelated to that expected. It is regarded as a combined test of 
verbal concept inhibition and generation (238). Administration takes around 2 
minutes. In the context of this study, the Hayling task is viewed as testing similar 
functions to the Delis-Kaplan test. 
4.2.4.1.17 Elevator test with distraction (from Test of Everyday Attention) 
The participant is asked, during a dummy run, to count the number of identical tones 
played on a pre-prepared audio file. During the test itself, additional high-pitched 
tones are added.  
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The participant is asked to ignore the high-pitched tones (“distractions”), and only to 
count the low-pitched tones (246). Administration of the test takes around 10 
minutes. The test is regarded as a test of auditory attention, attentional switching and 
cognitive flexibility. The TEA, of which this test is part, has been tested in MS and 
has been found to have reasonable ecological validity, ie relevance to real-world 
impairments (247). 
 
4.2.4.1.18 Reverse digit span 
During the reverse digit span test, the participant is read a list of numbers, and asked 
to read them back, without reference to written material, in reverse. The list of 
numbers starts at length of 2, and increases until the participant fails twice to recount 
the correct order. The reverse digit span (“digit span backwards”) is often 
administered as part of neuropsychological batteries such as the Wechsler Memory 
Scale III (248) and Wechsler Adult Intelligence Scale IV (55).  
It is thought to test a variety of functions. These include short term memory, however 
it is also thought to require focussed attention and manipulation, and is often thought 
to measure executive abilities, more than storage and rehearsal (64). 
Both of the above tests are included in the Edinburgh Cognitive and Behavioural 
ALS Screen (238) and are regarded as tests of concept generation and inhibition, as 
well as working memory particularly in the case of the reverse digit span (249). 
4.2.4.1.19 Number:letter sequencing 
During the number:letter alternation test, the participant is asked to continue a pattern 
of alternating numbers and letters, each increasing stepwise. The examiner reads 1:A, 
2:B, 3:C and the participant is asked to continue this pattern, until they are stopped at 
the letter “O”. This test is included in the ECAS as a combined executive and 
working memory test (238). It is conceptually similar to the “Trail Making Test B” 
(250) which asks participants to trace a path between alternating numbers and letters 
(1-A-2-B…). Executive control is felt to be required for set-switching between 
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sequential numbers and letters, including inhibition of the currently irrelevant task-
set (251), and the trail-making test is widely used to assess set-shifting ability (64). 
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Table 15: Overview of putative functions tested by individual neuropsychology tests 






























































































 Immediate Delayed       
BICAMS CVLT + +       
 BVMT   +      
 SDMT    +     
Phonemic Fluency     +    
Phonemic Fluency 
(constrained) 
    + +   
DKEFS     + + +  
Hayling      + +  
TEA       + + 
Reverse Digit 
Span 
+    +  + + 
Numb:letter 
sequence 
+     + +  
 
BICAMS = Brief International Cognitive Assessment in MS 
CVLT = California Verbal Learning Test 
BVMT = Brief Visuospatial Memory Test 
SDMT = Symbol Digits Modality Test 
DKEFS= Delis Kaplan Executive Function System card sorting task 
Hayling = Hayling Sentence Completion task 
TEA = Task of Everyday Attention auditory task with distraction 
Numb:letter sequence = number/letter sequence 
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Study instruments: assessment of sensory symptoms 
 
4.2.4.1.20 Distribution of pain and sensory symptoms 
4.2.4.1.20.1 Participants with neuropathic pain 
Each subject marked the distribution of their pain on a standardised diagram of the 
human body, included in the Brief Pain Inventory (221). Front and back views were 
completed. For each subject, an electronic copy of this map was created by using 
Microsoft Paint, for both front and back.  
A symptom distribution map for the pain group was then created by reading the 
individual files into Matlab, summing them, and dividing by the number of subjects 
included. Data were output as “.eps” vector images.  
Previous studies have used individual subject symptom maps (176), a computer 
drawing program to produce probability maps (252) or bespoke computerised 
software including computerised patient interface (253). 
4.2.4.1.20.2 Participants without neuropathic pain 
Identical procedures to the above were carried out, with the exception that 
distribution of non-painful sensory symptoms, rather than painful sensory symptoms, 
were marked. Where the participant did not have sensory symptoms, the symptom 
map for that participant was left blank. 
4.2.4.1.20.3 Comparison of symptom distribution in groups with and without pain 
The symptom distribution maps shown were compared visually for distribution of 
symptoms. 
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A focussed brief quantitative sensory testing protocol was devised, specifically 
targeted towards clinical signs which could suggest the presence of deficient 
descending pain modulation systems.  
Procedure: Quantitative Sensory Testing (QST) 
The following tests were administered (Table 16) to the affected limb, and the upper 
sternum in the midline:  
Wind-up ratio was defined as the ratio of average NRS (numerical rating scale) pain 
score 0-10 for 10 repeated pinprick stimuli administered at intervals of 
approximately one second, to NRS pain score 0-10 for a single pinprick stimulus. 
Where denominator of the ratio was 0 (i.e. where subjects reported a single pinprick 
as non-painful), the windup ratio was not calculated (in accordance with previous 
literature) (254, 255) and this data was recorded as not available.  
Table 16: Targetted Quantitative Sensory Testing 
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In addition, all subjects with neuropathic pain completed the sLANSS instrument in 
order to assess the extent of neuropathic nature of their pain, at the time seen (256). 
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Data anonymization  
Each subject was allocated a four-digit subject ID code, using a computerised 
number generator ( Microsoft Excel). All study data was marked with this ID code. 
With the exception of consent forms (which were stored separately from other study 
data), patient identifiable data were not present on paper copies of 
questionnaires/instruments.  
Data storage 
Subject data was stored in an individual folder in a locked cupboard, and identified 
only by 4-digit study ID. Consent forms were stored separately. Anonymised 
questionnaire data were scanned, saved electronically and backed up on secure 
University of Edinburgh servers.  
Data marking and curation 
Clinical assessment data were marked either prior to scanning, or after scanning 
when the electronic copy of the record was used.  
Where marking of the clinical data was complex (227, 234), spreadsheets were 
generated in Microsoft Excel, and used to calculate scores and subscores. To confirm 
appropriate marking within Excel spreadsheets, a random sample of questionnaire 
data were marked separately by hand and by spreadsheet, and results cross-checked. 
4.2.5.1.1 Analysis data format and software 
Data was recorded in a comma separated value (.csv) spreadsheet file in Microsoft 
Excel. The spreadsheet was read into R (v3.1.2) implemented in R Studio in 
Windows 7. Where additional R packages were required, these are specified below. 
4.2.5.1.2 Data distribution and statistical tests  
For continuous/pseudo-continuous data, data distribution was assessed for Gaussian 
distribution by inspection of data histograms and Quantile-Quantile (QQ) plot (137, 
257, 258).  
Where distribution was felt to be Gaussian, mean and standard deviation are reported 
as summary measures, and Students t-test used to test significance level. Where 
  Thesis: Pain in Multiple Sclerosis 




distribution was felt to be non-Gaussian, median and interquartile range are reported 
as summary measures. Wilcoxon rank-sum tests (also known as Mann-Whitney U 
test) was used to test significance level. No data transformations were used. (137, 
257, 258). 
For binary variables, a 2x2 table was generated. The Chi-squared test was used for 
larger samples, and the Fisher exact test for smaller samples (where overall total of 
the table was less than 20, or where the overall total was between 20 and 40, and the 
smallest of the four expected numbers was less than 5 (137)).  
Significance was assigned at the 5% level, unless otherwise stated. All statistical 
tests were two-tailed. Correction for multiple comparisons is discussed below. 
4.2.5.1.3 Missing data  
Missing data was recorded and is discussed where relevant. No imputation was 
carried out.  
4.2.6 Overall analysis strategy 
Comparison of subjects with MS, with and without neuropathic limb 
pain 
The principal comparison described in this thesis is between people with MS, with 
(n=31) and without (n=16) neuropathic pain.  
The following analyses are presented: 
 Demographics and core data 
 Medication 
 Psychological and affective morbidity (including depression, anxiety, fatigue 
and catastrophising) 
 Cognitive evaluation: Brief International Cognitive Assessment (BICAMS) 
 Cognitive evaluation: executive function 
 Sensory evaluation: Quantitative Sensory Testing (QST) 
 Sensory evaluation: anatomical distribution of symptoms 
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Correlates of pain severity in people with MS and neuropathic limb pain 
Furthermore, the above variables were explored as correlates of pain severity were 
explored within the group with neuropathic pain (n=31), where possible given 
available data. 
Type I error and correction for multiple comparisons 
In data tables, statistical significance at the 5% significance level before correction 
for multiple comparisons is indicated. Furthermore, statistical significance at the 5% 
significance level after correction for multiple comparisons using a straightforward 
Bonferroni procedure (137) is indicated.  
The role of medications 
Administration of medication was recorded as described above (Table 13). 
. Use of medications between groups was compared as described above.  
In post-hoc exploratory analyses, comparison of patients with MS with and without 
neuropathic pain, where subjects are not receiving any adjuvant analgesic, is also 
presented. 
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4.3.1 Participant Recruitment 
People with MS (with and without neuropathic pain) 
Participants were recruited between 5th August 2013, and 28th July 2015.  
A total of 93 referrals were made to the study. 68 people were referred for inclusion 
in the group with neuropathic limb pain, and 25 for inclusion in the control group 
without neuropathic pain. Of these 93 referrals, 92 were made from the Lothian 
regional MS service based at the Anne Rowling Clinic. One referral was made from 
the regional pain service for South East Scotland. This patient was not included in 
the study (because of a diagnosis of secondary progressive MS). Therefore all 
patients included in the study were referred from the regional MS service. Referrals 
were made either by the treating clinician, or MS specialist nurse. 
Potential participants were not included either because of meeting explicit study 
exclusion criteria, or because they were not contactable. Reasons for non-inclusion 
frequently coexisted in a single patient. Primary reasons for study exclusion are 
shown below (Table 17).  
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Table 17: Primary reasons for exclusion of potential participants with MS (decreasing frequency) 
Primary reason for 
exclusion 
 Number of potential  
participants excluded  
Contact Uncontactable, either at first 
or subsequent contacts 
12 
Pain Pain had settled,  
symptoms were not described 
as pain by participant,  





Including family, work, 
travel 
10 
SPMS Previously diagnosed, or 










 Known medical 
contraindication 
1 
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4.3.2 Application of research definitions of neuropathic pain 
to study cohort 
The two research definitions examined (see Methods: 127) use similar definitions of 
neuropathic pain (4, 217). All subjects described pain in a neuroanatomically 
plausible location. All had an existing diagnosis of multiple sclerosis (relapsing-
remitting) and had had relevant confirmatory tests to confirm this diagnosis 
according to contemporaneous guidelines (76). 
IASP criteria 
31 of 31 subjects (100%) included in the pain group of this study met all criteria 
listed, and can therefore be categorised as describing “definite neuropathic pain” on 
the basis of the IASP classification system.  
EFNS criteria, 2010 
All subjects (31 of 31, 100%) included in the pain group of this study meet all 
criteria listed, and therefore can be categorised as describing “definite neuropathic 
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4.3.3 Overview of participant medications 
An overview of participant medications is presented for reference.  
Please see below (Table 18) 
.
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Table 18: Participant Medication 
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Study 
ID  
Non-analgesic medication  Adjuvant 
Analgesics 







  Antidepressant 
other than  
analgesic 
Tricyclic GBP/PGB SNRI CBZ    





       
0193 none         




Y        
1272 none         
1491 none         




Y        
1602 Sumatriptan (last used 2/52 
previously) 
        
1883 HRT         
2283 Thyroxine         
2844 none         
3064 Salbutamol, Beclomethasone         
3337 none         
3478 none         
3583 none         
3740 Chlopheniramine         
3833 Ventolin, Citalopram Y        
3842 Oral Contraceptive Pill         
4168 none         
5233 none         
5270 citalopram Y        
5568 Topical antifungal         
5820 none         
6371 Oral contraceptive Pill, 
Limocycline 
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6471 none         
6703 Mirtazepine, Oral 
Contraceptive Pill 
Y        
6838 Spiriva, Ventolin, Seretide         
6983 Levothyroxine         
8105 None         
8196 Lansoprazole         
8872 None         
9484 none         
9782 none         
9840 none         
 STUDY GROUP:  
MS PAIN 
        
0104   AMI 50mg 
nocte 
      






0785 none         
0885 Flavoxane 1tab od, 
Fluoxetine 40mg od 
Y  PGB 300mg 
bd 
   Fingolimod Baclofen 
60mg/24hrs 
1976 Amantadine, Tamsulosin, 
Clonazepam 










2398 Oral Contraceptive Pill   GBP 300mg 
nocte 
   Natalizumab  
2399 Vitamin D, Multivitamin       Glatiramer  
2515 Lansoprazole, Simvastatin, 
Lisinopril, Folic Acid, 
Thiamine, Sertraline 
Y  PGB 
200mg/24h 




2742 Amantadine, Fluoxetine 
















  Dihydrocodeine 
30mg PRN 
Fingolimod  
3216 Nasal Decongestant  AMI 10-
20mg nocte 
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3317 Salbutamol, Venlafaxine 
75mg od 
      Dimethyl 
Fumarate 
 
3449 Atenolol, Oral 
Contraceptive, Vitamin D, 
Sumatriptan (not received 
for several week) 




   Beta-
Interferon 
 





4250 Cetirizine, Lansoprazole, 
Bendroflumethiazide, 
Amlodipine, Thyroxine,  
  PGB 
300mg/24h 








4269 Ventolin, Seretide         
4731   AMI 10mg 
nocte 
   Paracetamol 2-3 
grams/24h, 
Aspirin + 
caffeine (2 per 
week) 
  
4824 Eye drops (steroid, 
cyclopentilate), 






     
5028 Fluoxetine 30mg, Lactulose, 
Hyoscine, Omeprazole, 
Loperamide, Methylcellulose 
Y  GBP 600-
900mg/24h 
  Paracetamol 
approx. 2g/24h 




5877 Ferrous Sulphate      Ibuprofen 
600mg/week 
  
6216 Sertraline, Methylcellulose, 
Oral Contraceptive Pill 
Y  GBP 
2700mg/24h 
   Glatiramer 
Acetate 
 










6281 Oral Contraceptive Pill, oral 
acyclovir 
      Beta-
interferon 
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7157     Duloxetine 
?60mg 
 Co-codamol 
30/500 up to qds 
(PRN) 
Fingolimod  




  Co-codamol 
30/500 (PRN) 
  
8244 Alendronate, Evening 
Primrose Oil, Vitamin D, 
anti-oxidant supplement, 
cranberry supplement  











   Fingolimod  
8477 Lisinopril, 
Bendroflumethiazide 
  PGB 
450mg/24h 
  Paracetamol 
PRN occasional 
  




  Co-codamol 








9069 Simvastatin 40mg, 
Candesartan 4mg 
  GBP PRN      
9494 Inhalers, Oral Contraceptive 
Pill, Vitamin D 
      Beta-
interferon 
 
 STUDY GROUP: 
MS CONTROLS 
        
0735   AMI 75mg 
nocte 




Omeprazole, Vitamin D,  
 AMI 20mg 
nocte 






1294 Solifenacin, Ventolin, 
Sildenafil PRN 
      Dimethyl 
Fumarate 
 






2344 Vitamin D, 
Hydroxycobalamin 
      Dimethyl 
Fumarate 
 
3286 Fluoxetine 20mg od, 
melatonin 
Y      Beta-
interferon 
 
3724 Oral Contraceptive Pill         
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3800 Mirtazepine 45mg nocte, 
longterm Amoxycillin, 
Multivitamins, Oxybutynin,  
Y AMI 100mg 
nocte 




4038 Thryoxine, Fexofenadine, 
Adcal D3, Citalopram, 
Vesicare 
Y        
4360        Glatiramer 
Acetate 
 
7819 Loratadine, nasal 
decongestant spray 
      Fingolimod  
8532 Vitamin D, antihistamine       Dimethyl 
Fumarate 
 
8869 Venlafaxine 375mg/24h       Beta-
interferon 
 
9042        Dimethyl 
Fumarate 
 
9513 Vitamin D       Dimethyl 
Fumarate 
 







NSAID = Non Steroidal Anti Inflammatory Drug 
PRN = as required 
GBP = Gabapentin 
PGB = Pregabalin 
SNRI = Serotonin and Noradrenaline Reuptake Inhibitor 
CBZ = Carbamazepine 
 
Medication doses are given where available 
Where name of medication was not available (for instance purchased by patient), class of drug is indicated 
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4.3.4 Associations of the presence of pain: comparison of MS 
subjects with and without neuropathic pain 
Demographics and matching 
Participants with and without neuropathic limb pain are closely matched for age and 
gender (see Table 19). Groups are also balanced for disability, disease duration, years 
of full time education. Three participants in the pain group used codeine-containing 
medications (none in the control group) though this difference did not attain 
statistical significance at the 5% level (Fisher Exact test). Use of disease modifying 
therapy (DMT) was somewhat more common in the control group, though this 
difference did not attain statistical significance at the 5% level (Chi-Squared test). 
Use of adjuvant analgesics was significantly more common in the group with 
neuropathic pain, consistent with expectations. Note that a significant minority of the 
control group received these medications for indications other than pain. Indications 
for these medications, as related by patients, was recorded and included insomnia.  
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 Table 19: Demographics and Medication in Participants with and without neuropathic pain 
 
COMPARISON OF SUBJECTS WITH AND WITHOUT NEUROPATHIC PAIN 
 
DEMOGRAPHICS and MEDICATION 






Gender (% female) 81.2 80.6  1.00 











(1.0 to 2.12) 
2.00  
(1.50 to 3.02) 
0.23 


















Pain Severity (range 0-40) (median, IQR) NA 17.00 (10.00 
to 22.00) 
NA 
Medications Weak opiates (%) (codeine-
containing medication) 
(note that no participants 








































* = statistical significance at 5% level 
 
MS DMT = multiple sclerosis disease modifying therapy (including interferon and other 
therapy) 
No correction for multiple comparisons applied 
SD=Standard Deviation 
IQR=Interquartile range 
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Emotional and affective morbidity 
4.3.4.1.1 Symptom scores 
Subjects with neuropathic pain demonstrated significantly more emotional/affective 
comorbidity measured by scores for depression, fatigue, and catastrophising, even 
after Bonferroni correction for multiple comparison (Table 20 below). Anxiety 
scores were higher in the pain group (p<0.05 not corrected for multiple 
comparisons). 
Table 20: Psychological Comorbidity in participants with and without neuropathic pain 














5.00 (2.00 – 
8.50) 
0.99 to 5.00 0.005134 ** 



















16.00 (12.50 – 
25.00) 
4.00 to 15.00 0.003593  ** 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparison 
 
HADS = Hospital Anxiety and Depression Scale 
FSS = Fatigue Severity Scale 
PCS  = Pain Catastrophizing Scale 
 
 
4.3.4.1.2 Depression and Anxiety meeting diagnostic criteria 
11/47 (23.4%) of all subjects met diagnostic criteria for major depression (157). No 
subjects in the control group met these criteria, however 35% of the pain group met 
these criteria. Subjects whose scores met these cut-offs were more commonly found 
in the pain group (Table 21).  
26/57 (55.3%)  of all subjects met diagnostic criteria for generalized anxiety disorder 
(157). Subjects meeting these criteria were common in both control and pain groups. 
There was no statistically significant difference in prevalence of subjects meeting 
generalized anxiety disorder criteria in comparison of the two groups (see Table 21). 
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* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
HADS = Hospital Anxiety and Depression Scale 
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Cognitive evaluation: Brief international Cognitive Assessment in MS 
(BICAMS) 
Performance on immediate verbal memory and visual memory was worse in the 
group with neuropathic pain, than the control group, to a statistically significant 
degree (5% significance level after correction for multiple comparisons), and for 
delayed verbal memory to the 5% significance level (without correction for multiple 
comparisons).. 
Processing speed (SDMT) was not worse in the pain group, to a statistically 
significant degree (see Table 22). 
Table 22: Memory and Processing Speed in participants with and without neuropathic pain 




































-15.00 to 2.00 0.1275 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
CVLT-II = California Verbal Learning Test-II 
BVMR-R = Brief Visuospatial Memory Test –Revised T1-3  
SDMT = Symbol Digits Modality Test 
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Cognitive evaluation: executive function 
Measures of letter fluency and inhibition of extraneous (auditory) information were 
not different in the groups with and without pain, to a statistically significant degree.  
Three of four measures of set-shifting or cognitive flexibility generated by the DK-
EFS were significantly worse in the group with pain. Performance in the 
number:letter alternation task was often at ceiling (median score 12 in both groups, 
of maximum possible 12). Performance in the Hayling test was close to ceiling in 
both groups. Performance in the reverse digit span task was not significantly 
different in the pain and control groups (Table 23). 
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Table 23: Executive Functions in participants with and without neuropathic pain 











 Fluency, letter 
S 
(mean, SD) 









-3.00 to 2.00 0.6551 
Inhibition of extraneous information 







-3.00 to 1.00 0.7086 
Set shifting 











-1.00 to 1.00 0.8249 
Recognising 















































* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
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Sensory evaluation: Quantitative Sensory Testing 
4.3.4.1.3 Group demographics and testing sites 
There was no statistically significant difference in age or gender between healthy 
volunteers and people with MS, nor between people with MS with or without 
neuropathic pain. There was no statistically significant difference between site of 
QST testing (defined as right vs left limb, and upper vs lower limb) between healthy 
volunteers and people with MS, nor between people with MS with or without 
neuropathic pain (Table 24). 




















“p” value  
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4.3.4.1.4 Comparison of healthy volunteers and people with MS 
Pain score to single pinprick was not significantly different in the healthy volunteer 
or MS groups. 
Wind-up ratio, both in the limb affected by pain (or sensory disturbances) and over 
the xiphisternum, was higher in patients with MS, than healthy volunteers (5% 
significance level). There were high numbers of missing data for Wind-Up Ratio, in 
both healthy volunteers and people with MS. All cases of missing data occurred 
because of participants scoring a single pinprick as “0” severity. 
The presence of allodynia of any type was more frequent in people with MS, than 
healthy volunteers (5% significance level) though individual measures of allodynia, 
(cool and warm stimulus, and dynamic mechanical allodynia) were not significantly 
more frequent in the MS group (Table 25).  
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Table 25: Quantitative sensory testing in healthy volunteers, and people with MS 













(0 to 1.25) 
 
0.50  






1.0 (1.0 to 1.0) 
NA = 11 
1.25  
(1.0 to 1.63) 
NA = 24 
0.0026 ** 
 WUR (central) 
(median, IQR) 
1.0  
(1.0 to 1.46) 
NA = 9 
1.4 
(1.0 to 1.75) 
NA = 20 
0.037 * 






































* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
Limb = testing at affected limb 
Central = testing at xiphisternum in midline 
NA = missing data 
WUR = wind up ratio 
IQR = Interquartile Range 
  Thesis: Pain in Multiple Sclerosis 




4.3.4.1.5 Comparison of participants with and without neuropathic pain in MS 
Sensitivity to single pinprick was higher in those with neuropathic pain, than those 
without. Allodynia (when any type of allodynia was included) was more likely to 
occur in the pain group than the group without pain. Other differences did not attain 
statistical significance (Table 26). 
There were high numbers of missing data for Wind-Up Ratio. All cases of missing 
data occurred because of participants scoring a single pinprick as “0” severity. 
Table 26: Quantitative Sensory Testing in people with MS, with and without neuropathic pain 












(0.00 to 0.50) 
1.00  







(1.00 to 1.00) 
NA = 12 
1.50  
(1.00 to 2.50) 
NA = 12 
0.07 
 WUR (central) 
(median, IQR) 
1.17  
(1.0 to 1.38) 
NA = 8 
1.50  
(1.22 to 2.00) 
NA = 12 
0.09 






































sLANSS Total score 
(median, IQR) 
N/A 14.0  
(10.0 to 18.5) 
N/A 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
Limb = testing at affected limb 
Central = testing at xiphisternum in midline 
WUR = wind up ratio 
IQR = Interquartile Range 
sLANSS = self report Leeds Assessment of Neuropathic Symptoms and Signs 
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Anatomical symptom distribution 
4.3.4.1.6 Neuropathic pain group 
Of 31 patients with neuropathic limb pain, all indicated the location of pain on the 
body diagrams as part of the Brief Pain Inventory. 
Distribution of pain symptoms in subjects with neuropathic pain is shown below 
(Figure 10) 
Figure 10: Probability distribution of neuropathic pain (n=31) (JPEG data shown due to memory 
constraints) 
 
On review of the above distribution maps, probability of pain was highest in the 
limbs, and in the lower rather than upper limbs. Symptoms appeared symmetrical. 
Symptoms were also seen in the abdomen and torso, including (in some cases) in a 
band-like distribution across the chest.  







pain location in 
group  
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4.3.4.1.7 Group without neuropathic pain 
Of 16 patients without neuropathic pain, 14 described neuropathic sensory 
symptoms, which were not painful. All 14 marked the distribution of these symptoms 
on the Brief Pain Inventory body map as described. 
Distribution of non-painful neuropathic sensory symptoms in all 16 subjects without 
neuropathic pain is shown below (Figure 11). 
Figure 11: Probability distribution of non-painful neuropathic sensory symptoms (n=16)(JPEG 
data shown due to memory constraints) 
 
On review of the above distribution maps, probability of non-painful neuropathic 
sensory symptoms was highest in the limbs, and in the lower rather than upper limbs. 
Symptoms laterality appeared symmetrical. Symptoms were also seen in the 
abdomen and torso, though no patient described a band-like (radicular) distribution 
on the anterior chest. 
No patient reported symptoms on the anterior torso or abdomen, buttocks, or upper 
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4.3.4.1.8 Comparison of groups with and without neuropathic pain 
Both groups showed bilateral fairly symmetrical symptoms, mainly affecting the 
limbs, with a preponderance in the lower limbs. In both groups, the head was 
occasionally affected. The abdomen and torso appeared to be more frequently 
affected in the group with neuropathic pain. No formal statistical analysis of 
difference is currently possible, and the small group size in the control group in 
particular is noted.  
Quality of life and sleep 
Overall quality of life (sum SF36 score) was significantly worse in subjects with 
pain, than those without (median 592.2 vs median 425.2, p=0.000185) (Table 27).  
All eight quality of life subscale scores reflected worse quality of life in the pain 
group. Statistical significance at the 5% level was reached for all 4 of the physical 
subscales, and one of the 4 mental subscales. 
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Table 27: Quality of life: Comparison of subjects with and without pain 














Quality of life (total score) 
SF36 total score 
 
592.2 (507.6 to 
635.1) 









(61.5 to 95.0) 
60.0 





due to physical 
health 
75.0  
(50.0 to 100.0) 
25.0  
(0.0 to 50.0) 
-50.0 to  
-25.0 
0.00049 ** 
General Health 60.0 
(47.5 to 75.3) 
40.0 
(30.0 to 55.0) 
-30.0 to -5.0 0.0175 * 
Pain 100.0  
(90.0 to 100.0) 
45.0  
(32.5 to 67.5) 
-55.0 to -32.5 1.7x10-7 ** 




(58.0 to 92.0) 
72.0  
(58.0 to 78.0) 
-2.0 to  
4.5x10-6 
0.064 
Social functioning 75.0  
(59.3 to 100.0) 
62.5  
(43.75 to 75.0) 



















* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
QoL – Quality of Life 
SF36 – Short Form 36 Quality of Life instrument (higher values, better quality of life) 
Significance threshold set at 5% 
 
4.3.4.1.9 Sleep 
Median sum PSQI scores in the MS control group was 6.00 (IQR 3.75 to 7.25). 
Median sum PSQI score in the MS pain group was 8.00 (5.50 to 12.00). Sleep was 
rated as significantly worse in the group with neuropathic pain (p=0.028) 
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4.3.5 .Subgroup exploration of associations of the presence 
of pain: subjects not receiving adjuvant analgesics 
Demographics and matching 
Thirteen MS control patients, and nine MS pain patients, were not receiving any 
regular adjuvant analgesics. 
After exclusion of all subjects receiving adjuvant analgesic drugs, no significant 
difference was found between subjects with and without pain for gender, age, EDSS, 
disease duration, years full-time education, administration of baclofen, or 
administration of MS DMT (Table 28). 
Table 28: Exploration of demographics and matching: subjects not receiving adjuvant analgesics 
 
 
 Control  
























(1.00 to 2.00) 
1.50  
(1.0 to 1.5) 
0.53 
Disease duration (years)  
(median, IQR) 
9.50  
(3.00 to 15.50) 
6.00  
(5.00 to 10.00) 
0.71 









Medication Baclofen 0/13 0/9 1.0 
 MS DMT (%) 11/13 5/9 0.18 
* = statistical significance at 5% level 
 
MS DMT = multiple sclerosis disease modifying therapy (including interferon and other 
therapy) 
No correction for multiple comparisons applied 
SD=Standard Deviation 
IQR=Interquartile range 
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Psychological and affective morbidity 
After exclusion of all subjects receiving adjuvant analgesic drugs, statistically 
significant differences between those with and without neuropathic pain were found 
for depression scores, anxiety scores and fatigue scores. Catastrophising scores did 
not attain statistical significance at the 5% level (p=0.06) (Table 29). Directions of 
effect were the same as observed when all subjects were analysed together (see Table 
20).  
Table 29: Exploration of psychological and affective morbidity scores: subjects not receiving 
adjuvant analgesia 








(0.00 to 6.00) 
8.00  
(5.00 to 11.00) 
0.013 * 
Anxiety (HADS)  
(median, IQR) 
7.00  
(2.00 to 9.00) 
12.00  





(27.0 to 40.00) 
50.00 






(3.00 to 15.00) 
19.00  
(15.00 to 22.00) 
0.060 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
HADS = Hospital Anxiety and Depression Scale 
FSS = Fatigue Severity Scale 




Cognitive evaluation: Brief international Cognitive Assessment 
(BICAMS) 
After exclusion of all subjects receiving adjuvant analgesic drugs, no statistically 
significant differences were seen between groups with and without neuropathic pain 
on any measures from the BICAMS battery.  
In the cases of CVLT-II (word list), CVLT-II (delayed) and BVMR-R, there was a 
trend to worse performance in the pain group (p=0.052 to 0.078), in the same 
direction as observed in the overall analysis (Table 22). In the case of SDMT, no 
trend was observed, in keeping with results in the overall analysis (Table 30). 
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Table 30: Exploration of BICAMS measures: subjects not receiving adjuvant analgesia 







CVLT-II (word list)  61.00 
(54.00 to 67.00) 
46.00  





(13.00 to 16.00) 
11.00  
(9.00 to 14.00) 
0.078 
BVMR-R 33.00  
(32.00 to 35.00) 
29.00  
(25.00 to 31.00) 
0.076 
SDMT 63.00 
(61.00 to 65.00) 
64.00  
(62.00 to 79.00) 
0.35 
 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
CVLT-II = California Verbal Learning Test-II 
BVMR-R = Brief Visuospatial Memory Test –Revised T1-3  
SDMT = Symbol Digits Modality Test 
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Cognitive evaluation: executive function 
After exclusion of all subjects receiving adjuvant analgesic drugs, statistically 
significant differences (at the 5% significance level) were seen between the groups 
with and without pain, in three measures of cognitive flexibility (Table 31). 
Differences attaining statistical significance were the same as those found to be 
statistically significant in the overall analysis prior to exclusion of subjects not 
receiving adjuvant analgesics, and were in the same direction (see also Table 23). 
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Table 31: Exploration of executive functions: subjects not receiving adjuvant analgesia 






Concept Generation  
 
 Fluency, letter 
S 
(mean, SD) 
17.00 (4.08) 15.00 (4.44) 0.32 
Constrained 
fluency, letter T 
(median, IQR) 
9.00 
(7.00 to 14.00) 
7.00 
(6.50 to 9.50) 
0.50 
Inhibition of extraneous information 
 
 Elevator Test 
with Distraction 
9.00 
(9.00 to 10.00) 
9.00 




 Card Sorting 1 7.00  
(6.00 to 7.00) 
5.50 
(5.0 to 6.0) 
0.016 * 
Card Sorting 2 5.00 
(5.00 to 6.00) 
6.00  
(5.00 to 6.25) 
0.36 
Recognising 




















(6.00 to 8.00) 
8.00  


















(9.00 to 11.00) 
0.47 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
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After exclusion of all subjects receiving adjuvant analgesic drugs, no statistically 
significant differences were seen between the MS groups with and without 
neuropathic pain. Trends towards higher rates of allodynia and higher wind-up ratio 
(as seen in the overall analysis prior to exclusion of subjects receiving adjuvant 
analgesic drugs) (Table 26) were seen (p= 0.055 and 0.071 respectively) (Table 32). 
Table 32: Exploration of quantitative sensory testing: subjects not receiving adjuvant analgesics 












(0.00 to 0.46) 
1.50  







(1.0 to 1.00) 
NA = 9 
1.50 
(1.12 to 1.88) 
NA = 3 
0.071 
 WUR (central) 
(median, IQR) 
1.17 
(1.00 to 1.38) 
NA = 5 
1.33 
(1.25 to 1.50) 
NA = 4 
0.40 






































sLANSS Total score 
(median, IQR) 




* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
WUR = wind up ratio 
IQR = Interquartile Range 
sLANSS = self report Leeds Assessment of Neuropathic Symptoms and Signs 
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4.3.6 Correlates of pain severity 
Demographics  
Participants with neuropathic limb pain of low and high severities are balanced for 
age and gender, disease duration, pain duration, and years full time education.  
As would be expected pain severity is significantly higher in the “high pain” group. 
Disability (EDSS) is also significantly higher in the “high pain” group. Notably 
EDSS was not significantly different between groups with and without pain, 
although subjects were not deliberately matched for physical disability at any stage 
(see above). 
Table 33: Demographics and Medication in participants with varying severities of neuropathic pain 
COMPARISON OF SUBJECTS WITH LOW- AND HIGH-SEVERITY 
NEUROPATHIC PAIN 
 
DEMOGRAPHICS and MEDICATION 







Gender (% female) 81.25 80.00 1.00 
Age (years, sd) 44.50 (9.41) 43.27 
(10.98) 
0.74 
EDSS (median, IQR) 1.50(1.00 to 
2.00) 
5.50 (2.25 to 
5.75) 
0.0073 * 





Pain duration (years)  5.75(2.00 to 
6.62) 
6.00 (2.75 to 
15.00) 
0.23 











Medication:  MS DMT (%) 62.50 60.00 1.00 
strong opiates (%) (WHO level 
III) 
0 0 1.00 
Other opiates (%) (codeine-
containing medication) 
12.50 6.67 1.00 
Adjuvant analgesics 
(%)(gabapentin/tricyclic/other) 
68.75 73.33 1.00 
MS DMT = multiple sclerosis disease modifying therapy (including interferon and other 
therapy) 
* = statistical significance at 5% level 
 
No correction for multiple comparisons applied 
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Pain severity measures 
 
4.3.6.1.1 Pain severity: summary statistics  
Median “average” rating of pain severity was 5.00 from a maximum possible of 10 
(IQR 3.00 to 6.00). A score of 5 is at the upper end of a previously defined range 
from 3 to 5 for “moderate” pain in people with multiple sclerosis (259). 
Median “worst” pain severity was 7.00 from a maximum possible of 10 (IQR 3.00 to 
8.00). A score of 7 is at the upper end of a previously defined range for “moderate” 
pain in people with multiple sclerosis, which ranged from 5 to 7 (259). 
Pain Severity Index (PSI) median was 17.00 from a maximum of forty (IQR 10.00 to 
22.00). There are no published definitions of pain severity in MS relating to PSI 
scores, however a recent study of people with neuromyelitis optica described 
comparable PSI scores of median 15 (antibody negative patients, some of whom 
were felt possibly to have opticospinal MS) and 20 (antibody positive patients) (223). 
4.3.6.1.2 Pain severity: correlations between differing BPI measures 
 
In the MS Pain group, Pain Severity Index (PSI) was highly correlated with all 
measures of pain severity from the Brief Pain Inventory (Spearman’s Rho 0.86 to 
0.93).  
The Average Pain measure from the BPI was similarly highly correlated to other 
measures from the BPI, however to a lesser degree than the PSI (Spearman’s Rho 
0.76 to 0.85). 
PSI and average pain were less strongly correlated with the pain severity index from 
the SF-36 (Spearman’s Rho -0.58 for PSI, noting that SF-36 pain scale indicates 
worse pain with a lower score, so that negative correlation is expected). SF-36 
measures pain over the preceding four weeks, in comparison to one week for the 
BPI. Please see Table 34. 
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Table 34: Exploration of correlations between pain severity measures (Spearman’s Rho, n=31) 





















0.86 0.85 -    
Least pain 
(BPI) 
0.87 0.76 0.61 -   
Pain now 
(BPI) 




-0.58 -0.55 -0.58 -0.50 -0.50 - 
 
BPI = 
PSI =  
SF 36 =  
 
Brief pain Inventory 
Pain Severity Index 
Short Form 36 
 
Psychological and affective morbidity 
Symptoms of anxiety, fatigue and catastrophising were all significantly positively 
correlated with pain severity in those suffering from neuropathic pain, after 
Bonferroni correction for multiple comparisons (Table 35). Symptoms of depression 
were significantly correlated at the 5% level before correction for multiple 
comparisons. 
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0.414 0.021 * 
Anxiety  
(HADS) 
0.584 0.00056 ** 
Fatigue  
(FSS) 
0.60 0.0004 ** 
Catastrophising (PCS) 0.57 0.0009 ** 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
HADS = Hospital Anxiety and Depression Scale 
FSS = Fatigue Severity Scale 
PCS  = Pain Catastrophising Scale 
 
 
Cognitive evaluation: Brief International Cognitive Assessment in MS 
(BICAMS) 
Verbal memory (immediate or delayed), visual memory and processing speed were 
not correlated to pain severity at the 5% significance level (see Table 36). 
Table 36: Memory and Processing Speed: correlation with pain severity 
 Correlation (Spearman’s Rho) “p” value 
CVLT-II  





BVMR-R 0.209 0.259 
SDMT 0.081 0.672 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple 
comparisons 
 
CVLT-II = California Verbal Learning Test-11  
BVMR-R = Brief Visuospatial Memory Test –Revised T1-3  
SDMT = Symbol Digits Modality Test  
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Cognitive evaluation: executive function 
There was no statistically significant correlation of any executive function test with 
pain severity (Table 37). 

























 Card Sorting 1 -0.05 0.80 
Card Sorting 2 -0.24 0.21 
Recognising 
Card groups 1 
-0.22 0.25 
Recognising 
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Quality of life and related variables 
Overall quality of life (sum SF36 score) was significantly correlated with pain 
intensity, in those with neuropathic pain.  
All eight quality of life subscales (both physical and mental) were significantly 
correlated with pain intensity, at the 5% significance level (see Table 38, below). 
 
Table 38: Quality of Life: Correlation between pain severity and quality of life measures 




Quality of life (total score) 
SF36 total score 
 
-0.65 7.8x10-5 ** 
Quality of life subscales: “Physical” 
Physical Functioning -0.41 0.023 * 
Role limitations due to 
physical health 
-0.48 0.006 * 
General Health -0.57 0.00088 ** 
Pain -0.58 0.00066 ** 
Quality of life subscales: “Mental” 
Emotional well-being -0.60 0.00037 ** 
Social functioning -0.53 0.0023 ** 
Energy/Fatigue -0.47 0.008 * 
Role Emotional -0.54 0.002 ** 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for multiple comparisons 
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4.3.6.1.3 Pain interference 
In the MS Pain group, pain severity was significantly correlated with pain 
interference in all measured activities included in the Brief Pain Inventory (221). 





Pain Interference (total score) 
Pain Interference total 
score 
 
0.78 2.55 x 10 -7 ** 
Pain interference subscales 
General Activity 0.66 5.90 x 10-5 ** 
Mood 0.61 0.00028   **  
Walking Ability 0.80 5.96 x 10-8 ** 
Normal Work (includes 
work outside the home 
and housework) 
0.77 4.31 x 10-7 ** 
Relations with other 
people 
0.67 3.50 x 10-5 ** 
Sleep 0.63 0.00017 ** 
Enjoyment of Life 0.72 5.6 x 10-6 ** 
* = statistical significance at 5% level 
** = statistical significance at 5% level after Bonferroni correction for 
multiple comparisons 
 
SF36 – Short Form 36 Quality of Life instrument (higher values, better 




Sum Pittsburgh Sleep Inventory score was significantly related to pain severity, 
indicating worse ratings of sleep quality with increasing pain severity (Spearman’s 
Rho 0.68, p=2.14 x10-5). 
4.3.7 Participant experience of study 
The study protocol was well tolerated. No subjects withdrew from the clinical, 
behavioural and cognitive assessments. Specific data on participant experience of the 
study, including clinical, behavioural, cognitive and radiological assessments, was 
gathered separately and is presented in Appendix: Participant Experience. 
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4.4 . Discussion 
The results described in this chapter suggest that, in the population described, 
emotional/affective factors are associated with both the presence and severity of 
neuropathic limb pain in relapsing-remitting multiple sclerosis. Cognitive factors 
(specifically memory and cognitive flexibility) are associated with the presence of 
neuropathic pain, but not severity of existing pain.  
Please see the thesis Discussion (page 290) for a full discussion of findings, 
relevance to the wider field and study methodology. 
Interpretation of the difference between groups with and without neuropathic pain is 
limited by the higher prevalence of adjuvant analgesics in the pain group, however a 
post-hoc exploratory analysis limited only to those not receiving such drugs supports 
the conclusions of the wider analysis.  
Both emotional/affective, and cognitive factors have been repeatedly linked to 
descending modulation of pain. The described results could be compatible with the 
study hypothesis of impaired pain modulation, in the population described.  
These results, if confirmed in future larger studies, could be relevant to 
understanding of pain modulatory mechanisms in MS, and could lead to further 
investigation of how these systems might be impaired (for instance by focal 
demyelination, or by grey matter atrophy). These results are among the first to 
explore the cognitive correlates of neuropathic limb pain in MS, and support future 
consideration of cognitive as well as emotional/affective and sensory aspects of pain 
in this disorder. From a treatment perspective, these findings could eventually be 
relevant to development and administration of targeted therapies (57, 260).
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Chapter 5 Structural imaging correlates of 




This chapter describes structural imaging assessments undertaken as part of the 
prospective study described in Chapter Four. For a full discussion of background, 
aims, and hypotheses please see the Thesis Introduction (page 1). 
Existing studies examining neuroimaging correlates of pain syndromes in MS are 
described elsewhere in this thesis. Please see Chapter Three (page 90).  
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5.2 Methods 
5.2.1 Structural image acquisition 
All MRI imaging was performed on a single Siemens Verio 3Tesla (3T) MRI 
scanner (Erlangen, Germany) at the Clinical Research Imaging Centre (CRIC), 
University of Edinburgh. 
A 12-channel phased array head coil manufactured by Siemens was used. No scanner 
upgrades were carried out during the execution of this study.  
Imaging was acquired on the same day as completion of the Brief Pain Inventory 
(261) in all cases. Imaging was acquired in a single session in all cases. 
T1-weighted, T2-weighted and FLAIR sequences all acquired 1mm isotropic data (ie 
with 1 x 1 x 1mm voxels). The following structural imaging was acquired (Table 40): 
Table 40: Specifications of structural imaging sequences 
Sequence Specifications Acquisition time 
(total 15 minutes, 13s) 
T1 MPRAGE  
(T1-weighted) 
 
field of view 256 x 240 x 160 mm 
voxel dimensions 1 x 1 x 1mm 
flip angle 9 degrees   
TR 2300ms   
TE 2.98 ms 
TI 900ms.  




Field of view 256 x 256 x 160 mm 
voxel dimensions 1 x 1 x 1mm 
TR 3200ms 
TE 416ms.  
4 minutes, 18s 
T2 FLAIR 
 
Field of view 256 x 256 160mm voxel 
dimensions 1 x 1 x 1mm 
 TR 5000ms 
 TE 402ms 
 TI 1800ms.  
5 minutes, 52s 
TR = Repetition Time 
TE = Echo Time 
TI = Inversion recovery time 
SPACE = “Sampling Perfection with Application optimized Contrasts using different flip 
angle Evolution” (Siemens proprietary sequence) 
MPRAGE = Magnetization-Prepared Rapid Gradient-Echo 
FLAIR = Fluid-Attenuated Inversion Recovery 
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5.2.2 General Image Analysis 
General preprocessing of imaging data 
5.2.2.1.1 Anonymisation of data 
All imaging data was fully anonymised at source (Julian Sparrow), and subsequently 
identified only by a computer-generated random 4 digit numerical subject code. 
Subject codes were allocated by a random number generator in Microsoft Excel 
(262).  
5.2.2.1.2 Overview of analysis software 
Various image analysis programs were used, subject to specific requirements. These 
are further described below. The majority of analyses described use the FSL (FMRIB 
Software Library) package (Oxford, UK). Software versions used were as follows: 
FSL v5.0.1 (105), SPM version 12 (263), Mango Image Viewer version 3.4  (264) , 
Analyze version 11.0 (265), Spinal Cord Toolbox version 2.0 (266)  and Matlab 
2014a (267).  
Analysis was implemented on the BRIC imaging servers (University of Edinburgh, 
UK) (Dell Poweredge R620 with 32 cores and 96GB RAM, running Scientific Linux 
2.6.32-504.8.1.el6.x86_64). 
5.2.2.1.3 Data format 
Imaging data was output from the University of Edinburgh Clinical Research 
Imaging Centre in DICOM (Digital Imaging and COMmunication) format. DICOM 
files were converted to compressed Nifti format using Chris Rorden’s  dcm2nii 
(268). Subsequent conversion to Analyze or Nifti (uncompressed) format, if required, 
was done with fslchfiletype (105).  
5.2.2.1.4 Alignment of images to standard orientation 
MPRAGE, T2-weighted and FLAIR images were re-orientated to match the 
orientation of the MNI152 standard space template, using fslreorient2std (105) . 
Images were viewed in fslview.  
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5.2.2.1.5 Cropping of neck tissue 
Extraneous neck tissue was manually cropped from MPRAGE, T2 and FLAIR 
images at the level of the mid-C3 vertebra following visual identification for each 
individual subject, and using the fslroi tool within FSL. This step was carried out to 
optimise later preprocessing including brain extraction. 
5.2.2.1.6 Noise reduction 
For voxel base morphometry analyses, and lesion analyses, no smoothing was 
applied. 
For spinal cord analyses described, MPRAGE, T2 and FLAIR images were 
smoothed prior to further processing using FSL’s SUSAN, using the following 
parameters: “-1 3 3 1 0” ie threshold at 10% of robust range, halfwidth 3mm, 3 
dimensional smoothing with local median filter (269). 
5.2.3 Reporting of statistical significance 
5.2.3.1.1 Whole brain analyses 
Throughout, the 5% significance level, fully corrected for multiple comparisons, is 
reported in whole-brain analyses. These include analyses of lesion distribution or 
grey matter volume.  
Where appropriate, and where described, the less stringent threshold of p< 0.001, 
uncorrected for multiple comparisons, is reported as previously described in the 
literature (80).  
For the purposes of direct comparison with one previous VBM study of people with 
RRMS (214), with and without neuropathic pain, VBM results from the comparison 
of subjects with and without pain were thresholded at the 5% significance level, as 
used in that study.  
5.2.3.1.2 Region of interest analyses 
Results were assigned statistical significance at 5% significance level, fully corrected 
for multiple comparisons, in region of interest analyses.  
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In order to reduce the likelihood of Type 1 error, the less stringent threshold of p< 
0.001, uncorrected for multiple comparisons, was not reported for region of interest 
analyses.  
5.2.3.1.2.1 Pre-specified region of interest analyses  
Grey matter volume: single three-dimensional mask of descending pain modulatory 
system (see below) 
T2 hyperintense lesions: three-dimensional mask of brainstem (see below) 
Standard space templates 
Throughout this chapter, widely used standard space templates are used. The 
MNI152 templates at 1mm and 2mm resolution (referred to as MNI152 1mm and 
2mm templates) were used. These atlases are derived from 152 T1 structural brain 
images, averaged together after high-dimensional nonlinear registration into the 
common MNI152 co-ordinate system (270). 
For Voxel Based Morphometry the MNI 2mm template was used, because this is the 
standard template used for the well-validated FSL VBM protocol, and is 
recommended by the FSL group for use in this protocol (271). Use of this protocol 
additionally ensures comparability of results with other experiments. 
For lesion analysis used the MNI 1mm template was used, in order to maximise 
resolution of the lesion probability maps in relation to small structures, specifically 
T2 hyperintense lesions and the brainstem.  
In the latter case, a study-specific template was not used, as use of the widely-
recognised MNI template additionally allows exploration of results using 
probabilistic atlases packed with FSL (105, 116, 272), both for reporting anatomical 
location of results, and for creating standardised masks (see above). 
Anatomical localisation 
Where specified, the Harvard-Oxford cortical or subcortical atlases (116, 272), or, in 
the case of brainstem anatomy, the Duvernoy atlas of the human brainstem and 
cerebellum (273) have been used. 
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Creation of three-dimensional masks for region of interest analyses.  
Where available, masks were based on the Harvard-Oxford cortical or subcortical 
structural atlases, packaged with FSL (105, 116, 272). These atlases provide 
probability maps of structure locations, in MNI 2mm standard space.  
Probability maps of structures were saved locally, thresholded at 50% probability (to 
exclude voxels of <50% likelihood of involvement in the structure) and then 
binarised using fslmaths, to create a three-dimensional mask. All voxels within the 
mask were assigned the value “1”, and those outside the mask the value “0”. 
Masks of the dorsolateral prefrontal cortex were kindly supplied by Dr Katja Wiech, 
FMRIB centre, University of Oxford. DLPFC masks were created as previously 
described (65). Briefly, masks were hand-drawn on T1 images based on Brodmann 
areas 8, 9, 46, 9/46 (approximately corresponding to the superior and middle frontal 
gyrus) (65). 
5.2.3.1.3 Brainstem mask in 1mm standard space 
The binarised brainstem mask in 2mm standard space created using the above 
method was transformed to 1mm standard space for use in lesion analyses. FSL’s 
FLIRT (274) was used, and registration to the standard space template checked 
visually.  
5.2.3.1.4 Descending pain modulatory system mask 
A single mask was created including the bilateral dorsolateral prefrontal cortex, 
bilateral insula, brainstem, anterior cingulate cortex, bilateral amygdala, orbitofrontal 
cortex and frontal pole. These structures were chosen based on published reports of 
anatomical structures involved in descending modulation of pain. Orbitofrontal 
cortex and frontal pole were included given the particular focus on any role of 
cognitive variables including set-shifting (Table 2) (1, 29, 33, 64, 96).   
Because of the exploratory nature of this study, masks of the whole brainstem, whole 
anterior cingulate and whole insulae were used. In other words, analysis of these 
structures was not further restricted to subregions such as rostral anterior cingulate, 
anterior insula, periaqueductal gray matter and rostral ventromedial medulla. 
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This mask is illustrated below (Figure 12: Mask of supraspinal descending pain 
modulatory system) 
Figure 12: Mask of supraspinal descending pain modulatory system used in this study 
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5.2.4 Intracranial Volume Estimation: comparison of methods 
General  
Intracranial Volume (ICV) was estimated by manual and automated methods in a 
subset of 28 study subjects (the entire study sample available at time of this analysis). 
Manual and automated ICV estimates calculated by these methods were compared by 
exploratory scatterplots, analysis of correlation and Bland-Altman plots.   
Automated ICV estimation using SPM, and semi-automated ICV estimation were 
compared. These methods were chosen because ICV estimation in SPM has been 
reported to be an acceptable alternative to manual segmentation (275). The current 
study, however, includes patients with differing central nervous system pathology, 
and uses different acquisitions.  Therefore, automatic ICV estimation using SPM, 
and semi-automated ICV estimation were compared. A comparison of separate 
automated methods (SPM and FSL) was not carried out as this was not the focus of 
the current study. 
Manual estimation of ICV:  
Preliminary intracranial volume (ICV) estimates were calculated using BETSURF, a 
modification of FSL’s Brain Extraction Tool (BET) package (276, 277) using 
multispectral (T1- and T2-weighted) input. Brain extraction was centred on the 
approximate centre of each subject’s brain (identified visually in FSLVIEW), using 
the “-c” option within BET. The ‘innerskull mesh’ estimate output by BETSURF 
was used as an initial guide to the outer boundary of ICV. 
Resultant estimates were then manually edited for accuracy in Analyze v11.0 (265). 
A trained neurologist (PF, trained by Maria Valdes Hernandez) manually traced ICV 
for each subject, using native space MPRAGE images.  The inferior limit of the ICV 
was set as the foramen magnum (odontoid peg just visible on axial images). The ICV 
estimate resulting from BETSURF was edited in contiguous sagittal slices.  This 
process is further illustrated below (Figure 13). 
Figure 13: process of manual ICV estimation 
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The total volume of the resultant manually edited ICV estimate was calculated using 
fslmaths. 
Fully automated estimation of ICV 
Each subject’s smoothed and cropped T2-weighted and FLAIR images were linearly 
coregistered to each subject’s MPRAGE image using affine space transformation in 
FSL’s FLIRT (278, 279). A normalized mutual information cost function, with 12 
degrees of freedom, was used.  
The coregistered images were then subject to multispectral segmentation (using T1-, 
T2-weighted and FLAIR images) using New Segment in SPM12 (263). Three tissue 
classes were specified. Tissue volumes were calculated by the “tissue volumes” 
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utility supplied within the batch editor in SPM. This computes the totals of 
modulated warped tissue class segmentations (275). 
Intracranial volume was calculated by summing grey matter (GM), white matter 
(WM) and cerebrospinal fluid (CSF) estimates obtained from New Segment 
implemented in SPM 12 (263, 275). This method has been found to produce 
estimates of ICV which closely correlate with manual image segmentation, including 
in subjects with CNS neurodegenerative disease (275). 
Comparison of manual and automated ICV estimation 
Associations between ICV estimates for each subject were explored using a 
scatterplot. Correlation was calculated using Spearman’s Rho.  In order to further 
investigate mean difference between manual and automated estimates of ICV, a 
Bland Altman plot was then constructed using the Bland Altman function available 
from the MethComp package in R (280). 
Based on the above findings (see results), further analysis used automated estimates 
of ICV for the study group as a whole (n=45).  
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5.2.5 Tissue type segmentation 
General description and preprocessing 
Volumes of separate tissue classes (Grey Matter, White Matter and Cerebrospinal 
Fluid) (GM, WM and CSF) were calculated as described above (5.2.4). 
5.2.6 Lesion segmentation 
Working definition of T2 hyperintense lesions 
MS lesions (termed here white matter lesions, or WMLs) were defined as appearing 
hyperintense in relation to surrounding white matter or grey matter on T2 weighted 
and FLAIR images, with an irregular or ovoid appearance, and most commonly 
occurring in the periventricular white matter, juxtacortical and infratentorial regions 
(76, 281).  
Specifically, care was taken to avoid misclassification of enlarged perivascular 
spaces. In cases where there was any doubt as to whether an MRI hyperintensity 
represented a WML (in contradistinction to ischaemic lesion, enlarged perivascular 
space or imaging artefact), the hyperintensity was excluded from analysis.  
A semi-automated approach to generating single subject lesion maps was used. This 
process comprised the following steps: 
Independent blinded neuroradiologist review of imaging 
An experienced neuroradiologist (Professor Sellar), blinded to patient status with the 
sole exception of the diagnosis of multiple sclerosis, identified lesion location using 
each subject’s MPRAGE, T2-weighted and FLAIR images in native space.  A report 
was generated and subsequently anonymised. 
Provisional automated lesion map generated for each subject 
Intensity thresholding of FLAIR images at greater than 2 standard deviations above 
mean image intensity of the brain parenchyma was carried out using a program 
developed in-house (Maria Valdes-Hernandez) and implemented in MatlabR2014a 
(267).  Intensity thresholding of the FLAIR images was carried out automatically 
after applying the ICV mask generated by semi-automated techniques described 
above.  
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Creation of manually edited lesion map for each subject 
Lesion maps were then edited manually, using  each subject’s FLAIR image, by a 
neurologist trained in lesion identification (PF), with simultaneous review of T2-
weighted imaging using Mango image viewer (264), and using the existing 
neuroradiology report in order to minimise misclassification (see above). Each 
subject’s data was identified only by the subject’s computer-generated 4-digit subject 
code. Images were viewed in the axial plane and sagittal planes. 
This process is illustrated below (Figure 14). Please note the contrast of manual and 
automated lesion mask estimates (B and C). 
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Calculation of lesion volume in native space 
Total lesion volume for each subject was calculated in the subject’s native space 
using fslmaths in cubic millimetres. In order to take into account possible effects of 
head size, which was a covariate of no interest, lesion volume was expressed for each 
subject as a fraction of the intracranial volume (ICV).  
5.2.6.1.1 Calculation of brainstem lesion volume in native space 
In a further exploratory analysis, based on the study hypotheses, lesion volume 
within the brainstem only was calculated. 
A brainstem mask was created as described above (5.2.3.1.3). Subsequently the mask 
was registered to individual subjects’ native space (using the inverse of the nonlinear 
warp described below), registration checked visually in FSLVIEW, and lesion 
volume within the native space brainstem ROI calculated using fslmaths.  
Intra-rater reliability of manual lesion segmentation 
A sample of 9 study subjects were selected for evaluation of the reproducibility of 
manual lesion segmentation.  
5.2.6.1.2 Selection of study subjects 
9 study subjects were selected in order to approximate 20% of the total study sample. 
The subjects were selected at random from the whole study group (including subjects 
both with and without pain) using their computer-generated subject ID codes, and 
using the command “sample” implemented in R, n=9, no resampling). 
5.2.6.1.3 Calculation of intra-rater reliability 
Using identical methods to those outlined above, binary lesion masks were created 
without sight of the previous white matter hyperintensity map. The original 
automated lesion estimation was not repeated.  
Lesion volumes in subject native space were calculated as described above. Volumes 
derived by the first and second manual segmentation processes were calculated using 
fslmaths, and compared using a Bland-Altman plot, and the Intraclass Correlation 
Coefficient with accompanying 95% confidence interval (implemented in R using 
the packages ‘MethComp’(280), and ‘psych’(282), respectively). Time elapsed 
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(days) between first and second estimates were reported, as short times elapsed could 
make memory effects more prominent. 
5.2.7 Group-level lesion probability maps 
Transforming single-subject lesion masks to standard space 
Each subject’s MPRAGE T1 image was linearly registered to their T2 image using 
FSL’s FLIRT (with 12 degrees of freedom) and a correlation ratio cost function (278, 
279).  
For purposes of registration, this MPRAGE image was then skull-stripped using 
FSL’s BET, and this skull-stripped  image then registered to the Montreal 
Neurological Institute (MNI152) skull-stripped 1mm template with a nonlinear 
registration procedure, implemented in FSL’s FNIRT (274). Skull-stripped T1 
(MPRAGE) images were used for registration according to existing 
recommendations (274, 278, 279). 
The resulting nonlinear transformation matrix was then applied to each individual 
subject’s lesion mask to transform the mask into the space of the MNI152 1mm 
skull-stripped template. A nearest neighbour cost function was used, to remove the 
requirement for re-thresholding of binary lesion maps. Masks were reviewed visually 
after transformation to standard space, to ensure accuracy of registration. 
Creating group-level lesion probability maps 
Lesion probability maps for each group were created by summing and then averaging 
individual lesion maps in MNI space. In-house software implemented in Matlab 
(written by Maria Valdes-Hernandez) was used.  
The resulting lesion probability maps represent the percentage probability of lesion 
location at each voxel in the standard-space image, within the study group. Separate 
lesion probability maps were created for  
 The study group as a whole 
 Subjects with neuropathic pain 
 Control subjects without neuropathic pain 
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5.2.7.1.1 Comparison of group-level lesion probability maps 
Lesion probability maps for each group were firstly compared visually. To firstly 
explore the difference between group lesion probability, probability maps from each 
group were simply subtracted using fslmaths to create a ‘difference map’ using a 
method previously described (283).  
In order to identify any lesion location which might be statistically significantly 
different between groups with and without pain, after taking account of multiple 
comparisons in space, the nonparametric permutation inference tool Randomise was 
used (284) as described in previous work (283).  
For each study group, individual subjects’ lesion distribution maps were 
concatenated in the temporal dimension by using fslmerge (105), in order to create a 
single 4-dimensional ‘image’. An unpaired t-test analysis design was set up using 
FSL’s GLM GUI, and the concatenated lesion maps then analysed for difference 
between pain and control groups. Randomise was run with 5000 permutations, within 
a binary mask of the skull-stripped MNI 152 1mm template (distributed with FSL), 
and using threshold-free cluster extent (TFCE) statistics, with correction for multiple 
comparisons and 5% significance threshold. 
5.2.8 Voxel Based Morphometry 
Voxel Based Morphometry (VBM) was carried out using FSL VBM (271). T1 
MPRAGE images were used, having previously removed extraneous neck data using 
fslroi (see above for description 5.2.2.1.5), and carried out lesion filling,. 
Lesion filling 
Each subject’s binary lesion map, created as described above, was linearly 
transformed from T2 space to their native-space MPRAGE image, using a linear 
transformation in FSL’s FLIRT (278). Registration was checked visually. 
Automated lesion filling was carried out on each subjects MPRAGE images to 
minimise impact of MS lesions on subsequent tissue-class segmentation. 
Lesion_filling implemented in FSL (215) was used. Lesion filling has been 
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demonstrated to reduce misclassification of focal lesions as grey matter and has been 
implemented in FSL (215, 285) and SPM (286) 
VBM processing 
VBM processing followed standard protocols. Images were first brain-extracted 
within the FSL VBM pipeline. Brain extraction was checked manually in all cases. 
Where brain extraction was not satisfactory, further brain extraction was optimised 
on a per-subject basis using options within FSL-BET (276) including manual 
centring (“-c” call). Grey matter was then segmented and registered to the MNI 152 
standard space using non-linear registration (274). The resulting images were 
averaged and flipped along the x-axis to create a study-specific grey matter template 
which is symmetrical left:right. 
All native grey matter images were then non-linearly registered to this study-specfic 
template. Modulation by the Jacobian of the warp field was used to correct for local 
expansion due to the non-linear component of the spatial transformation.  
The modulated grey matter images were smoothed with an isotropic Gaussian kernel 
with a sigma of 3mm (approximate full-width-half-maximum 7mm). All templates 
were checked visually. 
A voxelwise general linear model was applied using permutation-based non-
parametric testing, correcting for multiple comparisons across space. Tests were 
applied across either the whole grey matter, or the predefined mask of the descending 
pain modulatory system (as described), specified by the “–m” call within randomise 
(287). Threshold-free cluster extent testing was used. 
ICV (estimated by summing GM, WM and CSF volumes (275, 288)) was included as 
a nuisance covariate in all VBM analyses. Age was included in all VBM analyses 
apart from where correlates of pain duration were investigated, because pain duration 
and age were found to be moderately collinear (Rho 0.41, p= 0.02) and non-inclusion 
of age in this model avoided this source of  collinearity (96). 
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5.2.8.1.1 Voxel Based Morphometry in SPM  
Voxel based morphometry is widely used in the SPM package as well as the FSL 
package. Although SPM was used for tissue class segmentation and consequent 
estimation of ICV, as described above, SPM was not used for the final VBM analysis 
described.  
In particular, estimates from the VBM analysis are output in a format comparable to 
other analyses in this thesis, which were carried out in FSL. For instance, SPM 
outputs images in neurological rather than radiological convention. By using FSL 
VBM,  estimates from the VBM analysis could be input into further analyses (such 
as resting state fMRI analyses) if required.  
 
5.2.9 Exploratory analysis of cervical cord cross-sectional 
area from MPRAGE brain acquisitions 
Review of available data 
All MPRAGE images were reviewed visually in sagittal, axial and coronal views 
using Mango image viewer (264) to establish 
1) Presence or otherwise of required levels of spinal cord within available data, 
and 
2) Visible degradation of data at that level (for instance by signal drop out or 
artefact) which was felt to preclude meaningful assessment of cord cross-
sectional area. 
a. For the latter estimate, because we aimed to establish the feasibility of 
these techniques, only data where meaningful assessment was felt to 
be impossible, was excluded.  
T2 and FLAIR images were also reviewed visually to establish presence of 
demyelinating lesions at the levels studied. Study subjects in whom demyelinating 
lesions were present at the levels of study, were excluded from further analysis.  
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Image pre-processing 
Volumetric MPRAGE images for each subject were reoriented and smoothed as 
described above (5.2.2) 
The resulting MPRAGE images were viewed in Mango image viewer (264) and 
rotated, as necessary, in the x,y and z planes so that axial slices orthogonal to the 
cord could be extracted (118). The resulting images were then cropped at the level of 
the mid-pons rostrally, and inferior extent of the available image, caudally.  
5.2.9.1.1 Cord cross-sectional area estimates: manual and automated 
Cervical cord cross-sectional area was estimated at two separate levels:  
 2.5 cm below the inferior margin of the pons (termed here “P2.5” level 
(118)), and  
 C2/3 level (termed here “C2/3”).  
These levels were chosen as they were most reliable in terms of inter-rater reliability 
in one previous study (118) and C2/3 level is commonly used in studies of cervical 
cord cross-sectional area (CC CSA) (117). 
Both manual and automated estimates were made for a subset of 15 subjects. For 
these purposes, 15 subjects were chosen at random using the function “sample” 
implemented within R (without resampling).  
Manual estimation: 
5.2.9.1.2 Level 2.5cm below pons (spinomedullary junction level) 
Please see Figure 15 below for a summary of this process. 
The caudal margin of the pons was identified visually, and a distance of 2.5cm below 
this level measured using Mango image viewer. This level was set as the rostral 
extent of an ROI for spinal cord cross-sectional area estimation. 
The image was then viewed in the axial plane, and zoom of 300% applied in Mango 
image viewer. A manual “paint to fill” approach using the ROI estimation drawing 
tool (“ellipse” setting) in Mango image viewer was used to create a spinal cord cross-
sectional area estimate. The same estimate was then made at a further 4 contiguous 
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slices, ie on 5 slices over a 5mm distance cranio-caudally. Mean cross-sectional area 
within this volume was then calculated (118) using Microsoft Excel .  
5.2.9.1.3 Level C 2/3 disc space 
The C2/3 disc space was identified using the sagittal MPRAGE images, and the 
middle of the anterior border of the disc space identified (118). This level was used 
as the middle slice of 5 contiguous 1mm slices over 5mm cranio-caudally, over 
which cross-sectional cord area was estimated manually using the procedure above.  
Automated estimation of CC-CSA: 
Cropped, reoriented MPRAGE images, as described above, were used to create a 
binary estimate of cervical cord using Spinal Cord Toolbox (266). Spinal cord 
segmentation used the ‘sct_propseg’ program within this toolbox, which has been 
validated in healthy controls, and two subjects with structural cord injury. This 
recently developed technique uses four steps (266):  
1) Detection of the median plane of the image 
2) Detection of potential spinal cord position, on multiple axial slices 
a. This step uses an elliptical Hough transform, and may initially 
misidentify nearby structures of similar shape, such as carotid artery, 
as spinal cord 
b. False positives are removed by discarding estimates which are not 
surrounded by spinal canal 
3) Resulting chains of ellipses representing possible spinal cord boundaries are 
identified by neighbourhood analysis 
4) A discriminant analysis determines correctness of the spinal cord border 
detection based on mean and standard deviation of the spinal cord radius, and 
cord:CSF signal contrast.  
Registration to a standard space template, and/or tissue-type segmentation were not 
carried out. Binary cord segmentation estimates were reviewed visually for accuracy.  
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5.2.9.1.4 CC-CSA estimates without correction for image alignment 
Automated CC-CSA estimates output by Spinal Cord Toolbox include a further 
correction for image alignment (266) . CC-CSA estimates output with this further 
correction might not be directly comparable to manual estimates.  
In order to estimate cross-sectional area in a manner directly comparable to the 
manual segmentation described above, firstly manual ROIs were created by 
extending the manual cord cross-sectional area estimates described above, in the 
antero-posterior axis, beyond the extent of the spinal canal. The intersection of the 
spinal cord segmentation estimate generated by Spinal Cord Toolbox, and the 
manual spinal canal estimate described, was then calculated using fslmaths. This 
procedure was carried out to ensure that the CC-CSA estimates obtained from 
manual and automated methods were derived from identical levels of the cervical 
cord. 
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Figure 15: manual and automated estimates of cervical spinal cord cross-sectional area 
(spinomedullary junction level) 
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Comparison of automated and manual estimation 
Automated and manual cord cross-sectional area estimates were then compared 
separately at the P2.5 and C2/3 level.  
Data distribution was examined by histogram and QQ plot. Where data was not 
normally distributed, between-group differences were tested by Mann-Whitney U 
test (Wilcoxon rank sum test) and correlation by Spearman’s Rho (137). 
Cross-sectional cord area estimates were firstly compared visually (see Figure 1), 
then correlation examined using an exploratory scatterplot, and, if appropriate, 
Spearman’s Rho. In order to further investigate mean difference between manual and 
automated estimates at each of these levels, and to look for associations between 
cord cross-sectional area and difference between the two described methods, a 
Bland-Altman plot was then constructed using the BlandAltman function available 
from the MethComp package in R (280). 
Based on the above findings (see results), further analysis used automated estimates 
of cord cross-sectional area for the study group as a whole (n=45). Further automated 
estimates used CC-CSA estimates further adjusted for centreline orientation within 
Spinal Cord Toolbox compute_csa program. 
Examining associations between cord cross-sectional area, imaging 
and clinical parameters 
Exploratory correlations between cord cross-sectional area at both levels examined, 
radiological and clinical variables (namely EDSS and disease duration) were 
examined in a correlation matrix using Spearman’s Rho. Associations with gender 
were separately examined using Wilcoxon’s rank sum test and 95% CI of difference 
between groups. Because the optimal use of this data is not established, both ‘raw’ 
cross-sectional area, and CSA corrected for ICV, were examined.  
Because correlations of cord cross-sectional area with EDSS and disease duration 
might be affected by pain severity in the pain group, but not the control group, these 
two groups were also examined separately in a further exploratory analysis.  
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Lastly cord cross-sectional area was compared between patients with and without 
neuropathic pain in this study. Throughout, significance levels were not corrected for 
multiple comparisons due to the exploratory nature of this substudy. 
5.3 Results 
5.3.1 Availability of data 
Structural MRI brain imaging data was available for 45 of the 47 subjects who 
entered the study (29 of 31 subjects with neuropathic pain, 16 of 16 control subjects 
without neuropathic pain).  
One subject in the pain group was unable to undergo MRI imaging because of 
claustrophobia, and the other because of a previously undisclosed contraindication to 
MRI imaging which became apparent at time of safety checks immediately prior to 
imaging. 
5.3.2 Comparison of Intracranial Volume (ICV) estimation 
techniques 
Visual comparison 
Semi-automated and automated estimates were compared in fslview for the 28 
subjects included in the substudy comparing these techniques.  
In all cases, results were comparable. SPM12 segmentations typically did not include 
venous sinuses within the intracranial volume, suggesting that ICV estimated by 
SPM might be systematically slightly lower than that estimated manually.  
Correlation of automated and semi-automated ICV estimates 
An exploratory scatterplot comparing automated and semi-automated approaches 
confirms that the ICV estimates output by the two approaches are highly correlated. 
The data are displayed alongside a hypothetical “line of equality”, where ICV 
estimates arising from the two approaches are identical. It can be seen that SPM ICV 
estimates tend to be lower than those arising from manual ICV estimation.  
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Figure 16: correlation of automated and semi-automated ICV estimates 
 
Spearman’s Rho confirmed that the two estimates were highly correlated, as 
expected (Rho 0.94; p = 8.6 x 10-14)
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Agreement between measurement techniques 
Construction of a Bland-Altman plot confirms that automated ICV estimation tends 
to estimate ICV as 0.135 litres lower than manual estimates, on average (Figure 17). 
On visual inspection of the plot, no systematic association between mean ICV 
measured by the two techniques, and difference between the two techniques, is 
apparent.  
 
Figure 17: Bland-Altman plot comparing manual and automated ICV estimates (n=28) 
 
Upper limit of 
agreement =  
0.195 litres 
 
Mean difference = 
0.135 litres 
 
Lower limit of 
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5.3.3 Intra-rater reliability of manual white matter lesion 
segmentation 
Repeat white matter hyperintensity volume estimates were derived for 9 subjects.  At 
the first analysis, mean lesion volume was 3369.3 mm3 (range 1033 to 7097). At the 
second analysis, mean lesion volume was 3387.9 mm3 (range 1046 to 7236). Median 
time elapsed between manual editing of lesion masks on the first and second 
occasions was 176 days (IQR 60 to 180 days, range 60 to 181 days). 
Correlation 
An exploratory scatterplot suggested that white matter hyperintensity volume 
estimates at first and second analysis were closely correlated. Results are plotted with 
a hypothetical “line of equality” along which first estimate would exactly match 
second estimate.  
Figure 18: Scatterplot of first and second white matter hyperintensity manual lesion mask (n=9) 
 
Intraclass correlation coefficient for this small sample was 1 (95% CI 0.98 to 1), 
suggesting high intra-rater reliability in this small sample.  
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Agreement between repeated measures 
Bland Altman plot demonstrated that average lesion volume per subject on the 
second analysis was 18.56 mm3 lower than at first estimate, with 2.5% and 97.5% 
limits of agreement -430.9, and 393.8 mm3 respectively (Figure 19).  




No relationship of subject lesion volume, and tendency to over- or under-estimate 
lesion volume in comparison with first estimation, was observed.  




Upper limit of 
agreement =  
-430.9 mm3 
 
Mean difference = 
-18.6 mm3 
 
Lower limit of 
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5.3.4 Associations of the presence of pain: comparison of MS 
subjects with and without neuropathic pain 
 
Volumes of overall tissue classes 
No statistically significant difference was found between subjects with and without 
neuropathic pain, in Intracranial Volume, total Grey Matter Volume, or Brain 
Parenchymal Volume (Table 41). 












(1.28 to 1.40) 
1.36 
(1.34 to 1.44) 
-0.12 to 0.04 0.23 
Total Grey 
Matter Volume 
(% of ICV) 
41.02  








(% of ICV) 
74.23  




-1.68 to 2.39 0.97 
ICV = Intracranial Volume 
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Lesion volume and distribution 
5.3.4.1.1 General description 
T2 hyperintense lesions consistent with the known diagnosis of Relapsing Remitting 
Multiple Sclerosis were observed in all patients included in the study.  Lesions were 
concentrated in the periventricular white matter, though distribution throughout the 
brain was variable, and included subcortical and brainstem locations.  
5.3.4.1.2 T2 hyperintense lesion volume (whole brain, and brainstem) 
Lesion volume (expressed as a percentage of ICV) was not significantly different 
between the pain and control groups. Lesion volume localised to the brainstem was 
significantly higher in the pain group than the control group (p=0.0049). 
Table 42: overall lesion volume, whole brain and brainstem – comparison between pain group and 
control group. 
 Control Group  
(% of ICV) 
(median, IQR) 
(n=16) 
Neuropathic Pain  




Total T2 visible 
lesion load  
0.12  
(0.06 to 0.42) 
0.20 
(0.12 to 0.42) 
0.21 
Brainstem T2 
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5.3.4.1.3 Lesion topography: overall and by group 
The highest probability of lesion location in the group as a whole was found at MNI 
coordinates x= -16, y= -15, z= 27, adjacent to the left lateral ventricle (percentage 
probability of lesion location 59.6%). 
The highest probability of lesion location in the group with pain was found at MNI 
coordinates x=18, y=-17, z=28, adjacent to the right lateral ventricle (percentage 
probability of lesion location 69.0%). 
The highest probability of lesion location in the control group was found at MNI 
coordinates x=-17, y=-13, z=27, adjacent to the left lateral ventricle (percentage 
probability of lesion location 62.5%).  
See below (Figure 20) for lesion probability maps throughout the study group (n=45) 
as a whole, as well as pain group (n=29) and control group (n=16) separately. 
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Figure 20: Lesion distribution probability maps: Whole group, pain group and control group (n=45 
total) 
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5.3.4.1.4 Lesion topography: comparison by subtraction maps 
For the contrast between pain group and control group, lesion distribution probability 
“difference maps” are shown in Figure 21. This figure shows the distributions where 
lesion location is more likely in the pain group (without correction for multiple 
comparisons) and where lesion location is more likely in the control group (without 
correction for multiple comparisons) as estimated by simple subtraction. 
The highest likelihood of lesion location in the pain group relative to the control 
group was at MNI coordinates x=-17, y=-22, z=27, adjacent to the left lateral 
ventricle (probability = 44.9%).  
The highest likelihood of lesion location in the control group relative to the pain 
group was at MNI coordinates x=-27, y=-51, z=15, also adjacent to left lateral 
ventricle (probability = 35.6%). 
On visual comparison of the two difference maps, no clear difference was observed 
in supratentorial white matter hyperintensity distribution. The volume of voxels 
where lesion location was more likely in the pain group than the control group 
appeared higher than the volume of voxels where lesion location was more likely in 
the control group. Lesions located in the brainstem appeared more likely in the pain 
group than the control group on visual comparison.  
Please see Figure 21. 
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Figure 21:  Difference in lesion probability maps, pain and control group, by groupwise subtraction 
 
  Thesis: Pain in Multiple Sclerosis 
Structural imaging associations of neuropathic limb pain in MS                         222 
5.3.4.1.5 Lesion topography (whole brain) at 5% significance level, corrected 
for multiple comparisons 
No statistically significant difference in lesion topography was found between pain 
and control groups, at the 5% significance level, and corrected for multiple 
comparisons in space.  
5.3.4.1.6 Lesion topography (whole brain) at 0.1% significance level, 
uncorrected for multiple comparisons 
In an exploratory analysis using a less stringent threshold of p<0.001, uncorrected for 
multiple comparisons across the whole brain, only a single voxel exceeded 
significance thresholds. This voxel was located at MNI coordinates x=22, y=-76, z=7 
(adjacent to the occipital horn of the right lateral ventricle). This finding is of 
doubtful clinical significance and should be interpreted with caution. 
5.3.4.1.7 Lesion topography (brainstem region of interest) at 5% significance 
level, corrected for multiple comparisons 
In a brainstem-restricted region of interest analysis, at 5% significance level and 
corrected for multiple comparisons in space, lesions were more likely to occur in the 
pain group at the following locations (Table 43; Figure 22). 
Table 43: anatomical location of T2 hyperintense lesions more likely in pain group than controls 
MNI 
coordinates 
  Region anatomical correlate on 
inspection of axial magnetic 
resonance microscopy 
images (Duvernoy atlas 
(273)) 
x y z   
10 -39 -34 Right cerebellar 
peduncle 
cerebellar peduncle 
-10 -24 -40 Lateral mid-pons Arcuate nuclei of pons 
0 -27 -45 Basal pons Arcuate nuclei of 
pons/pontine decussation 
 
No lesion location was found to be more likely to occur in the control group. 
 
  Thesis: Pain in Multiple Sclerosis 
Structural imaging associations of neuropathic limb pain in MS                         223 
Figure 22: Brainstem lesion topography - locations of T2 hyperintense lesions more likely in pain 
group than controls 
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Voxel Based Morphometry 
5.3.4.1.8 Whole grey matter analysis, 5% significance level corrected for 
multiple comparisons 
At the 5% significance level, with correction for multiple comparisons, no difference 
in grey matter volume was found between subjects with and without neuropathic 
pain.  
5.3.4.1.9 Whole grey matter analysis, 0.1% significance level uncorrected for 
multiple comparisons.  
In an exploratory whole-grey-matter analysis where p<0.001, uncorrected for 
multiple comparisons in space, differences in grey matter volumes were seen in the 
following locations (Table 44, Figure 23, Figure 24). 
Table 44: Localisation of VBM result; exploratory threshold p<0.001 uncorrected 
 MNI 
coordinates 
  Anatomical localisation (116, 
272) 
 x y z  
Volume 
greater in  
control 
group 
-6 -38 28 Mid-posterior cingulate, bilateral 
but centred on left 
 24 -16 -32 Right parahippocampal gyrus 
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Figure 23:Voxel based morphometry - grey matter volume greater in control group than pain 
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Figure 24: Voxel based morphometry: grey matter volume greater in pain group than control 
group; exploratory threshold p<0.001 uncorrected 
 
 
5.3.4.1.10 Grey matter analysis, restricted to mask of descending pain 
modulatory system, 5% significance level corrected for multiple 
comparisons 
No difference in grey matter volume was found at the 5% significance level. 
 
5.3.4.1.11 Whole grey matter analysis, 5% significance level uncorrected 
for multiple comparisons (for the purpose of comparison with 
previously published data (214)) 
Widespread differences were found between the pain and control groups at this 
significance threshold, which could be regarded as statistically relaxed. Conclusions 
drawn fromthese data should be limited. These are listed below, with particular 
emphasis on structures known to be relevant to central processing of pain. 
5.3.4.1.11.1 Structures where grey matter volume less in those with neuropathic 
pain, than those without: 
 Cerebellum: right cerebellar cortex and vermis 
 Orbitofrontal cortex (bilaterally) 
 Bilateral temporal lobes (mesial and lateral) including hippocampi but not 
amygdalae 
 Bilateral occipital lobes 
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 Bilateral frontal pole 
 Bilateral insular cortex (anterior and posterior) 
 Bilateral posterior cingulate, bilateral precuneous 
5.3.4.1.11.2 Structures where grey matter volume greater in pain group than control 
group:  
 Bilateral cerebellar hemispheres posteriorly 
 Bilateral pons and midbrain including PAG 
 Bilateral amygdalae 
 Bilateral thalamus 
 Bilateral anterior cingulate 
 Bilateral postcentral gyrus 
 Right superior parietal lobule 
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5.3.5 Correlates of pain severity 
Volumes of overall tissue classes 
 
No statistically significant association of Intracranial Volume, Grey Matter Volume 
or Brain Parenchymal Fraction with pain severity was found (Table 45). 
Table 45: Correlations of tissue class volumes with pain severity 




Total Grey Matter Volume 
(% of ICV) 
0.12 0.53 
Brain Parenchymal Volume 
(% of ICV) 
0.23 0.24 
 
Lesion volume and distribution 
5.3.5.1.1 T2 hyperintense lesion volume (whole brain) 
Whole-brain T2 hyperintense lesion volume was not significantly correlated with 
pain severity (Spearman’s Rho -0.20, p=0.29) 
5.3.5.1.2 T2 hyperintense lesion volume (brainstem only) 
Brainstem-restricted T2 hyperintense lesion volume was not significantly correlated 
with pain severity (Spearman’s Rho -0.36, p=0.056) 
5.3.5.1.3 Lesion topography (whole brain) at 5% significance level, corrected 
for multiple comparisons. 
Lesion topography was not correlated with pain severity at the 5% significance level, 
corrected for multiple comparisons across the whole brain using Randomise. No 
specific lesion location was positively or negatively associated with the severity of 
pain. 
5.3.5.1.4 Lesion topography (whole brain) at 0.001% significance level, 
uncorrected for multiple comparisons across space 
Lesion topography was not correlated with pain severity at the p<0.001 level, 
uncorrected for multiple comparisons in space. No specific lesion location was 
positively or negatively associated with the severity of pain. 
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5.3.5.1.5 Lesion topography (brainstem region of interest), 5% significance 
level, corrected for multiple comparisons 
Lesion topography was not correlated with pain severity at the 5% significance level, 
corrected for multiple comparisons in space across the brainstem. 
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 Voxel Based Morphometry 
 
5.3.5.1.6 Whole grey matter analysis, 5% significance level corrected for 
multiple comparisons 
No association of regional grey matter volume with pain severity was found 
5.3.5.1.7 Whole grey matter analysis, exploratory 0.1% significance level, 
uncorrected for multiple comparisons 
In this exploratory analysis, no regional grey matter volume change was significantly 
associated with pain severity, in either the positive or negative direction. Some 
regional grey matter volumes closely approached the statistical threshold applied, 
however are not reported here.  
5.3.5.1.8 Grey matter analysis, restricted to mask of descending pain 
modulatory system, 5% significance level 
No association of regional grey matter volume with pain severity within the 
described mask was identified. 
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5.3.6 Grey matter correlates of pain duration 
 
Positive correlation of grey matter volume with pain duration 
 
5.3.6.1.1 Whole grey matter analysis, 5% significance level corrected for 
multiple comparisons 
No local grey matter volumes were positively correlated with pain duration at this 
significance level 
5.3.6.1.2 Grey matter analysis restricted to DPMS mask, 5% significance 
level corrected for multiple comparisons 
No local grey matter volumes were positively correlated with pain duration at this 
significance level 
5.3.6.1.3 Whole grey matter analysis, 0.1% significance level not corrected 
for multiple comparisons 
No local grey matter volumes were positively correlated with pain duration at this 
exploratory significance level 
 
Negative correlation of grey matter volumes with pain duration 
 
5.3.6.1.4 Whole grey matter analysis, 5% significance level corrected for 
multiple comparisons 
No local grey matter volumes were positively correlated with pain duration at this 
significance level 
 
5.3.6.1.5 Grey matter analysis restricted to DPMS mask, 5% significance 
level corrected for multiple comparisons 
No local grey matter volumes were positively correlated with pain duration at this 
significance level 
 
5.3.6.1.6 Whole grey matter analysis, 0.1% significance level not corrected 
for multiple comparisons 
Lower grey matter volumes in the left anterior cingulate (x51,y59,z56) were 
negatively correlated with pain duration at this exploratory significance level. 
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5.3.7 Exploratory analysis of cross-sectional cord area 
 
Availability of data 
Structural brain MRI MPRAGE data was available for 45 subjects. All brain MRI 
data included the P2.5 level. 44 of 45 (97.8%) included the C2-3 level. 
Quality of data 
All images allowed an estimation of cord cross-sectional area. CC-CSA could be 
estimated in 45 subjects at P2.5 level, and 44 at C2/3 level.  No images were 
excluded on the basis of poor quality.  No subjects were excluded because of 
presence of demyelinating cord lesions at the levels studied. 
 Manual and automated cross-sectional area at P2.5 (spinomedullary 
junction) 
5.3.7.1.1 Performance of automated segmentation – visual inspection 
The techniques described were successful in generating estimates of cord cross-
sectional area in all cases. No misidentification of adjacent structures (such as the 
carotid artery) occurred.  Estimates arising from manual and automated techniques 
were visually comparable in all cases.  
5.3.7.1.2 Correlation 
An exploratory scatterplot confirmed close correlation across the range of available 
data in this small sample (Figure 25), presented with line of equality for the 
hypothetical case where automated estimate = manual estimate, for 
comparison).Mean cervical cord cross sectional area derived by automated and 
manual methods at the P2.5 level were highly correlated (Spearman’s Rho 0.87, 
p=2.2x10-5).  
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5.3.7.1.3 Bland-Altman plot 
A Bland-Altman plot confirmed close agreement of the two methods across the range 
of data in this small sample, with a mean difference of 0.47 mm2 (automated estimate 
tending to be larger, on average), and 2.5% and 97.5% limits of agreement -6.73 and 
5.80 mm2 respectively. On visual inspection of the plot, no association between cord 
cross-sectional area and difference between estimation methods was apparent.  
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Figure 26: Bland Altman plot comparing manual and automated CSA estimates at P2.5 
(spinomedullary junction level) (n=15) 
 
 
Manual and automated cross-sectional area at C2/3 level 
5.3.7.1.4 Visual inspection 
The techniques described were successful in generating estimates of cord cross-
sectional area in all cases at the C2/3 level. No misidentification of adjacent 
structures (such as the carotid artery) occurred.  Estimates arising from manual and 
automated techniques were visually comparable in all cases.  
5.3.7.1.5 Correlation 
An exploratory scatterplot confirmed close correlation across the range of available 
data in this small sample (Figure 4). Data are shown with the hypothetical line of 
equality, along which manual and automated estimates would be identical.  
Mean cervical cord cross sectional area derived by automated and manual methods at 
the C2/3  level were highly correlated (Spearman’s Rho 0.90, p=4.4x10-6).  
Upper limit of 
agreement =  
5.70 mm2 
 
Mean difference = 
-0.47 mm2 
 
Lower limit of 
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Figure 27: Scatterplot comparing manual and automated CSA estimates (C2/3 level) 
 
 
5.3.7.1.6 Bland Altman plot 
A Bland-Altman plot confirmed close agreement of the two methods across the range 
of data in this small sample, with a mean difference of 0.33 mm2 (manual estimate 
tending to be larger, on average), and 2.5% and 97.5% limits of agreement -5.97 and 
6.63 mm2 respectively. On visual inspection of the plot, no association between cord 
cross-sectional area and difference between estimation methods was apparent (Figure 
28). 
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Figure 28: Bland Altman plot comparing manual and automated techniques for CSA estimation 
(C2/3 level) 
 
Use of automated estimates for further analysis 
Because manual and automated estimates of CC-CSA were highly correlated, and 
Bland-Altman plots were judged to be satisfactory in a subgroup of 15 randomly 
selected patients, automated estimation was used for further analysis in the entire 
subject group (n=45).  
Upper limit of 
agreement =  
6.63  mm2 
 
Mean difference = 
0.33  mm2 
 
Lower limit of 
agreement =  
-5.97  mm2 
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Correlation between CC-CSA estimates and ICV. 
CC-CSA at P2.5 and C2/3 levels were positively correlated both with and without 
correction for ICV (Spearman’s Rho 0.53, uncorrected p<0.001, and 0.56, 
uncorrected p<0.001 respectively). 
The correlation between CC-CSA at P2.5 level and ICV was stronger than at C2/3 
level (Spearman’s Rho 0.32, uncorrected p=0.03; and 0.13, uncorrected p=0.39 
respectively). 
These data are further explored in Table 46. 
Table 46: Spearman correlations between automated cord cross-sectional area estimates, and 
intracranial volume (n=45) 














































CSA= mean cervical cord cross-sectional area measured across 5 contiguous 1mm 
slices 
C2/3= C2/C3 disc level  
P2.5 = 2.5 cm below caudal margin of pons. 
ICV=intracranial volume 
‘p’ values are not corrected for multiple comparisons in this exploratory analysis 
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Relationships between CC-CSA, ICV and clinical variables  
5.3.7.1.7 All subjects 
Examining the study group as a whole (n=45, subjects with and without pain), EDSS 
was weakly correlated with CC-CSA at both P2.5 and C2/3 level (with or without 
correction for ICV) (see Table 47).  
Disease duration was moderately/highly correlated with CC-CSA at the P2.5 level, 
when expressed as a fraction of ICV. Other correlations, including with CC-CSA at 
the C2/3 level, were weak (Table 47).  
EDSS and disease duration were only weakly correlated (Spearmans Rho 0.12, 
p=0.43) in the group as a whole.  
CC-CSA tended to be higher in males than females at both the P2.5 and C2/3 levels, 
before correction for ICV, though differences did not attain statistical significance 
(Table 48). 
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Table 47: Correlations between cord cross-sectional area estimates, intracranial volume, disability 
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CSA= mean cervical cord cross-sectional area measured across 5 contiguous 1mm slices at 
specified level 
 
C2/3= C2/C3 disc level  
P2.5 = 2.5 cm below caudal margin of pons. 
ICV=intracranial volume 
 
Significance thresholds are not corrected for multiple comparisons in this exploratory analysis 
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Table 48: variations in cervical cord cross-sectional area measures by gender (n=45) 












(52.44 to 61.35) 
62.40  
(56.79 to 74.40) 
-0.15 to 18.53 0.058 
CSA/ ICV, P2.5 
(median, IQR) 
41.86  
(38.73 to 47.00) 
45.61  
(39.82 to 47.13) 





(43.36 to 49.66) 
51.60  
(41.77 to 55.72) 
-4.56 to 10.09 0.44 
CSA/ ICV, C2/3 
(median, IQR) 
34.78  
(31.93 to 39.95) 
32.74 
(30.02 to 34.10) 
-6.85 to 1.02 0.194 
 
CSA= mean cervical cord cross-sectional area measured across 5 contiguous 1mm slices 
at specified level 
ICV = Intracranial Volume 
 
C2/3= C2/C3 disc level  
P2.5 = 2.5 cm below caudal margin of pons. 
ICV=intracranial volume 
 
Significance thresholds are not corrected for multiple comparisons in this exploratory 
analysis 
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Comparison of cord cross-sectional area in participants with and 
without pain 
CC-CSA at P2.5 level was not significantly different in subjects with and without 
neuropathic pain, whether expressed as a fraction of ICV or not.  
Median CC-CSA at C2/3 level after correction for ICV was 32.49 mm2 in subjects 
without pain as compared to 35.71 mm2 in those with pain. This difference did reach 
statistical significance at the 5% significance level (uncorrected for multiple 
comparisons) however is reported only for purposes of data exploration. 
 













area at C2/3 level, 
as fraction of ICV 
(median, IQR) 
35.71 
(33.34 to 38.37) 
32.49 
(29.88 to 33.67) 
0.58 to 6.88 0.02 
Cross-sectional 




(45.28 to 51.85) 
45.63 
(41.65 to 45.58) 
-1.23 to 6.81 0.13 
Cross-sectional 
cord area at P2.5 
level, as fraction 
of ICV  (median, 
IQR) 
41.91 
(39.10 to 47.35) 
42.41 
(38.73 to 45.29) 
-2.43 to 4.43 0.50 
Cross-sectional 




(52.09 to 58.73) 
55.61 
(54.03 to 62.17) 
-4.39 to 4.58 0.93 
 
Mean CSA= mean cervical cord cross-sectional area measured across 5 contiguous 1mm 
slices 
C2/3= C2/C3 disc level  
P2.5 = 2.5 cm below caudal margin of pons. 
ICV=intracranial volume 
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5.4 Discussion 
The current data explores possible relationships between the previously-described 
clinical and neuropsychological associations of the presence and severity of 
neuropathic limb pain in RRMS, and MRI measures of brain structure. Some trends 
to association were identified, for instance using the exploratory statistical threshold 
of p<0.001 uncorrected for multiple comparisons (which has been reported 
previously in the neuroimaging literature (80, 288) 
Please see the Thesis Discussion (page 271) for a full description and discussion of 
findings. 
At an exploratory statistical threshold, the pain group manifests lower grey matter 
volumes in the posterior cingulate and right parahippocampal gyrus, as well as higher 
volumes in the left midbrain trigeminothalamic nucleus area, adjacent to the 
periaqueductal grey matter. Increasing duration of pain is also negatively associated 
with grey matter volume in the anterior cingulate cortex. These findings are 
consistent with findings in previous studies of pain syndromes outside MS. 
Associations of increasing pain duration with decreased grey matter volume may 
suggest a causative link between the experience of pain and grey matter volumes, 
though further longitudinal studies would be needed to explore this hypothesis. 
T2 hyperintense MS lesions are found to be more common in specific brainstem 
locations in the pain group, when using a region of interest analysis. These findings, 
which should be viewed with caution, may be relevant to a disconnection syndrome, 
reflecting the complex interaction of white matter and grey matter abnormalities in 
MS (78, 85).  Regional grey matter volume differences between the groups in pre-
specified structures usually recognised to be key to the descending modulation of 
pain, were not found. The potential relevance of posterior cingulate and 
parahippocampal gyrus in pain, memory and attentional roles, all of which are highly 
relevant to the current study are discussed.  
In addition, an early exploration of cervical cord cross-sectional area measurements 
extracted from the current data using open source software has been included. This 
  Thesis: Pain in Multiple Sclerosis 
Structural imaging associations of neuropathic limb pain in MS                         243 
analysis may suggest that further exploration of the reproducibility, reliability and 
utility of this technique is warranted. 
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Chapter 6 Functional connectivity of the 
descending pain modulatory 
system examined using resting 
state functional MRI 
6.1 Introduction 
Chapters Four and Five of this thesis describe assessments of a range of variables 
relevant to the descending modulation of pain, in people with relapsing remitting 
multiple sclerosis, with and without neuropathic limb pain. Specifically, findings 
related to the descending pain modulatory system (DPMS) are emphasised. 
This chapter aims to further examine the functional integrity of this system, using 
resting state functional MRI (fMRI), in participants with and without neuropathic 
limb pain. Structures which are key to the endogenous modulation of pain are 
emphasised, specifically the rostral Anterior Cingulate Cortex (rACC), Dorsolateral 
Prefrontal Cortex (DLPFC) and Periaqueductal Grey matter (PAG).  
Please see the Thesis Introduction (page 1) for a detailed discussion of background, 
aims and hypotheses, and for a review of the functional neuroanatomy of the DPMS 
(page 9). 
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6.2.1 Estimation of sample size 
Overall sample size estimation has been based on sample size estimation for the 
functional MRI component of the study. I viewed fMRI outcomes of the study as the 
primary outcomes of interest in the study overall.  
Sample size/power calculations would ideally be based on existing functional MRI 
studies of people with relapsing remitting MS, comparing groups with and without 
pain, and using a design identical to (or at least comparable to) the current study. 
Specific tools are available to employ such pilot data in sample size calculations for 
fMRI studies (for instance the fmripower website (75)). Unfortunately, applicable 
pilot data was not available for the current study.  
At the time of design of this study, no published fMRI studies examined differences 
between people with RRMS, with and without neuropathic pain (166). During 
recruitment to this study, one functional MRI study comparing subjects with RRMS, 
with and without neuropathic pain was published (214).  
Existing studies are briefly reviewed in order to give context with regards to sample 
sizes. 
Existing studies: pain in pwMS examined using resting state fMRI 
One study from Professor Tracey’s group (214) used fMRI to assess resting state 
functional connectivity networks in people with MS who experienced pain, 
compared to those who did not. This study used a mixed sample of people with 
relapsing remitting, secondary progressive and primary progressive MS. Resting 
state fMRI was used, and analysis carried out according to “dual regression” 
methodology to examine and compare resting state networks (289). This study used a 
total sample size of 23 (group sizes 12 and 11). This study was able to discern a 
difference in resting connectivity of the default mode network between the groups 
with and without pain.  
No published studies in pain related to MS, however, have used a seed based analysis 
in common with the current study.  
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Existing studies: pain in healthy volunteers or subjects with other 
health conditions examined using resting state fMRI 
Published fMRI studies of other pain syndromes are typically carried out in patients 
with structurally normal brains, so that results are not directly comparable to the 
current study, in which MS lesions could be expected to alter the blood:brain barrier 
(even in normal-appearing tissue). Any such effects, in turn, could influence BOLD 
signal (290). Thus data from conditions other than MS may be used for general 
comparison however cannot be used for sample size estimation.  
Mainero and colleagues compared PAG connectivity in 17 subjects with migraine, 
and 17 age and gender-matched controls (103). Eippert and colleagues compared 
connectivity of PAG and other structures in 24 healthy controls receiving a sham 
intervention, with 24 healthy controls not receiving this intervention (110). Yu and 
colleagues compared functional connectivity of PAG in 18 subjects with chronic low 
back pain, and 18 healthy controls (115). 
A priori attempts to estimate ideal sample size in fMRI case-control studies (in the 
absence of applicable pilot data) have included statistical analyses by Professor 
Friston (291, 292) . Estimation of sample size was also discussed with my 
supervisory team, and others including Dr Yazhuo Kong (FMRIB). Professor 
Friston’s analyses suggest that a group size of approximately 16 in an fMRI study 
provides an optimal balance of sensitivity to medium/large effect sizes, while also 
minimising sensitivity to trivial effects. (292). 
Estimation for current study 
Based on the above work, it was not possible to calculate a precise required sample 
size on the basis of existing studies. In addition, methods for calculating sample size 
for resting state fMRI studies are not well developed.  
Given the case:control design of the study, a minimum group size of 16 was 
estimated to be sufficient. In order to maximise sensitivity to associations of pain 
severity, within the pain group, recruitment to the pain group was maximised within 
time and practical constraints associated with the study. 
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A single Siemens Verio scanner (3 Tesla, 12 channel head coil) was used as detailed 
in Chapter Five. No scanner upgrades were carried out during the study. 
Field maps 
Phase and magnitude field maps were acquired using standard Siemens acquisitions, 
with a total acquisition time of 1 minute 5 seconds.  
Resting state functional data 
Echo-planar images (EPI) were acquired with the following characteristics: 
Repetition time (TR) =3000ms, Echo Time (TE) = 30ms, flip angle = 90 degrees, 46 
slices, field of view (FOV) = 192mm, 3mm slice thickness, interleaved acquisition, 
acquisition time = 5 minutes 23 seconds.  
Clinical data acquired in scanner 
Following field map acquisition, and immediately prior to resting state acquisitions, 
subjects were given the following questions: 
 “could you tell me, on a scale of zero to ten, how much pain you are 
experiencing just now, due to the MS?” 
and 
 “could you tell me, on a scale of zero to ten, how unpleasant that pain is?”  
These responses were recorded as estimates of pain severity and unpleasantness at 
time of imaging. 
Instructions to participants 
Participants were then instructed to lie still, with their eyes open and to think of 
nothing in particular during the resting state fMRI acquisition, without falling asleep. 
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6.2.3 Preprocessing of resting state data 
Preparation of fieldmap data 
Two magnitude images were output by the scanner in a single folder. These were 
separated using a custom-written shell script written by Stephen Giles (University of 
Edinburgh). 
Siemens fieldmap data was prepared using fsl_prepare_fieldmap in the command 
line.  
In order to optimise brain extraction of the magnitude field maps (and specifically to 
maximise brain coverage while avoiding inclusion of non-brain tissue) standard brain 
extraction (f 0.7) was supplemented with erosion of the mask by one voxel using 
fslmaths. Brain extraction including non-inclusion of skull data was checked 
manually.  
Preprocessing 
Preprocessing of resting state data was carried out in FEAT version 6.00, 
implemented in FSL (105). The Graphical User Interface (GUI) was used.  
The following steps were followed: 
The first three volumes were deleted to allow equilibration of signal (115). 
A high pass filter cutoff of 90 seconds was applied 
Head motion was calculated using MCFLIRT implemented in FSL. 
Slice timing correction was applied (using a Fourier-space time-series phase-shifting) 
Spatial smoothing with a full width half maximum (FWHM) kernel of 5mm (115) 
(approximately double voxel size).  
Independent Components Analysis (ICA) implemented in FSL’s MELODIC (105) 
suite was used to investigate the possible presence of unexpected artefacts (103). 
Grand-mean intensity normalisation of the entire 4dimensional data set by a single 
multiplicative factor 
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Each subject’s resting state images were registered to their own brain-extracted 
MPRAGE data using a linear registration in FSL’s FLIRT, including a boundary 
based registration (BBR) implemented in FEAT (293). This tool is designed for 
registration of EPI to structural images, and uses white-matter:grey-matter 
boundaries to optimise registration. Fieldmap unwarping was included in the 
registration pipeline, as implemented in FEAT, in order to minimise any effect of B0 
inhomogeneity (105).  
Each subject’s resting state data was then registered to the MNI152 2mm brain-
extracted template using a non-linear transformation in FSL’s FNIRT (274), with 12 
degrees of freedom.  
Approach to potential sources of artefact and noise 
6.2.3.1.1 Head movement: gradual rotation/translation 
Rotational and translational movements of the head were calculated using MCFLIRT 
and included as covariates of no interest in the GLM model. For clarity and for 
reference, Figure 29 (below) shows an example of mixed gradual and sudden head 
motion. 
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Figure 29: Example of sudden head motion during resting state fMRI acquisition 
 
6.2.3.1.2 Exclusion of subjects with significant head movement 
All subjects in whom absolute head movement was equal to or greater than one 
millimetre during the resting state acquisition were excluded from subsequent 
analysis. 
For each subject, absolute head motion was recorded, and compared between the 
pain and control groups using a Wilcoxon Rank Sum test. 
6.2.3.1.3 Identification of structured noise using independent components 
analysis at individual subject level 
As detailed above, MELODIC was used to identify structured noise in the resting 
state data.  
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During preprocessing in FEAT, each subject’s data were decomposed into 
components on the basis of their spatial and temporal characteristics, without an 
explicit time series or number of components being specified.  
These components were reviewed in a web browser with particular attention to their 
spatial distribution and timecourse, and compared to published descriptions of noise 
sources in resting state analysis (75, 104). Components thought to represent subject 
head movement, CSF signal, white matter signal or other signals of no interest 
(including cardiorespiratory noise and scanner artefact) were noted (see Figure 30), 
and regressed out using fsl_regfilt.A relatively conservative (“non-aggressive”) 
approach was deliberately used, and where there was any doubt as to the possible 
neuronal origin of an identified component, it was not removed. This approach 
echoes others described in the literature (100). Please see Figure 30 for examples of 
structured noise identified using this approach. 
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Figure 30: Examples of structured noise sources identified in resting state data using ICA 
 
6.2.3.1.4 Regression of white matter and CSF signal at subject level 
White matter and CSF masks were hand-drawn in standard space (using the MNI 
2mm brain-extracted template), over the corona radiata and lateral ventricles 
respectively, using FSLview.  
White matter and CSF masks were transformed to each individual subject’s resting 
state functional data using a nonlinear registration implemented in FSL’s FNIRT. 
Specifically, the inverse of the transformation from each subject’s resting state 
functional data to standard space (including boundary based registration and 
fieldmap unwarping) implemented in FEAT as described above (see Para 6.2.3) was 
used.  
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Registration of white matter and CSF masks to each individual subject’s resting state 
functional data was checked visually using FSLview. 
Timecourses were extracted using fslmeants, and the timecourses for WM and CSF 
masks combined into a single file. These timecourses were subsequently employed 
as nuisance covariates (“covariates of no interest”) in the subject-level resting state 
data analysis in FEAT. 
 
6.2.4 Creation of region of interest masks 
Three region of interest masks were used for fMRI analysis. These structures were 
chosen as core components of the descending pain modulatory system. A seed mask 
was created centred on the rostral anterior cingulate cortex. Two further region of 
interest masks were centred on the periaqueductal grey matter and bilateral 
dorsolateral prefrontal cortex.  
For creation of each of these masks, previously published descriptions were 
considered in conjunction with data from the current study where appropriate. Please 
see Figure 31 for a summary. 
Rostral Anterior Cingulate Cortex (rACC) seed mask 
6.2.4.1.1 Delineation of extent of rACC 
As a guide for delineation of the boundaries of rACC, a mask created by Vishvarani 
Wanigasekera (FMRIB) was used. This bilateral mask of the rACC was created by 
first thresholding the Oxford-Harvard anterior cingulate cortex probabilistic mask 
(116) at 50% probability, and then setting the caudal boundary as defined by Vogt 
and colleagues (294).  
6.2.4.1.2 Previous literature 
In order to further delineate the volume of interest for rACC seed placement, a 
previous analysis of resting state connectivity of the anterior cingulate was used 
(Margulies and colleagues) (295). This work used systematically placed multiple 
resting state seeds to delineate connectivity of the anterior cingulate. The most 
rostrally placed bilateral seeds (described as “superior 7” or “s7”) were identified as 
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of particular interest because of functional connectivity with frontal cortex structures 
implicated in the cognitive modulation of pain, as well as temporal lobe structures. 
These seeds were located at MNI coordinates x ±5, y47, z11. Other authors (110) 
have used 6mm spheres centred around each subject’s maximal PAG:ACC 
connectivity. 
6.2.4.1.3 Mask for this study 
Based on the above, a 6mm spherical mask was set  in the midline centred on MNI 
coordinates x=0, y=42, z=8. Total volume of this mask was 984 mm3. Please see 
Figure 31 
Periaqueductal grey matter (PAG) region of interest mask 
Seed placement was drawn from a previous publication by Eippert and colleagues, 
which investigated the functional connectivity of the periaqueductal grey matter in 
relation to the descending pain modulatory system (110). A binarised spherical PAG 
mask of 6mm radius was created, centred on MNI coordinates x=0 y=-32 z=-10. 
Total mask volume was 984mm3. Please see Figure 31. 
Bilateral dorsolateral prefrontal cortex (DLPFC) region of interest mask 
6.2.4.1.4 Delineation of outer extent of DLPFC 
Masks of the dorsolateral prefrontal cortex were kindly supplied by Dr Katja Wiech, 
FMRIB centre, University of Oxford. These were created as previously described 
(65). Briefly, masks were hand-drawn on T1 images based on Brodmann areas 8, 9, 
46, 9/46 (approximately corresponding to the superior and middle frontal gyrus) (65). 
These masks were used to delineate the boundaries of DLPFC for creation of a 
region of interest mask. 
6.2.4.1.5 Previously published DLPFC seed masks 
Zubieta and colleagues (296) report the localisation of DLPFC involvement in 
placebo response as maximal at x= -36 y= 13 z= 39. Eippert and colleagues used the 
same coordinates (based on Zubieta’s publication and ignoring laterality) as the 
kernel for a spherical mask (110).  
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6.2.4.1.6 Study data 
Maximum mean rACC connectivity to the DLPFC was calculated (within the widest 
extent of the DLPFC as defined by Dr Wiech’s mask), using all 42 subjects (with and 
without pain) in a higher-level analysis implemented in FEAT (FLAME 1) in FSL. 
Maximal mean functional connectivity of rostral ACC to DLPFC was identified at 
MNI coordinates x=46, y=20, z=44 on the right, lateral to the coordinates identified 
by Zubieta and colleagues (296) and within the spherical ROI specified by Eippert 
and colleagues (110). This location was identified as middle frontal gyrus bilaterally 
(using published estimates packaged with FSL (116)). 
6.2.4.1.7 Creation of seed mask for current study 
A binarised spherical mask of 6mm radius was created centred on these MNI 
coordinates. An identical mask was then created on the left, mirrored across the x 
axis. These masks were combined to create a single bilateral DLPFC mask consisting 
of two spheres of 6mm radius. The location of the bilateral DLPFC mask was 
confirmed as within the larger anatomical DLPFC mask defined by Wiech and 
colleagues (65). Mask boundaries extending beyond grey matter were removed using 
grey matter tissue probability estimates packaged with FSL, thresholding at intensity 
of 50. Total mask volume was 1808 mm3. Please see Figure 31. 
Occipital cortex region of interest “control” mask 
In order to test specificity of any findings to the DPMS, a further 6mm radius 
spherical binary region of interest was created around the MNI coordinates x=0, y=-
74, z=8 (mid-occipital cortex) using the methods described above.  
The occipital cortex is not thought to be implicated in the descending modulation of 
pain. The mask was deliberately placed in the midline (x=0), similarly to the rACC 
seed described, and was of the same volume as the rACC and PAG seeds. This mask 
therefore was intended for use in examining the specificity of any findings to the 
DPMS. The mask was placed as anteriorly as possible, while still avoiding any 
structures known to be involved in the DPMS, and also avoiding CSF voids other 
than the interhemispheric fissure. 
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Figure 31: Seed mask and Region of Interest masks used in this chapter 
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Registration of rACC seed mask to resting state functional data 
For each subject, binarised masks (as described above) for the rostral ACC were 
registered to each subject’s ICA-processed resting state data, using the reverse of the 
linear and nonlinear registration procedures already established using FEAT, which 
included fieldmap unwarping. Successful registration was checked visually for every 
subject.  
 
6.2.5 Analysis of fMRI data 
 
Extraction of timecourses at subject level 
For each subject, the timecourse of the rACC mask (6.2.4) was extracted from 
resting state data which had been subject to ICA decomposition and regression of 
nuisance components as described above. In order to extract the timecourse, 
fslmeants  was used (“fsl mean timeseries”).  
The resultant timecourse was used in group analyses (see below) as the independent 
variable in a general linear model examining correlation with timecourses of all other 
voxels in the brain.  For each subject, and as described, CSF timecourse, white 
matter timecourse, and six head motion parameters were included as covariates of no 
interest. 
Group level analyses 
Group analyses were carried out using a mixed effects model implemented with 
FMRIB’s Local Analysis of Mixed Effects (FLAME) version 1 implemented in 
FEAT.    
6.2.5.1.1 Analyses within groups 
6.2.5.1.1.1 Group means 
For within-group analyses a one-sample analysis for the pain and control groups 
separately was used. A Z threshold of 2.3 and cluster forming p≤0.05 were used to 
create z-score statistical maps of rACC seed functional connectivity.  
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6.2.5.1.1.2 Correlations of rACC functional connectivity with T2 hyperintense lesion 
volume 
Because the influence of T2 lesion volume on rACC functional connectivity is 
unknown, and because previous studies have described patterns of increased or 
decreased connectivity, or both, tests were carried out for any such correlation in the 
current data. 
T2 hyperintense lesion volumes were expressed for each subject as a fraction of 
intracranial volume as described previously.  
In order to calculate correlations of rACC seed functional connectivity with lesion 
volume, data from all 42 subjects (26 with pain, 16 controls) was used, and T2 
hyperintense lesion volume was specified as a covariate of interest in a general linear 
model implemented in FEAT. Positive and negative correlations of rACC seed 
functional connectivity with lesion volume were calculated. 
6.2.5.1.1.3 Correlations of rACC functional connectivity with pain severity 
In order to calculate correlations of rACC seed functional connectivity with pain 
severity at the time of imaging, all 26 subjects with pain were included in a general 
linear model implemented in FEAT. Pain severity at the time of imaging was 
included as a covariate of interest. Positive and negative correlations of rACC seed 
functional connectivity with pain severity were calculated. 
6.2.5.1.2 Between-group analyses 
6.2.5.1.2.1 Whole brain 
A between-group comparison between the pain and control groups was carried out 
using an unpaired two-sample t-test design, across the whole brain. A Z threshold of 
2.3, and cluster forming p≤0.05 were used. 
6.2.5.1.2.2 Regions of interest (PAG and DLPFC) 
A between-group comparison within specified regions of interest (PAG and DLPFC 
as described in 6.2.4) was then calculated using nonparametric permutation testing 
implemented with Randomise, packaged in FSL. Threshold Free Cluster Extent was 
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calculated using 5000 permutations (as described in Chapter Five for VBM analysis, 
page 188) including correction for multiple comparisons in space. 
6.2.5.1.3 Incorporation of T2 lesion volume in models 
In order to examine any effects of T2 hyperintense lesion volume on findings in the 
above analyses, the above analyses were repeated with correction for T2 
hyperintense lesion volume. Analyses were carried out as specified above, with 
inclusion of T2 lesion volume as an additional covariate of no interest. 
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6.3.1 Clinical data 
6.3.1.1.1 Head movement and exclusion of subjects 
Two subjects in whom head movement of equal to, or over one millimetre over the 
course of the recording were excluded (2 subjects, absolute movement 1.33 
millimetres and 2.28 millimetres). Both of these subjects were in the neuropathic 
pain group. 
Subsequent analyses included 26 subjects in the neuropathic pain group, and 16 in 
the control group.  
6.3.1.1.2 Head movement at group level 
In the remaining 42 subjects, head movement in the pain group and control group 
was not significantly different (pain group: n=26 median 0.24mm, IQR 0.16 to 0.30, 
control group n=16 median 0.20mm, IQR 0.16 to 0.26, p=0.42). 
6.3.1.1.3 Pain severity and unpleasantness scores in the neuropathic pain 
group 
In the neuropathic pain group (n=26), median pain severity immediately prior to 
resting state fMRI acquisition (range 0-10) was 2.25 (IQR 1.00 to 7.00). 
Pain unpleasantness in the same group (scored 0-10) was median 3.00 (IQR 1.00 to 
7.00).  
Ratings of pain and pain unpleasantness were highly correlated (Spearman’s Rho 
0.93, p=1.8 x10-12). Because of this collinearity, functional connectivity correlates of 
pain unpleasantness ratings were not separately calculated. 
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6.3.2 Mean ACC seed connectivity by group 
Mean ACC seed connectivity for the pain group and control group, calculated 
separately, are shown below (Figure 32). Positive correlations with rACC 
timecourses are shown. No negative correlations were found.  
In both groups, functional connectivity of the rACC seed with a bilateral distributed 
network of cortical and subcortical structures including frontal and prefrontal 
cortices was observed. Functional connectivity was centred on grey matter (as 
expected). Little correlation with CSF or WM timecourses was observed.  
Both groups showed functional connectivity with frontal cortical structures thought 
to be important in the appraisal of painful stimuli (see Chapter Four, page 119) 
including frontal pole and dorsolateral prefrontal cortex. Parietal cortices, anterior 
and posterior cingulate cortices, bilateral thalamus, sensory cortices (postcentral 
gyri), cerebellum and brainstem (the latter including midbrain, pons and, in the case 
of the pain group, rostral medulla) were shown to be functionally connected to the 
rostral ACC seed. Images are shown for qualitative comparison (Figure 32). 
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Figure 32: Mean functional connectivity of rostral ACC seed, separately calculated in pain and 
control groups 
 
6.3.3 Associations of the presence of pain 
Unpaired t-test: whole brain level 
At the whole brain level, no statistically significant difference in functional 
connectivity of the rACC seed was found (z=2.3, p≤0.05, whole brain analysis).  
Unpaired t-test: PAG spherical ROI 
In a small volume comparison focussed on the periaqueductal grey matter (using the 
mask described above - 6.2.4), a statistically significant difference in rACC:PAG 
functional connectivity was observed. Specifically, functional connectivity between 
the rACC seed and left caudal PAG was higher in the control group, than in the pain 
group. No functional connectivity was found to be higher in the pain group, than in 
the control group (p≤0.05, threshold free cluster extent, corrected for multiple 
comparisons within PAG ROI) (Figure 33).  
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Maximal differential connectivity was observed at MNI coordinates x= -4, y= -32, z= 
-12. 
 
Figure 33: Differential functional connectivity between ACC seed and PAG, in pain and control 
groups 
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Unpaired t-test: PAG spherical ROI after correction for T2 hyperintense 
lesion volume 
After inclusion of T2 hyperintense lesion volume as a covariate of no interest, 
rACC:PAG functional connectivity was only found to be statistically significant at a 
single voxel. This should be interpreted with caution but may demonstrate a 
diminution of previously observed associations, when T2 hyperintense lesion volume 
is included in the model as a covariate of no interest (Figure 34, and compare to 
Figure 33). 
Figure 34: Differential functional connectivity between ACC seed and PAG in pain and control 
groups, after correction for T2 hyperintense lesion volume 
 
Unpaired t-test: bilateral DLPFC region of interest 
In a small volume comparison focussed on the bilateral dorsolateral prefrontal cortex 
(using the mask described above - 6.2.4), a statistically significant difference in 
rACC:DLPFC functional connectivity was observed. Specifically, functional 
connectivity between the rACC seed and right DLPFC was higher in the pain group, 
than in the control group. No functional connectivity was found to be higher in the 
control group, than in the pain group (p≤0.05, threshold free cluster extent, corrected 
for multiple comparisons within DLPFC ROI) (Figure 35). 
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Maximal differential connectivity was observed at MNI coordinates x=50, y=22, 
z=40 (middle frontal gyrus (116)). The area of differential connectivity overlapped 
with the spherical DLPFC ROI specified by Eippert and colleagues (110). 
Figure 35: Differential functional connectivity between rostral ACC seed and bilateral DLPFC 
region of interest, between pain and control groups 
 
Unpaired t-test: bilateral DLPFC region of interest after correction for T2 
hyperintense lesion volume 
After inclusion of T2 hyperintense lesion volume, no statistically significant 
differential connectivity of rACC seed and bilateral DLPFC region of interest was 
found. 
Unpaired t-test: “control” region of interest, occipital cortex 
No statistically significant differential functional connectivity between rACC seed 
and occipital region of interest was found. 
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6.3.4 Associations of the severity of pain 
Regression analysis: whole brain  
No association between rACC connectivity and pain severity rating at the time of 
imaging was observed at the statistical threshold applied (z=2.3, p≤0.05). 
Regression analysis: PAG region of interest 
No statistically significant association between rACC connectivity and pain severity 
rating at the time of imaging was observed (TFCE corrected p≤0.05). 
A trend to positive association between pain severity and rACC:PAG functional 
connectivity was noted at the statistical threshold TFCE p≤0.05, not corrected for 
multiple comparisons. Maximal correlation was observed at MNI coordinates x= -2, 
y = -28, z= -6 (Figure 36). No trend to negative association between pain severity 
and rACC:PAG functional connectivity was noted at the same threshold (Figure 36).  
Figure 36: Trend to positive correlation of rostral ACC: PAG connectivity, with pain severity at 
time of imaging 
 
 
Regression analysis: DLPFC region of interest 
No statistically significant association between rACC connectivity and pain severity 
rating at the time of imaging was observed (TFCE corrected p≤0.05). 
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A trend to negative association between pain severity and rACC:DLPFC functional 
connectivity was noted at the statistical threshold TFCE p≤0.05, not corrected for 
multiple comparisons. Maximal correlation was observed in the left middle frontal 
gyrus (116) at MNI coordinates x=-40, y=20, z=44.  No trend to positive association 
between pain severity and rACC:DLPFC functional connectivity was noted at the 
same threshold ( Figure 37). 
 
Figure 37: Trend to negative correlation of rostral ACC: DLPFC connectivity, with pain severity at 
time of imaging 
 
Regression analysis: “control” region of interest, occipital cortex 
No association of functional connectivity between the rACC seed and occipital 
region of interest was found with pain severity (in either positive or negative 
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6.3.5 Associations of T2 hyperintense lesion volume 
A positive correlation between T2 lesion volume and rACC seed functional 
connectivity to various regions including cortical and subcortical structures was 
observed.  
No negative correlation between T2 lesion volume and rACC seed functional 
connectivity was observed. Please see below (Figure 38, Table 50). 
Table 50: Structures manifesting higher functional connectivity to ACC seed in correlation with 
increasing T2 lesion volume 
Cortical structures MNI coordinates 
x y z 
Occipital cortex (right) 38 -76 28 
Frontal pole (bilateral) 18 64 -10 
-20 56 -14 
Nucleus accumbens (right) 8 14 -8 
Nucleus accumbens (left) -6 14 -8 
Caudate head (right) 10 12 0 
Temporal pole (left) -50 14 -20 
Paracingulate gyrus/anterior 
cingulate cortex (left) 
-6 38 -10 
Orbitofrontal cortex (left) -44 26 -16 
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Figure 38: Structures demonstrating positive correlation between T2 hyperintense lesion volume, 




This small cross-sectional seed-based resting state fMRI study provides first, early, 
evidence, that functional connectivity of the descending pain modulatory system 
could be disrupted in people with neuropathic limb pain in relapsing remitting MS.  
Functional connectivity of the dorsolateral prefrontal cortex, rostral anterior 
cingulate cortex and periaqueductal grey matter has been examined. Statistically 
significant differences in functional connectivity between the rACC seed and PAG, 
and separately rACC seed and DLPFC, were found between groups. MS lesion 
volume may contribute to this differential connectivity. Further exploration of the 
interface between structural and functional connectivity could include diffusion 
imaging to further explore any role of structurally disrupted white matter tracts. 
Please see the Thesis Discussion (page 271) for a detailed discussion of study 
findings, implications and methodology. 
 




Chapter 7 Participant experience of the study 
7.1 Introduction 
The experience of participants in this study was important. In particular, at the study 
design stage, it was important to estimate how well subjects might tolerate the 
proposed study (and its component parts). Component parts of the study included 
questionnaires, neuropsychological assessment, structural MRI, and fMRI including 
painful stimuli (all in the presence of a pre-existing central nervous system disease).  
When designing the study, estimates of anticipated participant experience formed 
part of an important balance between optimising participants’ experience of the 
study, and optimising scientific utility of the study. There is an ethical duty to 
minimise distress during study participation (297). Participant distress, however, 
should also be balanced against unnecessary restriction of study activities, if the 
study protocol was in fact well tolerated (297). Some previous studies of participant 
experience have found that researchers have significantly overestimated the negative 
effects of taking part in research, and underestimated any positive effects (298). 
I planned to base the study design on published evidence around participant 
experience of research studies, where available. Little published data, however, was 
available to guide estimates of participant experience. Study design choices (for 
instance acceptable duration of MRI protocol) were largely made on discussion with 
experienced colleagues, and based on their personal experience. 
7.1.1 Rationale for survey of participant experience 
I felt that it would be useful to formally assess subjects’ experience of the current 
study. There were several reasons for this.  
 Firstly I felt that the participants’ experience of the study was of intrinsic 
interest.  
 Furthermore, detailed assessment of their experience might reflect  
o overall experience of the study,  
o experience of particular aspects of the study  




 including opportunity to identify aspects which could be 
improved for future studies, and  
o motivation to undertake further studies.  
Importantly, this information might also inform development of any future studies of 
this type, with particular reference to likely participant tolerance of the proposed 
protocol.  Knowledge of participants’ experience might also help to inform research 
ethics committees (299). 
7.1.2 Aims 
1) To identify any existing questionnaire or survey instruments validated to 
establish participant experience of research studies 
2) If needed, to construct an instrument for this study 
3) To assess participant experience of the study using this instrument 
4) In addition I also sought to establish a pool of study participants who would 
be willing to be contacted to 
 give advice on design of future studies at, or closely associated with, the 
Anne Rowling Regenerative Neurology Clinic (ARRNC) and  
 Participate in future studies at, or closely associated with, ARRNC. 
 
7.2 Methods 
7.2.1 Ethical permissions 
All methods described were approved by the relevant medical ethics committee 
7.2.2 Identifying existing instruments 
I searched the existing literature for validated questionnaire or survey instruments 
which assess participant experience of research. I searched Google Scholar using 
combinations of the terms “participant” “experience” “satisfaction” “feedback” 
“survey” and “questionnaire”, and searched citation records of relevant articles. I 
also spoke to specialists in patient/public engagement and in relevant fields 
(neuroimaging, neuropsychology, pain research, neurology research).  




7.2.3 Survey design process 
A survey instrument was designed by PF, in discussion with others (including 
Allison Worth, Shuna Colville and Denise Cranley).  
Priorities were identified as simplicity, brevity, and assessment of experience of the 
study overall, as well as its component parts. 
A first draft was written by PF, circulated for comment and amended as required.  
Using the established study newsletter (see Appendix: Study Newsletters) study 
participants were also invited to comment on topics to be included in the survey. 
7.2.4 Survey design 
The survey was divided into sections reflecting the design of the study. These 
included 
 Exchange of information about the study, prior to participation 
 Overall rating of satisfaction 
 Assessments in Anne Rowling Regenerative Neurology Clinic (ARRNC) 
 Assessments at Clinical Research Imaging Centre (CRIC) 
 Motivations and further comments 
o Including motivation for taking part, positive and negative aspects of 
the current study, aspects which could be modified for future studies.  
 Feelings about participation in future discussion or research 
Scales of 0 to 7, where a single numerical rating had to be selected, were used for 
quantitative feedback. Anchors of  “1 – not at all” and “7-completely” were used 
throughout. Space for unrestricted qualitative feedback (free text, without word limit) 
was given at the end of each section. 
7.2.5 Delivering the survey 
The survey was delivered online using Bristol Surveys (www.onlinesurveys.ac.uk). 
Access to the survey was password-protected, using the same password for all 
participants. Participants did not have access to results.  




Where survey participants requested a written rather than online copy of the 
instrument (n=1), a PDF of the survey was printed out using inbuilt tools in Bristol 
Surveys, and posted to the participant with a stamped-addressed envelope (SAE). 
Survey participants were specifically requested not to input name, address, or other 
personal information during completion of the survey.  
All questions within the survey were optional, apart from the overall rating of 
satisfaction. 
Survey participants were told that their feedback was anonymous. They were given 
the option of enclosing their study ID number (included in the invitation to 
participate) which could be linked to their anonymised study data, but not to link 
their identity to their responses.  
7.2.6 Invitation to participate 
Upcoming delivery of the survey was highlighted using the study newsletter (see 
above) in order to maximise awareness.  
First invitation to participate was by written letter, giving a URL for the survey as 
well as email and phone contacts, and offering to send out paper copies of the survey 
(with SAE) to any participants who would prefer this. Each participant’s unique 
study identifier number was included in the invitation, and they were asked to input 
this number at time of completion of the survey if they wished.  
Second invitation was by email, including the URL in the email, so that the link 
could simply be clicked rather than typed into the browser. Emails were only sent to 
participants who had already given permission to be contacted by email, and where 
email contact had been established with the participant themselves (in one case email 
contact was largely with the participant’s spouse, and an email was not sent to this 
participant).  
A last reminder was included in a subsequent study newsletter. 






For numerical ratings of satisfaction, data distribution was assessed for Gaussian 
distribution by inspection of data histograms and Quantile-Quantile (QQ) plot.  
Where distribution was felt to be non-Gaussian, median and interquartile range were 
reported as summary measures. Boxplots were constructed. No data transformations 
were used. The Wilcoxon rank-sum test (Mann-Whitney U test) was used to test 
significance level of differences between groups. 
For binary variables (for instance gender), a 2x2 table was generated. The Chi-
squared test was used for larger samples, and the Fisher exact test for smaller 
samples. The Fisher Exact test was used where overall total of the table was less than 
20, or where the overall total was between 20 and 40, and the smallest of the four 
expected numbers was less than 5 (137). Alternatively the Fisher Exact test was used 
where Chi-squared analysis output from R identified the possibility of an inaccurate 
estimate because of small sample numbers. 
Significance was assigned at the 5% level, unless otherwise stated. In this 
exploratory analysis, no correction for multiple comparisons was applied. 
Qualitative data 
For the purposes of this thesis, qualitative data has been subject to informal analysis 
only.  
For comments on specific component parts of the study, text feedback was reviewed 
by PF, themes identified and a sample of representative quotes is reproduced.  
For comments on motivation to take part in research, where a larger volume of 
feedback was available, the text feedback was reviewed repeatedly by PF. General 
themes were identified. Statements of motivation within each participant’s free text 
feedback were identified, and grouped into general themes. For illustrative purposes, 
the number of statements falling into each theme were identified. This informal 
analysis forms an initial step in intended further formal thematic analysis (300, 301). 





7.3.1 Existing instruments 
I did not find any validated assessment instrument aiming to measure participants’ 
experience of research experience. This is in keeping with previous studies of 
treatment research, where no pre-existing instrument was found (298). 
7.3.2 Participant input into survey design 
Two research subjects made suggestions for survey design. These included inclusion 
of a question on perceived relevance of the study instruments for each participant. A 
question on this topic was therefore included in the survey. 
7.3.3 Survey Uptake 
30 subjects completed the survey overall. 12 responded to the first invitation (letter), 
17 to the second (email), and 1 to the last (study newsletter). No participant 
described difficulty in accessing or completing the survey. 
7.3.4 Demographics 
Of thirty respondents, median age (years) was 40.5 (IQR 35.00 to 51.25), 27 of 30 
(90%) were female, median EDSS was 1.50 (IQR 1.00 to 2.88) and 21 of 30 (70%) 
related chronic pain at the time of study participation.  
7.3.5 Comparison of survey responders and non-responders 
Survey responders were significantly less disabled then non-responders (Median 
EDSS 1.5 vs 2.0 in non-responders, p=0.04). There was a trend towards a higher 
proportion of females in survey responders which did not attain statistical 
significance (p=0.054). Age and presence of chronic pain did not vary significantly 
between responders and non-responders. Please see Table 51 below.   




Table 51: Comparison of demographics, survey responders and non-responders 
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IQR = Interquartile Range 
 
7.3.6 Overall satisfaction with study participation 
Participants were asked “How satisfied, overall, were you with your experience of 
taking part in the MS sensation/pain study?” Median satisfaction rating (0 = “not at 
all satisfied”, 7 = “completely satisfied”) was 7.0 (IQR 7.0 to 7.0). Please see Figure 
1 below.  
Figure 39: overall satisfaction with participation (0= "not at all", 7 = "completely") 
 




7.3.7 Information exchange and discussion 
Participant satisfaction was high for information given by post prior to participation 
(median 7.0, where 0 is not at all satisfied, and 7 completely satisfied), by telephone 
prior to first visit (median 7.0),  in person at first visit (median 7.0), and specifically 
regarding explanation of MRI procedures (median 7.0). Participants also felt that 
information given was adequate and appropriate to make a decision on study 
participation (median 7.0).  
Please see figure 2 below. 
Figure 40: satisfaction with information given (0 = "not at all", 7 = "completely") 
 
Free text comments 
In general, feedback on information exchange was positive. One respondent felt that 
they were given too much information.  
One respondent highlighted that her previous incidental coil embolization procedure 
had not precluded clinical MRI in the past (at 1.5T), and therefore she did not declare 
it at time of study entry. In this participant’s case, the situation was discussed with 
the CRIC physics team, who felt that imaging at 3T might be associated with risk, 
and therefore imaging was not carried out.  




“well conducted and all questions relevant” 
“In my personal opinion the word “pain” might be 
misleading. One might worry that it is going to be a traumatic 
experience (which it isn’t)” 
“Everything was very well explained and it was clear that 
informed consent was considered the most important thing” 
“There was more information than I required” 
“I had some metal in my kidney (sic)…but as I had had an 
MRI in another hospital… I assumed it would be OK… I did 
not know…it was not advisable”  
7.3.8 Study procedures carried out at Rowling Clinic 
Separate ratings were obtained for questionnaires, perceived relevance of questions 
asked to each individual, Quantitative Sensory Testing (QST), neuropsychological 
testing and genetic testing (in most cases venepuncture, in two cases obtaining saliva 
sample). Median satisfaction score was 7.0 for all ratings, apart from perceived 
relevance (median 6.5).  Please see figure 3 below.  
Figure 41: satisfaction with assessments at Rowling Clinic (0 = "not at all",  7 = "completely") 
 




Free text comments 
Free text feedback on neuropsychology assessment, in particular, was mixed (though 
overall quantitative feedback was positive, as detailed above). Some participants 
related finding the neuropsychology testing demanding or stressful, though others 
enjoyed it. 
“I found it all very fascinating and (PF) made it a pleasant 
experience” 
“Felt really stupid in the psychology part, but made me feel 
really at ease with the situation so really helped me to relax” 
“Found the psychology testing very emotional and 
exhausting” 
“Thoroughly enjoyed the psychology testing! Very 
interesting. Would like to know more about this” 
“Well conducted” 
7.3.9 MRI imaging at Clinical Research Imaging Centre (CRIC)  
Median satisfaction rating was 6.0 for comfort in MRI scanner, and noise in MRI 
scanner. Median rating was 7.0 for time in MRI scanner, and contact with staff 
during MRI procedure.  
Please see figure 4 below: 




Figure 42: satisfaction with aspects of MRI imaging at CRIC (0 = "not at all", 7 = "completely") 
 
Free  text comments 
Several participants related feeling cold during MRI imaging. Others related feelings 
of claustrophobia, or discomfort, but that they were able to overcome these, and in 
some cases were specifically glad that they did so. 
“Was really nervous about getting the scan, but everyone was 
lovely and made me feel really comfortable and at ease” 
“Quite cold in MRI room”  
“Low scores on a few of the questions …simply because I am 
extremely claustrophobic and was very anxious about being 
in the scanner. Staff were very patient, kind and helpful, no 
pressure to continue if I couldn’t do this part of the research 
and knew I could have stopped at any point. Pleased I did it!” 
“It made a huge difference having a mirror attached to the 
headpiece so I could see out. I hadn’t had this before and it 
made it much easier” 




7.3.10 fMRI procedures 
Satisfaction ratings were given for difficulty associated with physiological noise 
monitoring equipment (“how difficult did you find it to have the fingerclip and the 
thin cable round your lower chest, while in the scanner?”), noxious thermal stimuli 
during fMRI (“how difficult did you find it to experience the actual heating at the 
ankle, while in the scanner?”) and also giving numbers for pain ratings (“How 
difficult did you find it to give numbers to estimate pain or discomfort during the 
scan?”). 
Please note that ratings used in this section were different to those used previously, in 
that ratings from 0 “not at all difficult” to 7 “completely difficult” were used, in 
contrast to the ratings described above.  
Median rating for PNM equipment was 7.0, for noxious heat administration 5.5, and 
for giving a pain rating 4.0. Please see figure below.  
Figure 43: perceived difficulty associated with functional MRI procedures and equipment. (0 = 
"not at all ", 7 = “complete ") 
 




Free text comments 
Several participants mentioned that they found it difficult to estimate their own pain 
levels during imaging. No participants made specific comments regarding the PNM 
equipment.   
Some participants implied a comparison with others in their pain responses (despite 
subjects being specifically advised that their pain responses were highly individual). 
“It’s always difficult to allocate numbers to something 
subjective as you have no reference scale” 
“Difficult to have a subjective view to estimate pain…am I 
being tough or am I a complete wimp???” 
7.3.11 Motivation to participate in research 
29 free text comments were obtained. Some of these contained more than one reason 
for participation. Overall 39 statements of motivation were extracted 
26 of these described a wish to help others, often specifically others with multiple 
sclerosis.  
I decided to take part in the study as I feel that the more is 
understood about this condition, the better it is for everyone 
who suffers from it. 
I took part in study as my Ms pain has gradually gotten worse 
over time and it's a real struggle everyday with the pain I 
experience and hard to explain how I feel most days cause 
even me myself can't understand some of the pain/sensations 
I get so would do anything to help make more sense of things 
for others and myself for the future and hopefully one day 
maby with the research found might be able to ease some of 
the pain for myself and others 
Anything to help the understanding or potential treatment of 
MS 
Wish to help the study. Interested to know how my 
experiences compare to others. 




Because it is about the only thing that I can do to help with 
finding new treatments for this disease and because the drugs 
I take had to be tested on a previous cohort-you have to 'play 
it forward' 
Anything that helps provide more information to guide 
treatments for MS is a worthwhile cause 
 
Four mentioned personal interest, though this was mentioned as a motivator for 
participation, only in combination with other factors. 
…out of interest…  
…I was interested in learning more about the study… 
Four mentioned a desire to help themselves in some way 
I would like to think I was perhaps helping myself or 
others… 
Any research into ms is a good thing for me and my family 
(…) 
Three mentioned a desire specifically to “give back” to NHS or ARRNC staff, in 
return for care received.  
The Ann Rowling Clinic has been fantastic, very supportive 
and friendly every visit I have there. I would be happy to do 
take part in any study for them … 
Having received excellent care and treatment from the NHS 
Neurology Dept and Anne Rowling Centre I want to give 
something back to show my gratitude. 
One mentioned a desire to obtain an up to date MRI scan.  
(…) and I also knew it would put an up to date scan on my 
medical records 




One mentioned guilt around resources expended on their care through the NHS, and 
implied that they felt a need to repay this.  
I think like many MS sufferers you feel a bit guilty about the 
amount of NHS resources pumped into your care and 
medication, this is a small way of contributing (apart from via 
the tax system obviously). 
7.3.12 Changes suggested for future studies 
Some participants suggested specific changes, including weekend attendance (n=1), 
or payment for participation (n=1).  
Some participants mentioned that they would like individual feedback on their 
imaging results, although individualised feedback was provided to all participants by 
post. All participants were supplied with a formal written comment on their MRI 
imaging results, and result of imaging posted to GP, though these comments may 
have been made before this information was received by the participant. 
Taking time off work to attend can be an issue-weekend 
attendance could make that possible although I appreciate 
may not be possible 
I guess because it is quite subjective, it was sometimes a bit 
tricky to judge the pain levels from the heat device. Not sure 
how exactly it could be improved though, sorry! 
Tighten up on info re metal in body and explaining that 
research scanner is more powerful than hospital ones so even 
if a participant has had MRI since acquiring metal, best to 
double check suitability for MRI as part of research study. 
I cannot think of anything. I think it was conducted extremely 
well 
It will be good if we, as patients can get any update on our 
individual status or any founding during the test. 
I think a token payment or gift card for the time would have 
been a nice gesture. 




Very satisfied with professional yet personal format of this 
study. I felt that my experiences and feelings were important, 
nothing intrusive and everything explained well so no need to 
change anything from my point of view. 
7.3.13 Any specific strengths of study 
Some specific comments included positive feedback on the study newsletter, and on 
encounters with staff during the study in general (including ARRNC and CRIC).  
I have really appreciated the newsletter update. 
I found it really positive to no that I'm not the only one living 
with this pain and that every case is different and that there 
are people out there trying to help find cures for this 
The whole thing was really interesting and every person I 
spoke to was excellent. The mirror in the scan was the 
highlight ! - tell people about this beforehand 
(PF) was very easy to get on with and extremely helpful. 
Made the experience very worth my while. Hope it helps. 
I would like to express my thanks to the professional and 
caring attitude of all the members of staff I met during the 
study. 
It was very interesting to take part and to learn more about 
the research that is happening and gain a greater 
understanding of the disease 
7.3.14 Considering contribution to future study design 
71.4% of respondents stated that they would be interested in being contacted about 
giving advice on how future studies (at ARRNC or closely related facilities) might be 
designed (see figure below). All of these respondents consented to be included in a 
database held at ARRNC for these purposes. 




Figure 44: Would you be interested in being contacted about giving advice on how future studies 
might be designed? (n=29) 
 
7.3.15 Considering participation in a future study 
96.5% of respondents stated that they would be interested in taking part in a similar 
study in the future. (see figure below). All of these respondents consented to be 
included in a database held at ARRNC for these purposes. 
Figure 45: would you consider taking part in a similar study in the future? (n=30) 
 
 





The assessment of participant experience in this study provides early information 
which could help guide researchers designing or executing future similar studies.  
Some issues inherent in the acquisition of this data, which are relevant to possible 
biases and could influence results, and conclusions drawn from these results, are 
identified.  
Please see Chapter 8: Discussion for a more detailed coverage of related issues. 




Chapter 8 Discussion 
8.1 Overview 
In this thesis the following work is described: 
 Systematic Review and Meta-Analysis investigating prevalence, associations, 
and natural history of pain syndromes in adults with multiple sclerosis 
 Systematic Review of existing neuroimaging studies of pain syndromes in 
adults with multiple sclerosis 
And a prospective case-control study of adults with relapsing remitting multiple 
sclerosis, with and without neuropathic limb pain, specifically addressing the 
following aspects:  
 Clinical, behavioural and cognitive associations of neuropathic limb pain 
 Structural neuroimaging associations of neuropathic limb pain  
 Functional connectivity of the descending pain modulatory system in 
neuropathic limb pain  
In addition, a study of participant experience is described. 
8.1.1 Restatement of main study hypothesis 
As discussed, the overarching hypothesis of the prospective clinical study was that:  
In adults with relapsing remitting MS, dysfunction of the descending pain 
modulatory system will be associated with the presence, and severity, of neuropathic 
limb pain.  
The first two experimental chapters provide systematic review evidence to inform 
design of the prospective clinical study.  
The third, fourth and fifth chapters address this hypothesis in a prospective case-
control clinical and neuroimaging study. 





Findings are discussed as relevant to each of the experimental chapters in turn. 
8.2.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
Prevalence of pain, and pain syndromes 
Pain in MS was found to be common, affecting around 63% of adults with the 
condition (95%CI 55% to 70%). Individual pain syndromes including headache, 
extremity neuropathic pain, back pain, painful spasms, Lhermitte’s sign, and 
trigeminal neuralgia were, in turn, all found to be common. These results support 
previous findings that pain in the MS population is heterogeneous, and includes 
several pain syndromes and mechanisms.  
These  findings attempt to quantify the prevalence of these syndromes in the MS 
population, and suggest that headache, followed by extremity neuropathic pain, are 
the most common pain syndromes, and trigeminal neuralgia the least common of 
those investigated.  
Considerable heterogeneity is however associated with these estimates, and 
prevalence of some painful syndromes (in particular optic neuritis) remains unclear.  
Investigation of heterogeneity by meta-regression did not identify any of the tested 
demographic variables as significantly associated with the presence of pain, after 
Bonferroni correction for multiple comparisons (Table 6: Meta-regression analysis of 
study- and population- level associations with pain prevalence estimates). Tested 
variables were EDSS, proportion of female gender in population, proportion with 
progressive MS in population, and disease duration. On testing of study methodology 
variables, presence or otherwise of investigator blinding, study of inpatient vs 
outpatient population, and pain timeframe (whether pain was assessed within the last 
month or longer than this) were assessed. Only pain timeframe significantly 
explained estimate heterogeneity, and only within the headache prevalence studies. 




Although both neuropathic and nociceptive pain syndromes were found to be 
common in the described studies, my findings additionally suggest that neuropathic 
pain mechanisms may be more prevalent than somatic/nociceptive mechanisms. 
Estimation of pain prevalence throughout the disease course 
In order to study pain prevalence in relation to the MS disease course, 
characterisation of MS related pain was sought - either at disease milestones, or 
longitudinally in evolving disease. The natural history of pain in MS was poorly 
characterised in the identified studies.  
Firstly, no studies of pain incidence were found. No prospective studies of overall 
pain prevalence prior to disease onset were found (notwithstanding potential 
methodological challenges). In comparison, Vacca and colleagues (151) 
retrospectively found that headache was present prior to MS onset in 69.7% of MS 
headache patients, and that MS onset did not modify pre-existing headaches. Given 
descriptions elsewhere suggesting predisposition to chronic pain, (302)  these 
findings remain of interest. 
Only one prospective estimate of pain prevalence at disease onset (25) was found. 
Despite early recruitment, mean symptom duration was 30.5 months, and pain 
prevalence of 73.5% could be regarded as an estimate in early disease. Retrospective 
estimates from the included studies are lower (overall pain range 11% to 21%, 
headache range 1.7% to 6.7%). (11, 27, 136, 144, 150, 151) However, disease 
duration (where reported) for retrospective estimates ranged from 10.8 (11) to 23 
years, (144) and thus these figures are vulnerable to recall bias. The apparent 
discrepancy between prospective and retrospective results could suggest that 
retrospective estimates relatively under-report pain prevalence at disease onset. 
Optimal data ascertainment methods in pain epidemiology studies remain under 
investigation. (303) 
 




Pain in MS relapse 
Pain associated with relapse has similarly rarely been studied prospectively, despite 
clear potential clinical relevance. Several studies specifically excluded pain related to 
MS relapse, (20, 23)  or did not separately report this data. (44, 143) One prospective 
estimate (147) of headache prevalence in relapse was found (prevalence 38.9%), but 
no prospective studies of overall pain. In comparison, retrospective prevalence 
estimates ranged from 63% (145) for overall pain, to approximately 1% for headache 
or for central pain. (133, 144, 150) Katsiari and colleagues report no relationship 
between several headache subtypes and relapse activity, though methodology is not 
described.(148) Relapse-associated pain could be highly clinically relevant in 
informing immunomodulation decisions. The lack of prospective studies, and wide 
variation in estimates, suggest that further study is required.  
How does pain in MS vary with time? 
With regards to longitudinal follow-up of pain syndromes, Stenager and colleagues 
(7) describe increasing prevalence of several pain syndromes with disease 
progression (initial mean EDSS 3.4). Brochet and colleagues (25) describe a 
statistically non-significant decrease in pain prevalence in less disabled subjects with 
early disease (median EDSS 2). Given the limited available data, including only 117 
subjects and extending to a maximum of 5 years follow-up, it is not possible 
therefore to reliably describe any relationship of MS-related pain to disease 
evolution.   
 




8.2.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis  
Firstly issues identified in the existing literature, and then findings described by the 
literature are discussed.  
Study characteristics and methodology 
8.2.2.1.1 Number and quality of studies 
My findings suggest that the number of studies examining neuroimaging correlates 
of MS pain is relatively low, and that methodology and quality of these studies is 
variable.  
The majority of included articles are case reports or series. Specifically, only seven 
hypothesis-driven experimental studies were found. Of these studies, one (154) met 
all quality criteria. The median number of quality criteria met was eight (out of a 
maximum of twelve). Several aspects of methodology which could be improved in 
future studies were identified. Specifically, several authors did not fully specify 
inclusion or exclusion criteria; and did not fully describe the pain assessment 
methods used. 
In all but one of the studies, structural MR imaging of the brain or spine was used, 
most frequently used to analyse lesion location, or to investigate other structural 
causes of pain. No studies used volumetric techniques. The description of image 
acquisition and reading protocols, and investigator blinding in the original studies 
was, however, often incomplete. It was also not always clear who read and 
interpreted the images, and only five of seven experimental studies (154, 174, 176, 
183, 191) described blinded image interpretation  
8.2.2.1.2 Pain syndromes studied 
All identified studies investigated neuropathic pain syndromes, despite frequent 
observations in cross-sectional studies that both nociceptive and neuropathic pains 
are common in MS (approximate prevalence 18% and 29% respectively (76, 304). 
There was also an emphasis on investigation of headache disorders and facial pain 
(74% of all studies), in particular Trigeminal Neuralgia.  




This emphasis does not closely reflect current knowledge of prevalence of pain 
syndromes in MS. While headache is thought to affect around 43% of people with 
MS, Trigeminal Neuralgia is relatively rare (prevalence 3-4% in MS populations). 
Other pain syndromes including neuropathic extremity pain, back pain, painful 
spasms and Lhermitte’s sign were relatively understudied (304). Some cranial pain 
syndromes examined in included studies (such as occipital or glossopharyngeal 
neuralgia (172, 187, 193, 204) are even less common than trigeminal neuralgia. 
These observations could suggest that studies identifying neuroimaging correlates of 
neuropathic pain syndromes in general, and headache or facial pain syndromes in 
particular, are disproportionately represented by the current literature (305). The 
reasons for any such discrepancy are not clear, though these may include an 
emphasis on interventional techniques for trigeminal neuralgia in some studies.  No 
investigators explicitly studied transition from acute to chronic pain states. 
8.2.2.1.3 Headache studies 
The included headache studies largely aimed to examine neuroimaging correlates of 
specific headache subtypes. Small studies of migraine and unclassified headache 
including one to two subjects (184, 201) identified abnormalities in relation to the 
brainstem, in keeping with the putative role of the brainstem in pain transmission 
pathways, including the descending modulation of pain (1, 32). Larger experimental 
studies including those by Gee and colleagues (n=277) (183) and Tortorella and 
colleagues (n=79) (174) (quality assessment ten and eight respectively, from 
maximum 12) also suggested that presence of brainstem demyelinating plaques 
might be associated with the occurrence of migraine. In contrast, Kister and 
colleagues (154) (n=204) (quality assessment 12) compared MS groups with and 
without migraine, and found no differences in the number or distribution of lesions 
(including brainstem) between the two groups. 
8.2.2.1.4 Trigeminal Neuralgia and Trigeminal Autonomic Cephalalgias 
Studies characterizing trigeminal neuralgia (TN) and trigeminal autonomic 
cephalalgias (TACs), in contrast, focused on abnormalities related to the trigeminal 
nucleus and nerve. Interestingly there appears to be overlap in radiological findings 




between TN and TACs, though this observation may not be generalizable to patients 
without MS.  
8.2.2.1.5 Neuropathic extremity pain 
Neuropathic extremity pain of central origin (typically a chronic “burning” pain 
affecting the lower limbs (15)) is thought to be one of the most common pain 
syndromes in MS (5, 304). The included studies examined differing types of limb 
pain. The hypothesis that spinal lesions may be causative in limb or radicular pain 
has been examined in some studies.  
In particular, in case reports or series, (173, 194, 202, 205) dorsal cord lesions in the 
thoracic and/or cervical cord have been linked to limb pain. Authors have suggested 
that demyelinating lesions may be linked to the occurrence of pain by directly 
disturbing sensory afferent pathways, or by disrupting descending inhibitory 
pathways (176) (205). Svendsen et al, however, in a study including spinal and brain 
MRI (n=25, quality assessment 9) found no association between site of 
demyelination and presence of chronic central neuropathic pain (176). Only one 
study (176) examined brain MRI imaging correlates of the presence of neuropathic 
limb pain. 
8.2.2.1.6 Location of lesions in the included studies 
Taking into account all identified studies, demyelinating lesions thought to account 
for pain syndromes were most commonly reported in the brainstem, and less 
commonly in the spinal cord. This may well, however, be linked to the observations 
above that the majority of studies investigated headache or facial pain syndromes.  
Methods used for identification of culprit MS lesions also frequently relied on a 
priori anatomical hypotheses. This could in theory diminish the likelihood of 
identifying novel associations with a particular pain syndrome. 
8.2.2.1.6.1 Lesions affecting cortex, thalamus, or cortico-thalamic connectivity 
Limited studies specifically assessed the thalamus or its projections. 
Notably, among the included experimental studies, Svendsen and colleagues (176) 
investigated any effects of MS lesions on cortico-thalamic projections. They found 




no statistically significant difference in thalamic or thalamo-cortical projection lesion 
load in MS patients with or without pain.  
Deppe and colleagues, using serial Diffusion Tensor Imaging (DTI imaging), studied 
a patient with central pain and abnormal somatosensory and thermal sensations on 
the right side of the body, and compared serial DTI data from this patient with 
imaging data from 100 healthy volunteers. The patient was part of a pilot for a 
clinical trial (188). The imaging technique and post-processing methods were well 
described. The authors suggest that the unilateral temporary increase of the fractional 
anisotropy found in the contralateral thalamus may have played a causative role in 
development of this pain syndrome, though the pain syndrome was relatively poorly 
described.  
8.2.2.1.6.2 Normal-appearing tissue 
Disease processes affecting normal-appearing tissues may be apparent when more 
advanced acquisition and/or analysis techniques are used. In the identified studies, 
any possible role of MS-related damage in normal-appearing tissue was not 
considered, with the exception of Deppe and colleagues’ study, which used DTI 
imaging (188).  
8.2.2.1.7 Inferring causality: timing of MS lesion in comparison to occurrence 
of pain syndrome 
In many studies, the association of a demyelinating plaque with a specific pain 
syndrome was based on demonstration of the plaque’s presence in a 
neuroanatomically plausible location at time of imaging for investigation of the pain 
syndrome. In some studies, the temporal association between the plaque, and 
occurrence of the pain syndrome, was further investigated by either carrying out 
serial imaging, or by using contrast administration. Evidence for temporal 
association of a plaque with pain syndrome could be relevant to investigation of 
possible causality. 
 




8.2.3 Prospective experimental study: Clinical, behavioural 
and neuropsychological associations of neuropathic 
limb pain in adults with relapsing remitting multiple 
sclerosis 
 
Study groups: demographics and medication 
Groups of people with MS and neuropathic pain (“MS pain” group, n=31) and 
people with MS without pain (“MS control” group, n=16) were matched for age and 
gender, and furthermore balanced for disability, duration of MS disease and years of 
full-time education. All of the MS pain group, while meeting clinical definitions of 
established neuropathic limb pain, also met EFNS and IASP definitions of definite 
neuropathic pain (4, 217). Detailed phenotyping of the cohort is reported. 
Accounting for potential effects of medications is complex (56), however the groups 
did not vary to a statistically significant degree in consumption of weak opiates, 
antidepressants (when all antidepressants were considered), tricyclic antidepressants 
specifically, baclofen, or MS disease modifying treatments. A higher proportion of 
the MS pain group were receiving gabapentinoid medications (55% vs 0%, 
p=0.0001). 
Differences between MS pain and MS control groups 
Statistically significant differences between the pain and control groups were found 
in a range of variables relevant to established descending pain modulatory pathways. 
These included scores for depression, anxiety, fatigue and catastrophising, as well as 
number of subjects endorsing symptoms consistent with major depression by the 
HADS instrument (157).  
The MS pain group performed worse in tests of verbal and visual memory, but not in 
processing speed. The author is aware of only one previous study of cognition with 
respect to pain in MS, which reported differences in processing speed (53). The MS 
pain group performed worse in tests of cognitive flexibility, but not in other 
measures of executive functioning, including concept generation and inhibition. The 
author is not aware of any other tests of executive functioning, in particular cognitive 
flexibility, in relation to pain disorders related to MS. Given that processing speed is 




reported as one of the most frequently affected cognitive domains in people with MS 
(48, 51, 306), the data do not suggest a global cognitive dysfunction.   
Targeted quantitative sensory testing found higher rates of allodynia in the MS pain 
group, than the MS control group, consistent with deficient descending inhibitory 
systems. Distribution of symptoms drawn by subjects on body diagrams, and mapped 
at the group level using a novel tool, was however similar in the two groups. 
Quality of life measures from the SF-36 were worse in the MS pain than MS control 
groups. Statistically significant differences were seen in five of eight subscales (four 
of four physical subscales, one of which measures pain, and one of four mental 
subscales).  
8.2.3.1.1 Subgroup analysis: MS pain and MS control groups, after exclusion 
of subjects receiving adjuvant analgesia 
Because of the potential confounding effect of medications on the above analysis, in 
particular gabapentinoids, an exploratory post-hoc subgroup analysis specifically 
excluded subjects who were receiving any adjuvant analgesic drug. This analysis 
supported the findings of the overall analysis (above). Results should be interpreted 
with particular caution given the small sample size and post-hoc nature of this 
analysis, however in most cases the direction of any difference seen between the 
groups, and the differences attaining the 5% statistical significance level, were 
confirmed in this exploratory analysis.  
These results, interpreted with caution, would be consistent with group differences 
attributable to reasons other than medication administration. 
Correlates of pain severity 
Assessment of correlates of pain severity within the MS pain group demonstrated 
that scores for depression, fatigue, anxiety, and catastrophising were significantly 
associated with increased pain scores. These findings were broadly in keeping with 
findings on comparing the MS pain and MS control groups.  
Cognitive differences seen between the MS pain and MS control groups were not 
however seen in the analysis of correlates of pain severity. No statistically significant 




association of any measured cognitive variable with pain severity were found. No 
trend towards effect was observed. 
Consistent with the differences in quality of life between groups with and without 
pain, all eight of eight quality of life subscales generated by the SF36 instrument 
were significantly associated with pain severity. These included three “mental 
subscale” measures which were not significantly associated with the presence of 
neuropathic pain (social functioning, emotional wellbeing and role limitation by 
emotional problems). Pain interference data from the BPI further suggested that self-
reported pain levels were strongly associated with interference in all measured 
activities of daily life.  
Interpretation 
Taken together, these findings suggest that emotional and affective variables are 
strongly associated with both the presence and severity of pain. Cognitive variables 
(measures of memory, and importantly of set-shifting or cognitive flexibility) were 
associated with the presence, but not severity of pain.  
Post-hoc exploratory analysis of a small group of subjects who are not receiving 
adjuvant analgesics, suggests that the differences observed between groups may not 
be solely attributable to medication administration. Such inferences should however 









8.2.4 Prospective experimental study: Structural imaging 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis 
 
Comparison of groups with and without neuropathic pain 
8.2.4.1.1 Lesion volume and distribution 
Overall lesion volume was not significantly different on comparison of the pain and 
control groups. Some region of interest analyses, however, suggested trends in the 
data which should be interpreted with caution.  
When analysis was restricted only to the brainstem, lesion volume was significantly 
higher in the pain group. On whole-brain analysis of lesion topography using 
permutation testing, only a single voxel adjacent to the right lateral ventricle was 
found to be more likely to be involved by T2 hyperintense lesions in the pain group 
than the control group. In a brainstemrestricted region of interest topographical 
analysis, T2 hyperintense lesions were found to be more common in the lower/lateral 
pons and right cerebellar peduncle, in the pain group.  
8.2.4.1.2 Voxel based morphometry 
When regional grey matter volumes were compared across the entire grey matter, no 
significant differences were found between pain and control groups at the 5% 
significance level. Separately, the statistical threshold of p<0.001 (uncorrected for 
multiple comparisons) was used to explore trends in the data. Using the less stringent 
p<0.001 threshold (uncorrected for multiple comparisons) (in keeping with previous 
studies (80, 288)), grey matter volume was found to be increased in the pain group in 
the left midbrain, and decreased in the pain group in right parahippocampal gyrus 
and mid-posterior cingulate, as well as the occipital cortex.  
No evidence for alterations in volume of key structures thought to be relevant to the 
descending modulation of pain were found. (No differences were found at the 5% 
significance level on restricting analysis to a single pre-specified three-dimensional 
mask of DPMS structures (29, 33, 96)). 




Correlates of pain severity 
No statistically significant association of lesion volume (whole brain or brainstem), 
lesion distribution or regional grey matter volume distribution was found with pain 
severity. 
Correlates of pain duration 
Only regional grey matter volume distribution was assessed in relation to duration of 
pain, in keeping with previous studies (79, 87). Reduction in volume in the left 
anterior cingulate was found to correlate with pain duration, at an exploratory 
statistical threshold.  
Other findings 
8.2.4.1.3 Measurement of ICV using automated methods 
ICV measurement using SPM was judged to be satisfactory in comparison with the 
gold-standard manual ICV estimation, and was used for subsequent analyses. 
8.2.4.1.4 Exploration of cross-sectional cervical cord area estimation 
Cervical cord cross-sectional area data from these brain imaging acquisitions were 
comparable to limited data previously published in the literature, and may support 
further exploration of this technique. 
 




Interpretation of findings 
The findings discussed above could be in keeping with a multifocal and 
mechanistically heterogeneous disruption in relevant supraspinal structures and 
pathways. There are, however, several points to consider. 
8.2.4.1.5 Lack of statistically significant correlates of the presence or severity 
of pain, within the described DPMS mask 
Region of interest analyses within this mask are reported, at the 5% significance 
level corrected for multiple comparisons. Results at the p<0.001 level within this 
mask are not reported. It is interesting that, despite clinical evidence compatible with 
impaired descending pain inhibition, particularly including cortical/cognitive 
variables most often localised to the prefrontal cortices (Chapter Four, page 119) no 
grey matter volume abnormalities in this mask were found at the stated statistical 
threshold. These results do not support a hypothesis of significantly altered grey 
matter volume between the groups studied.  
It is possible that the mask does not include relevant structures. The creation of the 
mask was however based on established literature (1, 33, 65, 87, 96) as described 
above.  
The deliberate inclusion of cortical volumes which are relevant to cognitive 
flexibility as described elsewhere in this thesis (Chapter Four, page 119) will have 
increased the overall volume of the mask and the number of comparisons carried out 
within it. It is however unlikely that this effect will have led to subthreshold results. 
Please see below for further discussion. 
8.2.4.1.6 Statistical significance level of reported results 
The results reported are significant at the p< 0.001 level, uncorrected for multiple 
comparisons in space, across the whole brain. This should be viewed as an 
exploratory analysis. While this threshold is less stringent than the threshold of 
significance at the 5% level, after correction for multiple comparisons, VBM results 
at these significance levels are widely reported in neuroimaging studies (80, 288, 
307), even where subjects with a chronic painful disease are compared with healthy 
controls (in contrast to the current study which employs a disease control group). 




Small studies have occasionally reported findings at the 5% significance level 
uncorrected for multiple comparisons (214). 
The lack of statistically significant findings at the 5% level, after correction for 
multiple comparisons is therefore not unexpected. This would be in keeping with 
findings of several recent large studies of cognitive and affective symptoms 
published by other groups, including the MAGNIMS collaboration (91-93) as well as 
with recently reported studies of pain phenotypes in subjects with dementia (288). 
8.2.4.1.7 Structures implicated by the above analysis 
8.2.4.1.7.1 Brainstem  
The higher volume of lesions in the brainstem in the pain group is compatible with 
the overall study hypothesis of impaired descending inhibition of pain, mediated in 
part by a disconnection syndrome. The brainstem is a key location in the descending 
modulation of pain, specifically the periaqueductal grey matter and rostral 
ventromedial medulla.  
No differential lesion distribution affecting regions core to the descending pain 
modulatory system such as the periaqueductal grey matter, and rostral ventromedial 
medulla was found. The regions found to be differentially involved in the pain group 
are however thought to be involved in projections to the cerebellum and elsewhere in 
the brainstem, and could be associated with relevant tracts within the human 
brainstem (273). It should also be considered that T2 visible hyperintense lesions 
only partially reflect the local and wider distribution of white matter abnormalities in 
MS (78, 92), and in that context the reported findings regarding T2 hyperintense 
lesion should not be overinterpreted in terms of precise anatomical localisation. 
The finding of increased grey matter volume in the pain group (at the exploratory 
p<0.001 level, uncorrected for multiple comparisons), in the mid brain abutting the 
periaqueductal grey and the trigeminothalamic nuclei echoes previous similar 
findings in the literature (87, 95, 97) which have previously been interpreted as 
suggesting a response to tonic nociceptive inputs (79, 87). It should be noted in 
relation to the possibility of facial/cranial pain syndromes (previously associated in 
some studies with similar findings (96, 97) that facial/cranial pain was relatively 




rarely reported by our study subjects, and lateralised facial pain was only reported by 
three subjects (one of whom reported periorbital pain, and two lateral jaw pain – 
Chapter Four, page 119). A similar number of subjects with non-painful sensory 
disturbance reported lateralised head/facial sensory change. The lack of correlation 
between structural abnormalities in this area, and preponderance of cranial/facial 
pain syndromes may suggest that volume increase in this region is not specific to the 
presence of facial/cranial pain.  
8.2.4.1.7.2 Posterior Cingulate Cortex 
Decreased volumes in the posterior cingulate, in relation to healthy controls, have 
been found in studies of people with fibromyalgia, migraine, trigeminal neuropathic 
pain, temporomandibular joint dysfunction, and other types of headache including 
hypnic headache (79, 87). While these observations does not speak to the relevant 
function of these structures in the phenotype of chronic pain, they do lend support to 
the suggestion that these structures may be relevant to the experience of pain. In a 
recent VBM meta-analysis the posterior mid-cingulate was implicated as 
reproducibly reduced in volume in VBM studies of pain syndromes. An 
accompanying neuroinformatics analysis suggested that this structure (in addition to 
involvement in pain) has been involved in explicit memory and action execution 
(95). Explicit memory in particular may be relevant to the current study, given 
memory impairments demonstrated in the subjects with pain (Chapter Four page 
119). 
The posterior cingulate has been associated with a multitude of functions in 
functional imaging studies including executive functions, episodic memory retrieval, 
emotion and pain (308). Regarding pain, the posterior cingulate has been linked to 
central representation of various pain syndromes including rectal pain, phantom limb 
pain, dynamic mechanical allodynia in neuropathy, and irritable bowel syndrome 
(308). The mid-posterior cingulate has been reported to be involved in a variety of 
fMRI studies using noxious stimulation (both cutaneous and visceral) (309). It has 
been shown to be anatomically connected to structures such as medial temporal 
lobes, and ventromedial prefrontal cortex, and is a principal node of the default mode 
network of resting state brain activity (310).  




The posterior cingulate furthermore has been shown to be affected by a range of 
neurological and psychiatric disorder including depression, schizophrenia and 
Alzheimer’s disease. Interestingly, the PCC has been implicated in the focus of 
attention and arousal state, perhaps specifically in regulating the focus of attention 
(310). There is specific evidence of a role for the posterior cingulate in the regulation 
of pain by attentional distraction, in an fMRI study of distraction from painful stimuli 
by a cognitive task. The posterior cingulate (among other regions including 
midcingulate, hippocampus, cerebellum and insula) was found to be preferentially 
activated in association with the diminution of pain perception by attentional 
distraction (109). A role in the focus of attention/interoception could be particularly 
relevant to the current study. 
8.2.4.1.7.3 Parahippocampal gyrus 
In the same VBM meta-analysis described above (95), the right parahippocampal 
gyrus (as in the current study) was found to be commonly affected in pain studies. 
However, it was reported to be increased in volume on average in the assessed pain 
studies (95). A neuroinformatics analysis of the literature pointed to a role of the 
parahippocampal gyrus in symptoms of comorbid chronic pain, cognition and 
emotion. The authors hypothesised that the right parahippocampal gyrus might be 
particularly linked to modulation of pain, and pain sensitivity (95). Although this 
meta-analysis found that parahippocampal gyrus volume was, on average, increased 
in subjects with pain, multiple studies (as described above) have discussed an 
opposite difference (ie a decrease in volume in those with pain) (87) in keeping with 
the current study. 
Considering  the individual VBM studies discussed elsewhere in this thesis (80, 96, 
97, 288), Younger and colleagues described an increase in right parahippocampal 
grey matter volume in relation to increasing duration of temporomandibular joint 
pain. The authors hypothesised that this could be related to compensatory adaptations 
to chronic pain (97). Fletcher and colleagues hypothesized that temporal lobe volume 
changes might be compatible with a role in contextualizing painful experiences, 
perhaps by linking to interoceptive experience or autobiographical memories (288). 




Specific laterality of volumetric changes is repeatedly reported in imaging studies, as 
described above, where the right parahippocampal gyrus and related structures (as in 
the current study) have been implicated. The reason for any laterality is not well 
understood, and the authors mentioned above (80, 95, 288) neither identified any 
previous literature directly relevant to the laterality of these findings, nor made 
specific hypotheses in this regard. Possible explanations for laterality of volumetric 
findings (which could be explored with focussed experimental designs) could include 
differential structural and/or functional connectivity of the right and left 
parahippocampal gyri to relevant cortical/subcortical structures, differential 
susceptibility of the right and left parahippocampal gyri to atrophy or volume 
expansion, differential ability of imaging paradigms to correctly identify volumetric 
changes in these structures on the left and right, reporting bias, or type 1 statistical 
error (ie false positive results). 
8.2.4.1.7.4 Occipital cortex 
Although previous studies have identified changes in occipital cortex structure in 
pain disorders (214) there is not a well-recognised role of the occipital cortex in pain 
processing or sensation. This finding may simply reflect the use of a less stringent 
statistical threshold (ie type 1 statistical error) and is not further discussed here. 
Comments on exploration of cross-sectional cervical cord data, from 
available brain imaging acquisitions 
8.2.4.1.8 Feasibility of techniques: 
The upper cervical spinal cord was found to be included in nearly all available 
images at both P2.5 and C2/3 level, with the exception of one subject where C2/3 
level was not included. Manual and Automated CC-CSA estimation were both 
feasible, though manual estimation was considerably more time-consuming. 
8.2.4.1.9 Relationship between manual and automated estimation 
Scatterplots examining relationship between manual and automated CC-CSA 
estimates, at both P2.5 and C2/3 levels, confirmed that they were linearly related. 
Review of scatterplots in comparison with line of equality suggested that there was 
no clear trend for one method to over- or under-estimate CC-CSA in comparison to 
the other. Bland-Altman plots confirmed acceptable inter-method agreement.  




Neither of the two studies described above (118, 120) (Papinutto and colleagues in 
abstract form) have described comparison of manual and automated CC-CSA 
estimation. Future work should compare the utility of proprietary software (such as 
Jim (121)) and open-source software (such as Spinal Cord Toolbox (266)), as there is 
a potential cost implication for researchers and funders. Other aspects of reliability 
such as inter- and intra- rater reliability are also currently unknown. 
8.2.4.1.10 Inter-subject variability 
Sources of inter-subject variability are not well understood in spinal cord imaging in 
multiple sclerosis. Demographic variables such as age and gender, have been 
reported to show significant relationships with cross sectional cord area, as well as 
white matter and grey matter segmentations (122). ICV as well as vertebral 
dimensions have also been reported to show strong relationships with cord cross-
sectional area (118, 122).  
The current study suggests that CC-CSA at both the P2.5 and C2/3 levels are 
strongly correlated, and that these in turn are correlated to intracranial volume (ICV), 
though P2.5 CC-CSA appears more strongly correlated with ICV. CC-CSA estimates 
at both C2/3 and P2.5 levels also tend to be higher in males than females, though this 
difference did not attain statistical significance at the 5% level. This is consistent 
with previous literature (122). 
In the only study reporting correlations between cervical cord cross-sectional area 
and clinical measures, including EDSS, in measures derived from brain volumetric 
data, EDSS was only moderately correlated with CC-CSA, and only after addition of 
a healthy control group to the multiple sclerosis group (Spearman correlation P2.5 -
0.34, p=0.015, and at C2/3 -0.30, p=0.032). Separate data for MS patients only were 
not presented, though the authors stated that only once healthy control data was 
included, was there a significant correlation between EDSS and CC-CSA.  
Although the current data suggest a weaker relationship with EDSS in the current 
study, a differing statistical measure has been used, no healthy controls are included 
in the current study, and because the current study used patients with RRMS (median 
EDSS 2.5)  in comparison with a mixed cohort of  17 RRMs, 15 SPMS and 5 PPMS 




with median EDSS of 6.0 (118), both inter-subject CC-CSA variability and 
variability in EDSS might be expected to be lower in the current study. Separate 
pathological processes may also operate in subjects with relapsing-remitting, and 
progressive forms of the disease (28). 
In a conference abstract, Papinutto and colleagues (120) describe that  correlation 
coefficients for EDSS predicted by UCCA from MPRAGE were higher than in this 
study and Liu and colleagues’ study: Spearman r=−0.74 p=0.006 and  Pearson 
r=−0.66 in one centre, and in another and in the matched UCSF cohort: r=−0.73, 
p=0.007; Pearson r=−0.64. This difference might relate to the use of a specific spinal 
cord coil, differences in image analysis, lower sample size (n=24 total for the results 
described, as compared to 45 in the current study and 37 people with MS (and 13 
healthy controls) in Liu and colleagues’ study (118). Further analysis will be possible 
once this data has been peer-reviewed and is available for review. 
8.2.4.1.11 Differences between pain and control groups 
Data from the current study (Table 49: Comparison of CC-CSA in study participants 
with and without neuropathic limb pain) quantifies automated CC-CSA at two 
cervical cord levels, with and without correction for ICV, in groups with and without 
neuropathic pain. CC-CSA at the C2/3 level, but not at the P2.5 level, was found to 
be higher in subjects with pain, than those without.  
Possible explanations could include 1) statistical artefact (analogous to Type I error); 
2) presence of lesions at C2/3 level which are not readily visible on the current 
imaging protocol and which could contribute to cord expansion 3) confounding 
factors such as medication, the effects of which are unknown and  4) inflammation 
/oedema in the group with neuropathic pain. Increases in cord cross-sectional area 
have previously been reported in RRMS in comparison to healthy controls (311) and 
tentatively linked to inflammation or oedema. 
8.2.4.1.12 Wider applicability of method 
The current exploratory investigation has demonstrated that manual and automated 
CC-CSA estimates can be extracted from volumetric MPRAGE brain data in the 
current small study, and that manual and automated estimates are comparable in a 




subset of 15 subjects. Associations between CC-CSA and other imaging and clinical 
variables are similar to those previously reported (118, 122), however the wider 
utility of this method remains unclear, and would benefit from comparison with 
application of similar methods to tailored spinal imaging acquisitions in the same 
patient group. 
In conclusion, estimation of CC-CSA from volumetric brain data using Spinal Cord 
Toolbox may be feasible. Further analysis including inter- and intra-rater reliability 
is required. Relationships of CC-CSA derived from this method, and CC-CSA 
derived by gold standard methods including specific spinal MRI sequences also 
remain to be clarified. No firm conclusions regarding CC-CSA in groups with and 
without neuropathic pain can be drawn from this exploratory analysis. 
 




8.2.5 Prospective experimental study: Functional 
connectivity of the descending pain modulatory system 
in adults with neuropathic limb pain associated with 
multiple sclerosis 
 
Mean functional connectivity of rACC seed in subjects with and without 
pain 
In this study group of people with relapsing remitting MS, both subjects with and 
without neuropathic pain demonstrated widespread functional connectivity between a 
rostral Anterior Cingulate Cortex (rACC) seed and a bilateral network of cortical 
structures including frontal, prefrontal, parietal (including sensory cortex) and 
cingulate cortex, thalamus, cerebellum and brainstem. Many of these structures have 
been repeatedly implicated in central processing and representation of pain, as well 
as in execution of neuropsychological tasks discussed and described in Chapter Four 
(page 119)(64). 
Lower connectivity between rACC seed and PAG, in pain group 
In a prespecified analysis, those without neuropathic limb pain manifested stronger 
functional connectivity between the rostral ACC and the periaqueductal grey matter, 
than those with pain (p≤0.05, corrected for multiple comparisons within PAG ROI). 
A spherical mask encompassing all subdivisions of the PAG (110) was used. Despite 
the relatively large PAG ROI used, this difference was observed only in the 
ventrolateral PAG, a region repeatedly implicated in endogenous descending pain 
modulatory networks (115, 312). 
Higher connectivity between rACC seed and DLPFC, in pain group 
In a further prespecified analysis, those without neuropathic limb pain manifested 
weaker functional connectivity between the rostral ACC seed and the dorsolateral 
prefrontal cortex, than those with pain (p≤0.05, corrected for multiple comparisons 
within a bilateral DLPFC ROI). This difference was found in the right middle frontal 
gyrus (116), and overlapping with DLPFC regions of interest previously specified in 
the functional MRI literature (110, 296). 




Adjusting for T2 hyperintense lesion volume diminishes or eliminates 
differential connectivity 
Although T2 hyperintense lesion volume was not significantly different between the 
groups with and without pain (Chapter 5), adjusting for the overall lesion volume 
diminished (but did not abolish) the statistically significant functional connectivity 
differences between rACC and PAG. Adjusting for overall lesion volume removed 
any statistically significant difference in functional connectivity across groups, 
between rACC and DLPFC.   
Increasing T2 hyperintense lesion volume is associated with differential 
rACC functional connectivity at the whole brain level 
Increasing T2 hyperintense lesion volume was positively correlated with functional 
connectivity of the rACC seed to a range of structures including (but not limited to) 
frontal/prefrontal structures implicated in executive function and the descending 
modulation of pain, as well as the occipital cortex. The significance of this finding is 
not clear. 
Trends towards correlation of pain severity with rACC:DLPFC and 
rACC:PAG functional connectivity. 
Subject-rated pain intensity at the time of imaging was not correlated with 
rACC:PAG functional connectivity at the 5% significance level after correction for 
multiple comparisons in space. However, using a less stringent exploratory statistical 
threshold (without correction for multiple comparisons within the PAG ROI) there 
was a trend to increased connectivity to the dorsal/dorsolateral PAG in association 
with increased pain severity (p≤0.05, without correction for multiple comparisons). 
Similarly pain intensity was negatively correlated with rACC:DLPFC functional 
connectivity at the left middle frontal gyrus, but at the statistical threshold of p≤0.05, 
without correction for multiple comparisons. 
Anatomical specificity of differential connectivity 
Using a midline occipital cortex seed as a “region of no interest” to examine the 
specificity of the above functional connectivity findings, all connectivity analyses 
were negative at the specified statistical thresholds.  
 




Interpretation of findings 
These findings may support the hypothesis of differential DPMS functional 
connectivity patterns (including dorsolateral prefrontal cortex, rostral anterior 
cingulate and PAG, but not a “control” occipital region of no interest) in subjects 
with and without neuropathic pain. T2 hyperintense lesion volume might contribute 
to these differential patterns of connectivity, perhaps by interrupting relevant white 
matter tracts. 
Lower rACC:PAG connectivity in the pain condition may be compatible with the 
stated hypothesis of disrupted descending pain inhibitory pathways in the pain 
condition. The significance of higher rACC:DLPFC connectivity in the pain 
condition (given that cognitive flexibility and other cognitive variables are found to 
be impaired in the pain group, in comparison with the control group) is unclear, 
though a compensatory functional reorganization could be considered, and in 
explored further in future studies.  Some potential limitations of the current study are 
considered below (Section 8.4).  
 




8.2.6 Findings of prospective study in relation to overarching 
study hypothesis 
Clinical and neuropsychological data 
In comparison of the pain and control groups, the observed differences in 
emotional/affective variables (including depression, anxiety and catastrophising) as 
well as apparently selective impairment of cognitive variables (such as measures of 
memory and of cognitive flexibility, but not processing speed) are relevant to 
existing models of cognitive and emotional/affective contributions to the DPMS (29, 
33, 56, 87).  
Allodynia was more common in the pain group, and sensitivity to pinprick was 
higher (both at the 5% significance level, before correction for multiple 
comparisons). Both are consistent with either descending facilitation, or impaired 
descending inhibition, of pain. 
Structural Imaging 
Structural imaging findings on the whole suggested possible trends in lesion 
distribution and grey matter volume, between the groups, which were not significant 
at the 5% significance level, corrected for multiple comparisons, when whole-brain 
analysis was used. 
The findings of increased brainstem lesion volume could be relevant to disruption of 
descending DPMS tracts through the spinal cord to the brainstem, though 
topographical analysis did not identify lesions differentially situated around the PAG 
or RVM.  
Differences in grey matter volume between pain and control groups affected 
structures previously identified as implicated in structural imaging studies of chronic 
pain syndromes (95) (posterior cingulate, parahippocampal gyrus, pontine nuclei). 
All of these are implicated in the central processing of pain (as well as in other 
cognitive tasks including memory and executive function). However these structures 
are not thought to be key components of the DPMS. Similarly, no volume difference 
in known cognitive/modulatory structures (frontal/prefrontal cortex) in relation to the 




presence of pain was found. Decreased anterior cingulate cortex volume was found 
to be associated with increasing pain duration. 
These data suggest that WM lesion distribution in the brainstem may contribute to 
disruption of the DPMS in people with pain, but that key components of the DPMS 
are not differentially affected by grey matter volume loss (other than with increasing 
duration of pain). 
Functional imaging 
The findings of differential functional connectivity between key nodes of the DPMS 
(rostral ACC, DLPFC and PAG (1, 110)) in those with and without pain could 
support the overarching study hypothesis. The observation that differences in 
connectivity are diminished or removed by statistically adjusting for T2 lesion 
volume, along with the observation that rACC functional connectivity varies in 
proportion to T2 lesion volume, could be consistent with a role of T2 lesion volume 
in functional connectivity alterations, for instance by disrupting white matter tracts.  
8.2.7 Participant experience of study 
Overview 
Thirty study participants took part in a pseudo-anonymised survey of participant 
experience, which was administered using a standardised survey instrument, with 
research participant input into design of the survey.  The question format used was 
similar to that of previous studies (299) using a seven point scale for numerical 
feedback, and free text for comments. 
Participation in feedback 
Participation in feedback survey was relatively high (64% of study participants). 
Survey respondents and non-respondents were not significantly different in terms of 
age, or presence/otherwise of chronic pain at time of study participation.  Those who 
participated in the feedback survey were, however less disabled on average (p=0.04). 
There was also a trend to higher numbers of female respondents (p=0.054). This 
could reflect easier access to the survey instrument among people with less disability, 
though efforts were made to make it available both online, and in paper versions. 
Alternatively, there may be differing levels of interest in participation, or differing 




ability to take part due to, for example, competing priorities. Participation in research 
feedback has not been extensively studied, however one previous study of 252 
people taking part in RCTs of treatment for depression found that respondents to an 
experience study were more likely to be female, and older (Tallon et al) (313). Any 
reasons for a gender imbalance in respondents is not clear. 
Overall satisfaction with study participation 
Overall satisfaction with involvement in the study was rated as high, as were most 
individual aspects of the study including aspects of clinical, neuropsychological and 
imaging assessment. Participants gave useful, informative, comments on particular 
aspects of the study which might help to inform the design of future studies.  
Experience of particular parts of the study 
8.2.7.1.1 Information exchange 
The amount of information given in the current study, and the way in which it was 
presented, seemed to be viewed favourably by participants. The production of a 
study newsletter, while demanding in terms of workload to PF, was also viewed 
favourably and could be considered as a standard part of future studies.  
Limited previous research has found that study participants preferred detailed 
information prior to study information, and also feedback of study results (314). Both 
of these themes are mirrored by feedback given in the current survey, although a 
minority of participants related that they were given too much, rather than too little 
information. The amount of information given can be individualised to some extent, 
though the use of standardised patient information sheets and consent forms 
(necessary for research ethics committee review and approval) requires a certain 
degree of standardisation, and there is no established optimal amount of information 
required for particular participant groups (314). 
8.2.7.1.2 Clinical and neuropsychological evaluation 
Questionnaires on pain, and other related issues including mood were included in the 
study. Some people might find these challenging, or feel that material was personal 
or intrusive. However, the content and delivery of the questionnaires and 




neuropsychological assessment included in this study appear to be supported, overall, 
by the feedback obtained.  
While some participants found the neuropsychological evaluation, in particular, 
challenging, overall ratings of satisfaction with both questionnaire and 
neuropsychological evaluations were high. 
There is little existing consensus on which subjects participants are most likely to 
find distressing. A review of psychiatric studies has related that questionnaires 
exploring suicide, abuse, neglect, or bereavement have been found to be distressing 
to some participants in some studies (297). A minority in one study of 252 RCT 
participants with depression reported negative feedback about answering 
questionnaires in general  (313) . In that study 27 respondents (10.7%) made negative 
comments about questionnaires including covering personal issues, and difficulty 
understanding questions. In contrast, Schafer and colleagues (314) found that the 
majority of 763 European adults with depression or schizophrenia expressed 
willingness to take part in research using questionnaires (92%), interviews (84%) or 
psychological testing (83%) (314).  
8.2.7.1.3 MRI and fMRI imaging 
Participant feedback on MRI imaging was in general positive, for the current study. 
Some subjects did report that temperature of the scan room, noise levels, and comfort 
during MRI in general were a challenge. Overall, however, satisfaction with 
participation remained high, and contact with staff during MRI imaging was said to 
be good. This perhaps mitigated negative aspects of MRI imaging (315). 
These themes reflect previous findings on participant experience of MRI imaging, 
which has been subject to more detailed research than other aspects of research 
participants’ experience. 
I am aware of one previous study (299) which recounted numerical ratings of 
comfort during MRI (specifically fMRI) procedures. The ratings obtained in that 
study were comparable to the current feedback, though the questions asked were 
slightly different. In that study data from 22 older patients undergoing research 




neuroimaging, and 70 healthy volunteers undergoing research neuroimaging were 
presented. They were asked “how was the scanning procedure?” (answer via 7 point 
scale with the endpoints 1 “very comfortable” and 7 “very uncomfortable”). The 
healthy volunteers gave a median score of 3, and patients a median score of 2.5 
(299).  
Several studies of participants in clinical (rather than research) imaging have 
focussed on claustrophobia, which is viewed as a frequent reason for scan failure. In 
a clinical context, this may be justifiable, as the benefits of imaging usually outweigh 
the discomfort/risks to the participant. In a research study, however this is not 
necessarily the case, and study of participant experience should arguably be more 
detailed in a research context (299). Even seemingly minor aspects of the imaging 
experience – such as placement of the imaging department in the basement, as in this 
study – may adversely affect participant experience (315). The contrast between 
research and clinical imaging may be an artificial one, however, and limited data 
suggests that overall participant comfort is similar (299). It should also be 
highlighted, that people taking part in imaging research studies, are self-selected to 
tolerate imaging reasonably well (299). 
Various aspects of research MRI imaging might be experienced as challenging by 
some participants (316), though existing knowledge is limited (297). In a study of 
763 European adults with psychiatric problems, willingness to take part in research 
involving imaging was generally lower (75%) than willingness to take part in 
research using questionnaires or interviews (92% and 84% respectively) (314). 
One systematic review of qualitative studies of patient experience (including 15 
studies) mentioned several themes. Participants may dislike certain aspects of the 
MRI imaging process. They may need support during the scan, and available staff 
support may importantly impact on positive or negative experience (316).  Specific 
challenging aspects of MRI imaging in general might include lying in a narrow space 
(claustrophobia), being in a strange environment, having to stay still, duration of 
imaging (research scans can take up to 120 minutes, and frequently 45-75 minutes 
(299)), concern about results (particularly for clinical imaging), noise  (299), use of 
particular sequences (which may be particularly associated with varying noise levels 




(299)), and perceived loss of control (315). Apprehension about results is probably 
less for participants in this study, but cannot be dismissed, particularly in the context 
of concern about ongoing disease activity and disease-modifying therapy. 
8.2.7.1.4 Noxious stimuli during fMRI 
Numerical ratings supplied by research participants suggest that they did find 
administration of noxious stimuli during fMRI moderately difficult. These ratings are 
however difficult to interpret, in the light of the phrasing of the questions used for 
these specific aspects of the study. Specifically, ratings of one to seven were used, as 
in the other parts of the survey. The other parts of the survey had however given 
anchor points of “not at all satisfied” and “completely satisfied”, whereas questions 
in this part of the survey gave anchor points of “not at all difficult” and “completely 
difficult” (in effect reversing the anchor point associated with positive, or negative, 
feedback. I am not aware of any previous research studies which have examined 
participant experience of noxious stimuli during fMRI. 
8.2.7.1.5 Motivation for research participation 
By far the most frequently-mentioned reason for study participation was altruism. 
Other motivators such as sense of interest, perceived benefit for the participant, and 
giving back to NHS/ARRNC staff were also mentioned. In this sample, only one 
participant reported that they were motivated to participate partly by the possibility 
of an MRI scan. This may provide some degree of reassurance with respect to any 
covert sense of coercion in this regard. Similarly, feelings of guilt were mentioned by 
only one participant.  
These findings are similar to those previously reported, though published literature is 
small. In a multi-centre study of people with schizophrenia and depression (Schaefer 
et al)(314), the main motivation to take part in research was stated as altruism, 
though subjects also felt that they would like to help the medical profession. Some 
also felt that participation would give them access to better treatment. About a 
quarter considered financial incentives important (314), while only one participant 
mentioned this in the current study. In a further study of 252 people with depression 
who participated in trials of antidepressant drugs (Tallon et al)(313), most were glad 
they took part, and would consider participating in future research. In that study 




people related their principal motivators for participation as altruism, doing 
something positive, feeling supported by researchers, and having time to talk. Some 
stated that they gained understanding of their disorder, and valued feedback on 
progress (313). Reasons for not participating in research have previously included 
concerns about privacy, data protection, causing psychological problems, time, or 
causing physical problems (314). 
 




8.3  Relevance of this work to wider field 
8.3.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
On comparison with previous estimates of pain prevalence, my analysis includes all 
studies used for prevalence estimates in a previous systematic review (5) with the 
exception of one (10) which was excluded in favour of a study examining an 
overlapping patient group. (7) By contrast, however, estimates of overall pain 
prevalence (63%; 95%CI 55% to 70%) (17 studies, 5319 subjects), (7, 11, 20-27, 44, 
66, 142-146) and pain within the last month (62%; 95%CI 52% to 72%) (11 
estimates, 4224 subjects)(11, 21-26, 44, 66, 145, 146) vary significantly from 
previous estimates (5) of 50% for point prevalence (three studies, 1872 subjects), 
(10, 23, 66) and 75% for pain within the last month (three studies, 854 subjects) (24, 
44, 145).  
This work therefore suggests that point prevalence of pain is rather higher than had 
previously been reported. Several factors including the prospective design of all 
included studies, the larger number of included prospective studies in comparison to 
a previous review (28 studies, 7101 subjects, in comparison to nine prospective 
studies, 3311 subjects), and use of weighted random-effects meta-analysis are likely 
to augment the accuracy of the current estimates. 
This work is also the first to detail the prevalence of specific pain syndromes in MS 
(rather than overall pain prevalence) using a meta-analytic approach. Similarly this 
work was the first to quantify estimate heterogeneity, and to use a meta-regression 
approach to explore contributions to heterogeneity.  
The published work arising from this chapter was recommended by the post-
publication peer review “F1000 prime” website. 
Enquiry about pain should remain a priority for clinicians treating all patients with 
MS. Investigation of the temporal profile of MS-related pain, and characteristics of 
patients at risk – using standardised study design - should also be clinical research 
priorities. Better understanding of the epidemiology of pain in MS could contribute 
to investigation of its aetiology, management, and potentially its prevention. 




8.3.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis  
 
Neuroradiological studies of pain in MS are relatively low in number, and of variable 
design and quality. Some relatively rare pain syndromes (including Trigeminal 
Neuralgia) were the focus of a majority of studies. Other, more common, pain 
syndromes were less frequently studied. These findings may reflect the need for a 
shift in emphasis of neuroimaging studies in relation to pain in MS.  
Significant methodological issues relating to study design, execution and reporting 
were also identified. Investigators using different study methodologies have reached 
differing conclusions regarding the neuroimaging correlates of specific pain 
syndromes in MS. Methodologically higher-quality studies were however less likely 
to report positive associations of lesion location to the presence of headache, or of 
chronic central neuropathic pain (154, 176). 
Despite, therefore, the prevalence and impact of pain in MS, the insight into pain 
mechanisms currently afforded by neuroimaging studies remains limited.  
The current evidence does support the hypothesis that focal demyelinating lesions are 
sometimes associated with the occurrence of specific pain syndromes in MS, in some 
cases. Study methodology has not, however, always been sufficient to further explore 
any association. Several studies have not found a clear association of lesion location 
with the occurrence of specific pain syndromes, and it is possible that MRI-visible 
lesion location does not explain a significant proportion of the burden of pain 
syndromes in MS. There is considerable opportunity to advance our mechanistic 
understanding of MS-associated pain, and thus its therapy, through future research.  
 




8.3.3 Clinical, behavioural and neuropsychological 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis  
The results described in this chapter suggest that, in the population described, 
emotional/affective factors are associated with both the presence and severity of 
neuropathic limb pain in relapsing-remitting multiple sclerosis. Cognitive factors 
(specifically memory and cognitive flexibility) are associated with the presence of 
neuropathic pain, but not severity of existing pain.  
While the associations of affective and emotional variables with the presence and 
severity of pain in MS have been previously described, this study is one of the first to 
link cognitive factors to pain in MS, and to the descending modulation of pain 
specifically. 
Interpretation of the difference between groups with and without neuropathic pain is 
limited by the higher usage of adjuvant analgesics in the pain group, however a post-
hoc exploratory analysis limited only to those not receiving such drugs supports the 
conclusions of the wider analysis.  
Both emotional/affective, and cognitive factors have been repeatedly linked to 
descending modulation of pain. The described results could be compatible with the 
study hypothesis of impaired pain modulation, in the population described. The 
differential associations of emotional/affective factors (including fatigue) and 
cognitive factors, with the presence and severity of pain, could be compatible with a 
model of dissociable mechanisms within an overall framework of the descending 
pain modulatory system. These findings are relatively less likely to demonstrate a 
“global” effect whereby cognitive and affective variables are always closely 
interlinked.  
Such findings might be consistent with modulation of pain perception by both 
cognitive pathways and emotional/affective pathways. These pathways have 
previously been described as neuroanatomically and mechanistically distinct (31). 
These results, if confirmed in future larger studies, could be relevant to 
understanding of pain modulatory mechanisms in MS, and could lead to further 




investigation of how these systems might be impaired (for instance by focal 
demyelination, or by grey matter atrophy).  
These results are among the first to explore the cognitive correlates of neuropathic 
limb pain in MS, and support future consideration of cognitive as well as 
emotional/affective and sensory aspects of pain in this disorder. From a treatment 
perspective, these findings could eventually be relevant to development and 
administration of targeted therapies (57, 260), including cognitive behavioural 
therapies. The finding of deficits in memory and cognitive flexibility in the pain 
group should also be borne in mind, in the design of any cognitive behavioural 
intervention. 
8.3.4 Structural imaging associations of neuropathic limb 
pain in adults with relapsing remitting multiple sclerosis 
The current data suggests that the described clinical and neuropsychological 
associations of the presence and severity of neuropathic limb pain in RRMS are in 
turn associated with trends in MRI measures of brain structures. Although these 
findings echo findings in people with chronic pain disorders outside the context of 
MS (95), few of these are in structures usually recognised as key to the descending 
modulation of pain.  
Only one previous published study (214) has used computational techniques (voxel 
based morphometry) to assess grey matter volumes, and only in a subset of the 
included 23 patients. The current study is the first to report findings at a significance 
threshold more stringent than p<0.05 uncorrected for multiple comparisons. 
At an exploratory statistical threshold, the pain group manifests lower grey matter 
volumes in the posterior cingulate and right parahippocampal gyrus, as well as higher 
volumes in the left midbrain trigeminothalamic nucleus area, adjacent to the 
periaqueductal grey matter. Increasing duration of pain is also negatively associated 
with grey matter volume in the anterior cingulate cortex.  
These findings, reported for the first time in MS, are consistent with findings in 
previous studies of pain syndromes outside MS. Associations of increasing pain 
duration with decreased grey matter volume may suggest a causative link between 




the experience of pain and grey matter volumes, though further longitudinal studies 
would be needed to explore this hypothesis. 
In a brainstem-restricted analysis, T2 hyperintense MS lesions are found to be more 
common in specific brainstem locations in the pain group, and may be relevant to a 
disconnection syndrome, reflecting the complex interaction of white matter and grey 
matter abnormalities in MS (78, 85).  This study did not find, however, a regional 
grey matter volume difference between the groups in pre-specified structures usually 
recognised to be key to the descending modulation of pain including frontal and 
prefrontal cortices.  
The potential relevance of posterior cingulate and parahippocampal gyrus in pain, 
memory and attentional roles, all of which are potentially relevant to the current 
study (Chapter Four page 119) are discussed above.  
In addition, an early exploration of cervical cord cross-sectional area measurements 
(extracted from the current data using open source software) has been carried out. 
This exploratory analysis suggests that further exploration of the reproducibility, 
reliability and utility of this technique is warranted. 
 
8.3.5 Functional connectivity of the descending pain 
modulatory system in adults with neuropathic limb pain 
associated with multiple sclerosis 
 
This small cross-sectional seed-based resting state fMRI study provides early 
evidence that functional connectivity of the supraspinal descending pain modulatory 
system may be disrupted in people with neuropathic limb pain in relapsing remitting 
MS.  
Only one previous study has used functional MRI to examine neuroimaging 
correlates of the presence of pain in MS (214). The current work is the first to focus 
specifically on neuropathic limb pain, to focus on relapsing remitting MS (rather than 
a mixed-phenotype group), and to employ a hypothesis-driven seed-based approach 




to fMRI analysis. The current work is also the first to incorporate lesion volume in 
the analysis of resting state fMRI connectivity. 
Functional connectivity of the dorsolateral prefrontal cortex, rostral anterior 
cingulate cortex and ventrolateral periaqueductal grey matter is implicated in the 
presence of pain. T2 hyperintense lesion volume may contribute to this differential 
connectivity. These findings are described for the first time in people with multiple 
sclerosis. 
Trends towards differential functional connectivity in the above structures in relation 
to pain severity were also found. These did not however attain statistical significance 
at the predetermined threshold and are discussed briefly above. 
 
 




8.4 Weaknesses of methodology 
8.4.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
 
Inconsistent methodology even in relatively homogeneous studies 
The meta-regression analysis in this study demonstrated few significant links 
between study design, or study group, factors and pain prevalence estimates. These 
findings seemingly contradict previous findings that pain is more common with, for 
example, increasing disability and disease duration,(7, 20-23)  and could be in 
keeping with studies finding no relationship. (24-27) However, in my opinion, even 
within a selected group of included studies, underlying effects could be masked by 
inconsistent use of diagnostic, inclusion and exclusion criteria, (5)  or by low number 
of available studies. It is possible that the apparent significant effect of pain 
timeframe in headache studies, but not in overall pain studies, could reflect more 
consistent use of diagnostic, (155, 156) inclusion and exclusion criteria in headache 
studies. Higher adjusted R2 values for other variables in headache studies as 
compared to overall pain studies could be explained similarly. Significant correlates 
of pain may be unidentified, or inconsistently studied. Specifically, few studies 
quantified psychiatric or neuropsychological dysfunction.  
 
Although relatively high quality studies were selected, some methodological 
concerns in included studies were identified. Investigator blinding, longitudinal 
follow up, and control groups were all infrequently used, and externally available 
validated instruments were infrequently used in overall pain studies specifically. 
Deficient blinding and use of varying diagnostic criteria may be most likely to 
influence prevalence estimates. Infrequent use of follow up and of control groups 
may principally affect characterisation of the natural history of pain in MS, and 
assessment of differences between MS and other populations. In addition, all 
included studies were carried out in North America or Europe, which could limit 
wider generalisation of findings. 




This review had several limitations. Inclusion of a relatively low number of studies 
may have limited the power of our analyses, as discussed above. Pain severity, or 
quality of life have not been studied, and  pain related solely to MS treatment was 
excluded. The findings therefore do not reflect these factors. A lack of control data 
precludes direct comparison of pain prevalence in MS groups with the wider 
population, or to other chronic neurological diseases, although chronic pain 
prevalence in the general population (Europe and Israel) has been estimated at 
around 19%. (224) Lastly, retrospective estimates of pain prevalence at disease 
milestones from included studies are discussed in comparison to our prospective 
data, though all available retrospective estimates were not included, as this was not 
the focus of our review.  
 
8.4.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis  
Definition of multiple sclerosis 
Included studies, as discussed above, include those which do not fully describe 
diagnostic criteria used in application of the diagnosis of MS. Therefore although all 
study authors described the inclusion of only subjects with MS, the possibility of 
alternative pathology (such as similar disorders, including clinically isolated 
syndromes of demyelination, or neuromyelitis optica) contributing to pain needs to 
be borne in mind. Although inclusion of subjects experiencing such disorders might 
diminish my ability to draw conclusions with respect to pain syndromes specifically 
in multiple sclerosis, there may also be some considerable overlap in terms of 
pathological mechanisms, and symptoms (including neuropathic pain). For instance, 
neuropathic pain is well described in early MS (25) and in neuromyelitis optica 
(252). 
Limitation to English language studies 
This review was limited to studies published in English. This may limit 
generalisability of the study to patients, or to healthcare systems, other than in 
predominantly English-speaking cultures.  





The search strategy was designed to identify studies describing neuroimaging 
correlates of pain syndromes in multiple sclerosis. It is possible that it did not 
identify some studies which related neuroimaging features of pain syndromes, which 
were not, however, a primary focus of the study. Given that neuroimaging correlates 
of pain syndromes in MS are rarely studied, however, the number of studies of this 
type are likely to be low. 
Authors were not contacted to identify unpublished work. In particular this could 
lead to an over-representation of studies identifying a link between identified MRI 
abnormalities, when compared to those not identifying any abnormality, in the 
available literature. 
Quality assessment of studies 
The described quality assessment tool was used as a framework for evaluation of the 
quality of individual studies. This tool is similar to that previously used by Campbell 
and colleagues in two separate studies of people with low back pain (167, 168). It is 
comparable to other tools used to assess observational studies including the National 
Institute of Health “Quality Assessment Tool for Observational Cohort and Cross-
Sectional Studies” (317), and also takes into account comments on review and 
interpretation of methods in studies of pain, described by authors such as Hayden and 
colleagues in their study of prognostic reviews for low back pain (169).  
While presented a “total score” is presented for each study, by simply summing the 
number of quality assessment items identified in each study, this should not be 
interpreted as an ordinal scale, but rather as a brief overview of quality assessment of 
each study, as a framework for further discussion.  
 
8.4.3 Prospective Study: general comments 
Issues of methodology for the prospective study in general are discussed, followed 
by separate discussions of the relevant experimental chapters. 




Cross-sectional study design 
This cross-sectional study can only report associations between measured data. 
Causality cannot be inferred. Even in the presence of causality, the direction of any 
causality (or presence of a further mediating factor affecting both variables) could 
not be inferred from the current study design. 
A longitudinal study design might help to disentangle such relationships. This was 
not however feasible within the confines of the current study. Such a study design 
might furthermore be vulnerable to differential participant attrition over time. 
Generalizability of data 
8.4.3.1.1 Recruitment source 
The current study subjects are drawn exclusively from a tertiary MS clinic in a single 
region of Scotland. All have consented to take part in a potentially demanding 
research study. It seems likely, therefore, that the current data are not fully 
representative of the wider population with relapsing remitting MS in the 
community.  
Efforts are however made by the clinical team to ensure regular clinic review of all 
patients with RRMS in South East Scotland, in order to optimise provision of DMTs. 
This measure may act to improve comparability of the clinic population, from which 
this study population is drawn, to the wider MS population. 
8.4.3.1.2 Demographics 
Median age in the current sample was 42.5 in the MS control group and 41.0 in the 
group with pain. This is younger than the age at peak prevalence of multiple sclerosis 
in Scotland (56 years for women, 59 years for men (318)). This predominantly 
female sample (81.2% female in the control group, and 80.6% in the pain group), 
reflects the female preponderance of prevalent MS in Scotland, though estimates 
suggest that about 27% of prevalent cases are male in Scotland (318). 
8.4.3.1.3 Pain Severity 
Median average pain severity in the MS pain group was 5. Pain severity is 
comparable to several published studies which relate an average pain severity of 




between 4.8 and 5.8 on a 0-10 scale (70;105;106), though some describe less severe 
pain (79). 
8.4.3.1.4 Anxiety and Depression  
Symptoms of anxiety measured using the HADS instrument (107) were appreciable 
in both control and pain groups (median score 5.5 and 9.0 respectively). Symptoms 
of depression were most marked in the pain group (median score 5.00, compared to 
1.5 in the control group). The number of participants reaching a threshold score of 
eight for significant depression (11/47) and anxiety (26/47) was somewhat higher 
than reported by Korostil et al (108), who reporting elevated anxiety scores in 20% 
of the sample, and elevated depression scores in 10% of the sample. Korostil and 
colleagues however used a threshold score of 10, rather than 8. 
 
 




8.4.4 Clinical, behavioural and neuropsychological 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis 
Patient self-report measures 
Where possible, the measures used in this study were specifically validated in studies 
of people with multiple sclerosis. If this was not possible, measures validated in 
studies of people with other neurological disease, or which are widely used in studies 
of people with MS, were used. Preference was also given to measures meeting 
guidelines for pain research studies - including published expert consensus, and 
patient survey (3;4). In addition to these criteria, however, study instruments were 
also selected to minimize burden on potential study participants.  
This concern was balanced against theoretical priorities including ecological validity 
of specific instruments, and may have led to use of specific instruments which met 
the criteria detailed above, but where debate in the scientific literature remains 
regarding their relative merits as compared to other measures. For instance the SF-36 
is regarded as a quality of life measure (5;6) however has sometimes been criticized 
for undue emphasis on functional abilities (319). To this extent the choice of 
instruments included in this study has been influenced by pragmatism. 
Neuropsychology assessment 
The BICAMS battery used in this study is widely used in MS, incorporates validated 
instruments, and is relatively short and easy to administer. Tests of executive 
function are not, however, standardised and while every effort has been made to 
include tests which are validated, or at least widely used, in comparable studies, there 
is no readily available acknowledged executive function battery for people with MS. 
Measures of IQ were not available for the current study. Instruments such as the 
National Adult Reading Test (NART) (320) could be included to estimate IQ without 
completion of detailed testing such as the Wechsler Adult Intelligence Scale (55), 
which could be burdensome to participants . The NART instrument tests 
pronunciation of a standardised list of words, and was developed as an instrument to 
estimate pre-morbid cognitive functions in people with intellectual deterioration. It 
has been shown in some studies that there is an association between performance on 




the NART, and on tests including those for verbal fluency. In this study years of full 
time education was used to provide an estimate of intellectual attainment, and an 
estimate of premorbid IQ has not been used. It remains possible, therefore, that some 
of the associations seen in the study could be related to premorbid IQ (although the 
lack of difference between the pain and control groups for years full time education, 
as well as gender, age, EDSS and disease duration might make this less likely).  
The design of the current study, in that participants with known significant cognitive 
deficit are excluded, is also somewhat different to the original application of the 
NART in estimating premorbid IQ in those with established cognitive impairment. 
Sensory testing 
The quantitative sensory testing reported in this study was targeted to eliciting signs 
of central sensitization. It was based on existing QST protocols such as those 
suggested by the DFNS but is much shorter. Results reported here may therefore not 
be directly comparable with those reported in other studies using QST. Findings in a 
group of matched healthy volunteers, without pain or neurological disorders, and 
without recent use of analgesia are however reported. The findings reported are 
comparable to those from previous studies (15). 
Study analysis 
As described above, all data in this study was stripped of patient identifiable 
information, and was allocated a four-digit study ID number, generated at random by 
computer, before analysis. Where analysis was complex (as for the SF-36 instrument, 
for example), analysis was standardised by use of a computerised algorithm. PF was 
therefore blinded to the identity of the study participant and therefore their status as 
regards presence, or severity, of pain. Further attempts were made to mitigate effects 
of any unintentional unblinding by the use of computerised data marking where 
possible. A subsection of the neuropsychology data was marked by RM. This data 
was cross-checked by PF to ensure inter-rater reliability. 
Multiple comparisons 
As previously discussed, multiple comparisons between and within groups are made 
in this study. Results should therefore be interpreted with caution. For ease of 




interpretation, 5% significance level is used throughout (except where specifically 
discussed). Statistical correction for multiple comparisons has used only the most 
straightforward version of the Bonferroni correction. The Bonferroni correction was 
applied to each “group” of tests (for instance psychological/affective morbidity, or 
executive function tests) that were viewed as distinct by the author, and are presented 
in a single table in the Results section. It is possible that other authors might disagree 
with the grouping of tests (and therefore application of Bonferroni correction) though 
the anticipated purpose of tests was specified pre-administration by the author and 
study team.  
More complex procedures for multiple comparison correction such as False 
Discovery Rate (FDR) were not applied because of the grouping of tests by planned 
purpose (as described). Further techniques for dimensionality reduction (such as 
Principal Component Analysis) were not used in this thesis. While some measures 
applied could be seen to measure similar constructs (such as measures of severity of 
pain) the study was not designed to repeatedly measure similar constructs, and study 
variables were not in general directly comparable.  
Measures of pain severity from the Brief Pain Inventory, for example were highly 
correlated with each other, but while the BPI is validated for measurement of non-
malignant pain (221) and the Pain Severity Index is widely used (223), use of PCA 
components would remove any such advantage. Furthermore, pain measures from 
the BPI were only moderately correlated with the pain measure from the SF-36 
which enquires about pain over a different time scale. 
Effects of medication 
No subject stopped their regular medication for the purpose of study participation. 
Medication regimes are in some cases fairly complex. Study participants were not 
matched for administration of medications. On comparison of the MS pain group, 
and MS control group, significantly more people with pain were receiving adjuvant 
analgesics. This difference was explained specifically by administration of 
gabapentinoid medications (gabapentin and pregabalin) but not other medications 
such as tricyclic antidepressants. 




When designing the study, subjects were not asked to withhold medication. This is in 
keeping with a comparable recent study (214). This decision inevitably implied that 
analysis of the available data would be complicated by consideration of possible 
medication effects.  
The first reason for this decision was that it was not considered ethical to ask subjects 
to withdraw medication.  
Secondly it was considered that a request to stop medications might influence study 
recruitment, in ways that might be hard to estimate or account for (for instance 
perhaps only people with mild pain would agree to participate).  
Thirdly, the optimal duration of a medication-free period to avoid affecting the 
described study instruments (including fMRI) is not fully established.  
Fourthly, some subjects might surreptitiously take medication prior to study 
participation (for instance if pain was anticipated to be manageable, but in the event 
was not, and they felt that medication was required). This would make analysis 
particularly hard to interpret, particularly as any such effect would not be apparent at 
time of analysis, and could reasonably be expected to be non-randomly distributed 
among the study group. For instance, those with worse pain might be more likely to 
surreptitiously continue medication.  
8.4.4.1.1 Could Gabapentinoid medications account for the observed 
differences in clinical, behavioural and neuropsychological 
measures? 
There is limited evidence regarding the cognitive, behavioural and clinical effects of 
gabapentinoid medications (gabapentin and pregabalin). What evidence is available, 
is drawn from studies in subjects with MS as well as other neurological disorders, 
and uses both patient reported outcome measures, and objective measurements (for 
instance of cognitive processes). Patient reported and objective measures do not 
always support the same conclusions. 




8.4.4.1.1.1 People with epilepsy: objective measures of cognitive processes 
Leach and colleagues (321) assessed the cognitive effects of gabapentin on 21 people 
with poorly controlled epilepsy, in an older study. Participants were administered 
gabapentin as an adjunctive treatment in a double blind, dose ranging, placebo 
controlled, crossover study.  
Neuropsychological testing was administered repeatedly at 4-weekly intervals. 
Testing included measures of decision time, movement time, a threshold detection 
test, forward digit span, forward visual span, paired association learning, and Stroop 
test (the latter commonly used as a measure of cognitive flexibility or set shifting 
(64)). Symptom and life satisfaction indices were also measured.  
No psychomotor score showed a statistically significant difference between subjects 
receiving, or not receiving, gabapentin. No memory test showed a deficit in those 
receiving gabapentin relative to those not receiving it. No test of executive functions 
showed a statistically significant decrement associated with administration of 
gabapentin. In fact, those receiving high-dose gabapentin appeared to perform better 
on paired association learning test (though multiple comparisons were made, and the 
latter conclusion should be treated with caution). 
8.4.4.1.1.2 People with epilepsy: subjective self-report of symptoms 
In the same study (321), patient symptom scores for tiredness were higher when 
receiving gabapentin, but only on high-dose therapy of 2400mg/24hrs. Patient 
symptom scores for cognition and fatigue did not attain statistical significance, 
though there was a possible trend towards worse self-reported symptoms when 
receiving gabapentin.  
More recently (2007), Marson and colleagues carried out a large multi-centre 
unblinded randomized controlled trial of carbamazepine, gabapentin, lamotrigine, 
oxcarbazepine and topiramate for treatment of localization related epilepsy (322). 
This study is part of the “Standard And New Antiepileptic Drug” (SANAD) study. 
Of 1721 patients recruited, 377 were randomized to gabapentin. Self-reported 
symptoms were measured. Cognitive side effects reported on Gabapentin were 
comparable to those with other medications and included tiredness/drowsiness (34% 




of 377 subjects), depression (10%), memory problems (19%), confusion/difficulty 
thinking (15%) and sleep disturbance (4%). 
8.4.4.1.1.3 People with multiple sclerosis: subjective self-report of symptoms 
Gabapentin has been used for a variety of indications in people with multiple 
sclerosis. These indications include spasticity, neuropathic pain, painful tonic 
spasms, trigeminal neuralgia and acquired pendular nystagmus (323). Reported side-
effects in trials for spasticity and for pain include drowsiness, sleepiness, dizziness, 
and gastrointestinal symptoms (323). These overlap with patient-reported symptoms 
detailed above (321, 322).  
8.4.4.1.1.4 People with multiple sclerosis: objective measures of cognitive processes 
Despite suggestions that gabapentinoid medications may be associated with cognitive 
and fatigue symptoms, there is little literature addressing objectively-assessed 
cognitive processes in pwMS receiving gabapentinoid medications. 
Oken and colleagues (324) carried out a retrospective analysis using data from 70 
subjects with relapsing-remitting and progressive MS (EDSS less than 6.0, ie mobile 
without aid) who had been included in a trial of a 6-month yoga and exercise 
program. Results of the trial were reported separately.  
In their retrospective post-hoc analysis, they assessed objective measures of 
cognition in those receiving, and those not receiving, at least one drug with suspected 
CNS depressant effects. This category of drugs was specified as including SSRIs, 
antiepileptics (not necessarily administered for effect on seizures, and most 
commonly gabapentin), baclofen, benzodiazepines and others. They also measured 
patient-reported symptoms. 
Assessments administered included measures of sleepiness and mood, PASAT, a 
measure of set-shifting (adapted from the Cambridge neuropsychological test 
automated battery), Stroop colour-word test, and computerized measures of 
attentional shifting, divided attention, and reaction time. Measures of fatigue were 
also acquired.  




Importantly, 74% of their 70 subjects were taking at least one medication with 
suspected direct CNS-depressant action. These subjects took a mean of around two 
CNS-depressant medications. In comparison to those not receiving such medications, 
those receiving these medications were older (mean 50.3 vs mean 44.7 years), more 
disabled (mean EDSS 3.1 vs 2.4), and reported more depressive symptoms (CESD-
10 score 10.3 vs 6.2). All of these differences were statistically significant at the 5% 
significance level.  
The only cognitive test shown to vary significantly between the two groups was 
choice reaction time, which was longer in those receiving these medications. 
Performance on other tests including PASAT, set shifting and Stroop interference 
was not statistically significant between the two groups.  
Several measures of self-reported fatigue were however statistically significantly 
different on comparison of the two groups, with the medicated group reporting 
higher levels of fatigue. Fatigue was found to correlate with reported depressive 
symptoms, and given the higher prevalence of depressive symptoms in the medicated 
group, this introduced an important confounder.  
Important caveats in interpretation of this study include that the effects of individual 
drugs were not studied, and the retrospective nature of the study. It should also be 
noted that there were important differences in the groups of those receiving and not 
receiving drugs with a suspected CNS-depressant action, in terms of age, disability, 
and scores on a measure of depression. All of these could be considered potentially 
important confounders. 
8.4.4.1.1.5 Summary: limited literature regarding possible effects of gabapentinoid 
medications 
Taken together, there is limited available evidence describing the behavioural and 
cognitive effects of Gabapentin in people with multiple sclerosis, and with other 
disorders. Measures of patient-reported fatigue and other symptoms have been 
reported to be associated with administration of gabapentin. Objective measures of 
cognitive processes (including neuropsychological assessments aiming to described 




set-shifting/cognitive flexibility) have not, as yet, supported deficits in these 
measures associated with administration of gabapentinoid medications. 




8.4.5 Structural imaging associations of neuropathic limb 
pain in adults with relapsing remitting multiple sclerosis 
Specifically with regard to structural neuroimaging, the following weaknesses are 
noted: 
8.4.5.1.1 Measures of integrity of normal-appearing white matter are not 
included.  
Such measures could include Diffusion Tensor Imaging (DTI) for example. At 
conception of this study, it was felt that acquisition of these sequences would add an 
unacceptable time burden for subjects, and preferred to include resting state fMRI in 
order to explore hypotheses around connectivity of the descending pain modulatory 
system (see chapter Six page 243). 
8.4.5.1.2 Tailored spinal cord imaging is not included in this study.  
This was felt to be potentially time-consuming for the subject. In addition, at time of 
conception of the study a relevant spinal coil was not available, and it was not 
possible to access neuroradiological reports of spinal imaging at 3 Tesla field 
strength. While this means that necessarily the current study does not report full 
neuroaxis imaging, the decision to concentrate on supraspinal imaging is in keeping 
with the study hypothesis of disrupted descending inhibition of pain, and allows 
detailed focus on relevant well-characterised supraspinal structures using established 
methods. 
Exploration of the application of cervical cord cross-sectional area estimation 
techniques to this data has been described, in order to allow some estimation of upper 
spinal cord structure. 
8.4.5.1.3 White matter lesions are assessed by only one rater. 
It is not therefore possible to comment on inter-rater reliability of the approach 
detailed. I have however assessed intra-rater reliability (with a considerable time gap 
between the two ratings, which would serve to diminish recall of the original 
segmentation process).  
All structural imaging was, in addition, reviewed by an experienced consultant 
neuroradiologist (Robin Sellar) who was blinded to patient pain status (with regards 




to both presence and severity of pain), and commented specifically on lesion 
distribution. Maps of lesion distribution were created by PF, following specific 
training, and using these reports. This measure was designed to maximise sensitivity 
and specificity of lesion identification. In addition, a conservative approach to lesion 
identification was taken, if there was any doubt regarding misidentification of an 
artefact, perivascular space or similar. 
8.4.5.1.4 Potential effects of medications on brain structure 
There is limited published evidence concerning associations between medications 
administered to study participants, and measures of local brain volume. 
8.4.5.1.4.1 Brain structure and function in opiate addiction, without pain 
Upadhyay and colleagues (325) used structural MRI brain imaging along with resting 
state fMRI imaging to characterize structural and functional brain alterations that 
might be related to long-term prescription opioid use. They studied 10 individuals 
dependent on prescription opioids, and compared these with 10 healthy individuals 
who were matched for age, gender and handedness.  The study design was cross-
sectional. Notably, subjects were excluded if there was any known dependence on 
alcohol or on other drugs, if there was any comorbid psychiatric or neurological 
disease, or if there was any pre-existing medical condition. Specifically, subjects 
with pain were excluded. It was noted that two of the opioid-dependent group had 
initially started opiates because of pain, though this was not an ongoing issue.  
The authors describe that, in this very small study, opioid-dependent subjects had a 
significant decrease in functional connectivity for insular, amygdalar and nucleus 
accumbens seeds. They also demonstrated decreased anisotropy in pathways relevant 
to the amygdala, and in internal and external capsules. Amygdala volume, along with 
white matter anisotropy, was found to be related to resting state functional 
connectivity of the amygdala.  
Because this study specifically assessed subjects who were addicted to opiates, and 
excluded those with pain or with neurological or psychiatric disease, I do not think 
that it is directly relevant to the current thesis. It does however suggest a context for 
other studies discussed below.  




8.4.5.1.4.2 Brain structure in subjects receiving opiates, with pre-existing chronic 
low back pain 
Younger and colleagues (326) used structural MRI brain imaging to assess 
longitudinal changes in brain structure in subjects given opiates for chronic low back 
pain. 10 participants with chronic non-radicular low back pain were administered 
oral long-acting morphine for one month, and completed structural brain imaging 
before commencing morphine, at completion of the one-month course (when 
morphine was stopped) and thereafter. Opiate dose was titrated by clinicians 
according to patient response (within pre-specified limits) and ranged from 165mg to 
3120mg over one month (mean 2170mg).  
Separately, a similar imaging protocol was applied to 9 subjects with low back pain 
who were administered placebo. These subjects were however scanned on a different 
scanner and coil than the opiate patients.   
Both groups reported a decrease in pain severity (calculated using a mean of the four 
pain severity items from the BPI (221)). In the opiate group, pain severity decreased 
from mean 4.5 to mean 2.6 at the end of the month. In the placebo group pain 
severity decreased from 5.3 to 3.9.  
Right amygdala structures were found to decrease in volume in the pain group, on 
comparison between the pre- and post-opiate structural images. Amygdala volume 
decrease correlated with opiate dose. Right hippocampus, rostroventral pons, and 
orbitofrontal cortex were also found to decrease in volume, though these decreases 
did not correlate to opiate dose.  
Grey matter volume increases were found in the right hypothalamus, left ACC, right 
posterior cingulate, right ventral caudal pons and left inferior frontal gyrus. These 
changes correlated with morphine dose. Further regions showed a volume increase 
that was not correlated to morphine dosage and these included bilateral mid-
cingulate, ventral posterior cingulate and adjacent parietal lobe. Significant volume 
decreases were not seen in the “placebo” group. Volume decreases were maintained 
at further interval imaging (average time interval 4.7 months).  




This small study demonstrates volumetric changes in a range of structures which 
appear to be related to administration of opiates for a period of one month, and are 
not seen with administration of placebo. Weakness of the study however include very 
small sample size, use of placebo group with data acquired on different scanner and 
with different coil (though noise characteristics were similar), lack of matching of the 
groups, lack of randomization, lack of comment on any other medications 
administered and lack of behavioural measures other than pain severity. 
Lin and colleagues (with Younger as the senior author) (327) carried out a further 
study to address some of the methodological concerns mentioned above, and to 
assess reproducibility of the previously-reported results.  
In this study, 21 subjects with chronic nonradicular low back pain were randomly 
assigned to receive placebo or morphine therapy. Morphine was titrated as 
previously described, and placebo was also “titrated”. Imaging assessments were 
carried out in the same way as described above, though opiate and placebo groups 
were imaged on the same scanner with the same coil (3 Tesla acquisition, 8 channel 
coil, 1.2 x 0.86 x 0.86 voxel resolution). In this study the groups did not differ 
significantly for age, or duration of pain.  
Both opiate and placebo groups reported a decrease in pain severity across the 
duration of the study (opiate group reduction 1.52 on the pain severity index of the 
BPI, and placebo reduction 1.46). Reduction in pain severity was not statistically 
significantly different between the pain and placebo groups.  
As previously described, study groups were assessed for any longitudinal change in 
grey matter volumes. In the placebo group, no grey matter volume changes were 
found. In the opiate group, reduced grey matter volume was found in the amygdala 
(bilateral), orbitofrontal cortex, and pre-supplementary motor areas. Increases in grey 
matter volume were found in the cingulate including mid-cingulate, dorsal anterior 
cingulate and ventral posterior cingulate. These locations overlapped with, though 
were not the same as, those previously reported by Younger and colleagues (326).  




Strengths of this study (considered in relation to the above study in particular) 
include use of the same scanner and head coil, and re-testing of the previous 
experimental findings. Randomised allocation was used. Pain severity was not 
statistically different between the groups at study start. Weaknesses include that 
groups were not matched for age and gender, that other medications including 
analgesia were not recorded, that behavioural measures were not reported and that 
subjects’ belief regarding taking opiates (ie whether they believed they were taking 
opiates, or not) were not reported. Method of randomisation was also not specified. 
Importantly, this study is also very small.  
These studies, taken together, do suggest that opiate therapy may be associated with 
a change in volume of particular grey matter structures, in people with low back 
pain. Both increases and decreases in local grey matter volume were reported.  
The current study excluded subjects who were receiving morphine or other WHO 
step III opiates. While these studies provide a useful context, and suggest that 
administration of medications may be linked to local brain volumes (by unknown 
mechanisms) it is not known whether the medications administered to the study 
participants might be associated with similar changes. 
8.4.5.1.4.3 Relevance to current study 
The current study excluded subjects who were receiving morphine or other WHO 
step III opiates. While the studies described above provide a useful context, and 
suggest that administration of medications may be linked to local brain volumes (by 
unknown mechanisms) it is not known whether the medications administered to the 
study participants might be associated with similar changes. I did not find any studies 
examining structural correlates of administration of gabapentinoid medications, 
measured using brain MRI. 
8.4.5.1.5 Subset of MS lesions analysed 
Only T2 hyperintense lesion distribution has been described in the current analysis. 
Some other studies have also added analyses of T1 hypointense lesions, thought to 
represent focal atrophy (78). This was not felt to be necessary for the current study 
design. 




8.4.5.1.6 Collinearity between pain duration and age 
Age and pain duration were found to be positively correlated and thus age was not 
included as a variable of no interest in the VBM analysis of correlates of pain 
duration. This is in keeping with previous reports (96). Therefore findings reported 
here could reflect the effect of age, rather than pain duration per se. 
 




8.4.6 Functional connectivity of the descending pain 
modulatory system in adults with neuropathic limb pain 
associated with multiple sclerosis 
Could these findings be an epiphenomenon related to altered grey 
matter volume? 
Detailed structural analysis of the described cohort has been carried out, focussing on 
voxel based morphometry, and analysis of the volume and distribution of T2 
hyperintense lesions (Chapter Five page 188). The pain group, relative to the control 
group, were found to have higher grey matter volumes in an area of the 
midbrain/pons (trigeminothalamic nucleus, overlapping with pontine reticular 
formation). This difference was significant at the relatively lenient threshold of 
p<0.001, not corrected for multiple comparisons. The PAG mask used for functional 
MRI analysis lies outside this area, and thus while it is not possible to entirely rule 
out altered grey matter volumes within this ROI, even at a relatively relaxed 
statistical threshold of p<0.001 uncorrected, no volumetric difference was found 
within this region of interest. Similarly, no volumetric difference was found in 
volumes of cortical pain modulatory structures including DLPFC and rACC, in the 
VBM analysis. 
Could these findings be an artefact of CSF signal? 
CSF signal is a well-recognised source of extraneous noise in resting state fMRI data 
(75, 110, 115). Shared CSF signal between regions might act to either reduce or 
increase apparent functional connectivity, depending on local CSF dynamics. The 
rostral ACC seed and PAG ROI used may both incorporate CSF (from the 
interhemispheric fissure and aqueduct of Sylvius respectively), and the voxel size 
available for fMRI data makes it difficult to fully define the border between CSF and 
other tissues, as discussed by other authors (115). The DLPFC seed used could also 
incorporate CSF signal. While CSF signal may influence the above-described 
findings, the following observations may make this less likely: 
1.1.1.1.1 Efforts to remove CSF signal from resting state data 
All subjects’ resting state data was subject to ICA denoising (Preprocessing of 
resting state data) including removal of CSF signal, where identified.  Furthermore 
all subjects’ resting state data was analysed including a CSF seed timecourse as a 




covariate of no interest. Both of these strategies are intended to diminish the 
contribution of CSF signal to the overall findings, and are applied at the single 
subject preprocessing stage. 
1.1.1.1.1.1 Were these strategies successful? 
Qualitative inspection of the functional connectivity of the rACC seed region in both 
pain and control groups (Figure 32) confirms that CSF regions’ timecourses are not 
typically closely correlated with the timecourse of the rACC seed (after the above 
preprocessing). Functional connectivity is seen to be strongly centred on grey matter 
structures with sparing of CSF structures (for instance lateral ventricles). 
1.1.1.1.2 Anatomical restriction of DLPFC mask to grey matter 
For the DLPFC mask, analysis  was restricted to regions most likely to include grey 
matter (as described) by thresholding using a publically available grey matter tissue 
probability map packaged with FSL.  
1.1.1.1.3 Repeat of analyses using mid-occipital cortex “region of no interest” 
Furthermore, analysis of an occipital “region of no interest” was included. This was 
deliberately centred over the interhemispheric fissure, in order to mimic placement of 
the rACC seed in this respect. No statistically significant findings described using 
PAG and DLPFC regions of interest were recapitulated on analysis of functional 
connectivity with the occipital region of interest. 
Could these findings reflect head motion during image acquisition? 
As discussed above, head motion is known to not only introduce noise into resting 
state fMRI models, but also to induce spurious correlations in resting BOLD 
timecourses due to shared variance, especially in structures which are closely 
anatomically related (101, 102). This is felt to be an unlikely explanation for the 
observed findings for the following reasons.  
1.1.1.1.4 Preprocessing of resting state data with respect to head motion 
A range of methods have been used to “clean” the resting state data of extraneous 
noise, including the inclusion of 6 head motion parameters in the GLM model, and 
Independent Components Analysis (ICA) denoising. These strategies are thought to 




have complementary roles in addressing any contribution from “gradual” and 
“sudden” head motion (100, 102).  
1.1.1.1.5 Exclusion of subjects moving more than one millimetre 
Any subject moving more than 1mm during the entire run (before ICA denoising) 
was excluded from analysis. This threshold is more stringent than used in some 
comparable studies (for instance Yu and colleagues (115) report that subjects had no 
more than 3mm translational movement, and Mainero and colleagues did not 
describe any exclusion of high-movement subjects (103)). Mean head movement 
between the groups with and without pain (prior to preprocessing) was small, and did 
not vary to a statistically significant degree between the pain and control groups  
(Preprocessing of resting state data).  
1.1.1.1.6 Role of “sudden” head movement in introducing shared variance in 
anatomically local, as opposed to distant, structures 
Regarding spurious correlations induced by sudden head motion (102) specifically, 
the functional connectivity examined in this study is between anatomical structures 
which are relatively anatomically distant (anterior cingulate and PAG, and anterior 
cingulate and DLPFC). In statistical analyses of preprocessing approaches to short 
and long-range functional connectivity, sudden head movements have tended to 
reduce functional connectivity between comparably placed structures (such as 
prefrontal cortex and cerebellum), whereas preprocessing strategies intended to 
reduce the effects of head motion in the relevant statistical models have tended to 
increase functional connectivity between similar structures (101, 102). In other 
words, sensitivity to correlation in timecourses would be expected to be decreased, 
rather than increased, by sudden head movement over the anatomical space 
discussed. Sudden head movement is therefore a less likely explanation for the 
described functional connectivity patterns.  
Could these findings reflect differential lesion topography? 
In a whole-brain analysis, lesion topography was not found to preferentially involve 
any specific structure at a threshold of p≤0.05 corrected for multiple comparison 
(Chapter 5). Even at the less stringent statistical threshold of p<0.001, uncorrected 
for multiple comparisons, only an increased likelihood of posterior periventricular 




lesions in a single voxel was observed. This finding is unlikely to be directly relevant 
to disrupted integration of the DPMS. 
1.1.1.1.7 Focal Periaqueductal Grey matter lesions: distribution of brainstem 
lesions 
As reported in Chapter Five (page 188), brainstem lesion volume was higher in the 
group with pain, than those without pain. It therefore should be considered that 
alterations in local neurovascular dynamics related to focal demyelinating lesions 
(78) could contribute to the findings in this fMRI study. The observed anatomical 
distribution of brainstem lesions however makes this less likely. 
In the contrast of pain group: control group, using a nonparametric permutation 
technique to assess lesion topography (distribution in three dimensions), T2 
hyperintense lesions were found to be more likely in the cerebellar peduncle, and 
basal/lateral pons. None of these regions overlaps with the described PAG seed, 
making a direct contribution of focal demyelinating lesions less likely. 
1.1.1.1.8 Differential lesion topography affecting tracts linking rACC with 
DLPFC, and rACC with PAG. 
In a whole-brain analysis, no preponderance of lesions in regions anatomically 
linking these structures was found. Future work will include masks of white matter 
tracts linking these structures, identified from DTI studies (65, 111). 
It is possible that the observed diminution of differential connectivity between these 
structures, when T2 hyperintense lesion volume is included in the statistical model as 
a covariate of no interest (page 260) may reflect an overall role of lesion volume in 
disrupted connectivity, relevant to the current study. 
1.1.1.1.9 Functional connectivity of rACC seed varies according to overall 
lesion volume 
The observed findings that rACC functional connectivity varies in correlation with 
overall T2 hyperintense lesion volume (page 259) may support a hypothesis that 
white matter lesion volume is associated with altered functional connectivity. The 
observed positive correlation of lesion volume with functional connectivity (and 
absence of negative correlation) could suggest compensatory functional 
reorganization as has been reported previously in fMRI studies of people with MS. 




This finding is in common with some, but not all, of the published literature (108). 
This finding is not yet, however, fully explained. Other explanations, including the 
possibility of differential mean head movement or type of head movement in 
association with lesion volume, should be considered. Strategies as described above 
have however been adopted to minimise the contribution of head movement to the 
observed data. 
Could functional connectivity findings reflect differences in subjects’ 
medications? 
As discussed in Chapter Four, the subjects included in the pain and control groups 
were matched for age and gender. Furthermore there was no statistically significant 
difference between these groups in disability, disease duration, years full time 
education, current use of strong opiates (no subject was using strong opiates), current 
use of weak opiates (dihydrocodeine), current use of baclofen, current use of MS 
disease modifying therapy , current use of any antidepressant medication, or current 
use of tricylic antidepressants (Table 19).  
The pain group, however, were more frequently current users of gabapentinoid 
medication (gabapentin and pregabalin).  While the effects of these medications on 
functional connectivity within the DPMS are currently unknown, it is possible that 
administration of these medications may influence the reported findings.  
8.4.6.1.1.1 Discussion of previously published data 
There is limited available evidence of the effects of gabapentin or pregabalin on 
resting state functional connectivity. I am not aware of any evidence of the effects of 
gabapentin/pregabalin on resting state functional connectivity in adults with MS. 
8.4.6.1.1.1.1 Effects of medications on fMRI measures: pharmaco-fMRI 
Knowledge of the effects of medication on functional MRI measures is most often 
drawn from task fMRI experiments, in which reproducible patterns of activation or 
deactivation in response to a “task” or condition, are modulated by administration of 
a medication (75). So-called pharmaco-fMRI may allow investigation of drug effects 
at a network level, and to identify anatomical or functional correlates of CNS drug 
action (328).  




While this field is in its infancy, the available literature is expanding. Actions 
investigated include those of SSRIs and similar drugs in depressive disorders, anti-
epileptic drugs, and medication for attention deficit hyperactivity disorder. A variety 
of tasks, however, are used in different studies, and often it is challenging to identify 
what (apparent) effects may be specific to a drug or class of drugs, to compare or 
combine separate studies, and to make inferences on application of these observed 
effects in clinical drug development. Approaches to this problem are under 
development (328, 329). 
8.4.6.1.1.1.2 fMRI examination of effects of pregabalin 
Harris and colleagues (330) studied the effects of pregabalin in 17 patients with 
chronic pain related to fibromyalgia. They used proton magnetic resonance 
spectroscopy, task fMRI and resting state functional MRI in order to better delineate 
possible central effects of pregabalin. 14 participants underwent fMRI. There was no 
control group. A 3.0 Tesla scanner with eight-channel head coil and concurrent 
physiological monitoring was used.  
Seed based connectivity analyses using seeds in the right insula were employed. The 
task fMRI paradigm employed pressure pain applied to the nail bed.  
Subjects with greater pre-treatment pain levels were found to manifest greater 
connectivity between the insula and posterior cingulate, and insula and inferior 
parietal lobule. Connectivity of the insula to the IPL was correlated to reductions in 
pain when pregabalin was administered. In task fMRI analyses, restricted to regions 
of interest in the inferior parietal lobule and PCC, both the IPL and PCC showed 
greater deactivations in response to evoked pressure pain after pregabalin (330). 
This small study, without a control group, which focussed on specific regions of 
interest (anterior and posterior insula, inferior parietal lobule and posterior cingulate) 
suggested that functional connectivity of these regions might be linked to both pain 
severity, and to efficacy of pregabalin. Further studies, in subjects with fibromyalgia 
and with other pain conditions would however be required to test the reproducibility 
and relevance of these findings.  




8.4.6.1.1.1.3 fMRI examination of effects of gabapentin 
Iannetti and colleagues (331) assessed the effects of gabapentin administration on 
brain activity in response to painful mechanical stimulation of normal skin, and also 
to capsaicin-induced secondary hyperalgesia. They studied twelve right-handed male 
normal volunteers using a double-blind placebo-controlled design. A single high 
dose of 1800mg gabapentin (administered orally) was used. 
Gabapentin was found to reduce pain-related activations in the bilateral 
insular/operculoinsular cortex, whether or not central sensitization was present. 
During central sensitization only, gabapentin reduced activation in the brainstem, and 
suppressed stimulus-induced deactivations.  
8.4.6.1.1.1.4 fMRI studies examining possible effects of gabapentinoid drugs: themes 
The work discussed above explores responses in volunteers with fibromyalgia, or in 
healthy volunteers. I did not find any study examining effects either in MS, or in 
subjects with structurally abnormal brains. The limited available evidence may 
suggest modulation of central pain mechanisms by administration of high dose oral 
gabapentin. The implications for functional connectivity in subjects with pain 
conditions are not clear. 
8.4.6.1.1.1.5 fMRI study of pain mechanisms in MS: relevance to potential role of 
gabapentinoid medications 
In one study of resting state functional connectivity in people with MS, with and 
without pain (214), three of 12 subjects with pain, and two of 11 subjects without 
pain were receiving gabapentin or pregabalin. Because of small sample size, no 
separate analysis regarding associations of the administration of these medications 
could be carried out. This study did not specifically assess any potential role of 
medications, including gabapentioid medications. 
8.4.6.1.1.2 Discussion of data from the current study 
A post-hoc subgroup analysis of clinical data comparing people with and without 
pain, but restricted only to those not receiving adjuvant analgesics (Chapter Four, 
page 119) examined cognitive and affective variables in this small subgroup (n=13 
from control group, n=9 from pain group). Although this analysis should be viewed 




as strictly exploratory, similar data trends were observed within this subgroup 
analysis, in comparison to the larger analysis including those receiving medication. 
This finding is not conclusive but may support a hypothesis that these findings are 
related to presence of pain, and not solely administration of medication.  
The differential connectivity patterns between rACC:PAG, and rACC:DLPFC, do 
not reflect the same direction of association (the former is increased in the control 
condition, the latter increased in the pain condition). Any general effect of 
gabapentinoid medication in reducing, or increasing, functional connectivity within 
the DPMS would not therefore explain these findings. A more complex interaction of 
gabapentinoid medications with DPMS functional connectivity however remains 
possible.  
Although a small number of subjects in the pain group (n=3, see Chapter Four, page 
119) were receiving weak opiates, this difference did not attain statistical 
significance. It is not possible in the current study to rule out a role of weak opiates 
in disrupting pain connectivity in the DPMS, which is thought to rely at least 
partially on opioid signalling (110). Subjects receiving strong opiates were however 
excluded from this study. 
Lastly, it is a common finding that subjects with neuropathic pain, are more likely to 
be receiving therapy for neuropathic pain, than those without (81, 115, 214). It could 
be argued that, in approaching subjects with neuropathic pain from a clinical 
perspective, the effects of medication comprise an intrinsic part of the experience and 
phenotype of people with established neuropathic pain. Thus an attempt, in a clinical 
population, to reliably separate the roles of medication from those of other factors, 
would be very challenging, if not impossible, and may limit the applicability of 
findings to a real-world clinical population. 
Use of seed based analysis, and default mode network (DMN) 
This chapter (as discussed) uses a seed-based approach to investigate functional 
connectivity relevant to the descending modulation of pain. The rostral ACC seed 
used in this study demonstrates connectivity with a range of cortical and subcortical 
structures (Figure 32: Mean functional connectivity of rostral ACC seed, separately 




calculated in pain and control groups), some of which overlap to a degree with the 
well-established default mode network (289). This is not surprising, as this network 
is consistently described to include the prefrontal, anterior cingulate, posterior 
cingulate, inferior temporal gyrus and superior parietal region (289). 
Activity of the DMN has been linked to the brain lying “at rest”, and is consistently 
found to be deactivated during performance of tasks. Other resting state networks 
including a network thought to be related to executive control and working memory 
have been found to involve the anterior cingulate. The latter network has been said to 
involved the frontopolar area, prefrontal cortex, dorsal ACC, and superior parietal 
cortex (289). These networks have been found to be relatively consistent across 
subjects and across studies, with the posterior components of the DMN 
demonstrating most consistency. 
The use of a seed based analysis in this study allows investigation of specific 
hypotheses regarding the functional connectivity of the descending pain modulatory 
system. The design of the current study does not allow comment on broader network 
connectivity in the neuropathic pain state in comparison to the control group, and it is 
possible that structures other than those investigated are differentially functionally 
connected in those with, and without, neuropathic pain in MS.  
8.4.7 Participant experience study 
Timing of acquisition of data 
A particular potential weakness of this study is that feedback was gathered at 
completion of the study, when passage of time might lead to recall bias.  Previous 
comparable studies have posted out surveys a week after study completion (though 
time to response not stated) (298), or used interviews immediately after study 
completion (299, 315) . The data reported from this study could be more prone to 
recall bias, though it may also reflect established reflection on study participation, 
rather than immediate reaction (described in one study as pre-contemplative (315)). 
The relative significance of immediate or delayed appreciation of study participation 
is not established. In this context, it is interesting that the general substance of 
feedback provided was similar to previous studies (taking into account differing 
contexts and methodologies). 




Possible bias in participation 
The sample obtained was apparently biased towards less disabled participants, and 
perhaps towards females. This is in keeping with previous studies (313), and raises 
questions around generalisation of the results. The reasons for greater participation 
from less disabled participants might include physical barriers to accessing study 
materials, or completing a form online or in paper format. The reasons for any trend 
towards gender bias are not however clear.  
Sample size 
The sample described is small, which again suggests that conclusions drawn from the 
available data should be viewed with caution. Given the size of the available 
literature, however, these data may still be useful to those designing future studies, or 
assessing their design (such as through research ethics committees). In particular, I 
am not aware of any such studies examining the research experience of people with 
MS, nor of people undergoing noxious stimulation as part of a study protocol. The 
findings described are of course specific to this study (299). 
Numerical outcomes 
The use of a one to seven scale is not validated though this was similar to 
methodology used by Szameitat and colleagues (299). I did not examine the effect of 
demographic or other variables on overall satisfaction rating, because sample size 
was small, and because overall satisfaction rating was high, with little variability 
between subjects (Median 7, IQR 7 to 7). Previous studies have found some 
variability between participants of different genders (299).  
Questions used in instrument 
Questions were deliberately simple and kept in a very similar format, with no attempt 
at assessing internal validity, or test-retest validity. Some questions (for instance 
those around specific fMRI procedures, where the scale 1 to 7 referred to a degree of 
difficulty rather than a degree of satisfaction) might have misled participants, and 
might contribute to the broad spread of results seen (see Error! Reference source 
not found.). This procedure should be modified for future feedback surveys. 
 





We also do not know to what extent the reports given reflect the experience of the 
study, and how much underlying personal and/or psychiatric factors. It is likely not 
possible to separate these factors, particularly taking into account the high prevalence 
of psychiatric comorbidity in the study sample. A control group (in this context, 
perhaps a group undergoing a clinic appointment but not research study assessment) 
has also not been included. Inference of causality must therefore be limited (297). 
Previous studies in psychiatric patients have found that participants who are 
distressed by study participation, are more likely to have mental disorders or 
symptoms, or risk factors for these (such as adverse experience, neuroticism or low 
social support(297)). In the current study, however, despite high levels of psychiatric 
comorbidity, satisfaction with participation was high. 
I have also not explicitly assessed subjects’ coping mechanisms (315), nor the 
perceived impact of study participation per se (297) . Analysis of qualitative data is 
so far limited, and would benefit from a more formal approach. 
 




8.5 Strengths of methodology 
8.5.1 Systematic Review: Prevalence, associations and 
natural history of pain in multiple sclerosis 
This review has used a variety of methodologies which may act to increase the utility 
of findings.  
In particular 
 Only prospective studies have been selected (in order to maximize 
comparability of included studies) 
 Only studies recruiting subjects with definite MS have been selected. 
 A thorough search strategy including a “forward” search of cited articles (in 
order to increase sensitivity) was employed. 
 Foreign language articles were included. 
o Translators of foreign language papers were almost all from a clinical 
neurosciences background 
 Formal statistical meta-analysis techniques were used to quantify and to 
explore potential sources of estimate heterogeneity.  
 Complementary methods were used to examine the natural history of pain in 
MS, including searching for longitudinal studies, and also looking for cross-
sectional studies at particular disease “milestones” 
8.5.2 Systematic Review: Neuroimaging correlates of pain 
syndromes in multiple sclerosis  
 
This review is the first to examine neuroimaging correlates of pain in multiple 
sclerosis.  




A qualitative descriptive approach to the literature has been used, including  
describing and assessing the methodology of included studies, as well as describing 
and assessing their findings.   
This review should therefore act as a useful point of reference for the development of 
future study methodology, including the study described in this thesis. In addition, 
the findings of the described studies are also useful in providing an early insight into 
any links between imaging correlates of the MS disease process, and the occurrence 
of pain syndromes. 




8.5.3 Clinical, behavioural and neuropsychological 
associations of neuropathic limb pain in adults with 
relapsing remitting multiple sclerosis 
 
Clinical phenotyping 
This study describes data from a well-phenotyped group of people with definite 
relapsing remitting MS, and definite neuropathic limb pain. The latter is defined both 
clinically, and (post-hoc) by research criteria (4, 217).  
Preference has been given to use of instruments which are validated in MS 
populations. Where this has not been possible,  instruments which are validated in 
non-malignant pain studies, or widely used in studies of people with MS (to ensure 
comparability with existing literature) have been used (see Methods: 119). 
Burden to participants 
The study protocol described was designed in order to minimise burden to 
participants. In particular, where possible, duration of tests was minimised, and care 
was taken to ensure adequate breaks and refreshment. These measures should 
mitigate any effect of fatigue on the data gathered in the study, though such an effect 
cannot be ruled out (56). 
The study was in fact well tolerated by subjects. This data is presented separately . 
Study assessments 
Assessment was carried out by PF (all instruments) or RM (neuropsychology 
instruments). Both have experience of research studies assessing people with 
neurological disorders, in particular MS. PF was trained in administration of 
neuropsychology instruments by RM, in order to ensure that the same methodology 
was used.  
The study design could be further enhanced by increasing participant numbers, by 
longitudinal recruitment, by multi-centre design, and by addition of IQ estimation. 
These measures were not however felt to be possible within the confines of a PhD 
project.  




8.5.4 Structural imaging associations of neuropathic limb 
pain in adults with relapsing remitting multiple sclerosis 
 
Study design 
Only one previously published study has examined grey matter volumes in relation 
to the presence of pain in multiple sclerosis (in a small subgroup of subjects, using a 
statistical threshold of 5% in order to report trends in the data) (214). No previous 
study has used lesion distribution mapping, and no previous study has examined the 
grey matter correlates of the severity or duration of pain. The included subjects are 
phenotyped in some detail (see Chapter Four, page 119). 
Use of matched disease control group 
In comparison to many other structural imaging studies of clinical pain syndromes 
(79, 87, 95), groups of people with relapsing remitting MS, with and without 
neuropathic limb pain have been compared. Healthy  volunteers are not included. 
The current study therefore examines a contrast in relation to a specific symptom 
(neuropathic pain) and its associated variables (see chapter Four, page 119) within 
the context of a chronic neurological disease. This could be compared to many 
previous studies which have examined the contrast between healthy volunteers, and 
those with a chronic pain syndrome (without matching for the presence of chronic 
disease or other associated variables).   
The pain and control groups are closely matched for age and gender. Furthermore the 
groups are balanced for a range of further variables (Table 19).  
High resolution isotropic structural imaging 
The use of high-resolution isotropic structural imaging meets subsequent 
recommendations for studies of structural imaging in MS (332) and allows higher 
resolution of relevant structures, including MS lesions which are typically of the size 
of millimetres-centimetres. A lesion filling approach was employed to diminish the 
impact of local MS lesions on grey matter segmentation in VBM. 




Visual review of analysis data 
Statistical analysis of imaging data can be complex, and is prone to error which can 
be promulgated throughout subsequent analysis stages (75). In this study, care was 
taken to check analysis steps visually wherever possible. This was particularly the 
case for registration, and brain extraction in the VBM pipeline (which required 
adaptation in a number of subjects).  
 
8.5.5 Functional connectivity of the descending pain 
modulatory system in adults with neuropathic limb pain 
associated with multiple sclerosis 
Clinical control group 
In contrast with most published pain imaging literature (103, 110, 115) a control 
group with relapsing remitting multiple sclerosis (but without neuropathic limb pain) 
has been employed, rather than a control group of healthy controls. This study design 
therefore helps to minimise possible effects of chronic disease in general.  
Previous studies of DPMS functional connectivity have focussed on subjects with 
macroscopically normal brains (such as healthy volunteers (110), and those with 
chronic pain conditions which are not associated with a macroscopically lesioned 
central nervous system – including chronic back pain and fibromyalgia (115, 333)). 
This study is among the first to study the DPMS in a central nervous system disease 
associated with overt CNS lesions. 
Clinical phenotyping and structural imaging.  
The subjects with and without neuropathic pain are carefully clinically phenotyped, 
as discussed in Chapter Four (page 119). In particular the matching of subjects in 
pain and control groups for age and gender, and balancing of groups for a variety of 
other variables, acts to reduce the number of factors which could contribute to the 
described findings. They have also undergone detailed structural imaging assessment 
as discussed in Chapter Five (page 188).  





No published study has previously specifically investigated functional connectivity 
of the descending pain modulatory system in people with multiple sclerosis (166). 
One previous study has used a network connectivity approach (dual regression) to 
examine network connectivity in people with and without neuropathic pain in 
multiple sclerosis (214), and identified reduced connectivity of basal ganglia 
structures to the default mode network, in people with pain (in comparison to those 
without). Specific functional connectivity of the rACC seed to basal ganglia 
structures in this study has not been examined, as this was not a prespecified aim of 
the study. Seixas and colleagues did however recruit a group of people with mixed 
subtypes of MS, and the clinical phenotype of the patients described is not directly 
comparable to those described here. 
Processing strategies to minimise contribution of extraneous 
signal/noise 
As described in some detail, preprocessing strategies have been used which are 
designed to diminish the influence of head motion, CSF and white matter signal 
among other factors. These included the exclusion of subjects manifesting head 
movement of over one millimetre, ICA denoising of all individual data sets with 
particular emphasis on sudden head motion, and inclusion of WM and CSF 
regressors as covariates of no interest in the fMRI analysis models. In addition, a 
“control” region of interest analysis was carried out using a target region in the 
occipital lobe, to examine specificity of the reported findings.  
Overall absolute head motion of included subjects was low (less than one millimetre 
in all cases, following exclusion of only two subjects). 
Location and functional connectivity of seed and masks is comparable 
to previous literature 
As described, masks were set up according to previously published literature (both 
with respect to the structures assessed, and the specific masks used (29, 33, 65, 110, 
296), and findings demonstrate some consistency with previously published 
accounts. For instance mean connectivity of rACC seed is comparable to Margulies 
and colleagues’ findings (295), and the ventrolateral PAG is specifically identified as 




implicated in differential connectivity between the pain and control groups, as in 
previous studies (113, 115), even though this specific location within the PAG was 
not prespecified in the analysis). The DLPFC mask used was based on previously 
published findings, but also on maximal mean connectivity of rACC to DLPFC 
(within a prespecified volume of the DLPFC defined by Wiech and colleagues (65)). 
Thus, this mask assesses a volume of the DLPFC which is found to be maximally 
functionally connected to the rACC in this study, and findings may not reflect 
functional connectivity within the whole DLPFC.   
8.5.5.1.1 PAG: findings in current study 
The finding in the current study of increased rACC:PAG connectivity centred on 
MNI coordinates x= -4, y= -32, z= -12 is consistent with the involvement of 
ventrolateral PAG (defined in Coulombe and colleagues’ study as centring on MNI 
coordinated ±3, -32, -12), which has repeatedly been implicated in endogenous 
descending modulation of pain. This finding is also consistent with the authors’ 
finding of vlPAG:rostral ACC functional connectivity (113).  
The trend in the current study of increased ACC:PAG functional connectivity with 
increasing pain severity, centred on MNI coordinates x= -2, y = -28, z= -6, could be 
consistent with involvement of the dorsolateral PAG or lateral PAG (reported by 
Coulombe and colleagues as centring on MNI coordinates ±2, -32, -5, and ±4, -31, -8 
respectively). Both are reported to show functional connectivity to frontal/prefrontal 
cortex, striatum and hippocampus (113). Ezra and colleagues’ structural atlas 
suggests that this location is closely related to dorsolateral PAG, and may be 
involved in lateral or ventrolateral PAG (114). 
8.5.6 Participant Experience Study 
Novelty of data 
Data of this type are not routinely reported in patient research studies of any type, 
and in particular not in studies of MS or of pain. The data presented suggest which 
parts of the research experience may usefully be improved for future studies, as well 
as suggesting which parts are well tolerated. The current work has shown that it is 
feasible to gather such data (298), and that both numerical and free-text feedback 
have given useful information, which is applicable to design of future studies. 




Pseudo-anonymisation of data 
The data gathered during this study was pseudo-anonymous. This might help to 
minimise any perceived pressure which could influence the feedback provided. The 
anonymity of feedback provided was emphasised at several points, though it should 
be noted that participants (voluntarily) provided their study ID number at completion 
of the survey. This was included in order to allow linkage to their study data, and 
was not used to link to person-identifiable data. Having said this, participants may 
have felt that the data could be used in this way. 
Participant engagement in development and execution of future studies 
at the Anne Rowling Regenerative Neurology Clinic 
A part of this sub-study I have also set up a group of people who have RRMS, and 
are willing to be contacted for advice/discussion on design of any future studies at, or 
allied to, ARRNC (n=21). Similarly, a group of people who have RRMS and are 
willing to be contacted for participation in any future studies has been set up (n=29).  
 




8.6 How has the field changed during the course of 
this PhD? 
Some recent developments in relation to the broad themes of each experimental 
chapter are summarised. 
8.6.1 Prevalence, associations and natural history of pain in 
multiple sclerosis 
Further studies published since the initial systematic review described in Chapter 2, 
are described in more detail at 2.3.7. 
These studies include estimates of pain prevalence in countries other than those 
included in my original systematic review (17, 41). These estimates are comparable 
to the estimates of pain prevalence suggested by my systematic review, however they 
expand our knowledge of the prevalence of pain in MS worldwide.  
Knowledge of longitudinal variation in pain related to MS has similarly been 
enhanced, with a further longitudinal study from Australia (17). A large NARCOMS 
study, while not using detailed confirmation of each included case, suggests general 
trends in pain prevalence over time, using a large database in North America (165). 
Pain related to MS relapse, however, remains very poorly understood (despite 
publication of one further study (160)). A significant opportunity remains to better 
understand how the incidence and prevalence of MS pain relates to 
neuroinflammatory episodes (and of course this knowledge might be relevant to 
study of any interface between immunomodulatory treatments, and MS-related pain). 
8.6.2 Neuroimaging correlates of pain syndromes in multiple 
sclerosis  
Published evidence 
Since execution of the search strategies described, only a small number of further 
relevant studies have been published (212, 214). A published description of headache 
along with a diagnosis of MS (especially where the clinical presentation might 
overlap strongly with ADEM) (212) does not add significantly to the conclusions 
described previously.  




Seixas and colleagues (214) used a range of techniques which have not previously 
been applied to the study of pain in MS, in a small case-control study of people with 
mixed subtypes of MS, with and without neuropathic pain. While a difference was 
reported in Default Mode Connectivity (5% significance level corrected for multiple 
comparisons, using Dual Regression), differences reported in Voxel Based 
Morphometry appeared to be at the 5% significance level without correction for 
multiple comparisons. In addition, the direction of association (for instance if 
increased volume in a structure was associated with presence, or absence, of pain) 
was unclear. This work does therefore expand the emphasis of the existing field, both 
in analysis techniques used and in the perspective of analysis (for instance a focus on 
cerebral connectivity rather than lesion location). Seixas and colleagues’ findings, 
however, should in my view be viewed as posing interesting further questions in the 
field. 
Approach to MRI imaging experiments 
MRI studies are increasingly set up as large international collaborative studies (for 
instance, for pwMS, as part of the European MAGNIMS collaboration, (92, 93)). A 
further large international collaborative study is the Human Connectome Project 
(100), and other large epidemiological projects such as UK Biobank (334) are 
acquiring imaging data on a subset of participants. These studies are able to take 
advantage of optimised MRI imaging paradigms including resting state fMRI.  These 
paradigms (in particular for UK Biobank) are optimised for older and/or more 
disabled patients in that there is a short duration of imaging, with (in the case of 
resting state acquisitions) short TR (Cathie Sudlow, personal communication). 
Large collaborative studies, using a centralised approach to analysis, may have 
advantages including a standardised, blinded, centralised approach to expert analysis; 
large sample size (or increased ability to recruit in rare disorders); spread of cost 
among many centres and ability to investigate technical inter-centre differences. 
Disadvantages may include the complexity of organising such experiments as well as 
technical factors such as accounting for different scanners or scanner set-ups at 
different centres.  




Approach to resting state fMRI analysis 
Substantial work has been carried out on optimal denoising of resting state data, 
partly driven by the collaborative projects described above, in particular the Human 
Connectome Project (HCP). Multiple automated approaches to ICA denoising, or 
“scrubbing” (motion censoring) are now available (104, 335), though these may 
require training on a sample dataset before use. There is no single accepted best 
method for elimination of head motion artefact currently, though optimal protocols 
will be evolved for the HCP and other projects.  
Comparably, the approach to segmenting white matter lesions in MS is not currently 
standardised, and many authors use a semi-automated approach, perhaps with in-
house software (which limits reproducibility of data). Recent work such as BIANCA, 
an automated lesion segmentation program which will, in future, be packaged with 
FSL (open source), may partially standardise approaches to lesion segmentation, 
therefore maximising comparability between studies and centres (336). 
 




8.7 Potential improvements in methodology 
Potential improvements to the methodology of the described study are discussed 
below: 
Longitudinal study design 
A longitudinal study design would allow investigation of possible causality (or at the 
very least, temporal relationships) in the development of a pain phenotype. This 
would allow investigators to address specific questions such as those posed below 
(8.8) .This study design was considered at time of inception of this study, and ruled it 
out for the following reasons: 
 Limitation of resources within constraints of PhD project.  
 Limitation of time within constraints of PhD project. 
 Complexity of analysis with large volume of data (particularly for imaging 
outcomes).  
 Strong possibility of differential loss to follow-up (attrition) in pain and 
control groups, which could bias results in ways which would be hard to 
predict. 
 Potential for MS relapses occurring during follow-up would be high. Any 
requirement for freedom from relapses at follow up would therefore be 
challenging, and could lead to delays in imaging. 
Neuropsychological testing 
As discussed above, IQ could be regarded as a potential confounder in this study, and 
has not been measured. Formal measurement of IQ might be too time-consuming, 
and a surrogate marker of IQ such as NART (320) could be used. This study does 
however include a measure of years full-time education (which was not statistically 
different in comparing the pain and control groups). 




Some of the suggested neuropsychological examinations were relatively time-
consuming and, while interesting, were often scored at ceiling or close to ceiling, 
thus limiting utility in the analysis. These included the Hayling sentence completion 
task drawn from the ECAS screen (238)and the “elevator with distraction” test from 
the Test of Everyday Attention (241). Future similar studies could consider, for 
example, a more difficult version of the Hayling. 
Quantitative Sensory Testing (QST) 
While, as discussed, a full QST protocol was felt not to be optimal for this study (in 
terms of duration and participant acceptability), future examinations could consider 
the use of calibrated stimuli (including vonFrey stimuli) in place of NeuroTips which 
do not allow fully calibrated stimulation. 
Pain tolerance could be measured using a test such as the Cold Pressor Test (337) in 
order to further investigate pain responses. 
Structural imaging 
In order to more fully investigate hypotheses around connectivity of the DPMS, use 
of Diffusion Tensor Imaging (DTI) would help to delineate structural connectivity, in 
tandem with the lesion probability mapping approach described. This 
multiparametric approach is increasingly frequently used to study structural and 
functional connectivity in tandem (93, 100, 107). The acquisition of DTI data was 
considered for this study, but DTI was not employed for the following reasons: 
 Increased duration of imaging 
o This is potentially relevant to participant tolerance of imaging, as well 
as available time in-scanner. 
 Complexity and timescales of analysis taking into account other imaging data 
acquired, within the constraints of a PhD project.  
 Anecdotal evidence that DTI imaging might be associated with reduced 
subject tolerance of imaging (due to noise, and muscle twitching) 




Resting state functional imaging 
The data in the currently described study includes 105 volumes (TR 3 seconds, total 
imaging acquisition 5min 23 seconds). Because of signal equilibration, the first three 
volumes were discarded, leaving a remainder of 102 volumes. This relatively small 
amount of data might limit sensitivity of analyses in this study. Accelerated 
acquisitions using TR of approximately 0.4s, as in the Human Connectome Project 
(HCP) have been found to increase the sensitivity of detection of resting-state signal 
fluctuation by up to 60% (despite loss in signal level) (100). Use of accelerated 
acquisitions of this type might increase sensitivity to salient experimental findings, 
while maintaining an acceptable scanner time for subjects.  
At time of setting up this study, use of a TR of 2 seconds (which was available at the 
time of imaging acquisition, and would have allowed around 150 volumes in the 
same timeframe) was considered. I did not use a TR of 2 seconds, because of the 
potential for combining data with a separate study which was ongoing at that time at 
Oxford University (214). 




8.8 Selected possible future research questions 
Epidemiology 
The prevalence and associations of pain in MS have now been well investigated, and 
it seems that that while further research studies may well be published, it is relatively 
unlikely that there will be major changes in the current understanding of the field, in 
the near future. Knowledge of the precise associations of the presence and severity of 
pain may be increased by future studies.  
8.8.1.1.1 Pain in MS relapse 
Pain associated with MS relapse is poorly understood and quantified. It is not known 
how often pain is associated with relapse, and, perhaps more importantly, its impact 
on patient function, recovery from relapse, and later progress is also unknown.  
A study assessing the pain symptoms of patients in MS relapse (and their self-rated 
pain related impairments, using the BPI for example), and then again at a follow-up 
point, could help to assess the above factors. A particular difficulty in design of such 
a study is case ascertainment – in particular sensitivity and specificity (considering 
that patients may not always wish to attend healthcare providers with an MS relapse, 
or that a deterioration in MS symptoms may be due to other causes than relapse).  
A grant application for a similar study was submitted to the MS Society. This was 
well received by pwMS reviewing the application, but was not funded. 
Clinical correlates of the presence of pain in RRMS 
8.8.1.1.2 Does presence of pain predict poorer outcome? 
Neuropathic pain in MS is associated with a range of adverse outcomes including 
pain interference, depression, anxiety, catastrophising, fatigue, poor sleep and poor 
quality of life. Any of these might correlate with disability or functional impairment, 
which might increase over time.  
Given the associations of pain with a range of adverse clinical and behavioural 
outcomes, longitudinal follow-up of people with MS with and without pain could 
assess any divergence of clinical trajectories in those with and without pain at 
baseline.  




Objective assessment of physical activity (eg using accelerometers) could 
furthermore assess physical activity levels, which could be an important mediator of 
any associations of pain.  
8.8.1.1.3 Can behavioural/affective phenotype predict future pain 
development? 
In a comparable experiment, examining the associations of pain as predictors rather 
than consequences of pain, baseline measurements of straightforward clinical 
variables (fatigue, anxiety, depression, catastrophising) could be evaluated as risk 
factors for the future development of pain in subjects with early RRMS. An 
experiment might take the form of baseline measurement followed by follow-up at 
one year and analysis using a logistic regression model, or similar. 
Are the current experimental findings reproducible in RRMS, as well as 
other MS phenotypes and other related disorders (eg NMO)? 
Similar experiments to those described in this thesis could be carried out in people 
with other subtypes of MS, or similar analysis could be carried out in data already 
acquired. Studies in more disabled populations could be particularly vulnerable to 
movement artefacts. 
Similarly, comparable experiments could be carried out in limb pain not associated 
with apparent structural abnormalities of the central nervous system. A typical 
experimental “model” would include fibromyalgia. If similar fMRI findings to those 
described in RRMS were found, this could suggest that applicability of MS as a 
model of the “lesioned” central nervous system, to diseases of the “non-lesioned” 
CNS, could be further explored. 
Mechanistic significance of study findings 
Given the cross-sectional nature of this study, it is not known whether the described 
findings relate to factors predisposing to pain, factors associated with pain 
persistence, or may be sequelae of pain. 
8.8.1.1.4 Do structural and functional imaging characteristics precede or 
follow the development of a neuropathic pain state? 
A longitudinal study beginning at first presentation with Clinically Isolated 
Syndrome or early RRMS could be used to assess whether any identified correlates 




of the presence of pain are noted before, or after, the onset of pain symptoms. Any 
longitudinal study would be potentially vulnerable to differential attrition (ie those 
with more severe health problems, or more severe pain, might be less likely to attend 
follow-up).  
8.8.1.1.5 Does treatment of a neuropathic pain state modify or reverse the 
clinical, psychological and imaging characteristics detailed? 
This study could be conceived of as a longitudinal intervention study, and could take 
various forms for instance a cross-over, or placebo-controlled, design. 
8.8.1.1.6 Does detailed analysis of task fMRI support the proposed 
‘heirarchical’ model of DPMS connectivity? 
Does task fMRI analysis using a model designed to assess possible causality (such as 
dynamic causal modelling, or structural equation modelling) support the hypothesis 
of aberrant top-down regulation of the DPMS by DLPFC? 
During the study described above acquired “task” fMRI has been acquired  using 
controlled painful stimuli to the lower limb, administered via a Medoc Pathway 
system during fMRI acquisition. While this data is reported in the Appendix, this 
data could be amenable to such analysis.  
8.8.1.1.7 Is there a genetic component to the specified findings? 
As part of my study (not described in this thesis) DNA has been gathered from all 
participants, and ethical permissions to use this in local or collaborative studies has 
been obtained. Data from this small sample may need to be combined with other 
studies. To my knowledge, only one study has assessed any possible genetic 
component to pain in MS to date (338). 
Participant satisfaction with study involvement 
8.8.1.1.8 What factors determine subjects’ satisfaction with research 
participation? 
A database of study participants engaging in studies locally could be linked to patient 
satisfaction scores gathered, for example, electronically at time of study 
participation. Large numbers of participants would be available and multiple 
regression models regarding type of study assessments (for instance, with respect to 
MRI - duration of MRI, inclusion of specific sequences and so on) could be entered 




as explanatory variables. This work could be useful in informing design of future 
studies, and in justifying design of studies to research ethics committees. 
For researchers designing future studies, this information may be useful in the design 
of studies, and to support applications to ethics committees. A systematic review of 
factors influencing participant experience of studies, perhaps focussing particularly 
on people with MS, would further help to inform design of future studies. Design of 
future studies specifically at ARRNC may be assisted by creation of the patient 
involvement groups described.





Participant experience of research studies













(("multiple sclerosis"[MeSH Terms] OR "multiple 
sclerosis/analysis"[MeSH Terms] OR "multiple 
sclerosis/anatomy and histology"[MeSH Terms] OR "multiple 
sclerosis/blood"[MeSH Terms] OR "multiple 
sclerosis/cerebrospinal fluid"[MeSH Terms] OR "multiple 
sclerosis/chemically induced"[MeSH Terms] OR "multiple 
sclerosis/chemistry"[MeSH Terms] OR "multiple 
sclerosis/classification"[MeSH Terms] OR "multiple 
sclerosis/complications"[MeSH Terms] OR "multiple 
sclerosis/congenital"[MeSH Terms] OR "multiple 
sclerosis/cytology"[MeSH Terms] OR "multiple 
sclerosis/diagnosis"[MeSH Terms] OR "multiple sclerosis/diet 
therapy"[MeSH Terms] OR "multiple sclerosis/drug 
therapy"[MeSH Terms] OR "multiple 
sclerosis/economics"[MeSH Terms] OR "multiple 
sclerosis/embryology"[MeSH Terms] OR "multiple 
sclerosis/enzymology"[MeSH Terms] OR "multiple 
sclerosis/epidemiology"[MeSH Terms] OR "multiple 
sclerosis/ethnology"[MeSH Terms] OR "multiple 
sclerosis/etiology"[MeSH Terms] OR "multiple 
sclerosis/genetics"[MeSH Terms] OR "multiple 
sclerosis/history"[MeSH Terms] OR "multiple 
sclerosis/immunology"[MeSH Terms] OR "multiple 
sclerosis/legislation and jurisprudence"[MeSH Terms] OR 
"multiple sclerosis/metabolism"[MeSH Terms] OR "multiple 
sclerosis/microbiology"[MeSH Terms] OR "multiple 




sclerosis/mortality"[MeSH Terms] OR "multiple 
sclerosis/nursing"[MeSH Terms] OR "multiple 
sclerosis/organization and administration"[MeSH Terms] OR 
"multiple sclerosis/parasitology"[MeSH Terms] OR "multiple 
sclerosis/pathology"[MeSH Terms] OR "multiple 
sclerosis/physiology"[MeSH Terms] OR "multiple 
sclerosis/physiopathology"[MeSH Terms] OR "multiple 
sclerosis/prevention and control"[MeSH Terms] OR "multiple 
sclerosis/psychology"[MeSH Terms] OR "multiple 
sclerosis/radiography"[MeSH Terms] OR "multiple 
sclerosis/radionuclide imaging"[MeSH Terms] OR "multiple 
sclerosis/radiotherapy"[MeSH Terms] OR "multiple 
sclerosis/rehabilitation"[MeSH Terms] OR "multiple 
sclerosis/statistics and numerical data"[MeSH Terms] OR 
"multiple sclerosis/surgery"[MeSH Terms] OR "multiple 
sclerosis/therapy"[MeSH Terms] OR "multiple 
sclerosis/transmission"[MeSH Terms] OR "multiple 
sclerosis/ultrasonography"[MeSH Terms] OR "multiple 
sclerosis/urine"[MeSH Terms] OR "multiple 
sclerosis/veterinary"[MeSH Terms] OR "multiple 
sclerosis/virology"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive/analysis"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/anatomy and histology"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/blood"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive/cerebrospinal fluid"[MeSH Terms] OR 
"multiple sclerosis, chronic progressive/classification"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/complications"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/cytology"[MeSH Terms] OR 
"multiple sclerosis, chronic progressive/diagnosis"[MeSH 




Terms] OR "multiple sclerosis, chronic progressive/diet 
therapy"[MeSH Terms] OR "multiple sclerosis, chronic 
progressive/drug therapy"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/economics"[MeSH Terms] OR 
"multiple sclerosis, chronic progressive/enzymology"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/epidemiology"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/ethnology"[MeSH Terms] OR 
"multiple sclerosis, chronic progressive/etiology"[MeSH Terms] 
OR "multiple sclerosis, chronic progressive/genetics"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/immunology"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/metabolism"[MeSH Terms] OR 
"multiple sclerosis, chronic progressive/microbiology"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/mortality"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive/nursing"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/organization and 
administration"[MeSH Terms] OR "multiple sclerosis, chronic 
progressive/pathology"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive/physiology"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/physiopathology"[MeSH Terms] 
OR "multiple sclerosis, chronic progressive/prevention and 
control"[MeSH Terms] OR "multiple sclerosis, chronic 
progressive/psychology"[MeSH Terms] OR "multiple sclerosis, 
chronic progressive/radiography"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/radionuclide imaging"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/rehabilitation"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/statistics and numerical 
data"[MeSH Terms] OR "multiple sclerosis, chronic 
progressive/surgery"[MeSH Terms] OR "multiple sclerosis, 




chronic progressive/therapy"[MeSH Terms] OR "multiple 
sclerosis, chronic progressive/ultrasonography"[MeSH Terms] 
OR "multiple sclerosis, chronic progressive/urine"[MeSH 
Terms] OR "multiple sclerosis, chronic 
progressive/virology"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/analysis"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/anatomy and histology"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/blood"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/cerebrospinal fluid"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/chemically 
induced"[MeSH Terms] OR "multiple sclerosis, relapsing 
remitting/classification"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/complications"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/cytology"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/diagnosis"[MeSH 
Terms] OR "multiple sclerosis, relapsing remitting/diet 
therapy"[MeSH Terms] OR "multiple sclerosis, relapsing 
remitting/drug therapy"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/economics"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/embryology"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/enzymology"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/epidemiology"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/ethnology"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/etiology"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/genetics"[MeSH Terms] 
OR "multiple sclerosis, relapsing remitting/history"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/immunology"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/metabolism"[MeSH Terms] OR "multiple 




sclerosis, relapsing remitting/microbiology"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/mortality"[MeSH Terms] 
OR "multiple sclerosis, relapsing remitting/nursing"[MeSH 
Terms] OR "multiple sclerosis, relapsing remitting/organization 
and administration"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/parasitology"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/pathology"[MeSH Terms] OR 
"multiple sclerosis, relapsing remitting/physiology"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/physiopathology"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/prevention and control"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/psychology"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/radiography"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/radionuclide imaging"[MeSH 
Terms] OR "multiple sclerosis, relapsing 
remitting/radiotherapy"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/rehabilitation"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/statistics and numerical 
data"[MeSH Terms] OR "multiple sclerosis, relapsing 
remitting/surgery"[MeSH Terms] OR "multiple sclerosis, 
relapsing remitting/therapy"[MeSH Terms] OR "multiple 
sclerosis, relapsing remitting/ultrasonography"[MeSH Terms] 
OR "multiple sclerosis, relapsing remitting/urine"[MeSH Terms] 




Pain (("pain"[MeSH Terms] OR "pain/analysis"[MeSH Terms] OR 
"pain/anatomy and histology"[MeSH Terms] OR 




"pain/blood"[MeSH Terms] OR "pain/cerebrospinal 
fluid"[MeSH Terms] OR "pain/chemically induced"[MeSH 
Terms] OR "pain/classification"[MeSH Terms] OR 
"pain/complications"[MeSH Terms] OR 
"pain/congenital"[MeSH Terms] OR "pain/cytology"[MeSH 
Terms] OR "pain/diagnosis"[MeSH Terms] OR "pain/diet 
therapy"[MeSH Terms] OR "pain/drug effects"[MeSH Terms] 
OR "pain/drug therapy"[MeSH Terms] OR 
"pain/economics"[MeSH Terms] OR "pain/education"[MeSH 
Terms] OR "pain/embryology"[MeSH Terms] OR 
"pain/enzymology"[MeSH Terms] OR 
"pain/epidemiology"[MeSH Terms] OR "pain/ethics"[MeSH 
Terms] OR "pain/ethnology"[MeSH Terms] OR 
"pain/etiology"[MeSH Terms] OR "pain/genetics"[MeSH 
Terms] OR "pain/history"[MeSH Terms] OR 
"pain/immunology"[MeSH Terms] OR "pain/injuries"[MeSH 
Terms] OR "pain/instrumentation"[MeSH Terms] OR 
"pain/legislation and jurisprudence"[MeSH Terms] OR 
"pain/metabolism"[MeSH Terms] OR 
"pain/microbiology"[MeSH Terms] OR "pain/mortality"[MeSH 
Terms] OR "pain/nursing"[MeSH Terms] OR "pain/organization 
and administration"[MeSH Terms] OR 
"pain/parasitology"[MeSH Terms] OR "pain/pathology"[MeSH 
Terms] OR "pain/physiology"[MeSH Terms] OR 
"pain/physiopathology"[MeSH Terms] OR "pain/prevention and 
control"[MeSH Terms] OR "pain/psychology"[MeSH Terms] 
OR "pain/radiation effects"[MeSH Terms] OR 
"pain/radiography"[MeSH Terms] OR "pain/radionuclide 
imaging"[MeSH Terms] OR "pain/radiotherapy"[MeSH Terms] 
OR "pain/rehabilitation"[MeSH Terms] OR 
"pain/standards"[MeSH Terms] OR "pain/statistics and 
numerical data"[MeSH Terms] OR "pain/surgery"[MeSH 




Terms] OR "pain/therapy"[MeSH Terms] OR 
"pain/ultrasonography"[MeSH Terms] OR "pain/urine"[MeSH 
Terms] OR "pain/veterinary"[MeSH Terms] OR 
"pain/virology"[MeSH Terms] OR "pain clinics"[MeSH Terms] 
OR "pain clinics/classification"[MeSH Terms] OR "pain 
clinics/economics"[MeSH Terms] OR "pain 
clinics/ethics"[MeSH Terms] OR "pain clinics/history"[MeSH 
Terms] OR "pain clinics/legislation and jurisprudence"[MeSH 
Terms] OR "pain clinics/manpower"[MeSH Terms] OR "pain 
clinics/organization and administration"[MeSH Terms] OR 
"pain clinics/standards"[MeSH Terms] OR "pain 
clinics/statistics and numerical data"[MeSH Terms] OR "pain 
clinics/supply and distribution"[MeSH Terms] OR "pain 
clinics/trends"[MeSH Terms] OR "pain 
clinics/utilization"[MeSH Terms] OR "pain insensitivity, 
congenital"[MeSH Terms] OR "pain insensitivity, 
congenital/analysis"[MeSH Terms] OR "pain insensitivity, 
congenital/anatomy and histology"[MeSH Terms] OR "pain 
insensitivity, congenital/blood"[MeSH Terms] OR "pain 
insensitivity, congenital/cerebrospinal fluid"[MeSH Terms] OR 
"pain insensitivity, congenital/classification"[MeSH Terms] OR 
"pain insensitivity, congenital/complications"[MeSH Terms] OR 
"pain insensitivity, congenital/cytology"[MeSH Terms] OR 
"pain insensitivity, congenital/diagnosis"[MeSH Terms] OR 
"pain insensitivity, congenital/drug therapy"[MeSH Terms] OR 
"pain insensitivity, congenital/epidemiology"[MeSH Terms] OR 
"pain insensitivity, congenital/ethnology"[MeSH Terms] OR 
"pain insensitivity, congenital/etiology"[MeSH Terms] OR "pain 
insensitivity, congenital/genetics"[MeSH Terms] OR "pain 
insensitivity, congenital/immunology"[MeSH Terms] OR "pain 
insensitivity, congenital/metabolism"[MeSH Terms] OR "pain 
insensitivity, congenital/mortality"[MeSH Terms] OR "pain 




insensitivity, congenital/pathology"[MeSH Terms] OR "pain 
insensitivity, congenital/physiology"[MeSH Terms] OR "pain 
insensitivity, congenital/physiopathology"[MeSH Terms] OR 
"pain insensitivity, congenital/psychology"[MeSH Terms] OR 
"pain insensitivity, congenital/radiography"[MeSH Terms] OR 
"pain insensitivity, congenital/statistics and numerical 
data"[MeSH Terms] OR "pain insensitivity, 
congenital/surgery"[MeSH Terms] OR "pain insensitivity, 
congenital/therapy"[MeSH Terms] OR "pain insensitivity, 
congenital/urine"[MeSH Terms] OR "pain management"[MeSH 
Terms] OR "pain management/adverse effects"[MeSH Terms] 
OR "pain management/classification"[MeSH Terms] OR "pain 
management/contraindications"[MeSH Terms] OR "pain 
management/economics"[MeSH Terms] OR "pain 
management/epidemiology"[MeSH Terms] OR "pain 
management/ethics"[MeSH Terms] OR "pain 
management/history"[MeSH Terms] OR "pain 
management/instrumentation"[MeSH Terms] OR "pain 
management/methods"[MeSH Terms] OR "pain 
management/mortality"[MeSH Terms] OR "pain 
management/nursing"[MeSH Terms] OR "pain 
management/organization and administration"[MeSH Terms] 
OR "pain management/pharmacology"[MeSH Terms] OR "pain 
management/psychology"[MeSH Terms] OR "pain 
management/standards"[MeSH Terms] OR "pain 
management/statistics and numerical data"[MeSH Terms] OR 
"pain management/therapeutic use"[MeSH Terms] OR "pain 
management/therapy"[MeSH Terms] OR "pain 
management/trends"[MeSH Terms] OR "pain 
management/utilization"[MeSH Terms] OR "pain 
management/veterinary"[MeSH Terms] OR "pain 
measurement"[MeSH Terms] OR "pain measurement/adverse 




effects"[MeSH Terms] OR "pain 
measurement/classification"[MeSH Terms] OR "pain 
measurement/contraindications"[MeSH Terms] OR "pain 
measurement/drug effects"[MeSH Terms] OR "pain 
measurement/economics"[MeSH Terms] OR "pain 
measurement/epidemiology"[MeSH Terms] OR "pain 
measurement/ethics"[MeSH Terms] OR "pain 
measurement/history"[MeSH Terms] OR "pain 
measurement/instrumentation"[MeSH Terms] OR "pain 
measurement/methods"[MeSH Terms] OR "pain 
measurement/mortality"[MeSH Terms] OR "pain 
measurement/nursing"[MeSH Terms] OR "pain 
measurement/organization and administration"[MeSH Terms] 
OR "pain measurement/pharmacology"[MeSH Terms] OR "pain 
measurement/psychology"[MeSH Terms] OR "pain 
measurement/radiation effects"[MeSH Terms] OR "pain 
measurement/standards"[MeSH Terms] OR "pain 
measurement/statistics and numerical data"[MeSH Terms] OR 
"pain measurement/therapeutic use"[MeSH Terms] OR "pain 
measurement/therapy"[MeSH Terms] OR "pain 
measurement/trends"[MeSH Terms] OR "pain 
measurement/utilization"[MeSH Terms] OR "pain 
measurement/veterinary"[MeSH Terms] OR "pain 
perception"[MeSH Terms] OR "pain 
perception/classification"[MeSH Terms] OR "pain 
perception/drug effects"[MeSH Terms] OR "pain 
perception/ethics"[MeSH Terms] OR "pain 
perception/physiology"[MeSH Terms] OR "pain 
perception/radiation effects"[MeSH Terms] OR "pain 
threshold"[MeSH Terms] OR "pain 
threshold/classification"[MeSH Terms] OR "pain threshold/drug 
effects"[MeSH Terms] OR "pain 




threshold/epidemiology"[MeSH Terms] OR "pain 
threshold/ethics"[MeSH Terms] OR "pain 
threshold/ethnology"[MeSH Terms] OR "pain 
threshold/physiology"[MeSH Terms] OR "pain 
threshold/psychology"[MeSH Terms] OR "pain 
threshold/radiation effects"[MeSH Terms] OR "pain 
threshold/statistics and numerical data"[MeSH Terms] OR 
"pain, intractable"[MeSH Terms] OR "pain, 
intractable/analysis"[MeSH Terms] OR "pain, 
intractable/anatomy and histology"[MeSH Terms] OR "pain, 
intractable/blood"[MeSH Terms] OR "pain, 
intractable/cerebrospinal fluid"[MeSH Terms] OR "pain, 
intractable/chemically induced"[MeSH Terms] OR "pain, 
intractable/classification"[MeSH Terms] OR "pain, 
intractable/complications"[MeSH Terms] OR "pain, 
intractable/cytology"[MeSH Terms] OR "pain, 
intractable/diagnosis"[MeSH Terms] OR "pain, intractable/diet 
therapy"[MeSH Terms] OR "pain, intractable/drug 
therapy"[MeSH Terms] OR "pain, 
intractable/economics"[MeSH Terms] OR "pain, 
intractable/enzymology"[MeSH Terms] OR "pain, 
intractable/epidemiology"[MeSH Terms] OR "pain, 
intractable/ethnology"[MeSH Terms] OR "pain, 
intractable/etiology"[MeSH Terms] OR "pain, 
intractable/genetics"[MeSH Terms] OR "pain, 
intractable/history"[MeSH Terms] OR "pain, 
intractable/immunology"[MeSH Terms] OR "pain, 
intractable/metabolism"[MeSH Terms] OR "pain, 
intractable/microbiology"[MeSH Terms] OR "pain, 
intractable/mortality"[MeSH Terms] OR "pain, 
intractable/nursing"[MeSH Terms] OR "pain, 
intractable/organization and administration"[MeSH Terms] OR 




"pain, intractable/pathology"[MeSH Terms] OR "pain, 
intractable/physiology"[MeSH Terms] OR "pain, 
intractable/physiopathology"[MeSH Terms] OR "pain, 
intractable/prevention and control"[MeSH Terms] OR "pain, 
intractable/psychology"[MeSH Terms] OR "pain, 
intractable/radiography"[MeSH Terms] OR "pain, 
intractable/radionuclide imaging"[MeSH Terms] OR "pain, 
intractable/radiotherapy"[MeSH Terms] OR "pain, 
intractable/rehabilitation"[MeSH Terms] OR "pain, 
intractable/statistics and numerical data"[MeSH Terms] OR 
"pain, intractable/surgery"[MeSH Terms] OR "pain, 
intractable/therapy"[MeSH Terms] OR "pain, 
intractable/ultrasonography"[MeSH Terms] OR "pain, 
intractable/urine"[MeSH Terms] OR "pain, 
intractable/veterinary"[MeSH Terms] OR "pain, 
intractable/virology"[MeSH Terms] OR "pain, 
postoperative"[MeSH Terms] OR "pain, 
postoperative/analysis"[MeSH Terms] OR "pain, 
postoperative/anatomy and histology"[MeSH Terms] OR "pain, 
postoperative/blood"[MeSH Terms] OR "pain, 
postoperative/cerebrospinal fluid"[MeSH Terms] OR "pain, 













(("magnetic resonance imaging"[MeSH Terms] OR "magnetic 
resonance imaging/adverse effects"[MeSH Terms] OR 
"magnetic resonance imaging/classification"[MeSH Terms] OR 
"magnetic resonance imaging/contraindications"[MeSH Terms] 
OR "magnetic resonance imaging/drug effects"[MeSH Terms] 
OR "magnetic resonance imaging/economics"[MeSH Terms] 
OR "magnetic resonance imaging/education"[MeSH Terms] OR 
"magnetic resonance imaging/epidemiology"[MeSH Terms] OR 
"magnetic resonance imaging/ethics"[MeSH Terms] OR 
"magnetic resonance imaging/history"[MeSH Terms] OR 
"magnetic resonance imaging/instrumentation"[MeSH Terms] 
OR "magnetic resonance imaging/methods"[MeSH Terms] OR 
"magnetic resonance imaging/mortality"[MeSH Terms] OR 
"magnetic resonance imaging/nursing"[MeSH Terms] OR 
"magnetic resonance imaging/organization and 
administration"[MeSH Terms] OR "magnetic resonance 
imaging/pharmacology"[MeSH Terms] OR "magnetic resonance 
imaging/psychology"[MeSH Terms] OR "magnetic resonance 
imaging/standards"[MeSH Terms] OR "magnetic resonance 
imaging/statistics and numerical data"[MeSH Terms] OR 
"magnetic resonance imaging/supply and distribution"[MeSH 
Terms] OR "magnetic resonance imaging/therapeutic 
use"[MeSH Terms] OR "magnetic resonance 
imaging/therapy"[MeSH Terms] OR "magnetic resonance 
imaging/trends"[MeSH Terms] OR "magnetic resonance 
imaging/utilization"[MeSH Terms] OR "magnetic resonance 
imaging/veterinary"[MeSH Terms] OR "magnetic resonance 
imaging, cine"[MeSH Terms] OR "magnetic resonance imaging, 
cine/adverse effects"[MeSH Terms] OR "magnetic resonance 
imaging, cine/classification"[MeSH Terms] OR "magnetic 
resonance imaging, cine/contraindications"[MeSH Terms] OR 
"magnetic resonance imaging, cine/economics"[MeSH Terms] 




OR "magnetic resonance imaging, cine/epidemiology"[MeSH 
Terms] OR "magnetic resonance imaging, 
cine/instrumentation"[MeSH Terms] OR "magnetic resonance 
imaging, cine/methods"[MeSH Terms] OR "magnetic resonance 
imaging, cine/mortality"[MeSH Terms] OR "magnetic 
resonance imaging, cine/nursing"[MeSH Terms] OR "magnetic 
resonance imaging, cine/organization and 
administration"[MeSH Terms] OR "magnetic resonance 
imaging, cine/pharmacology"[MeSH Terms] OR "magnetic 
resonance imaging, cine/standards"[MeSH Terms] OR 
"magnetic resonance imaging, cine/statistics and numerical 
data"[MeSH Terms] OR "magnetic resonance imaging, 
cine/therapeutic use"[MeSH Terms] OR "magnetic resonance 
imaging, cine/therapy"[MeSH Terms] OR "magnetic resonance 
imaging, cine/trends"[MeSH Terms] OR "magnetic resonance 
imaging, cine/utilization"[MeSH Terms] OR "magnetic 
resonance imaging, cine/veterinary"[MeSH Terms] OR 
"magnetic resonance imaging, interventional"[MeSH Terms] 
OR "magnetic resonance imaging, interventional/adverse 
effects"[MeSH Terms] OR "magnetic resonance imaging, 
interventional/economics"[MeSH Terms] OR "magnetic 
resonance imaging, interventional/epidemiology"[MeSH Terms] 
OR "magnetic resonance imaging, interventional/history"[MeSH 
Terms] OR "magnetic resonance imaging, 
interventional/instrumentation"[MeSH Terms] OR "magnetic 
resonance imaging, interventional/methods"[MeSH Terms] OR 
"magnetic resonance imaging, interventional/mortality"[MeSH 
Terms] OR "magnetic resonance imaging, 
interventional/organization and administration"[MeSH Terms] 
OR "magnetic resonance imaging, 
interventional/pharmacology"[MeSH Terms] OR "magnetic 
resonance imaging, interventional/psychology"[MeSH Terms] 




OR "magnetic resonance imaging, 
interventional/standards"[MeSH Terms] OR "magnetic 
resonance imaging, interventional/statistics and numerical 
data"[MeSH Terms] OR "magnetic resonance imaging, 
interventional/therapeutic use"[MeSH Terms] OR "magnetic 
resonance imaging, interventional/trends"[MeSH Terms] OR 








(("positron emission tomography"[MeSH Terms] OR "positron 
emission tomography/adverse effects"[MeSH Terms] OR 
"positron emission tomography/classification"[MeSH Terms] 
OR "positron emission tomography/contraindications"[MeSH 
Terms] OR "positron emission tomography/economics"[MeSH 
Terms] OR "positron emission 
tomography/epidemiology"[MeSH Terms] OR "positron 
emission tomography/ethics"[MeSH Terms] OR "positron 
emission tomography/history"[MeSH Terms] OR "positron 
emission tomography/instrumentation"[MeSH Terms] OR 
"positron emission tomography/methods"[MeSH Terms] OR 
"positron emission tomography/mortality"[MeSH Terms] OR 
"positron emission tomography/nursing"[MeSH Terms] OR 
"positron emission tomography/organization and 
administration"[MeSH Terms] OR "positron emission 
tomography/pharmacology"[MeSH Terms] OR "positron 
emission tomography/psychology"[MeSH Terms] OR "positron 
emission tomography/standards"[MeSH Terms] OR "positron 
emission tomography/statistics and numerical data"[MeSH 
Terms] OR "positron emission tomography/therapeutic 




use"[MeSH Terms] OR "positron emission 
tomography/therapy"[MeSH Terms] OR "positron emission 
tomography/trends"[MeSH Terms] OR "positron emission 









(("tomography, emission computed, single photon"[MeSH 
Terms] OR "tomography, emission computed, single 
photon/adverse effects"[MeSH Terms] OR "tomography, 
emission computed, single photon/classification"[MeSH Terms] 
OR "tomography, emission computed, single 
photon/contraindications"[MeSH Terms] OR "tomography, 
emission computed, single photon/economics"[MeSH Terms] 
OR "tomography, emission computed, single 
photon/epidemiology"[MeSH Terms] OR "tomography, 
emission computed, single photon/ethics"[MeSH Terms] OR 
"tomography, emission computed, single photon/history"[MeSH 
Terms] OR "tomography, emission computed, single 
photon/instrumentation"[MeSH Terms] OR "tomography, 
emission computed, single photon/methods"[MeSH Terms] OR 
"tomography, emission computed, single 
photon/mortality"[MeSH Terms] OR "tomography, emission 
computed, single photon/nursing"[MeSH Terms] OR 
"tomography, emission computed, single photon/organization 
and administration"[MeSH Terms] OR "tomography, emission 
computed, single photon/pharmacology"[MeSH Terms] OR 
"tomography, emission computed, single 
photon/psychology"[MeSH Terms] OR "tomography, emission 
computed, single photon/standards"[MeSH Terms] OR 







"tomography, emission computed, single photon/statistics and 
numerical data"[MeSH Terms] OR "tomography, emission 
computed, single photon/therapeutic use"[MeSH Terms] OR 
"tomography, emission computed, single 
photon/therapy"[MeSH Terms] OR "tomography, emission 
computed, single photon/trends"[MeSH Terms] OR 
"tomography, emission computed, single 
photon/utilization"[MeSH Terms] OR "tomography, emission 
computed, single photon/veterinary"[MeSH Terms])) 
 
 ) 




Appendix: Study newsletters 
 
Overview 
Newsletters were sent out to all study participants with MS throughout the duration 
of the study.  
The aim of these was to keep participants informed, and in particular to make them 
aware of the use their research date was being put to.  
Feedback from previous studies had suggested that study participants were often 
uncertain how their research data was being used, and appreciated this feedback.  
All participants consented to receive this newsletter, at time of giving consent to 
participate in the study. 
Newsletters were designed to be read by patients and/or relatives, rather than a 
scientific reader. A priority was to impart insight  into study progress and findings, 
while avoiding too much detail, and maintaining brevity. One of the later newsletters 
was also used to remind study participants about the patient experience substudy. 
Feedback on the study newsletters from study participants was positive (Appendix: 








































Appendix: Exploration of BOLD response to 
extrinsic thermal noxious 
stimulation: task fMRI 
8.9 Introduction 
In order to supplement data and methods reported elsewhere in this thesis, a task-
based functional MRI paradigm was employed, in the same scan session as the 
resting state fMRI described previously.  
In order to directly investigate the BOLD response to pain, a noxious stimulus was 
used. Because the perception of a stimulus was expected to vary across subjects, a 
thermal stimulus was employed. A thermal stimulus was used because this allowed 
variation of temperature, titrated against subject report of pain severity.  The 
temperatures of thermal stimuli were calibrated individually against pain rating for 
each subject. In addition, the noxious thermal stimulation was judged to be 
qualitatively comparable to the burning pain reported by many patients with 
neuropathic limb pain in MS  
8.10 Methods 
8.10.1 Subject assessment 
Immediately prior to imaging, each research subject was assessed in the mock scan 
room, adjacent to the 3T Siemens scan room, at the Clinical Research Imaging 
Centre, University of Edinburgh.  
8.10.2 Thermal stimulation 
An MRI-compatible Pathway device was used to enable thermal stimulation during 
the scan session as well as prior to the session (Medoc systems, Israel)(339). 
Set-up and installation of Pathway device 
Set-up and usage of the device was discussed with local physicists (especially Neil 
Roberts, Scott Semple and Gill MacNaught, as well as researcher Jonathan Murnane) 
and with researchers from other centres (Irene Tracey, Oxford and Jon Brooks, 
Bristol). Jon Brooks assisted directly in setup of the device. 




The Pathway device is shown below. Please note: 
 Windows laptop [A]  running proprietary software which controls the 
temperature administered by the thermode.  
 The Pathway base unit [B] which generates the appropriate temperature for 
the ceramic thermode 
 MRI-safe cabling [C] encompassing electronics as well as coolant circulating 
to the thermode (10 metres). 
 The Ceramic Thermode [D] (ceramic disc enclosed within black box) 
including Velcro strapping 
 
Figure 46: Pathway device set up in mock MRI room, Clinical Research Imaging Centre 
 
Note: use of wave guide to allow connection to control room 
During scan session, the Pathway device needed to be attached to the command 
module (see image above) from the scan room, to the control room. Because the 
device could not be left in situ (psychophysics assessment needed to be carried out 
before imaging because of time constraints for the imaging session), it required to be 




connected and disconnected through the wave guide for each scan session. There 
were some initial practical issues with connecting the coolant pipes, which were 
overcome after some practice in setting up the equipment. 
Thermode 
A proprietary CHEPS (“Contact Heat Evoked Potentials”) thermode was employed 
to administer thermal stimuli to the study participant. The thermode incorporates a 
27mm diameter ceramic disc, which is set up to be in contact with the participant’s 
skin (339). The temperature of the disc is controlled to within 0.5 degrees Centigrade 
by a user interface, employing a laptop running proprietary software. The 
manufacturer data states that the heating of the thermode disc is very rapid (70 
degrees Centigrade/second), and that temperature is checked around 200 times per 
second, to ensure close temperature control (339). 
Interface with study participant 
In order to standardise site of administration, the Pathway device was attached to the 
medial right lower leg, 10 centimetres above the medial malleolus in every subject. 
The device was attached using proprietary Velcro strapping. 
Psychophysical session prior to imaging 
Assessments were carried out using a pre-prepared standardised written script. In all 
cases, the assessments were carried out by PF, in the same room and using the same 
equipment.  
Prior to imaging, a short psychophysical session was carried out to establish two 
separate temperatures, for each research subject. This session was carried out in the 
mock scan room, adjacent to the MRI scan room, within the Clinical Research 
Imaging Centre (CRIC).  
The first of these was a temperature which was reported as mildly painful (1/10 using 
a numerical rating scale, with the anchors of  0 being no pain, and 10 the worst pain 
imaginable). The second was a temperature which was reported as moderately 
painful (4-5/10 on the same scale). These temperatures were recorded individually 
for each subject. The temperature administered was adjustable within 0.5 degrees 




Centigrade using proprietary software. These methods were comparable to previous 
studies of other pain syndromes, using similar equipment (340). 
  




8.10.3 Scan session 
Imaging acquisition 
As described elsewhere in this thesis, a 3Tesla Siemens Verio system using a 12 
channel head coil was employed. No scanner upgrades were carried out during the 
study.  
Whole-brain EPI sequences were acquired (TR 2.5s, TE 30ms, 240 volumes, voxel 
size 3.0mm3) following acquisition of the structural, fieldmap and resting state fMRI 
data described elsewhere. Two separate scans of 10 minutes duration each were 
acquired (see below). 
fMRI task 
In the scan session, three second pulses of heat, at the predetermined temperatures 
(“Temp 1” and “Temp 2”) were administered with a jittered interstimulus interval of 
mean  60 seconds (range 55-65 seconds) (340). Presentation software (341) (set up 
by Cyril Pernet)  was used to synchronize stimuli. 
“Temp 1” was repeated 10 times, and in a separate EPI acquisition, “Temp 2” was 
repeated 10 times. For each subject, the order of Temp 1 and Temp2 was randomised 
so that half the cohort received Temp 1 then Temp 2, and the other half Temp 2 then 
Temp 1. 
At the end of each 10 minute acquisition, the subject was asked for average pain 
rating (0 to 10, on the same scale) and also a rating of pain unpleasantness on a 
comparable numerical rating scale (0= not at all unpleasant, 10= most unpleasant 
imaginable).  
Note: use of goggles during scan session 
Initially, during exploratory work, the task fMRI scan session incorporated goggles, 
in order to allow visual presentation of stimuli to scan participants. Use of this 
equipment, however, in combination with the Pathway device described above, 
resulted in the introduction of extraneous radiofrequency (RF) noise during the scan 
acquisition. This was visible during imaging acquisition as a stripe through the brain 
at the level of the brainstem (an important region of interest in analyses of response 




to painful stimuli). Subsequent imaging therefore did not use goggles. None of the 
data presented was acquired using goggles during the scan session. 
Note: use of physiological noise modelling during session 
Physiological noise monitoring was acquired during imaging acquisition (Cardiac 
and respiratory waveforms using a pulse oximeter and respiratory bellows, MP100, 
Linton Instruments, UK). Unfortunately there were several equipment and recording 
issues during scan sessions, and this data was not useable for physiological noise 
modelling in the subsequent analysis. Issues included fractured cabling, and 
problems with synchronisation with the MRI acquisition. There were also difficulties 
in some cases with maintaining adequate placement of the saturation probe, in 
particular. Because these issue were inconsistent and varied between and within 
acquisitions, this data was not used in subsequent analyses. 
 
  






The following clinical variables were recorded 
 Order of stimulation in fMRI (order of Temp 1 and Temp 2) 
 Temperature 1 and Temperature 2 separately (degrees Centigrade). 
 Pain score (numerical rating scale) for Temp 1 and Temp 2 
 Unpleasantness score (numerical rating scale) for both Temp 1 and Temp 2 
 Presence or otherwise of pre-existing neuropathic pain at stimulation site 
 Pre-existing thermal allodynia at stimulation site 
Normality of distribution of data was assessed using the Quantile-quantile plot. 
Median and Interquartile Range were presented as summary statistics where data 
distribution did not follow Gaussian distribution. Statistical significance of 
differences between groups was assessed using the Wilcoxon rank sum test. 
Statistical significance was accepted at the 5% level. 
Task fMRI 
Subject-level task fMRI was analysed by PF using FEAT version 6 packaged in FSL 
version 5.0.1 (105). The following analysis was carried out:  
8.10.3.1.1 Pre-statistics 
Motion correction using MCFLIRT  (279) slice-timing correction using Fourier-
space time-series phase-shifting; non-brain removal using BET (276); spatial 
smoothing using a Gaussian kernel of FWHM 5mm; grand-mean intensity 
normalisation of the entire 4D dataset by a single multiplicative factor; highpass 
temporal filtering (Gaussian-weighted least-squares straight line fitting, with 
sigma=45.0s). 
8.10.3.1.2 Statistical analysis at the single-subject level 
Time-series statistical analysis was carried out using FILM with local autocorrelation 
correction. A double-gamma haemodynamic response function was used, in order to 
allow for undershoot in the BOLD response (71, 75). The time series was modelled 
in FEAT, using a temporal derivative (105).  





Registration to high resolution structural and/or standard space images was carried 
out using FLIRT (279). B0 unwarping was used as described elsewhere in this thesis. 
Registration from high resolution structural to standard space was further refined 
using FNIRT (274). 
8.10.3.1.4 Higher level analysis 
A design matrix was constructed to calculate the contrasts of pain group BOLD 
activation> control group, as well as the opposite contrast, and mean BOLD 
activation within each group.  
Higher level analysis was carried out using FMRIB Analysis of Mixed Effects 
(FLAME) version 1 implemented in FSL. Statistical significance was assigned at 
z=2.3 and corrected cluster forming threshold p<0.05 (342). 
8.10.3.1.5 Visual checking of results 
Brain extraction, B0 unwarping and registration were visually checked throughout 
the fMRI analysis procedure, using registration summaries produced by FSL and 
viewed in Firefox  
  





8.11.1 Recruitment and Patient data  
45 subjects were included in the analysis (pain group n=29, control group n=16). Of 
the pain group, there was pre-existing pain at stimulation site (right lower limb) in 
13. No subjects manifested thermal allodynia at the stimulation site. 
23 of 39 underwent stimulation using “temperature 1” followed by “temperature 2” 
and 16 of 39 the converse. 
8.11.2 Psychophysical assessment 
For “temp 1” (pain severity 1/10 in the psychophysical session) median pain rating in 
the pain group was 2.0, and for the control group 1.0. Temperature applied in the 
pain group was higher in the pain group but this did not attain statistical significance.  
For “temp 2” (pain severity 5/10 in the psychophysical session) median pain rating in 
the pain group was 4.0 and in the control group 3.0. Temperature applied in the pain 
group was higher in the pain group. Both of these differences attained statistical 
significance at the 5% level. 
Table 52: Psychophysical data 
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44.5) 
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44.50 (43.75 to 
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46.00 (45.00 to 
47.50) 
P=0.01383 






3.50 (3.00-4.75) 3.00 (2.00 to 
3.50) 




Individual patient issues 
Some individual participants found giving a reliable pain rating very problematic 
(see participant feedback for further description of this issue). 
In some participants, reported pain due to stimulus in-scanner was markedly higher 
than reported pain due to stimulus pre-scan. For example, in one subject in particular 
(subject 0326) in-scanner pain was reported at 9/10, having previously been reported 
at 5 prior to imaging. Although this subject manifested high scores for anxiety and 
catastrophising (HADS A 14, PCS 25 (157, 233)) these were not the highest scores 
in the group. Therefore these issues in this particular patient were not easily 
predictable. This patient was a member of the pain group (ie had pre-existing 
neuropathic pain). These issues further increased the care that was taken to ensure 
that temperatures administered in-scanner were in a range acceptable to the 
participant. 
 
8.11.3 Mean BOLD signal in pain group and control 
group 
In both the pain group and control group, mean BOLD response included a variety of 
cortical and subcortical structures closely associated with pain response in previous 
studies (1). These included Insula, Somatosensory and Motor Cortices, Prefrontal 
Cortex, Anterior and Posterior Cingulate, Thalamus and brain stem. Please see the 
figures below. 
 




Figure 47: Mean BOLD signal in control group, n=16. Z=2.3, p=0.05 (moderate pain severity 
stimulus: "Temp 2") 
 
 




Figure 48: Mean BOLD signal in pain group, n=29. Z=2.3, p=0.05 (moderate pain severity 
stimulus: "Temp 2") 
 
8.11.4 Statistical Contrasts between control and pain 
groups 
In whole-brain contrasts between the two groups (5% significance level, and 
corrected for multiple comparisons) no statistically significant difference between the 
groups was found. 
Further post-hoc subgroup comparisons contrasting those within the pain group who 
received the noxious stimulus at a site of pre-existing pain (the right lower limb) and 
those who did not have pre-existing pain at that site, did not reveal any statistically 
significant difference between groups.  
Similarly, a contrast between participants in the pain group who received, and who 
did not receive, adjuvant analgesics did not demonstrate any statistically significant 
difference between groups 
  





This study is presented as a work in progress, as part of the overall thesis. Specific 
strengths and weaknesses, and potential relevance to methods and data described 
elsewhere in this thesis, are discussed. 
8.12.1 Weaknesses  
Variability in pain scores 
Pain scores generated immediately prior to the imaging session (in all cases) proved 
to be only moderately useful in estimating pain severity during noxious stimulation 
in-scanner. This introduced some difficulty in interpretation, which was addressed by 
recording both temperatures and pain scores for each scan session in each subject. 
Stimulus-correlated motion 
Stimulus-correlated motion was a potential issue in the interpretation of this data. 
This concept refers to subject head motion which is correlated to stimulus 
presentation during an fMRI scan session. This may particularly be marked in 
“pathological” populations such as people with multiple sclerosis, and/or with 
chronic pain. The interaction between chronic pain and presence of MS in the 
context of subject motion in a noxious stimulation fMRI study is unknown  (75, 
166). Removal (“scrubbing” or “censoring”) of high-motion timepoints however 
risks removal of the BOLD signal of interest (75, 102). 
Average pain ratings across ten trials 
Pain ratings were averaged over 10 consecutive stimuli. All though the 10 
consecutive stimuli were identical, trial-by-trial ratings were not possible. This issue 
relates in particular to technical problems in use of the goggles during fMRI 




This study represents, to the best of the author’s knowledge, the first use of task 
based fMRI paradigms of any type, to investigate the mechanisms of neuropathic 




limb pain in MS. The study is also the first to use noxious thermal stimuli in an fMRI 
paradigm to investigate the mechanisms of neuropathic limb pain in MS. Although 
unpublished data may exist, systematic review of existing data supports these 
conclusions (166). 
Nature of stimulus 
The temperature of the noxious stimulus, while it can be calibrated for each 
participant’s response, can be measured to the nearest 0.5 degrees Centigrade 
(according to manufacturer data (339)). Administration of the stimulus, once the 
equipment is set up, is entirely computer-controlled, with subsequent limitation in 
variability in the stimuli during the imaging session. This might lead to less 
variability in the stimulus than might be expected for, for instance, a manually-
controlled stimulus. 
The nature of the thermal noxious stimulus is designed to qualitatively mimic the 
nature of neuropathic limb pain in MS, which is often related to have a “burning” 
quality (5, 69, 144). 
A jittered inter-stimuls interval was used to minimise participants’ ability to correctly 
anticipate the administration of the noxious stimulus (75). 
 
8.12.3 Perspectives in relation to resting state analysis 
The use of a task fMRI paradigm in addition to a resting state fMRI paradigm may 
from some perspectives be viewed as complementary. A  resting state paradigm 
allows exploration of the brain’s functional connectivity “at rest” (which may be 
viewed as closer to the participant’s own experience of the situation explored, in this 
instance neuropathic limb pain, at least in as much as the condition of lying in an 
MRI scanner may mimic real life). A task fMRI paradigm is however useful to 
explore BOLD signal associated with extrinsic stimuli. While these may not directly 
mimic the participant’s own experience of pain, the high degree of control a 
researcher exerts over the stimulus allows detailed examination of the BOLD signal 
associated with administration of the stimulus  (75, 340). 




The use of an extrinsic stimulus can be criticised in that, while it allows investigation 
of specific physiology underlying the participant’s pain experience, it is necessarily 
different from the subject’s own pain experience. It may therefore introduce 
interpretation difficulties, particularly where used in isolation, and other methods 
such as resting state fMRI or ASL (Arterial Spin Labelling) may be preferred from 
this perspective (343).  
 
8.12.4 Conclusions 
The data presented here may be useful as the subject of future analysis.  
In particular, this data could be used to explore specific hypotheses regarding the 
functional integrity of the descending pain modulatory system, suggested by the 
analysis of the resting state data. Techniques developed for the analysis of functional 
connectivity in task-based fMRI paradigms, for instance psychophysical interaction 
(PPI) and dynamic causal modelling (DCM) might be particularly useful in this 
regard (344, 345). 
Because of the methodological issues outlined above, particular care will need to be 
taken in such analyses, to ensure that results are readily interpretable. Such measures 
could include appropriate correction for confounders (covariates of no interest), or 
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